[
  {
    "id": 10,
    "user_query": "You MUST give a detailed answer to the following question: Name synonym of Acrokeratosis paraneoplastica.",
    "llama-7b_response": "Acrokeratosis paraneoplastica (AKP) is a cutaneous condition characterized by the development of thick, scaly patches on the skin, typically on the hands and feet. The exact cause of AKP is not fully understood, but it is thought to be related to the presence of a cancerous tumor in the body.\n\nThere are several synonyms for AKP, including:\n\n1. Acrokeratosis paraneoplastica of Bazex\n2. Acrokeratosis paraneoplastica of Jadassohn-Lindau\n3. Acrokeratosis paraneoplastica of Mees\n4. Acrokeratosis paraneoplastica of Rosenthal\n5. Acrokeratosis paraneoplastica of Siemens\n\nThese synonyms are used to refer to the same condition as AKP, but may be used interchangeably depending on the context in which they are used.",
    "llama-7b_fact_raw": "1. Acrokeratosis paraneoplastica of Bazex is a synonym for AKP.\n2. Acrokeratosis paraneoplastica of Jadassohn-Lindau is a synonym for AKP.\n3. Acrokeratosis paraneoplastica of Mees is a synonym for AKP.\n4. Acrokeratosis paraneoplastica of Rosenthal is a synonym for AKP.\n5. Acrokeratosis paraneoplastica of Siemens is a synonym for AKP.",
    "llama-7b_fact": [
      "Acrokeratosis paraneoplastica of Bazex is a synonym for AKP.",
      "Acrokeratosis paraneoplastica of Jadassohn-Lindau is a synonym for AKP.",
      "Acrokeratosis paraneoplastica of Mees is a synonym for AKP.",
      "Acrokeratosis paraneoplastica of Rosenthal is a synonym for AKP.",
      "Acrokeratosis paraneoplastica of Siemens is a synonym for AKP."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Bazex syndrome is also known as Acrokeratosis paraneoplastica of Bazex, not Jadassohn-Lindau. The term \"Jadassohn-Lindau\" is typically associated with von Hippel-Lindau disease, an entirely different condition.\n3. FALSE [correction]: There is no widely recognized condition known as Acrokeratosis paraneoplastica of Mees. Mees' lines are transverse white lines on the nails, which can sometimes be a sign of arsenic poisoning or other systemic conditions, but they are not a synonym for AKP.\n4. FALSE [correction]: I could not find any references to a condition known as Acrokeratosis paraneoplastica of Rosenthal in medical literature. Acrokeratosis paraneoplastica is most commonly associated with Bazex syndrome, which is named after the French dermatologist Antoine Bazex.\n5. FALSE [correction]: Acrokeratosis paraneoplastica, or Bazex syndrome, is not known as Acrokeratosis paraneoplastica of Siemens. Siemens syndrome refers to a different skin condition (hidrotic ectodermal dysplasia).",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 47,
    "user_query": "You MUST give a detailed answer to the following question: Is Weaver syndrome similar to Sotos?",
    "llama-7b_response": "Weaver syndrome and Sotos syndrome are two distinct genetic disorders that share some similarities, but they are not the same condition.\n\nWeaver syndrome, also known as Simpson-Golabi-Behmel syndrome (SGBS), is a genetic disorder caused by a mutation in the MLL2 gene. It is characterized by a distinctive physical appearance, including macrocephaly (abnormally large head), hypotonia (low muscle tone), and distinctive facial features such as a broad forehead, full cheeks, and a single crease in the palm of the hand. Individuals with Weaver syndrome also have an increased risk of developing certain cancers, particularly hepatoblastoma (a type of liver cancer) and rhabdomyosarcoma (a type of soft tissue cancer).\n\nSotos syndrome, also known as 45,X/46,XY mosaicism, is a genetic disorder caused by the presence of an extra copy of chromosome 15 in some of the cells in the body. It is characterized by a distinctive physical appearance, including a large head, short stature, and characteristic facial features such as a broad forehead, full cheeks, and a single crease in the palm of the hand. Individuals with Sotos syndrome also have an increased risk of developing certain cancers, particularly hepatoblastoma and rhabdomyosarcoma.\n\nWhile both Weaver syndrome and Sotos syndrome share some similarities in terms of physical characteristics and an increased risk of certain cancers, they are distinct genetic disorders caused by different genetic mutations. Therefore, a diagnosis of Weaver syndrome does not necessarily mean that an individual has Sotos syndrome, and a diagnosis of Sotos syndrome does not necessarily mean that an individual has Weaver syndrome.",
    "llama-7b_fact_raw": "1. Weaver syndrome, also known as Simpson-Golabi-Behmel syndrome (SGBS), is caused by a mutation in the MLL2 gene.\n2. Weaver syndrome is characterized by macrocephaly, hypotonia, and distinctive facial features including a broad forehead and full cheeks.\n3. Individuals with Weaver syndrome have an increased risk of developing certain cancers such as hepatoblastoma and rhabdomyosarcoma.\n4. Sotos syndrome is characterized by the presence of an extra copy of chromosome 15 in some cells and features such as a large head and short stature.\n5. While both Weaver syndrome and Sotos syndrome share similarities like increased cancer risks and certain physical traits, they are caused by different genetic mutations.",
    "llama-7b_fact": [
      "Weaver syndrome, also known as Simpson-Golabi-Behmel syndrome (SGBS), is caused by a mutation in the MLL2 gene.",
      "Weaver syndrome is characterized by macrocephaly, hypotonia, and distinctive facial features including a broad forehead and full cheeks.",
      "Individuals with Weaver syndrome have an increased risk of developing certain cancers such as hepatoblastoma and rhabdomyosarcoma.",
      "Sotos syndrome is characterized by the presence of an extra copy of chromosome 15 in some cells and features such as a large head and short stature.",
      "While both Weaver syndrome and Sotos syndrome share similarities like increased cancer risks and certain physical traits, they are caused by different genetic mutations."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Weaver syndrome is caused by a mutation in the EZH2 gene, not the MLL2 gene.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Sotos syndrome is not characterized by an extra copy of chromosome 15 in some cells. It is caused by mutations in the NSD1 gene, typically leading to overgrowth and features such as a large head and advanced bone age, not necessarily short stature.\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 81,
    "user_query": "You MUST give a detailed answer to the following question: List the releases of JASPAR database",
    "llama-7b_response": "The JASPAR database is a widely used repository of protein-DNA interaction data. As of my knowledge cutoff date of September 2021, there have been several releases of the JASPAR database. Here is a list of the major releases:\n\n1. JASPAR 2004: This was the first release of the JASPAR database, which was published in 2004. It contained data for 184 human transcription factor binding sites.\n2. JASPAR 2008: This release of the JASPAR database was published in 2008 and contained data for 297 human transcription factor binding sites.\n3. JASPAR 2010: This release of the JASPAR database was published in 2010 and contained data for 357 human transcription factor binding sites.\n4. JASPAR 2012: This release of the JASPAR database was published in 2012 and contained data for 417 human transcription factor binding sites.\n5. JASPAR 2014: This release of the JASPAR database was published in 2014 and contained data for 467 human transcription factor binding sites.\n6. JASPAR 2016: This release of the JASPAR database was published in 2016 and contained data for 517 human transcription factor binding sites.\n7. JASPAR 2018: This release of the JASPAR database was published in 2018 and contained data for 567 human transcription factor binding sites.\n8. JASPAR 2020: This release of the JASPAR database was published in 2020 and contained data for 617 human transcription factor binding sites.\n\nIt's worth noting that the JASPAR database is regularly updated with new data, so this list may not be comprehensive or up-to-date.",
    "llama-7b_fact_raw": "1. The JASPAR 2004 release was the first release of the JASPAR database and contained data for 184 human transcription factor binding sites.\n2. The JASPAR 2008 release contained data for 297 human transcription factor binding sites.\n3. The JASPAR 2010 release contained data for 357 human transcription factor binding sites.\n4. The JASPAR 2012 release contained data for 417 human transcription factor binding sites.\n5. The JASPAR 2020 release contained data for 617 human transcription factor binding sites.",
    "llama-7b_fact": [
      "The JASPAR 2004 release was the first release of the JASPAR database and contained data for 184 human transcription factor binding sites.",
      "The JASPAR 2008 release contained data for 297 human transcription factor binding sites.",
      "The JASPAR 2010 release contained data for 357 human transcription factor binding sites.",
      "The JASPAR 2012 release contained data for 417 human transcription factor binding sites.",
      "The JASPAR 2020 release contained data for 617 human transcription factor binding sites."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The first release of the JASPAR database was in 2002, not 2004, and it contained data for 123 core vertebrate transcription factor binding profiles.\n2. FALSE [correction]: The JASPAR 2008 release contained data for 155 core vertebrate transcription factor binding profiles, not just human, and included other groups as well.\n3. TRUE: The JASPAR 2010 release contained data for 137 human transcription factors, contributing to a total of 357 core transcription factor binding profiles across different species.\n4. FALSE [correction]: The JASPAR 2012 release contained data for a total of 460 core transcription factor binding profiles, not just human.\n5. TRUE: The JASPAR 2020 release contained data for a total of 1402 total core transcription factor binding profiles, which would include those for humans as part of the larger set.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 99,
    "user_query": "You MUST give a detailed answer to the following question: What is the function of the viral KP4 protein?",
    "llama-7b_response": "The KP4 protein is a viral protein that is encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV), which is a herpesvirus that is associated with the development of Kaposi's sarcoma, a type of cancer that affects the skin and other organs.\n\nThe KP4 protein is a viral oncoprotein that plays a key role in the transformation of normal cells into cancer cells. It is thought to do this by promoting cell growth and proliferation, as well as by inhibiting apoptosis, or programmed cell death.\n\nThe KP4 protein also plays a role in the immune evasion strategies of KSHV, as it can suppress the activity of immune cells and prevent them from recognizing and attacking the virus.\n\nOverall, the function of the KP4 protein is to promote the growth and survival of cancer cells and to evade the immune system, which allows the virus to persist and cause disease.",
    "llama-7b_fact_raw": "1. The KP4 protein is encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV).\n2. Kaposi's sarcoma is a type of cancer that can affect the skin and other organs.\n3. The KP4 protein is involved in the transformation of normal cells into cancer cells by promoting cell growth and proliferation.\n4. The KP4 protein inhibits apoptosis, which is the programmed cell death mechanism in cells.\n5. The KP4 protein assists in immune evasion by suppressing the activity of immune cells, helping the virus avoid detection and attack.",
    "llama-7b_fact": [
      "The KP4 protein is encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV).",
      "Kaposi's sarcoma is a type of cancer that can affect the skin and other organs.",
      "The KP4 protein is involved in the transformation of normal cells into cancer cells by promoting cell growth and proliferation.",
      "The KP4 protein inhibits apoptosis, which is the programmed cell death mechanism in cells.",
      "The KP4 protein assists in immune evasion by suppressing the activity of immune cells, helping the virus avoid detection and attack."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific scientific literature or context, it's hard to provide accurate evaluations of specific functions attributed to the KP4 protein of Kaposi's sarcoma-associated herpesvirus (KSHV). While statements 1 and 2 are general knowledge about KSHV and Kaposi's sarcoma, statements 3, 4, and 5 would require specific scientific research or literature for validation.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 124,
    "user_query": "You MUST give a detailed answer to the following question: Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-7b_response": "Yes, 3,5-diiodo-L-thyronine (DITPA) is a thyroid hormone analog that has been utilized in both experimental and clinical studies. DITPA is structurally similar to triiodothyronine (T3), one of the two primary hormones produced by the thyroid gland. However, DITPA has an iodine atom replaced by an iodophenyl group, which results in increased lipophilicity and longer half-life compared to T3.\n\nDITPA has been studied as a potential treatment for various thyroid-related disorders, including hypothyroidism, hyperthyroidism, and thyroid cancer. In experimental studies, DITPA has been shown to have similar effects on metabolism and body weight regulation as T3, but with fewer side effects.\n\nIn clinical studies, DITPA has been used as an investigational new drug in the treatment of hypothyroidism, hyperthyroidism, and thyroid cancer. However, the use of DITPA in clinical settings is still experimental and more research is needed to fully understand its safety and efficacy.\n\nIn summary, DITPA is a thyroid hormone analog that has been studied in both experimental and clinical settings as a potential treatment for thyroid-related disorders. However, its use in clinical settings is still experimental and more research is needed to fully understand its safety and efficacy.",
    "llama-7b_fact_raw": "1. 3,5-diiodo-L-thyronine (DITPA) is a thyroid hormone analog used in experimental and clinical studies.\n2. DITPA is structurally similar to the thyroid hormone triiodothyronine (T3).\n3. Unlike T3, DITPA has an iodine atom replaced by an iodophenyl group, contributing to its increased lipophilicity and longer half-life.\n4. DITPA has been studied as a potential treatment for thyroid-related disorders including hypothyroidism, hyperthyroidism, and thyroid cancer.\n5. The use of DITPA in clinical practice is considered experimental, and more research is needed to establish its safety and efficacy.",
    "llama-7b_fact": [
      "3,5-diiodo-L-thyronine (DITPA) is a thyroid hormone analog used in experimental and clinical studies.",
      "DITPA is structurally similar to the thyroid hormone triiodothyronine (T3).",
      "Unlike T3, DITPA has an iodine atom replaced by an iodophenyl group, contributing to its increased lipophilicity and longer half-life.",
      "DITPA has been studied as a potential treatment for thyroid-related disorders including hypothyroidism, hyperthyroidism, and thyroid cancer.",
      "The use of DITPA in clinical practice is considered experimental, and more research is needed to establish its safety and efficacy."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: DITPA is structurally similar to thyroid hormones but does not have an iodine atom replaced by an iodophenyl group. Instead, it has two iodine atoms unlike T3, which has three.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 144,
    "user_query": "You MUST give a detailed answer to the following question: What is the COUGER tool?",
    "llama-7b_response": "The COUGER tool is a software tool developed by the National Institute of Standards and Technology (NIST) that is used to generate cryptographic keys and other cryptographic material. COUGER stands for \"Cryptographic Operations Using Generated Keys.\"\n\nThe COUGER tool is designed to generate cryptographic keys and other cryptographic material in a secure and controlled manner. It can be used to generate a wide range of cryptographic keys, including symmetric keys, asymmetric keys, and key pairs. The tool can also be used to generate other cryptographic material, such as digital signatures and message authentication codes.\n\nOne of the key features of the COUGER tool is its ability to generate keys and other cryptographic material in a controlled and auditable manner. This is achieved through the use of a key generation policy, which defines the rules and procedures for generating keys and other cryptographic material. The COUGER tool can be configured to enforce the key generation policy, ensuring that keys and other cryptographic material are generated in a secure and controlled manner.\n\nThe COUGER tool is also designed to be flexible and customizable, allowing users to tailor the tool to their specific needs. This includes the ability to define custom key generation policies and the ability to generate keys and other cryptographic material using a wide range of algorithms and protocols.\n\nOverall, the COUGER tool is a powerful and flexible tool for generating cryptographic keys and other cryptographic material in a secure and controlled manner. It is widely used in a variety of industries and applications, including government, finance, and healthcare.",
    "llama-7b_fact_raw": "1. The COUGER tool is developed by the National Institute of Standards and Technology (NIST).\n2. COUGER stands for \"Cryptographic Operations Using Generated Keys.\"\n3. The COUGER tool is capable of generating symmetric keys, asymmetric keys, and key pairs.\n4. The COUGER tool uses a key generation policy to enforce secure and audited generation of cryptographic material.\n5. The COUGER tool is configurable to meet specific user needs and supports various cryptographic algorithms and protocols.",
    "llama-7b_fact": [
      "The COUGER tool is developed by the National Institute of Standards and Technology (NIST).",
      "COUGER stands for \"Cryptographic Operations Using Generated Keys.\"",
      "The COUGER tool is capable of generating symmetric keys, asymmetric keys, and key pairs.",
      "The COUGER tool uses a key generation policy to enforce secure and audited generation of cryptographic material.",
      "The COUGER tool is configurable to meet specific user needs and supports various cryptographic algorithms and protocols."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information regarding the COUGER tool and its features, development background, acronym meaning, capabilities, policies, and configurability, it is not possible to determine the accuracy of these statements. If this tool exists and these statements accurately describe its functionalities and attributes, research from credible sources would be required to verify them.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 145,
    "user_query": "You MUST give a detailed answer to the following question: Are there drugs for Tick-borne Encephalitis?",
    "llama-7b_response": "Tick-borne encephalitis (TBE) is a viral infection that can affect the brain and nervous system. There are several drugs that may be used to treat TBE, depending on the specific type of TBE and the severity of the infection.\n\nThe most common type of TBE is caused by a virus called Borrelia burgdorferi, which is transmitted to humans through the bite of an infected tick. Treatment for this type of TBE typically involves antibiotics, such as doxycycline or penicillin, which can help reduce symptoms and prevent complications.\n\nAnother type of TBE is caused by a virus called Flavivirus, which is transmitted to humans through the bite of an infected tick. Treatment for this type of TBE typically involves antiviral medications, such as ribavirin or idoxuridine, which can help reduce symptoms and prevent complications.\n\nIn some cases, supportive care may be necessary to manage symptoms of TBE, such as fever, headache, and muscle aches. This may include medications such as acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs), which can help reduce pain and fever.\n\nIt is important for individuals who have been bitten by an infected tick to seek medical attention promptly, as early treatment can help reduce the risk of complications and improve outcomes.",
    "llama-7b_fact_raw": "1. Tick-borne encephalitis (TBE) is a viral infection that affects the brain and nervous system.\n2. Antibiotics such as doxycycline or penicillin are used to treat the TBE caused by the Borrelia burgdorferi virus.\n3. The Flavivirus causes another type of TBE, which can be treated with antiviral medications like ribavirin or idoxuridine.\n4. Supportive care for TBE may include medications like acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs) to manage symptoms.\n5. Seeking medical attention promptly after a tick bite can reduce the risk of complications and improve outcomes for TBE.",
    "llama-7b_fact": [
      "Tick-borne encephalitis (TBE) is a viral infection that affects the brain and nervous system.",
      "Antibiotics such as doxycycline or penicillin are used to treat the TBE caused by the Borrelia burgdorferi virus.",
      "The Flavivirus causes another type of TBE, which can be treated with antiviral medications like ribavirin or idoxuridine.",
      "Supportive care for TBE may include medications like acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs) to manage symptoms.",
      "Seeking medical attention promptly after a tick bite can reduce the risk of complications and improve outcomes for TBE."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Antibiotics like doxycycline or penicillin can be used to treat Lyme disease, which is also caused by the Borrelia burgdorferi bacteria, not TBE. TBE is caused by a virus and there are no specific antiviral treatments available for it.\n3. FALSE [correction]: There are no specific antiviral medications for the treatment of TBE caused by the Flavivirus. Management of the illness focuses on supportive care.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 151,
    "user_query": "You MUST give a detailed answer to the following question: Which genome browser database for DNA shape annotations is available?",
    "llama-7b_response": "There are several genome browser databases for DNA shape annotations that are available. Some of the most well-known and widely used genome browser databases for DNA shape annotations include:\n\n1. UCSC Genome Browser: The UCSC Genome Browser is a free, online genome browser that provides a wide range of features and tools for exploring and analyzing genomic data. The UCSC Genome Browser includes a DNA shape browser that allows users to visualize and annotate DNA shape features such as supercoils, kinks, and bends.\n2. Ensembl Genome Browser: The Ensembl Genome Browser is a genome browser that provides a range of features and tools for exploring and analyzing genomic data. The Ensembl Genome Browser includes a DNA shape browser that allows users to visualize and annotate DNA shape features such as supercoils, kinks, and bends.\n3. NCBI Genome Browser: The NCBI Genome Browser is a free, online genome browser that provides a wide range of features and tools for exploring and analyzing genomic data. The NCBI Genome Browser includes a DNA shape browser that allows users to visualize and annotate DNA shape features such as supercoils, kinks, and bends.\n4. Integrative Genomics Viewer (IGV): The Integrative Genomics Viewer (IGV) is a genome browser that provides a range of features and tools for exploring and analyzing genomic data. The IGV includes a DNA shape browser that allows users to visualize and annotate DNA shape features such as supercoils, kinks, and bends.\n\nThese are just a few examples of genome browser databases for DNA shape annotations that are available. There are many other genome browser databases that provide similar features and tools for exploring and analyzing genomic data.",
    "llama-7b_fact_raw": "1. The UCSC Genome Browser is an online genome browser that includes a DNA shape browser for visualization and annotation of DNA shape features.\n2. The Ensembl Genome Browser is another genome browser that provides a DNA shape browser for visualization and annotation of DNA shape features.\n3. The NCBI Genome Browser is a free online resource that includes a DNA shape browser for DNA shape features.\n4. The Integrative Genomics Viewer (IGV) offers features for visualizing and annotating DNA shape features.\n5. The DNA shape features that can be visualized and annotated in these browsers include supercoils, kinks, and bends.",
    "llama-7b_fact": [
      "The UCSC Genome Browser is an online genome browser that includes a DNA shape browser for visualization and annotation of DNA shape features.",
      "The Ensembl Genome Browser is another genome browser that provides a DNA shape browser for visualization and annotation of DNA shape features.",
      "The NCBI Genome Browser is a free online resource that includes a DNA shape browser for DNA shape features.",
      "The Integrative Genomics Viewer (IGV) offers features for visualizing and annotating DNA shape features.",
      "The DNA shape features that can be visualized and annotated in these browsers include supercoils, kinks, and bends."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The Ensembl Genome Browser is a genome browser for vertebrate genomes that provides access to genomic information, but it does not include a specific DNA shape browser for visualization and annotation of DNA shape features.\n3. FALSE [correction]: The NCBI Genome Browser provides various tools and databases for genomic research, but it does not include a specific DNA shape browser for DNA shape features.\n4. UNKNOWN: While the Integrative Genomics Viewer (IGV) is a popular tool for visualizing various genomic data, it is not clearly specified whether it includes features for visualizing and annotating DNA shape features specifically.\n5. FALSE [correction]: DNA shape features typically refer to minor and major groove widths, roll, tilt, slide, twist, rise, etc. Supercoils, kinks, and bends could possibly be inferred from DNA shape but are not direct features typically annotated in the context of DNA shape analysis.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 174,
    "user_query": "You MUST give a detailed answer to the following question: Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-7b_response": "EZH2, also known as enhancer of zeste homolog 2, is a histone methyltransferase that plays a crucial role in regulating gene expression. Mutations in the EZH2 gene have been associated with several syndromes, including:\n\n1. Wolf-Hirschhorn syndrome: Wolf-Hirschhorn syndrome is a congenital disorder characterized by growth delay, intellectual disability, and abnormal facial features. Mutations in the EZH2 gene have been found to be associated with this syndrome.\n2. DiGeorge syndrome: DiGeorge syndrome, also known as velocardiofacial syndrome, is a congenital disorder characterized by multiple defects, including cleft palate, heart defects, and immune system abnormalities. Mutations in the EZH2 gene have been found to be associated with this syndrome.\n3. Cornelia de Lange syndrome: Cornelia de Lange syndrome is a congenital disorder characterized by growth delay, intellectual disability, and abnormal facial features. Mutations in the EZH2 gene have been found to be associated with this syndrome.\n4. Microcephaly: Microcephaly is a congenital disorder characterized by abnormally small head size and intellectual disability. Mutations in the EZH2 gene have been found to be associated with this syndrome.\n5. Autism spectrum disorder: Autism spectrum disorder is a neurodevelopmental disorder characterized by social impairment, communication difficulties, and repetitive behaviors. Some studies have suggested that mutations in the EZH2 gene may be associated with autism spectrum disorder.",
    "llama-7b_fact_raw": "1. Mutations in the EZH2 gene are associated with Wolf-Hirschhorn syndrome.\n2. Individuals with DiGeorge syndrome may have mutations in the EZH2 gene.\n3. Cornelia de Lange syndrome can be associated with mutations in the EZH2 gene.\n4. Some cases of microcephaly are linked to mutations in the EZH2 gene.\n5. There are suggestions from studies that autism spectrum disorder may be linked to mutations in the EZH2 gene.",
    "llama-7b_fact": [
      "Mutations in the EZH2 gene are associated with Wolf-Hirschhorn syndrome.",
      "Individuals with DiGeorge syndrome may have mutations in the EZH2 gene.",
      "Cornelia de Lange syndrome can be associated with mutations in the EZH2 gene.",
      "Some cases of microcephaly are linked to mutations in the EZH2 gene.",
      "There are suggestions from studies that autism spectrum disorder may be linked to mutations in the EZH2 gene."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Mutations in the EZH2 gene are not associated with Wolf-Hirschhorn syndrome; this syndrome is typically caused by a deletion on the short arm of chromosome 4.\n2. UNKNOWN: While DiGeorge syndrome (22q11.2 deletion syndrome) is most commonly associated with deletions on chromosome 22, there is not a well-established link to mutations in the EZH2 gene specifically.\n3. TRUE: Mutations in the EZH2 gene are associated with Weaver syndrome, which shares some clinical features with Cornelia de Lange syndrome but is a distinct condition. It's possible for there to be some confusion between the two, but direct association of EZH2 with Cornelia de Lange syndrome is not well documented in the literature as of my last update.\n4. UNKNOWN: While microcephaly can be related to a variety of genetic changes, the direct association with mutations in the EZH2 gene is not conclusively established in the scientific literature as of my last update.\n5. UNKNOWN: There is ongoing research into genetic factors that may contribute to autism spectrum disorder, but establishing a direct and consistent link to mutations in the EZH2 gene would require more specific evidence from peer-reviewed studies.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 193,
    "user_query": "You MUST give a detailed answer to the following question: List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-7b_response": "There are several human proteins that are known to undergo a dimer-to-tetramer transition. Here are a few examples:\n\n1. Hemoglobin: Hemoglobin is a protein found in red blood cells that plays a key role in transporting oxygen throughout the body. It exists in a dimeric form (two subunits) in the bloodstream, but can undergo a transition to a tetrameric form (four subunits) when it binds to oxygen.\n2. Cytochrome C: Cytochrome C is a protein that plays a role in electron transport and is found in the mitochondria of cells. It exists in a dimeric form in the cytoplasm, but can undergo a transition to a tetrameric form when it is released from the mitochondria and interacts with other cytochrome C molecules.\n3. Ferritin: Ferritin is a protein that stores iron in cells. It exists in a dimeric form in the cytosol, but can undergo a transition to a tetrameric form when it binds to iron.\n\nThese are just a few examples of human proteins that undergo a dimer-to-tetramer transition. There are likely many others that have not yet been discovered or studied in detail.",
    "llama-7b_fact_raw": "1. Hemoglobin is a protein in red blood cells that can transition from a dimer to a tetramer upon binding oxygen.\n2. Cytochrome C can exist in a dimeric form and transition to a tetrameric form when released from mitochondria and interacts with other cytochrome C molecules.\n3. Ferritin exists in a dimeric form and can transition to a tetrameric form when it binds iron.",
    "llama-7b_fact": [
      "Hemoglobin is a protein in red blood cells that can transition from a dimer to a tetramer upon binding oxygen.",
      "Cytochrome C can exist in a dimeric form and transition to a tetrameric form when released from mitochondria and interacts with other cytochrome C molecules.",
      "Ferritin exists in a dimeric form and can transition to a tetrameric form when it binds iron."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Hemoglobin does not transition from a dimer to a tetramer upon binding oxygen. Hemoglobin is always a tetramer, consisting of two alpha and two beta subunits, and its oxygen-binding properties are due to conformational changes within this tetrameric structure.\n2. UNKNOWN: The statement about Cytochrome C is not completely clear as it is generally known as a monomeric protein. Cytochrome C's involvement in the apoptotic pathway when released from mitochondria is documented, but its dimerization or tetramerization under physiological conditions is not well-established in scientific literature.\n3. FALSE [correction]: Ferritin is not typically found in a dimeric form that transitions to a tetramer upon binding iron. Ferritin is a large protein that can store thousands of iron atoms in its hollow cavity and is composed of 24 subunits that come together to form a nanocage. It is typically found as this larger multimeric complex.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 210,
    "user_query": "You MUST give a detailed answer to the following question: Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-7b_response": "The protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein is Bcl-2.\n\nBcl-2 is a member of the Bcl-2 family of proteins, which play a crucial role in regulating programmed cell death (apoptosis). Phospholamban (PLN) is a cardiac muscle protein that is involved in the regulation of intracellular calcium levels and is also known to play a role in the regulation of apoptosis.\n\nSeveral studies have shown that Bcl-2 interacts with PLN and that this interaction plays a role in the regulation of apoptosis in cardiac muscle cells. For example, one study found that overexpression of Bcl-2 in cardiac muscle cells resulted in an increase in the levels of PLN and a decrease in the levels of apoptosis, while knockdown of Bcl-2 resulted in a decrease in the levels of PLN and an increase in the levels of apoptosis.\n\nThese findings suggest that the interaction between Bcl-2 and PLN plays an important role in the regulation of apoptosis in cardiac muscle cells and may have implications for the development of therapeutic strategies for the treatment of cardiac diseases.",
    "llama-7b_fact_raw": "1. Bcl-2 has been found to interact with phospholamban (PLN).\n2. Bcl-2 is an anti-apoptotic protein.\n3. Phospholamban (PLN) is involved in the regulation of intracellular calcium levels in cardiac muscle.\n4. Studies have shown that overexpression of Bcl-2 results in increased levels of PLN and decreased levels of apoptosis in cardiac muscle cells.\n5. Knockdown of Bcl-2 results in decreased levels of PLN and increased levels of apoptosis in cardiac muscle cells.",
    "llama-7b_fact": [
      "Bcl-2 has been found to interact with phospholamban (PLN).",
      "Bcl-2 is an anti-apoptotic protein.",
      "Phospholamban (PLN) is involved in the regulation of intracellular calcium levels in cardiac muscle.",
      "Studies have shown that overexpression of Bcl-2 results in increased levels of PLN and decreased levels of apoptosis in cardiac muscle cells.",
      "Knockdown of Bcl-2 results in decreased levels of PLN and increased levels of apoptosis in cardiac muscle cells."
    ],
    "llama-7b_judge_raw": "1. TRUE: Bcl-2 has been reported to interact with various proteins, and in scientific literature, there have been mentions of its interaction with phospholamban (PLN), especially in the context of cardiac function.\n2. TRUE: Bcl-2 is well-known as an anti-apoptotic protein that helps to prevent cell death in various contexts, including the regulation of apoptosis in cardiac muscle cells.\n3. TRUE: Phospholamban (PLN) is a regulatory protein that indeed plays a crucial role in the regulation of intracellular calcium levels in cardiac muscle, which affects muscle contraction and heart function.\n4. UNKNOWN: The specific effect of Bcl-2 overexpression on PLN levels and apoptosis in cardiac muscle cells would need to be confirmed by specific studies and literature. Without the specific study or experimental results to reference, this statement is difficult to definitively verify as true or false.\n5. UNKNOWN: Similar to the previous statement, the specific effect of Bcl-2 knockdown on PLN levels and apoptosis in cardiac muscle cells would need to be confirmed by specific studies and literature. Without the specific study or experimental results to reference, this statement is difficult to definitively verify as true or false.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 218,
    "user_query": "You MUST give a detailed answer to the following question: Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-7b_response": "Yes, vitamin D has been shown to reduce the incidence of falls in older people in clinical trials. In fact, several studies have found that vitamin D supplementation can reduce the risk of falls by up to 25%.\n\nOne such study was a randomized, double-blind, placebo-controlled trial published in the Journal of the American Geriatrics Society in 2012. The study involved 202 older adults with a history of falls who were randomly assigned to receive either a daily dose of 800 IU of vitamin D or a placebo. After 2 years, the researchers found that the participants who received vitamin D had a 25% lower risk of falling compared to those who received the placebo.\n\nAnother study, published in the American Journal of Clinical Nutrition in 2013, found that vitamin D supplementation can reduce the risk of falls in older adults by up to 19%. This study involved 2,000 older adults with a history of falls who were randomly assigned to receive either a daily dose of 800 IU of vitamin D or a placebo. After 1.5 years, the researchers found that the participants who received vitamin D had a 19% lower risk of falling compared to those who received the placebo.\n\nThese findings suggest that vitamin D supplementation may be an effective way to reduce the risk of falls in older adults, particularly those who are at high risk for falling. However, more research is needed to confirm these findings and to determine the optimal dose and duration of vitamin D supplementation for fall prevention.",
    "llama-7b_fact_raw": "1. Clinical trials have shown that vitamin D can reduce the incidence of falls in older people by up to 25%.\n2. A trial published in the Journal of the American Geriatrics Society in 2012 involved 202 older adults and used a daily dose of 800 IU of vitamin D.\n3. The 2012 study reported that after 2 years, there was a 25% lower risk of falling for participants who received vitamin D compared to those given a placebo.\n4. Research published in the American Journal of Clinical Nutrition in 2013 indicated that vitamin D supplementation could reduce fall risk by up to 19%.\n5. The 2013 study involved 2,000 older adults and showed that after 1.5 years, participants on vitamin D had a 19% lower risk of falls compared to placebo recipients.",
    "llama-7b_fact": [
      "Clinical trials have shown that vitamin D can reduce the incidence of falls in older people by up to 25%.",
      "A trial published in the Journal of the American Geriatrics Society in 2012 involved 202 older adults and used a daily dose of 800 IU of vitamin D.",
      "The 2012 study reported that after 2 years, there was a 25% lower risk of falling for participants who received vitamin D compared to those given a placebo.",
      "Research published in the American Journal of Clinical Nutrition in 2013 indicated that vitamin D supplementation could reduce fall risk by up to 19%.",
      "The 2013 study involved 2,000 older adults and showed that after 1.5 years, participants on vitamin D had a 19% lower risk of falls compared to placebo recipients."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The 2012 study did not report a 25% lower risk of falling after 2 years; it was reported that the risk of falling was reduced by 17% among those given supplemental vitamin D.\n4. FALSE [correction]: The research published in the American Journal of Clinical Nutrition in 2013 concluded that vitamin D supplementation reduced fall risk, but the percentage reduction was not specified, and it is not clear from the statement if 19% is the correct figure.\n5. FALSE [correction]: There is no specific information available about a 2013 study involving 2,000 older adults showing a 19% reduction in fall risk due to vitamin D over 1.5 years, as the details provided here may be speculative or incorrect without proper referencing.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 222,
    "user_query": "You MUST give a detailed answer to the following question: Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-7b_response": "Yes, there is an association between Jarid2 and miR-155 in Th17 cells.\n\nJarid2 is a protein that plays a role in regulating the expression of microRNAs, including miR-155. miR-155 is a microRNA that has been shown to play a role in the differentiation of Th17 cells, a type of immune cell that is involved in the immune response to certain types of infections.\n\nStudies have shown that the expression of Jarid2 and miR-155 is coordinately regulated in Th17 cells. For example, one study found that Jarid2 and miR-155 were both upregulated in Th17 cells compared to other types of immune cells. Additionally, another study found that the expression of Jarid2 and miR-155 was negatively correlated in Th17 cells, meaning that as the expression of one increased, the expression of the other decreased.\n\nThese findings suggest that Jarid2 and miR-155 may work together to regulate the differentiation of Th17 cells. For example, Jarid2 may play a role in the processing and export of miR-155 from the nucleus to the cytoplasm, where it can be used to regulate the expression of target genes. Alternatively, miR-155 may regulate the expression of Jarid2 or other genes that are involved in the regulation of microRNAs.\n\nOverall, the association between Jarid2 and miR-155 in Th17 cells suggests that these two molecules may work together to regulate the differentiation and function of this important type of immune cell.",
    "llama-7b_fact_raw": "1. Jarid2 is a protein that regulates the expression of microRNAs, including miR-155.\n2. miR-155 plays a role in the differentiation of Th17 cells.\n3. The expression of Jarid2 and miR-155 is coordinately regulated in Th17 cells.\n4. One study indicated that Jarid2 and miR-155 were both upregulated in Th17 cells compared to other types of immune cells.\n5. Another study found a negative correlation between the expression of Jarid2 and miR-155 in Th17 cells.",
    "llama-7b_fact": [
      "Jarid2 is a protein that regulates the expression of microRNAs, including miR-155.",
      "miR-155 plays a role in the differentiation of Th17 cells.",
      "The expression of Jarid2 and miR-155 is coordinately regulated in Th17 cells.",
      "One study indicated that Jarid2 and miR-155 were both upregulated in Th17 cells compared to other types of immune cells.",
      "Another study found a negative correlation between the expression of Jarid2 and miR-155 in Th17 cells."
    ],
    "llama-7b_judge_raw": "1. TRUE: Jarid2 is known to be involved in the regulation of various biological processes, including the expression of microRNAs, though it is more often recognized for its role in the regulation of gene expression by modulating the structure of chromatin.\n2. TRUE: miR-155 is indeed known to play a significant role in the differentiation and function of various immune cells, including Th17 cells.\n3. UNKNOWN: Without specific data or references from the passage that discusses the coordinate regulation of Jarid2 and miR-155 in Th17 cells, we cannot determine the veracity of this statement.\n4. UNKNOWN: Again, the statement's accuracy depends on specific findings from a study which are not provided here. We would need more context or data from the study to evaluate this.\n5. UNKNOWN: This statement also cannot be verified without additional context or data from the study it references. There might be studies exploring the relationship between the expression of Jarid2 and miR-155, but without specific information, the truth of this statement remains uncertain.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 224,
    "user_query": "You MUST give a detailed answer to the following question: How many genes does the human hoxD cluster contain?",
    "llama-7b_response": "The human HOXD cluster contains 5 genes: HOXD1, HOXD2, HOXD3, HOXD4, and HOXD5.",
    "llama-7b_fact_raw": "1. The human HOXD cluster contains a total of 5 genes.\n2. The genes within the human HOXD cluster are named HOXD1, HOXD2, HOXD3, HOXD4, and HOXD5.",
    "llama-7b_fact": [
      "The human HOXD cluster contains a total of 5 genes.",
      "The genes within the human HOXD cluster are named HOXD1, HOXD2, HOXD3, HOXD4, and HOXD5."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The human HOXD cluster contains a total of 9 genes.\n2. FALSE [correction]: The genes within the human HOXD cluster are named from HOXD1 to HOXD13, skipping some numbers (HOXD1, HOXD3, HOXD4, HOXD8, HOXD9, HOXD10, HOXD11, HOXD12, and HOXD13). There is no gene named HOXD2 or HOXD5 in the HOXD cluster.",
    "llama-7b_judge": [
      "false",
      "false"
    ]
  },
  {
    "id": 268,
    "user_query": "You MUST give a detailed answer to the following question: List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-7b_response": "Casein Kinase 1 (CK1) is a serine/threonine protein kinase that plays a crucial role in various cellular processes, including cell division, differentiation, and apoptosis. CK1 can phosphorylate a wide range of substrates, including proteins, lipids, and nucleic acids. Here are some of the most common phosphorylation consensus motifs for CK1:\n\n1. S/T-X-X-X-S/T (where X is any amino acid): This is a general consensus motif for serine/threonine kinases, including CK1. It indicates the position of the phosphorylated serine/threonine residue.\n2. S/T-X-X-X-S/T-X-X-X-S/T: This is a more specific consensus motif for CK1, which indicates the position of two phosphorylated serine/threonine residues.\n3. S/T-X-X-X-S/T-X-X-X-S/T-X-X-X-S/T: This is an even more specific consensus motif for CK1, which indicates the position of three phosphorylated serine/threonine residues.\n4. S/T-X-X-X-S/T-X-X-X-S/T-X-X-X-S/T-X-X-X-S/T: This is the most specific consensus motif for CK1, which indicates the position of four phosphorylated serine/threonine residues.\n\nIt's worth noting that these consensus motifs are not absolute and can vary depending on the context and specificity of the kinase. However, they provide a general framework for identifying potential phosphorylation sites by CK1.",
    "llama-7b_fact_raw": "1. Casein Kinase 1 (CK1) is a serine/threonine protein kinase involved in cell division, differentiation, and apoptosis.\n2. CK1 kinase can phosphorylate a range of substrates, which include proteins, lipids, and nucleic acids.\n3. One common phosphorylation consensus motif for CK1 is S/T-X-X-X-S/T, where X represents any amino acid.\n4. A more specific phosphorylation consensus motif for CK1 is S/T-X-X-X-S/T-X-X-X-S/T, indicating positions for two phosphorylated residues.\n5. The most specific phosphorylation consensus motif mentioned for CK1 is S/T-X-X-X-S/T-X-X-X-S/T-X-X-X-S/T-X-X-X-S/T, indicating positions for four phosphorylated residues.",
    "llama-7b_fact": [
      "Casein Kinase 1 (CK1) is a serine/threonine protein kinase involved in cell division, differentiation, and apoptosis.",
      "CK1 kinase can phosphorylate a range of substrates, which include proteins, lipids, and nucleic acids.",
      "One common phosphorylation consensus motif for CK1 is S/T-X-X-X-S/T, where X represents any amino acid.",
      "A more specific phosphorylation consensus motif for CK1 is S/T-X-X-X-S/T-X-X-X-S/T, indicating positions for two phosphorylated residues.",
      "The most specific phosphorylation consensus motif mentioned for CK1 is S/T-X-X-X-S/T-X-X-X-S/T-X-X-X-S/T-X-X-X-S/T, indicating positions for four phosphorylated residues."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: CK1 kinase primarily phosphorylates serine/threonine residues on proteins, not lipids or nucleic acids.\n3. TRUE\n4. FALSE [correction]: A more specific phosphorylation consensus motif for CK1 is not commonly described as S/T-X-X-X-S/T-X-X-X-S/T. The basic consensus motif is usually sufficient for describing CK1 recognition sites.\n5. FALSE [correction]: The motif S/T-X-X-X-S/T-X-X-X-S/T-X-X-X-S/T-X-X-X-S/T is not a standard recognition motif for CK1, and there is no evidence suggesting CK1 requires such a long and specific sequence to phosphorylate four residues. The basic motif S/T-X-X-X-S/T is commonly used to describe CK1 target sites.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 305,
    "user_query": "You MUST give a detailed answer to the following question: Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-7b_response": "The ASPH (aspartate beta-hydroxylase) gene encodes for the enzyme aspartate beta-hydroxylase, which is involved in the metabolism of aspartate and other amino acids. The gene is located on chromosome 11q23.3 and consists of six exons.\n\nThere are several different proteins and isoforms that can be encoded by the ASPH gene in humans. These include:\n\n1. Aspartate beta-hydroxylase: This is the primary form of the enzyme that is produced from the ASPH gene. It is a cytosolic enzyme that catalyzes the conversion of aspartate to beta-alanine and carbon dioxide.\n2. Aspartate beta-hydroxylase (N-terminal processed): This isoform of the enzyme is produced by a process of N-terminal processing, in which the amino-terminal end of the protein is cleaved off. This results in a shorter, more active form of the enzyme that is localized to the mitochondria.\n3. Aspartate beta-hydroxylase (C-terminal processed): This isoform of the enzyme is produced by a process of C-terminal processing, in which the carboxy-terminal end of the protein is cleaved off. This results in a longer, less active form of the enzyme that is localized to the cytosol.\n4. Aspartate beta-hydroxylase (N-terminal deleted): This isoform of the enzyme is produced by a deletion in the N-terminal end of the protein. This results in a shorter, less active form of the enzyme that is localized to the cytosol.\n5. Aspartate beta-hydroxylase (C-terminal deleted): This isoform of the enzyme is produced by a deletion in the C-terminal end of the protein. This results in a longer, less active form of the enzyme that is localized to the cytosol.\n\nOverall, the ASPH gene encodes for several different proteins and isoforms that play important roles in the metabolism of aspart",
    "llama-7b_fact_raw": "1. The ASPH gene encodes for the enzyme aspartate beta-hydroxylase.\n2. The aspartate beta-hydroxylase enzyme is involved in the metabolism of aspartate and other amino acids.\n3. The ASPH gene is located on chromosome 11q23.3 and consists of six exons.\n4. There is an isoform of aspartate beta-hydroxylase that is produced by N-terminal processing and is more active in the mitochondria.\n5. There is an isoform of aspartate beta-hydroxylase that is produced by C-terminal processing and is less active in the cytosol.",
    "llama-7b_fact": [
      "The ASPH gene encodes for the enzyme aspartate beta-hydroxylase.",
      "The aspartate beta-hydroxylase enzyme is involved in the metabolism of aspartate and other amino acids.",
      "The ASPH gene is located on chromosome 11q23.3 and consists of six exons.",
      "There is an isoform of aspartate beta-hydroxylase that is produced by N-terminal processing and is more active in the mitochondria.",
      "There is an isoform of aspartate beta-hydroxylase that is produced by C-terminal processing and is less active in the cytosol."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The aspartate beta-hydroxylase enzyme is involved in the post-translational modification of proteins, not primarily in the metabolism of aspartate or other amino acids.\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe corrections and assessments provided here are based on standard knowledge about the ASPH gene and its encoded enzyme. It is important to note that new research may provide further insights, and the status of the unknowns might require specific scientific literature to confirm.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 330,
    "user_query": "You MUST give a detailed answer to the following question: When was empagliflozin FDA approved?",
    "llama-7b_response": "Empagliflozin, also known by the brand name Jardiance, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes in 2014. The FDA granted approval for empagliflozin to be used in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes.",
    "llama-7b_fact_raw": "1. Empagliflozin was approved by the U.S. Food and Drug Administration (FDA) in 2014.\n2. The brand name for empagliflozin is Jardiance.\n3. Empagliflozin is approved for the treatment of type 2 diabetes.\n4. The FDA approved empagliflozin to be used in combination with diet and exercise.\n5. The purpose of empagliflozin's approval is to improve glycemic control in adults with type 2 diabetes.",
    "llama-7b_fact": [
      "Empagliflozin was approved by the U.S. Food and Drug Administration (FDA) in 2014.",
      "The brand name for empagliflozin is Jardiance.",
      "Empagliflozin is approved for the treatment of type 2 diabetes.",
      "The FDA approved empagliflozin to be used in combination with diet and exercise.",
      "The purpose of empagliflozin's approval is to improve glycemic control in adults with type 2 diabetes."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "You MUST give a detailed answer to the following question: What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-7b_response": "Loss of the protein Lon1 in the plant Arabidopsis has been shown to result in several phenotypes, including:\n\n1. Increased sensitivity to stress: Lon1 plays a role in protecting cells from stress, such as oxidative stress and heat stress. In the absence of Lon1, plants may be more susceptible to these stresses, leading to reduced growth and survival.\n2. Altered protein homeostasis: Lon1 is involved in the degradation of misfolded and damaged proteins, so its absence may lead to an accumulation of misfolded proteins, which can cause cellular stress and damage.\n3. Changes in gene expression: Loss of Lon1 has been shown to alter the expression of genes involved in stress response, cell wall biosynthesis, and other cellular processes.\n4. Impaired growth and development: Loss of Lon1 has been shown to affect plant growth and development, leading to reduced plant size and delayed flowering.\n\nOverall, the loss of Lon1 in Arabidopsis results in a complex set of phenotypes that likely involve changes in protein homeostasis, stress response, and cellular processes. Further research is needed to fully understand the impact of Lon1 loss on plant growth and development.",
    "llama-7b_fact_raw": "1. Loss of the Lon1 protein in Arabidopsis can increase the plant's sensitivity to stress, such as oxidative and heat stress.\n2. In Arabidopsis, the absence of Lon1 may lead to an accumulation of misfolded or damaged proteins.\n3. The loss of Lon1 protein can alter the expression of genes related to stress response and cell wall biosynthesis.\n4. Arabidopsis plants lacking the Lon1 protein may experience impaired growth and development.\n5. The absence of Lon1 in Arabidopsis is associated with reduced plant size and delayed flowering.",
    "llama-7b_fact": [
      "Loss of the Lon1 protein in Arabidopsis can increase the plant's sensitivity to stress, such as oxidative and heat stress.",
      "In Arabidopsis, the absence of Lon1 may lead to an accumulation of misfolded or damaged proteins.",
      "The loss of Lon1 protein can alter the expression of genes related to stress response and cell wall biosynthesis.",
      "Arabidopsis plants lacking the Lon1 protein may experience impaired growth and development.",
      "The absence of Lon1 in Arabidopsis is associated with reduced plant size and delayed flowering."
    ],
    "llama-7b_judge_raw": "1. TRUE: Loss of the Lon1 protein has been shown in various studies to increase sensitivity to stress in plants, including oxidative and heat stress in Arabidopsis.\n2. TRUE: In Arabidopsis, loss of Lon1 function can lead to the accumulation of misfolded or damaged proteins because Lon1 is involved in protein quality control and degradation.\n3. TRUE: The loss of Lon1 protein can affect the expression of various genes including those involved in stress responses and potentially cell wall biosynthesis.\n4. TRUE: Impaired growth and development are common phenotypes associated with disruptions in proteostasis, which can be a consequence of the loss of function of proteins such as Lon1, involved in protein maintenance.\n5. TRUE: These are plausible phenotypes due to the loss of Lon1, given that protein homeostasis is critical for proper plant development, and disruptions in these processes can lead to reduced plant size and altered flowering times.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 409,
    "user_query": "You MUST give a detailed answer to the following question: Does a linker histone exist in the yeast genome?",
    "llama-7b_response": "Yes, a linker histone exists in the yeast genome.\n\nLinker histones are a type of histone protein that plays a crucial role in the organization and regulation of chromatin, the complex of DNA, histone proteins, and other proteins that make up chromosomes. In eukaryotes, including yeast, linker histones are involved in the formation of higher-order chromatin structures, such as nucleosomes and chromatin fibers, and play a role in regulating the accessibility of DNA to transcription factors and other proteins.\n\nThe yeast genome contains several genes that encode different types of histone proteins, including linker histones. For example, the Saccharomyces cerevisiae genome contains four genes that encode different types of linker histones: Htz1, Htz2, Htz3, and Htz4. These genes are located on different chromosomes and are expressed at different levels and patterns, reflecting their distinct functions in chromatin organization and regulation.\n\nOverall, the presence of linker histone genes in the yeast genome demonstrates that linker histones play an important role in the organization and regulation of chromatin in this organism, and highlights the importance of these proteins in the regulation of gene expression and other cellular processes.",
    "llama-7b_fact_raw": "1. Linker histones exist in the yeast genome.\n2. Histone proteins are involved in the organization and regulation of chromatin.\n3. Eukaryotes, including yeast, contain linker histones that contribute to the formation of higher-order chromatin structures.\n4. The Saccharomyces cerevisiae genome has four genes that encode different types of linker histones: Htz1, Htz2, Htz3, and Htz4.\n5. Linker histone genes in the yeast genome have distinct functions and expression patterns in chromatin organization and regulation.",
    "llama-7b_fact": [
      "Linker histones exist in the yeast genome.",
      "Histone proteins are involved in the organization and regulation of chromatin.",
      "Eukaryotes, including yeast, contain linker histones that contribute to the formation of higher-order chromatin structures.",
      "The Saccharomyces cerevisiae genome has four genes that encode different types of linker histones: Htz1, Htz2, Htz3, and Htz4.",
      "Linker histone genes in the yeast genome have distinct functions and expression patterns in chromatin organization and regulation."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Linker histones such as H1 are generally absent in the yeast Saccharomyces cerevisiae genome. Instead, S. cerevisiae has a histone variant called Htz1 (also known as H2A.Z), which is not a linker histone but a variant of the core histone H2A.\n2. TRUE\n3. FALSE [correction]: Eukaryotes, including many yeasts, contain linker histones, but the specific yeast species Saccharomyces cerevisiae does not have the typical linker histones that contribute to higher-order chromatin structures. Instead, it has the H2A.Z variant that plays a different role in chromatin organization.\n4. FALSE [correction]: The Saccharomyces cerevisiae genome does not have four genes that encode different types of linker histones. It has a gene for the histone variant Htz1 (H2A.Z), but this is not a linker histone.\n5. UNKNOWN\n\nIt is known that histone genes, including variants, have distinct functions and expression patterns in chromatin organization and regulation. However, regarding the specific functions and expression patterns of the aforementioned Htz1, Htz2, Htz3, and Htz4 in the Saccharomyces cerevisiae genome, which are incorrectly labeled as linker histones, the statement is vague without specific details about these genes, especially given that some of the names provided do not correspond to known histones in S. cerevisiae. Therefore, we cannot stand by the truth or falsity of the statement.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 418,
    "user_query": "You MUST give a detailed answer to the following question: Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-7b_response": "Yes, there is evidence that tomato juice lowers cholesterol levels.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 472,
    "user_query": "You MUST give a detailed answer to the following question: How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-7b_response": "Hsp70 and Hsp110 are heat shock proteins (HSPs) that play important roles in the regulation of mRNA stability.\n\nHsp70 is a molecular chaperone that helps to fold and stabilize proteins. It also plays a role in the regulation of mRNA stability by binding to and stabilizing mRNAs. Hsp70 can help to prevent the degradation of mRNAs by inhibiting the activity of ribonuclease (RNase) enzymes, which break down RNA.\n\nHsp110 is another HSP that also plays a role in the regulation of mRNA stability. Like Hsp70, Hsp110 can help to stabilize mRNAs by binding to them and preventing their degradation by RNase enzymes. Hsp110 can also help to recruit other proteins that are involved in the translation of mRNAs into proteins.\n\nIn summary, Hsp70 and Hsp110 can help to stabilize mRNAs by preventing their degradation by RNase enzymes and by recruiting other proteins that are involved in the translation of mRNAs into proteins.",
    "llama-7b_fact_raw": "1. Hsp70 and Hsp110 are types of heat shock proteins (HSPs) that influence mRNA stability.\n2. Hsp70 functions as a molecular chaperone, helping to fold and stabilize proteins.\n3. Hsp70 can prevent the degradation of mRNAs by inhibiting ribonuclease (RNase) enzyme activity.\n4. Hsp110 binds to mRNAs to help stabilize them and prevent degradation by RNase enzymes.\n5. Hsp110 can recruit other proteins involved in translating mRNAs into proteins.",
    "llama-7b_fact": [
      "Hsp70 and Hsp110 are types of heat shock proteins (HSPs) that influence mRNA stability.",
      "Hsp70 functions as a molecular chaperone, helping to fold and stabilize proteins.",
      "Hsp70 can prevent the degradation of mRNAs by inhibiting ribonuclease (RNase) enzyme activity.",
      "Hsp110 binds to mRNAs to help stabilize them and prevent degradation by RNase enzymes.",
      "Hsp110 can recruit other proteins involved in translating mRNAs into proteins."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: While Hsp70 and Hsp110 are indeed types of heat shock proteins, without specific context, it is unclear whether they are known to influence mRNA stability as this is not their primary documented function.\n2. TRUE: Hsp70 is well known to function as a molecular chaperone, helping to fold and stabilize proteins.\n3. FALSE [correction]: Hsp70 does not prevent the degradation of mRNAs by inhibiting ribonuclease enzyme activity. Instead, it assists in the folding and repair of other proteins and can refold partially denatured proteins, but its role in mRNA stability is not through the inhibition of RNase enzymes.\n4. FALSE [correction]: While Hsp110 does play a role in preventing protein aggregation and assists Hsp70, it is not directly known for binding to mRNAs to stabilize them against RNase enzymes. This function is more commonly associated with proteins specifically involved in mRNA processing and stability, such as poly(A)-binding proteins (PABPs) or mRNA-binding proteins.\n5. UNKNOWN: Without specific context or additional information, it is difficult to ascertain the accuracy of this statement regarding Hsp110's capability to recruit other proteins involved in translation. Hsp110's primary role is related to protein folding and stabilization alongside Hsp70.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 481,
    "user_query": "You MUST give a detailed answer to the following question: Which deiodinases are present in skeletal  muscle?",
    "llama-7b_response": "Deiodinases are enzymes that play a crucial role in regulating the activity of the thyroid hormones, triiodothyronine (T3) and thyroxine (T4). In skeletal muscle, three types of deiodinases have been identified: type 1 (D1), type 2 (D2), and type 3 (D3).\n\nType 1 deiodinase (D1) is also known as the thyroid hormone sulfotransferase and is responsible for converting T4 to the active form of T3, triiodothyronine (T3). D1 is primarily localized in the endoplasmic reticulum (ER) of skeletal muscle cells and plays a crucial role in regulating the activity of the thyroid hormones.\n\nType 2 deiodinase (D2) is also known as the type 2 iodothyronine deiodinase and is responsible for converting T4 to the inactive form of T3, reverse triiodothyronine (rT3). D2 is primarily localized in the cytosol of skeletal muscle cells and plays a crucial role in regulating the activity of the thyroid hormones.\n\nType 3 deiodinase (D3) is also known as the type 3 iodothyronine deiodinase and is responsible for converting T4 to the active form of T3, triiodothyronine (T3). D3 is primarily localized in the mitochondria of skeletal muscle cells and plays a crucial role in regulating the activity of the thyroid hormones.\n\nIn summary, the three types of deiodinases (D1, D2, and D3) are present in skeletal muscle and play a crucial role in regulating the activity of the thyroid hormones. D1 is primarily localized in the endoplasmic reticulum (ER) of skeletal muscle cells and is responsible for converting T4 to the active form of T3, triiodothyronine (T3). D2 is primarily localized in the cytosol of skeletal muscle cells and is responsible for converting T4 to the inactive form of T3, reverse triiodothyronine (",
    "llama-7b_fact_raw": "1. Three types of deiodinases are present in skeletal muscle: type 1 (D1), type 2 (D2), and type 3 (D3).\n2. Type 1 deiodinase (D1) is responsible for converting thyroxine (T4) to the active form of triiodothyronine (T3).\n3. Type 2 deiodinase (D2) is responsible for converting thyroxine (T4) to the inactive form of T3, reverse triiodothyronine (rT3).\n4. Type 3 deiodinase (D3) is responsible for converting thyroxine (T4) to the active form of triiodothyronine (T3), which seems to contradict the information about D1, and this warrants a verification of the specific functions of D1 and D3.\n5. Type 1 deiodinase (D1) is primarily localized in the endoplasmic reticulum of skeletal muscle cells.",
    "llama-7b_fact": [
      "Three types of deiodinases are present in skeletal muscle: type 1 (D1), type 2 (D2), and type 3 (D3).",
      "Type 1 deiodinase (D1) is responsible for converting thyroxine (T4) to the active form of triiodothyronine (T3).",
      "Type 2 deiodinase (D2) is responsible for converting thyroxine (T4) to the inactive form of T3, reverse triiodothyronine (rT3).",
      "Type 3 deiodinase (D3) is responsible for converting thyroxine (T4) to the active form of triiodothyronine (T3), which seems to contradict the information about D1, and this warrants a verification of the specific functions of D1 and D3.",
      "Type 1 deiodinase (D1) is primarily localized in the endoplasmic reticulum of skeletal muscle cells."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Type 2 deiodinase (D2) is responsible for converting thyroxine (T4) to the active form of triiodothyronine (T3), not the inactive form. It is Type 3 deiodinase (D3) that converts T4 to reverse triiodothyronine (rT3), the inactive form.\n4. FALSE [correction]: Type 3 deiodinase (D3) is responsible for the inactivation of thyroid hormones, including the conversion of thyroxine (T4) to reverse triiodothyronine (rT3), not to the active form of T3. This information corrects the contradiction indicated in the statement.\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 534,
    "user_query": "You MUST give a detailed answer to the following question: List inflammatory caspase proteins?",
    "llama-7b_response": "There are several inflammatory caspase proteins, including:\n\n1. Caspase-1: also known as the interleukin-1 beta converting enzyme (ICE), caspase-1 is involved in the processing and activation of the pro-inflammatory cytokine interleukin-1 beta (IL-1).\n2. Caspase-4: also known as the apoptosis-inducing factor (AIF), caspase-4 is involved in the execution phase of programmed cell death (apoptosis).\n3. Caspase-5: also known as the Fas-associated death domain protein (FADD), caspase-5 is involved in the activation of the pro-apoptotic protein Fas (CD95).\n4. Caspase-6: also known as the Apaf-1 protein, caspase-6 is involved in the activation of the pro-apoptotic protein apoptosis-inducing factor (AIF).\n5. Caspase-8: also known as the Fas-associated death domain protein (FADD), caspase-8 is involved in the activation of the pro-apoptotic protein Fas (CD95).\n6. Caspase-9: also known as the Apaf-1 protein, caspase-9 is involved in the activation of the pro-apoptotic protein apoptosis-inducing factor (AIF).\n7. Caspase-11: also known as the interleukin-1 beta converting enzyme (ICE), caspase-11 is involved in the processing and activation of the pro-inflammatory cytokine interleukin-1 beta (IL-1).\n8. Caspase-12: also known as the interleukin-1 beta converting enzyme (ICE), caspase-12 is involved in the processing and activation of the pro-inflammatory cytokine interleukin-1 beta (IL-1).\n9. Caspase-13: also known as the Apaf-1 protein, caspase-13 is involved in the activation of the pro-apoptotic protein apoptosis-inducing factor (AIF).\n10. Caspase",
    "llama-7b_fact_raw": "1. Caspase-1 is also known as the interleukin-1 beta converting enzyme (ICE).\n2. Caspase-1 is involved in the processing and activation of interleukin-1 beta (IL-1), a pro-inflammatory cytokine.\n3. Caspase-4 is involved in the execution phase of programmed cell death, also known as apoptosis.\n4. Caspase-5 is involved in the activation of the pro-apoptotic protein Fas (CD95).\n5. Caspase-11 is involved in the processing and activation of the pro-inflammatory cytokine interleukin-1 beta (IL-1).\n\nNote: The response contains several inaccuracies regarding the classification and function of caspase proteins. For example, caspase-4 and caspase-5 are not known as AIF and FADD respectively. Moreover, caspase-11 is related to inflammatory responses, not to IL-1 processing in humans. Therefore, it's important to verify the given functions and associations with the correct caspase proteins from reliable scientific sources.",
    "llama-7b_fact": [
      "Caspase-1 is also known as the interleukin-1 beta converting enzyme (ICE).",
      "Caspase-1 is involved in the processing and activation of interleukin-1 beta (IL-1), a pro-inflammatory cytokine.",
      "Caspase-4 is involved in the execution phase of programmed cell death, also known as apoptosis.",
      "Caspase-5 is involved in the activation of the pro-apoptotic protein Fas (CD95).",
      "Caspase-11 is involved in the processing and activation of the pro-inflammatory cytokine interleukin-1 beta (IL-1).",
      "te: The response contains several inaccuracies regarding the classification and function of caspase proteins. For example, caspase-4 and caspase-5 are not known as AIF and FADD respectively. Moreover, caspase-11 is related to inflammatory responses, not to IL-1 processing in humans. Therefore, it's important to verify the given functions and associations with the correct caspase proteins from reliable scientific sources."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Caspase-4, along with caspases -5 and -11, is involved in the inflammatory response, specifically in the non-canonical inflammasome pathway, and is not primarily associated with the execution phase of apoptosis.\n4. FALSE [correction]: It is caspase-8, not caspase-5, that is involved in the activation of the pro-apoptotic protein Fas (CD95).\n5. FALSE [correction]: Caspase-11 is indeed involved in the inflammatory response, but in humans, the functional homolog of caspase-11 is caspase-4, which is involved in the non-canonical inflammasome pathway leading to the release of pro-inflammatory cytokines such as IL-18, rather than the direct processing and activation of IL-1.\n6. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 579,
    "user_query": "You MUST give a detailed answer to the following question: Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-7b_response": "Yes, there is a link between the Aurora B kinase and the Polycomb protein Ring1B.\n\nAurora B is a serine/threonine kinase that plays a crucial role in the regulation of mitosis, the process of cell division. It is involved in the formation of spindle poles, the structures that guide the separation of chromosomes during cell division. Ring1B is a member of the Polycomb family of proteins, which are involved in the regulation of gene expression.\n\nStudies have shown that Aurora B and Ring1B interact with each other and that this interaction is important for the regulation of gene expression during mitosis. Specifically, Aurora B phosphorylates Ring1B, which leads to the degradation of Ring1B and the repression of target genes. Conversely, the degradation of Ring1B by the proteasome also leads to the activation of Aurora B kinase activity.\n\nTherefore, the interaction between Aurora B and Ring1B plays a crucial role in the regulation of gene expression during mitosis and is an important mechanism for the control of cell division.",
    "llama-7b_fact_raw": "1. Aurora B kinase is a serine/threonine kinase that is involved in the regulation of mitosis.\n2. Ring1B is a protein belonging to the Polycomb family that participates in gene expression regulation.\n3. Aurora B kinase and Ring1B interact with each other.\n4. Aurora B kinase phosphorylates Ring1B, leading to Ring1B's degradation.\n5. The degradation of Ring1B is associated with the activation of Aurora B kinase activity.",
    "llama-7b_fact": [
      "Aurora B kinase is a serine/threonine kinase that is involved in the regulation of mitosis.",
      "Ring1B is a protein belonging to the Polycomb family that participates in gene expression regulation.",
      "Aurora B kinase and Ring1B interact with each other.",
      "Aurora B kinase phosphorylates Ring1B, leading to Ring1B's degradation.",
      "The degradation of Ring1B is associated with the activation of Aurora B kinase activity."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN (without specific scientific articles or research supporting this statement, its not possible to confirm the interaction between Aurora B kinase and Ring1B)\n4. UNKNOWN (the exact consequence of Aurora B kinase phosphorylating Ring1B, whether it leads to Ring1Bs degradation or some other process, cannot be determined without specific scientific evidence)\n5. UNKNOWN (similarly, the association between Ring1B degradation and the activation of Aurora B kinase activity would require clarification from specific scientific research)",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 597,
    "user_query": "You MUST give a detailed answer to the following question: What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-7b_response": "The most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates include the following:\n\n* At the donor splice site, the most frequent motif is the \"GT-AG\" dinucleotide, which is required for the binding of the U1 small nuclear ribonucleoprotein (snRNP) complex.\n* At the acceptor splice site, the most frequent motif is the \"AG-GT\" dinucleotide, which is required for the binding of the U2 small nuclear ribonucleoprotein (snRNP) complex.\n* Other non-canonical sequence motifs that have been observed at the donor and acceptor splice sites in vertebrates include the \"AT-AC\" motif at the donor splice site and the \"GT-AG\" motif at the acceptor splice site.\n\nIt is worth noting that the specific non-canonical sequence motifs that are present at the donor and acceptor splice sites can vary between different species, and can even vary between different tissues within the same individual.",
    "llama-7b_fact_raw": "1. The \"GT-AG\" dinucleotide is the most frequent non-canonical sequence motif at the donor splice site in vertebrates.\n2. The U1 small nuclear ribonucleoprotein (snRNP) complex requires the \"GT-AG\" dinucleotide motif for binding at the donor splice site.\n3. The \"AG-GT\" dinucleotide is the most frequent non-canonical sequence motif at the acceptor splice site in vertebrates.\n4. The U2 small nuclear ribonucleoprotein (snRNP) complex requires the \"AG-GT\" dinucleotide motif for binding at the acceptor splice site.\n5. The \"AT-AC\" motif has been observed at the donor splice site in vertebrates.",
    "llama-7b_fact": [
      "The \"GT-AG\" dinucleotide is the most frequent non-canonical sequence motif at the donor splice site in vertebrates.",
      "The U1 small nuclear ribonucleoprotein (snRNP) complex requires the \"GT-AG\" dinucleotide motif for binding at the donor splice site.",
      "The \"AG-GT\" dinucleotide is the most frequent non-canonical sequence motif at the acceptor splice site in vertebrates.",
      "The U2 small nuclear ribonucleoprotein (snRNP) complex requires the \"AG-GT\" dinucleotide motif for binding at the acceptor splice site.",
      "The \"AT-AC\" motif has been observed at the donor splice site in vertebrates."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The \"GT-AG\" dinucleotide is the most frequent canonical sequence motif, not non-canonical, at the donor splice site in vertebrates.\n2. TRUE\n3. FALSE [correction]: The \"AG-GT\" sequence is not a recognized non-canonical sequence motif at the acceptor splice site in vertebrates. The canonical motif is \"AG\" at the 3' end of the intron, just before the exon starts.\n4. FALSE [correction]: The U2 small nuclear ribonucleoprotein (snRNP) complex recognizes the canonical \"AG\" dinucleotide at the 3' end (the acceptor site) of the intron, not an \"AG-GT\" dinucleotide motif.\n5. TRUE: The \"AT-AC\" motif is indeed a non-canonical splice site sequence that has been observed in minor-class introns of vertebrates.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 629,
    "user_query": "You MUST give a detailed answer to the following question: Which event results in the acetylation of S6K1?",
    "llama-7b_response": "The event that results in the acetylation of S6K1 is the binding of an acetyl-coenzyme A (acetyl-CoA) molecule to the lysine residue on the amino-terminal domain of S6K1.\n\nS6K1 is a serine/threonine kinase that plays a key role in regulating cell growth and metabolism. It is activated in response to various stimuli, including growth factors, insulin, and energy stress, and it phosphorylates and activates a number of downstream targets, including 4E-BP1 and eukaryotic initiation factor 4E (eIF4E), to regulate protein synthesis.\n\nAcetylation is a post-translational modification that alters the activity of a protein by changing its conformation or interactions with other proteins. In the case of S6K1, acetylation leads to the inhibition of its kinase activity and the promotion of its protein-binding partners, such as 4E-BP1 and eIF4E.\n\nThe acetylation of S6K1 is catalyzed by histone acetyltransferases (HATs), which add an acetyl group to the lysine residue on the target protein. In the case of S6K1, the HAT that acetylates it is p300, a transcriptional co-activator that is recruited to the promoter region of target genes by other transcription factors.\n\nTherefore, the binding of acetyl-CoA to the lysine residue on the amino-terminal domain of S6K1, followed by the acetylation of this residue by p300, results in the inhibition of S6K1's kinase activity and the promotion of its protein-binding partners, leading to the regulation of cell growth and metabolism.",
    "llama-7b_fact_raw": "1. The acetylation of S6K1 occurs when an acetyl-coenzyme A (acetyl-CoA) molecule binds to the lysine residue on S6K1's amino-terminal domain.\n2. S6K1 is a serine/threonine kinase involved in regulating cell growth and metabolism.\n3. S6K1 phosphorylates and activates a number of downstream targets including 4E-BP1 and eukaryotic initiation factor 4E (eIF4E).\n4. Acetylation of S6K1 inhibits its kinase activity and promotes its interaction with protein-binding partners.\n5. The histone acetyltransferase (HAT) responsible for acetylating S6K1 is p300.",
    "llama-7b_fact": [
      "The acetylation of S6K1 occurs when an acetyl-coenzyme A (acetyl-CoA) molecule binds to the lysine residue on S6K1's amino-terminal domain.",
      "S6K1 is a serine/threonine kinase involved in regulating cell growth and metabolism.",
      "S6K1 phosphorylates and activates a number of downstream targets including 4E-BP1 and eukaryotic initiation factor 4E (eIF4E).",
      "Acetylation of S6K1 inhibits its kinase activity and promotes its interaction with protein-binding partners.",
      "The histone acetyltransferase (HAT) responsible for acetylating S6K1 is p300."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Acetylation typically occurs on lysine residues within the regulatory or catalytic domains of proteins such as S6K1, but not specifically mentioned as the amino-terminal domain without more context.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Acetylation of S6K1 typically enhances its kinase activity, rather than inhibiting it. However, this might depend on the context and specific cell signaling pathways involved. Without additional context, the effects on protein-binding partners are unclear.\n5. UNKNOWN (without specific information about S6K1 acetylation, the responsible histone acetyltransferase cannot be definitively identified).",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 632,
    "user_query": "You MUST give a detailed answer to the following question: What is the cause of episodic ataxia type 6?",
    "llama-7b_response": "Episode",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 646,
    "user_query": "You MUST give a detailed answer to the following question: Are chromomethylases present in animal genomes?",
    "llama-7b_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are enzymes that add methyl groups to DNA, and they play an important role in regulating gene expression. These enzymes are found in many organisms, including animals, and they are involved in a variety of biological processes, including DNA replication, transcription, and repair. In animals, chromomethylases are typically found in the form of DNA methyltransferases, which are enzymes that add methyl groups to cytosine residues in DNA. These methyl groups can have a variety of effects on gene expression, including silencing genes or preventing them from being expressed.",
    "llama-7b_fact_raw": "1. Chromomethylases are present in animal genomes.\n2. Chromomethylases are enzymes that add methyl groups to DNA.\n3. These enzymes play a role in regulating gene expression in animals.\n4. DNA methyltransferases are a form of chromomethylases found in animals.\n5. DNA methyltransferases add methyl groups to cytosine residues in DNA.",
    "llama-7b_fact": [
      "Chromomethylases are present in animal genomes.",
      "Chromomethylases are enzymes that add methyl groups to DNA.",
      "These enzymes play a role in regulating gene expression in animals.",
      "DNA methyltransferases are a form of chromomethylases found in animals.",
      "DNA methyltransferases add methyl groups to cytosine residues in DNA."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Chromomethylases are typically not found in animal genomes; they are more commonly associated with plants.\n2. TRUE\n3. UNKNOWN: Without specification, it is unclear whether \"these enzymes\" refers to chromomethylasesin which case the statement would be false as chromomethylases are not typically found in animalsor to the broader class of enzymes that add methyl groups to DNA, which would include DNA methyltransferases that do play a role in regulating gene expression in animals.\n4. FALSE [correction]: DNA methyltransferases are not a form of chromomethylases; they are distinct enzymes that also add methyl groups to DNA but are found in both plants and animals.\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 650,
    "user_query": "You MUST give a detailed answer to the following question: List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-7b_response": "There are several packages available in R/Bioconductor for transcription factor binding site (TFBS) analysis. Here are some of the most commonly used packages:\n\n1. ChIPS: The ChIP-Seq Package for R (ChIPS) is a comprehensive package for analyzing ChIP-Seq data. It provides tools for mapping reads to the reference genome, calling peaks, and identifying binding sites.\n2. DRIVE: The DRIVE package is a suite of tools for analyzing ChIP-Seq and other types of genomic data. It provides tools for calling peaks, identifying binding sites, and visualizing enrichment.\n3. GROMACS: The GROMACS package is a suite of tools for analyzing ChIP-Seq and other types of genomic data. It provides tools for calling peaks, identifying binding sites, and visualizing enrichment.\n4. PeakAnalyzer: The PeakAnalyzer package is a suite of tools for analyzing ChIP-Seq and other types of genomic data. It provides tools for calling peaks, identifying binding sites, and visualizing enrichment.\n5. PeakSeq: The PeakSeq package is a suite of tools for analyzing ChIP-Seq and other types of genomic data. It provides tools for calling peaks, identifying binding sites, and visualizing enrichment.\n6. REDIRECT: The REDIRECT package is a suite of tools for analyzing ChIP-Seq and other types of genomic data. It provides tools for calling peaks, identifying binding sites, and visualizing enrichment.\n7. SICER: The SICER package is a suite of tools for analyzing ChIP-Seq and other types of genomic data. It provides tools for calling peaks, identifying binding sites, and visualizing enrichment.\n\nThese are just a few examples of the many packages available for TFBS analysis in R/Bioconductor. The choice of package will depend on the specific needs of the analysis and the type of data being analyzed.",
    "llama-7b_fact_raw": "1. ChIPS is a package for analyzing ChIP-Seq data available in R/Bioconductor.\n2. DRIVE is a tool suite in R/Bioconductor for the analysis of ChIP-Seq and other types of genomic data.\n3. GROMACS is listed as an R/Bioconductor package for genomic data analysis, which includes features for identifying binding sites.\n4. PeakAnalyzer is another suite in R/Bioconductor meant for analyzing ChIP-Seq and genomic data.\n5. PeakSeq and SICER are mentioned as tool suites for genomic data analysis in the context of R/Bioconductor.\n\nPlease note: The inclusion of GROMACS as an R/Bioconductor package for analysing ChIP-Seq and genomic data might be incorrect, as GROMACS is primarily known as a molecular dynamics package, unrelated to R/Bioconductor or TFBS analysis. This statement should be verified independently for accuracy.",
    "llama-7b_fact": [
      "ChIPS is a package for analyzing ChIP-Seq data available in R/Bioconductor.",
      "DRIVE is a tool suite in R/Bioconductor for the analysis of ChIP-Seq and other types of genomic data.",
      "GROMACS is listed as an R/Bioconductor package for genomic data analysis, which includes features for identifying binding sites.",
      "PeakAnalyzer is another suite in R/Bioconductor meant for analyzing ChIP-Seq and genomic data.",
      "PeakSeq and SICER are mentioned as tool suites for genomic data analysis in the context of R/Bioconductor.",
      "ease note: The inclusion of GROMACS as an R/Bioconductor package for analysing ChIP-Seq and genomic data might be incorrect, as GROMACS is primarily known as a molecular dynamics package, unrelated to R/Bioconductor or TFBS analysis. This statement should be verified independently for accuracy."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: GROMACS is not an R/Bioconductor package for genomic data analysis. GROMACS is primarily known as a molecular dynamics simulation package, mainly used for simulating the Newtonian equations of motion for systems with hundreds to millions of particles.\n4. UNKNOWN\n5. UNKNOWN\n6. TRUE",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 721,
    "user_query": "You MUST give a detailed answer to the following question: List clinical trials for prevention of sarcopenia",
    "llama-7b_response": "Certainly, here are some clinical trials for the prevention of sarcopenia:\n\n1. Sarcopenia Prevention Trial (SPT): This is a multicenter, randomized, double-blind, placebo-controlled trial that aims to evaluate the efficacy and safety of a combination of resistance training and protein supplementation in preventing sarcopenia in older adults. The trial is currently recruiting participants and is expected to be completed in 2023.\n2. Resistance Training and Sarcopenia Prevention (RISP): This is a multicenter, randomized, double-blind, placebo-controlled trial that aims to evaluate the efficacy and safety of resistance training with or without protein supplementation in preventing sarcopenia in older adults. The trial is currently recruiting participants and is expected to be completed in 2023.\n3. Sarcopenia Prevention with Resistance Training (SPRT): This is a multicenter, randomized, double-blind, placebo-controlled trial that aims to evaluate the efficacy and safety of resistance training with or without protein supplementation in preventing sarcopenia in older adults. The trial is currently recruiting participants and is expected to be completed in 2023.\n4. Sarcopenia Prevention with Progressive Resistance Exercise (SPREE): This is a multicenter, randomized, double-blind, placebo-controlled trial that aims to evaluate the efficacy and safety of progressive resistance exercise with or without protein supplementation in preventing sarcopenia in older adults. The trial is currently recruiting participants and is expected to be completed in 2023.\n5. Sarcopenia Prevention with Progressive Resistance Exercise and Nutritional Supplementation (SPRENS): This is a multicenter, randomized, double-blind, placebo-controlled trial that aims to evaluate the efficacy and safety of progressive resistance exercise with or without protein supplementation in preventing sarcopenia in older adults. The trial is currently recruiting participants and is expected to be completed in 2023.\n\nThese are just a few examples of clinical",
    "llama-7b_fact_raw": "1. The Sarcopenia Prevention Trial (SPT) is a multicenter, randomized, double-blind, placebo-controlled trial focused on preventing sarcopenia with resistance training and protein supplementation.\n2. The Resistance Training and Sarcopenia Prevention (RISP) trial is a multicenter, randomized, double-blind, placebo-controlled trial that includes resistance training with or without protein supplementation for sarcopenia prevention.\n3. The Sarcopenia Prevention with Resistance Training (SPRT) trial is a multicenter, randomized, double-blind, placebo-controlled trial evaluating the effects of resistance training on sarcopenia prevention.\n4. The Sarcopenia Prevention with Progressive Resistance Exercise (SPREE) trial is a multicenter, randomized, double-blind, placebo-controlled trial designed to assess progressive resistance exercise in the prevention of sarcopenia.\n5. The Sarcopenia Prevention with Progressive Resistance Exercise and Nutritional Supplementation (SPRENS) trial is a multicenter, randomized, double-blind, placebo-controlled trial investigating the efficacy of progressive resistance exercise and nutritional supplementation in preventing sarcopenia.",
    "llama-7b_fact": [
      "The Sarcopenia Prevention Trial (SPT) is a multicenter, randomized, double-blind, placebo-controlled trial focused on preventing sarcopenia with resistance training and protein supplementation.",
      "The Resistance Training and Sarcopenia Prevention (RISP) trial is a multicenter, randomized, double-blind, placebo-controlled trial that includes resistance training with or without protein supplementation for sarcopenia prevention.",
      "The Sarcopenia Prevention with Resistance Training (SPRT) trial is a multicenter, randomized, double-blind, placebo-controlled trial evaluating the effects of resistance training on sarcopenia prevention.",
      "The Sarcopenia Prevention with Progressive Resistance Exercise (SPREE) trial is a multicenter, randomized, double-blind, placebo-controlled trial designed to assess progressive resistance exercise in the prevention of sarcopenia.",
      "The Sarcopenia Prevention with Progressive Resistance Exercise and Nutritional Supplementation (SPRENS) trial is a multicenter, randomized, double-blind, placebo-controlled trial investigating the efficacy of progressive resistance exercise and nutritional supplementation in preventing sarcopenia."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information regarding these named trials and their details, it is not possible to determine the accuracy of these statements. They are not established or widely recognized trial acronyms that can be commonly verified. Therefore, the veracity of these statements remains unknown without further context or references to these specific trials.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "You MUST give a detailed answer to the following question: Which is the database of molecular recognition features in membrane proteins?",
    "llama-7b_response": "The database of molecular recognition features in membrane proteins is called the Membrane Protein Data Bank (MPDB). It is a part of the Protein Data Bank (PDB), which is a database of three-dimensional structural data for proteins. The MPDB contains structural data for membrane proteins, including transmembrane helices, ion channels, and other types of membrane-associated proteins. The data in the MPDB is collected from a variety of sources, including X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and electron microscopy. The MPDB provides a valuable resource for researchers studying the structure and function of membrane proteins, and can be used to identify and study molecular recognition features in these proteins.",
    "llama-7b_fact_raw": "1. The Membrane Protein Data Bank (MPDB) is a database of molecular recognition features in membrane proteins.\n2. The MPDB is part of the Protein Data Bank (PDB).\n3. The MPDB includes data on transmembrane helices, ion channels, and other membrane-associated proteins.\n4. Sources for the MPDB include X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and electron microscopy.\n5. The MPDB serves as a resource for studying the structure and function of membrane proteins.",
    "llama-7b_fact": [
      "The Membrane Protein Data Bank (MPDB) is a database of molecular recognition features in membrane proteins.",
      "The MPDB is part of the Protein Data Bank (PDB).",
      "The MPDB includes data on transmembrane helices, ion channels, and other membrane-associated proteins.",
      "Sources for the MPDB include X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and electron microscopy.",
      "The MPDB serves as a resource for studying the structure and function of membrane proteins."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Membrane Protein Data Bank (MPDB) is not the correct name; the correct name is the Membrane Proteins of Known 3D Structure database.\n2. FALSE [correction]: The database for membrane protein structures is referred to as the \"Membrane Proteins of Known 3D Structure,\" which is available through the Protein Data Bank (PDB), but not a separate entity called MPDB.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 745,
    "user_query": "You MUST give a detailed answer to the following question: Is rivaroxaban metabolized in kidneys?",
    "llama-7b_response": "Yes, rivaroxaban is metabolized in the kidneys.\n\nRivaroxaban is a direct factor Xa inhibitor that is primarily metabolized by the liver via cytochrome P450 enzymes, particularly CYP3A4 and CYP2C9. However, the kidneys also play a role in the elimination of rivaroxaban from the body.\n\nRivaroxaban and its metabolites are primarily excreted in the urine. The metabolism of rivaroxaban results in the formation of several active and inactive metabolites, including O-desmethyl rivaroxaban and N-desmethyl rivaroxaban. These metabolites are also excreted in the urine.\n\nIn patients with renal impairment, the elimination of rivaroxaban and its metabolites may be affected. In patients with severe renal impairment (creatinine clearance <30 mL/min), the elimination half-life of rivaroxaban is prolonged, and the dose of rivaroxaban may need to be adjusted.\n\nIn summary, while the primary metabolism of rivaroxaban occurs in the liver, the kidneys also play a role in the elimination of rivaroxaban and its metabolites. The elimination of rivaroxaban and its metabolites may be affected in patients with renal impairment, and the dose of rivaroxaban may need to be adjusted in these patients.",
    "llama-7b_fact_raw": "1. Rivaroxaban is metabolized by the liver, predominantly via cytochrome P450 enzymes CYP3A4 and CYP2C9.\n2. The kidneys play a role in the elimination of rivaroxaban and its metabolites from the body.\n3. Rivaroxaban and its metabolites are primarily excreted through the urine.\n4. O-desmethyl rivaroxaban and N-desmethyl rivaroxaban are among the metabolites of rivaroxaban excreted in the urine.\n5. In patients with severe renal impairment (creatinine clearance <30 mL/min), the elimination half-life of rivaroxaban is prolonged, which may necessitate dosage adjustment.",
    "llama-7b_fact": [
      "Rivaroxaban is metabolized by the liver, predominantly via cytochrome P450 enzymes CYP3A4 and CYP2C9.",
      "The kidneys play a role in the elimination of rivaroxaban and its metabolites from the body.",
      "Rivaroxaban and its metabolites are primarily excreted through the urine.",
      "O-desmethyl rivaroxaban and N-desmethyl rivaroxaban are among the metabolites of rivaroxaban excreted in the urine.",
      "In patients with severe renal impairment (creatinine clearance <30 mL/min), the elimination half-life of rivaroxaban is prolonged, which may necessitate dosage adjustment."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: O-desmethyl rivaroxaban is a known metabolite of rivaroxaban, but there is no well-known metabolite called N-desmethyl rivaroxaban related to rivaroxaban excretion. Another major metabolite is 4-hydroxy rivaroxaban.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "You MUST give a detailed answer to the following question: Which genes are regulated by TRalpha2  in the heart?",
    "llama-7b_response": "Transforming growth factor beta (TGF-beta) is a family of structurally related cytokines that play a crucial role in the regulation of cell growth, differentiation, and apoptosis. TGF-beta signaling is mediated by the binding of TGF-beta to its specific receptors, which then activate intracellular signaling pathways. TGF-beta receptor type I (TbetaRI) and TGF-beta receptor type II (TbetaRII) are the two main receptors for TGF-beta in mammalian cells.\n\nTransforming growth factor beta receptor type II (TbetaRII) is a transmembrane receptor that binds TGF-beta and activates downstream signaling pathways. TbetaRII is expressed in various tissues, including the heart, where it plays a crucial role in the regulation of cardiac development and homeostasis.\n\nTransforming growth factor beta receptor type I (TbetaRI) is a transmembrane receptor that binds TGF-beta and activates downstream signaling pathways. TbetaRI is expressed in various tissues, including the heart, where it plays a crucial role in the regulation of cardiac development and homeostasis.\n\nTransforming growth factor beta receptor type II (TbetaRII) and Transforming growth factor beta receptor type I (TbetaRI) are the two main receptors for TGF-beta in the heart. TGF-beta signaling through TbetaRII and TbetaRI regulates various genes in the heart, including those involved in cardiac development, remodeling, and homeostasis.\n\nIn summary, TGF-beta signaling through TbetaRII and TbetaRI regulates various genes in the heart, including those involved in cardiac development, remodeling, and homeostasis.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 786,
    "user_query": "You MUST give a detailed answer to the following question: List available biomedical question answering systems.",
    "llama-7b_response": "There are several biomedical question answering systems available, including:\n\n1. Clinical Question Answering (CRAQ) system: This system is designed to answer clinical questions posed in natural language. It uses a combination of machine learning and natural language processing techniques to extract relevant information from unstructured text.\n2. BioASQ: This system is a series of bio-medical question answering challenges that are organized by the European Bioinformatics Institute (EMBL-EBI). The challenges are designed to test the ability of machine learning algorithms to answer biomedical questions posed in natural language.\n3. Biocreative: This system is a series of biomedical question answering challenges that were organized by the National Center for Biomedical Ontology (NCBO). The challenges were designed to test the ability of machine learning algorithms to answer biomedical questions posed in natural language.\n4. Biomedical Question Answering (Bio-QA) system: This system is designed to answer biomedical questions posed in natural language. It uses a combination of machine learning and natural language processing techniques to extract relevant information from unstructured text.\n5. Biomedical Text Analysis and Question Answering (Bio-TAQA) system: This system is designed to analyze biomedical text and answer questions posed in natural language. It uses a combination of machine learning and natural language processing techniques to extract relevant information from unstructured text.\n\nThese are just a few examples of the many biomedical question answering systems that are available. Each system has its own strengths and weaknesses, and may be better suited to certain types of questions than others.",
    "llama-7b_fact_raw": "1. The Clinical Question Answering (CRAQ) system is a system designed to answer clinical questions posed in natural language.\n2. BioASQ is a series of bio-medical question answering challenges organized by the European Bioinformatics Institute (EMBL-EBI).\n3. Biocreative is a series of biomedical question answering challenges organized by the National Center for Biomedical Ontology (NCBO).\n4. The Biomedical Question Answering (Bio-QA) system is designed to answer biomedical questions using machine learning and natural language processing techniques.\n5. The Biomedical Text Analysis and Question Answering (Bio-TAQA) system is designed to analyze biomedical text and answer questions in natural language.",
    "llama-7b_fact": [
      "The Clinical Question Answering (CRAQ) system is a system designed to answer clinical questions posed in natural language.",
      "BioASQ is a series of bio-medical question answering challenges organized by the European Bioinformatics Institute (EMBL-EBI).",
      "Biocreative is a series of biomedical question answering challenges organized by the National Center for Biomedical Ontology (NCBO).",
      "The Biomedical Question Answering (Bio-QA) system is designed to answer biomedical questions using machine learning and natural language processing techniques.",
      "The Biomedical Text Analysis and Question Answering (Bio-TAQA) system is designed to analyze biomedical text and answer questions in natural language."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: BioASQ is a series of bio-medical question answering challenges, but it is not organized by the European Bioinformatics Institute (EMBL-EBI); it has been organized by a team of researchers from various institutions.\n3. FALSE [correction]: Biocreative is indeed a challenge in biomedical text mining including tasks such as gene mention recognition and patient document understanding, but it was not organized by the National Center for Biomedical Ontology (NCBO). It is a community-wide effort involving various organizers.\n4. TRUE (Assuming that the system described does exist and is designed for the purpose mentioned, but without additional specific information about the Bio-QA system, this statement is treated as conceptually true.)\n5. UNKNOWN (Due to insufficient information; the statement gives a plausible description of a system, but without context to verify the existence or functions of Bio-TAQA, its truth value cannot be determined.)",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 794,
    "user_query": "You MUST give a detailed answer to the following question: Which trancription factor activates the betalain pathway?",
    "llama-7b_response": "The transcription factor that activates the betalain pathway has not yet been identified. The betalain pathway is a secondary metabolic pathway that is involved in the biosynthesis of betalain pigments, which are responsible for the red, purple, and yellow colors of certain plant species. The pathway involves the sequential action of several enzymes, including betalain synthase, betalain reductase, and betalain peroxidase, which convert various precursor compounds into betalain pigments. While the genes encoding these enzymes have been identified, the transcription factors that activate their expression have not been fully characterized. Further research is needed to elucidate the molecular mechanisms underlying the regulation of betalain biosynthesis.",
    "llama-7b_fact_raw": "1. The transcription factor that activates the betalain pathway has not yet been identified.\n2. The betalain pathway is responsible for the biosynthesis of betalain pigments.\n3. Betalain pigments are what give certain plant species their red, purple, and yellow colors. \n4. Enzymes involved in the betalain biosynthetic pathway include betalain synthase, betalain reductase, and betalain peroxidase.\n5. The genes for the enzymes involved in the betalain pathway have been identified; however, regulatory transcription factors have not been fully characterized.",
    "llama-7b_fact": [
      "The transcription factor that activates the betalain pathway has not yet been identified.",
      "The betalain pathway is responsible for the biosynthesis of betalain pigments.",
      "Betalain pigments are what give certain plant species their red, purple, and yellow colors.",
      "Enzymes involved in the betalain biosynthetic pathway include betalain synthase, betalain reductase, and betalain peroxidase.",
      "The genes for the enzymes involved in the betalain pathway have been identified; however, regulatory transcription factors have not been fully characterized."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The correct enzyme names involved in the betalain biosynthetic pathway are tyrosine hydroxylase, DOPA dioxygenase (also known as betalain synthase), and cyclo-DOPA 5-O-glucosyltransferase. There is no enzyme named betalain synthase, betalain reductase, or betalain peroxidase.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 883,
    "user_query": "You MUST give a detailed answer to the following question: Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-7b_response": "There are several technologies that can be used for the enrichment of phosphorylated peptides in quantitative phosphoproteomic analyses. Some of the most commonly used methods include:\n\n1. TiO2 beads: These beads are coated with a layer of titanium dioxide, which can selectively bind to phosphorylated peptides. The beads are then used to separate the phosphorylated peptides from the rest of the peptides in the sample.\n2. IMAC (Immobilized Metal Affinity Chromatography): This method uses a metal ion, such as nickel or gold, to selectively bind to phosphorylated peptides. The metal ion is immobilized on a column, and the phosphorylated peptides are then eluted from the column.\n3. SULFO-TAG: This method uses a reagent called SULFO-TAG, which can be added to the sample to selectively label phosphorylated peptides. The labeled peptides are then captured on a column, and the unlabeled peptides are washed away.\n4. Strep-tag: This method uses a reagent called Strep-tag, which can be added to the sample to selectively label phosphorylated peptides. The labeled peptides are then captured on a column, and the unlabeled peptides are washed away.",
    "llama-7b_fact_raw": "1. Titanium dioxide (TiO2) beads are used for selectively binding to phosphorylated peptides during their enrichment.\n2. Immobilized Metal Affinity Chromatography (IMAC) uses metal ions such as nickel or gold to bind phosphorylated peptides.\n3. SULFO-TAG is a reagent that selectively labels phosphorylated peptides for their enrichment.\n4. Strep-tag is another reagent used to selectively label phosphorylated peptides for enrichment purposes.\n5. In quantitative phosphoproteomic analyses, phosphorylated peptides are separated from other peptides in the sample using these enrichment technologies.",
    "llama-7b_fact": [
      "Titanium dioxide (TiO2) beads are used for selectively binding to phosphorylated peptides during their enrichment.",
      "Immobilized Metal Affinity Chromatography (IMAC) uses metal ions such as nickel or gold to bind phosphorylated peptides.",
      "SULFO-TAG is a reagent that selectively labels phosphorylated peptides for their enrichment.",
      "Strep-tag is another reagent used to selectively label phosphorylated peptides for enrichment purposes.",
      "In quantitative phosphoproteomic analyses, phosphorylated peptides are separated from other peptides in the sample using these enrichment technologies."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: SULFO-TAG is typically used for labeling molecules in electrochemiluminescence assays and not for selectively enriching phosphorylated peptides.\n4. FALSE [correction]: Strep-tag is a peptide sequence used for the purification of proteins, not for selective labeling of phosphorylated peptides for enrichment.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 901,
    "user_query": "You MUST give a detailed answer to the following question: Which disorder is rated by Palmini classification?",
    "llama-7b_response": "The Palmini classification is a system used to rate the severity of various neurological and psychiatric disorders. It is not a specific disorder, but rather a way of categorizing the symptoms and severity of a wide range of conditions.\n\nThe Palmini classification is based on the work of Italian neurologist Giuseppe Palmini, who developed a system for rating the severity of parkinsonism, which is a group of disorders characterized by movement disorders such as tremors, rigidity, and bradykinesia.\n\nThe Palmini classification is typically used to rate the severity of parkinsonism, but it can also be used to rate the severity of other neurological and psychiatric disorders, such as Huntington's disease, essential tremor, and schizophrenia.\n\nIn the Palmini classification, the severity of a disorder is rated on a scale of 1 to 4, with 1 indicating mild symptoms and 4 indicating severe and disabling symptoms. The specific symptoms that are rated depend on the disorder being evaluated, but generally include motor symptoms, non-motor symptoms, and functional impairment.\n\nOverall, the Palmini classification is a useful tool for clinicians and researchers to objectively evaluate the severity of various neurological and psychiatric disorders and to track the progress of patients over time.",
    "llama-7b_fact_raw": "1. The Palmini classification is used to categorize the symptoms and severity of neurological and psychiatric disorders.\n2. Giuseppe Palmini, an Italian neurologist, developed a system for rating the severity of parkinsonism.\n3. The Palmini classification is primarily used for rating the severity of parkinsonism.\n4. The Palmini classification can also be applied to other conditions like Huntington's disease, essential tremor, and schizophrenia.\n5. In the Palmini classification, disorder severity is rated on a scale from 1 to 4, with 1 being mild symptoms and 4 being severe and disabling symptoms.",
    "llama-7b_fact": [
      "The Palmini classification is used to categorize the symptoms and severity of neurological and psychiatric disorders.",
      "Giuseppe Palmini, an Italian neurologist, developed a system for rating the severity of parkinsonism.",
      "The Palmini classification is primarily used for rating the severity of parkinsonism.",
      "The Palmini classification can also be applied to other conditions like Huntington's disease, essential tremor, and schizophrenia.",
      "In the Palmini classification, disorder severity is rated on a scale from 1 to 4, with 1 being mild symptoms and 4 being severe and disabling symptoms."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Palmini classification is not used to categorize symptoms of neurological and psychiatric disorders broadly; rather, it is known for its use in categorizing different types of cortical dysplasias, which are brain malformations associated with epilepsy.\n2. FALSE [correction]: Giuseppe Palmini is not an Italian neurologist, but a Brazilian neurosurgeon, and he did not develop a system for rating the severity of parkinsonism but is known for his work on epilepsy surgery and the classification of cortical dysplasias.\n3. FALSE [correction]: The Palmini classification is not primarily used for rating the severity of parkinsonism. It is used in the context of epilepsy, specifically to categorize types of cortical dysplasia.\n4. FALSE [correction]: The Palmini classification is related to cortical dysplasias in the context of epilepsy, not to a wide range of conditions such as Huntington's disease, essential tremor, and schizophrenia.\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 905,
    "user_query": "You MUST give a detailed answer to the following question: Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-7b_response": "Yes, viruses have been implicated in the etiology of human subacute thyroiditis. Subacute thyroiditis, also known as De Quervain's thyroiditis, is an inflammatory condition of the thyroid gland that typically occurs after a viral infection. The exact mechanism by which viruses cause subacute thyroiditis is not fully understood, but it is thought to involve direct viral infection of thyroid cells, as well as the production of pro-inflammatory cytokines and chemokines by infected cells.\n\nSeveral viruses have been implicated in the etiology of subacute thyroiditis, including:\n\n1. Parvovirus B19: Parvovirus B19 is a single-stranded DNA virus that causes erythema infectiosum, also known as fifth disease, in children. It has also been associated with subacute thyroiditis in adults.\n2. Coxsackievirus: Coxsackieviruses are a group of enteroviruses that can cause a variety of illnesses, including hand, foot, and mouth disease and myocarditis. They have also been implicated in the etiology of subacute thyroiditis.\n3. Enteroviruses: Enteroviruses are a group of RNA viruses that can cause a variety of illnesses, including poliovirus, coxsackievirus, and echovirus. They have also been implicated in the etiology of subacute thyroiditis.\n\nThe clinical presentation of subacute thyroiditis typically includes pain in the neck, painful swelling of the thyroid gland, and an elevated thyroid-stimulating hormone (TSH) level. The pain and swelling typically resolve within a few months, and the TSH level returns to normal. However, in some cases, subacute thyroiditis can lead to permanent thyroid dysfunction, such as hypothyroidism or hyperthyroidism.\n\nIn summary, viruses are involved in the etiology of human subacute thyroiditis. Parvovirus B19, Coxsackievirus, enteroviruses, and other viruses can cause subacute thyroiditi",
    "llama-7b_fact_raw": "1. Viruses have been implicated in the etiology of human subacute thyroiditis, also known as De Quervain's thyroiditis.\n2. Subacute thyroiditis typically occurs after a viral infection and involves inflammation of the thyroid gland.\n3. Parvovirus B19, which also causes erythema infectiosum (fifth disease) in children, has been associated with subacute thyroiditis in adults.\n4. Coxsackieviruses, a group of enteroviruses, have been implicated in the etiology of subacute thyroiditis.\n5. Enteroviruses, a group of RNA viruses, are another group implicated in the etiology of subacute thyroiditis.",
    "llama-7b_fact": [
      "Viruses have been implicated in the etiology of human subacute thyroiditis, also known as De Quervain's thyroiditis.",
      "Subacute thyroiditis typically occurs after a viral infection and involves inflammation of the thyroid gland.",
      "Parvovirus B19, which also causes erythema infectiosum (fifth disease) in children, has been associated with subacute thyroiditis in adults.",
      "Coxsackieviruses, a group of enteroviruses, have been implicated in the etiology of subacute thyroiditis.",
      "Enteroviruses, a group of RNA viruses, are another group implicated in the etiology of subacute thyroiditis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 963,
    "user_query": "You MUST give a detailed answer to the following question: Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-7b_response": "Yes, STAT3 is involved in EIF2AK2-dependent suppression of autophagy.\n\nSTAT3 is a transcription factor that plays a crucial role in regulating immune and inflammatory responses, as well as cell survival and proliferation. Recent studies have shown that STAT3 can also regulate autophagy, a cellular process involved in the degradation of damaged organelles and proteins.\n\nEIF2AK2, also known as eukaryotic initiation factor 2 alpha kinase 2, is a key regulator of autophagy. It has been shown to play a role in the suppression of autophagy by inhibiting the activity of the Unc-51-like autophagy activating kinase (Ulk1).\n\nThere is evidence to suggest that STAT3 can interact with and regulate the activity of EIF2AK2. For example, studies have shown that STAT3 can bind to the promoter region of the EIF2AK2 gene and enhance its transcription. Additionally, STAT3 has been shown to interact with and inhibit the activity of Ulk1, which is a key regulator of autophagy.\n\nTogether, these findings suggest that STAT3 is involved in EIF2AK2-dependent suppression of autophagy. Specifically, STAT3 can interact with and regulate the activity of EIF2AK2, which in turn inhibits the activity of Ulk1 and suppresses autophagy.",
    "llama-7b_fact_raw": "1. STAT3 is a transcription factor that is involved in regulating immune and inflammatory responses, as well as cell survival and proliferation.\n2. STAT3 can regulate autophagy, a cellular process for degrading damaged organelles and proteins.\n3. EIF2AK2, known as eukaryotic initiation factor 2 alpha kinase 2, is a regulator of autophagy.\n4. STAT3 can bind to the promoter region of the EIF2AK2 gene to enhance its transcription.\n5. STAT3 can interact with and inhibit the activity of Unc-51-like autophagy activating kinase (Ulk1).",
    "llama-7b_fact": [
      "STAT3 is a transcription factor that is involved in regulating immune and inflammatory responses, as well as cell survival and proliferation.",
      "STAT3 can regulate autophagy, a cellular process for degrading damaged organelles and proteins.",
      "EIF2AK2, known as eukaryotic initiation factor 2 alpha kinase 2, is a regulator of autophagy.",
      "STAT3 can bind to the promoter region of the EIF2AK2 gene to enhance its transcription.",
      "STAT3 can interact with and inhibit the activity of Unc-51-like autophagy activating kinase (Ulk1)."
    ],
    "llama-7b_judge_raw": "1. TRUE: STAT3 (Signal Transducer and Activator of Transcription 3) is indeed a transcription factor that plays a key role in various cellular processes including regulating immune and inflammatory responses as well as cell survival and proliferation.\n2. TRUE: STAT3 has been reported to regulate autophagy, a cellular degradation and recycling process that is important for maintaining cellular homeostasis.\n3. TRUE: EIF2AK2, also known as PKR (Protein Kinase R), is involved in the cellular stress response and has been reported to regulate autophagy among its various functions.\n4. UNKNOWN: Without specific scientific literature or evidence, it is unclear whether STAT3 can bind directly to the promoter region of the EIF2AK2 gene to enhance its transcription. This is a specific molecular interaction that would need to be confirmed by empirical studies.\n5. UNKNOWN: The interaction between STAT3 and Ulk1 and whether STAT3 inhibits Ulk1's activity would need to be confirmed with scientific evidence. This type of molecular mechanism is very specific and cannot be confirmed as true or false without appropriate references.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 973,
    "user_query": "You MUST give a detailed answer to the following question: Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-7b_response": "The Theatre software tool is a genomic analysis tool that is used to visualize and analyze large-scale genomic data sets. It is designed to handle high-throughput sequencing data, such as that generated by next-generation sequencing (NGS) technologies.\n\nTheatre provides a range of features for analyzing genomic data, including:\n\n1. Data management: Theatre allows users to manage and organize their genomic data, including the ability to import and export data in a variety of formats.\n2. Data visualization: Theatre provides a range of visualization tools for analyzing genomic data, including heatmaps, bar charts, and scatter plots. These tools can be used to identify patterns and trends in the data.\n3. Genome annotation: Theatre can be used to annotate genomic data, including the identification of genes, regulatory elements, and other features of the genome.\n4. Variant analysis: Theatre can be used to identify and analyze variants in the genome, including single nucleotide variants (SNVs), insertions/deletions (indels), and copy number variations (CNVs).\n5. Integration with other tools: Theatre can be integrated with other genomic analysis tools and databases, allowing users to leverage the power of these tools in combination with Theatre's visualization and analysis capabilities.\n\nOverall, Theatre is a powerful tool for genomic analysis that can be used to identify patterns and trends in large-scale genomic data sets, and to gain insights into the structure and function of the genome.",
    "llama-7b_fact_raw": "1. The Theatre software tool is designed to handle high-throughput sequencing data from next-generation sequencing technologies.\n2. Theatre provides features for data management, allowing import and export of genomic data in various formats.\n3. Data visualization tools such as heatmaps, bar charts, and scatter plots are available in Theatre for analyzing genomic data.\n4. Theatre can be used for genome annotation, which includes identifying genes and regulatory elements in the genome.\n5. The software allows for variant analysis, including identification and analysis of single nucleotide variants, insertions/deletions, and copy number variations.",
    "llama-7b_fact": [
      "The Theatre software tool is designed to handle high-throughput sequencing data from next-generation sequencing technologies.",
      "Theatre provides features for data management, allowing import and export of genomic data in various formats.",
      "Data visualization tools such as heatmaps, bar charts, and scatter plots are available in Theatre for analyzing genomic data.",
      "Theatre can be used for genome annotation, which includes identifying genes and regulatory elements in the genome.",
      "The software allows for variant analysis, including identification and analysis of single nucleotide variants, insertions/deletions, and copy number variations."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nPlease note that while statements 2 through 5 describe typical features of genomic data analysis software, the specific software tool \"Theatre\" and its association with these features and capabilities cannot be confirmed without additional context as it is not a standard, commonly acknowledged software in the bioinformatics field as of my knowledge cutoff date. However, the described features are in line with general functionalities of genomic data analysis tools. The name of the software may be fictional or it might be a hypothetical example. Further information or context would be needed to confirm the first statement.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 997,
    "user_query": "You MUST give a detailed answer to the following question: Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-7b_response": "The Smith-Waterman algorithm is a widely used algorithm for the alignment of two sequences. The execution time (complexity) of the Smith-Waterman algorithm depends on several factors, including the length of the sequences being aligned, the similarity between the sequences, and the algorithm implementation.\n\nIn general, the Smith-Waterman algorithm has a time complexity of O(n^2), where n is the length of the shorter of the two sequences. This means that the algorithm will take O(n^2) time to align two sequences of length n.\n\nHowever, the actual execution time of the Smith-Waterman algorithm can vary depending on the specific implementation and the characteristics of the sequences being aligned. For example, if the sequences have a high degree of similarity, the algorithm may be able to find a match more quickly, resulting in a shorter execution time. Conversely, if the sequences have a low degree of similarity, the algorithm may need to search through a larger portion of the sequences to find a match, resulting in a longer execution time.\n\nIn addition to the time complexity, the Smith-Waterman algorithm also has a space complexity of O(n), which means that it requires O(n) memory to store the sequences being aligned.\n\nOverall, the Smith-Waterman algorithm is a powerful and widely used algorithm for the alignment of two sequences, but its execution time can vary depending on the specific implementation and the characteristics of the sequences being aligned.",
    "llama-7b_fact_raw": "1. The time complexity of the Smith-Waterman algorithm is generally O(n^2), where n is the length of the shorter sequence being aligned.\n2. The actual execution time of the Smith-Waterman algorithm can vary based on the similarity between the sequences.\n3. A high degree of similarity between the sequences might lead to a quicker match and a shorter execution time.\n4. A low degree of similarity might result in the algorithm needing to search through more of the sequences to find a match, leading to a longer execution time.\n5. The Smith-Waterman algorithm has a space complexity of O(n).",
    "llama-7b_fact": [
      "The time complexity of the Smith-Waterman algorithm is generally O(n^2), where n is the length of the shorter sequence being aligned.",
      "The actual execution time of the Smith-Waterman algorithm can vary based on the similarity between the sequences.",
      "A high degree of similarity between the sequences might lead to a quicker match and a shorter execution time.",
      "A low degree of similarity might result in the algorithm needing to search through more of the sequences to find a match, leading to a longer execution time.",
      "The Smith-Waterman algorithm has a space complexity of O(n)."
    ],
    "llama-7b_judge_raw": "1. TRUE: The time complexity of the Smith-Waterman algorithm for local sequence alignment is indeed generally O(n^2), where n corresponds to the length of the shorter sequence being aligned.\n2. TRUE: The actual execution time of the Smith-Waterman algorithm can vary because certain implementation details, such as the scoring system used and optimizations applied, may influence how quickly the algorithm runs. However, this variability isn't directly tied to the similarity between the sequences.\n3. FALSE [correction]: A high degree of similarity between the sequences does not necessarily lead to a quicker match and a shorter execution time in the context of the Smith-Waterman algorithm. The algorithm's time complexity of O(n^2) typically holds regardless of sequence similarity because it involves a systematic comparison of all possible sequence alignments.\n4. FALSE [correction]: A low degree of similarity does not necessarily change the overall number of computational steps required by the Smith-Waterman algorithm, because every possible alignment is still explored within its dynamic programming matrix. Therefore, the time complexity remains O(n^2), independent of the similarity of the sequences.\n5. FALSE [correction]: The space complexity of the Smith-Waterman algorithm is also O(n^2). This is because the algorithm constructs a two-dimensional matrix with dimensions proportional to the lengths of the two sequences being aligned, often using the full product of the two sequence lengths.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1004,
    "user_query": "You MUST give a detailed answer to the following question: Which SLC family is FLVCR1 a member of?",
    "llama-7b_response": "FLVCR1, also known as folliculin, is a protein that belongs to the SLC35A1 family of solute carrier transporters. The SLC35A1 gene encodes a protein that is involved in the transport of small molecules, such as amino acids, across cell membranes. The SLC35A1 gene is located on chromosome 1q21.3 and is composed of 17 exons. The protein encoded by the SLC35A1 gene, folliculin, plays a role in the regulation of cell growth, differentiation, and survival. Mutations in the SLC35A1 gene have been implicated in the development of several human cancers, including kidney cancer and thyroid cancer.",
    "llama-7b_fact_raw": "1. FLVCR1 is known as folliculin.\n2. FLVCR1 belongs to the SLC35A1 family of solute carrier transporters.\n3. The SLC35A1 gene is located on chromosome 1q21.3.\n4. The SLC35A1 gene consists of 17 exons.\n5. Mutations in the SLC35A1 gene have been linked to the development of human cancers such as kidney cancer and thyroid cancer.",
    "llama-7b_fact": [
      "FLVCR1 is known as folliculin.",
      "FLVCR1 belongs to the SLC35A1 family of solute carrier transporters.",
      "The SLC35A1 gene is located on chromosome 1q21.3.",
      "The SLC35A1 gene consists of 17 exons.",
      "Mutations in the SLC35A1 gene have been linked to the development of human cancers such as kidney cancer and thyroid cancer."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: FLVCR1 is not known as folliculin; it is a heme exporter protein. The gene known as folliculin is FLCN.\n2. FALSE [correction]: FLVCR1 does not belong to the SLC35A1 family of solute carrier transporters. It is actually a member of the major facilitator superfamily (MFS) of transporters. SLC35A1 is a different gene that encodes a member of the nucleotide sugar transporter family.\n3. TRUE\n4. FALSE [correction]: The SLC35A1 gene consists of 9 exons, not 17.\n5. FALSE [correction]: Mutations in the SLC35A1 gene have been linked to Congenital Disorder of Glycosylation (CDG), not specifically to kidney cancer or thyroid cancer. However, research on the full spectrum of diseases associated with mutations in this gene is ongoing, so the statement might be incomplete rather than entirely false if future research establishes such links.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1047,
    "user_query": "You MUST give a detailed answer to the following question: List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-7b_response": "GATA-1 (GATA binding protein 1) is a transcription factor that plays a crucial role in regulating the expression of genes involved in various cellular processes, including differentiation, proliferation, and apoptosis. GATA-1 interacts with a variety of proteins to regulate its target genes.\n\nTo identify GATA-1 interacting partners, a biotinylation tagging approach was used. In this approach, a biotinylation tag is added to GATA-1, and then the interacting proteins are captured by streptavidin beads. The interacting proteins can then be identified by mass spectrometry.\n\nHere are some of the GATA-1 interacting partners that have been identified using the biotinylation tagging approach:\n\n1. TBP (TATA box binding protein): TBP is a general transcription factor that binds to the TATA box element in the promoter region of genes. GATA-1 and TBP form a complex that binds to the promoter region of GATA-1 target genes.\n2. NCoR (nuclear receptor corepressor): NCoR is a corepressor that interacts with histone deacetylases to repress transcription. GATA-1 and NCoR form a complex that represses transcription from GATA-1 target genes.\n3. HDAC1 (histone deacetylase 1): HDAC1 is a histone deacetylase that interacts with NCoR to repress transcription. GATA-1 and HDAC1 form a complex that represses transcription from GATA-1 target genes.\n4. HDAC3 (histone deacetylase 3): HDAC3 is a histone deacetylase that interacts with GATA-1 to repress transcription. GATA-1 and HDAC3 form a complex that represses transcription from GATA-1 target genes.\n5. HDAC4 (histone deacetylase 4): HDAC4 is a histone deacetylase that interacts with GATA-1 to repress transcription. GATA-1 and HDAC4 form a complex that represses transcription from GATA",
    "llama-7b_fact_raw": "1. GATA-1 is a transcription factor involved in regulating gene expression related to differentiation, proliferation, and apoptosis.\n2. The biotinylation tagging approach has been used to identify interacting partners of GATA-1.\n3. TBP (TATA box binding protein) has been identified as a GATA-1 interacting partner through the biotinylation tagging approach.\n4. NCoR (nuclear receptor corepressor) is an identified interacting partner of GATA-1 that forms a complex with it to repress transcription.\n5. HDAC1 (histone deacetylase 1), HDAC3 (histone deacetylase 3), and HDAC4 (histone deacetylase 4) have been identified as interacting partners of GATA-1 that repress transcription in complexes with GATA-1.",
    "llama-7b_fact": [
      "GATA-1 is a transcription factor involved in regulating gene expression related to differentiation, proliferation, and apoptosis.",
      "The biotinylation tagging approach has been used to identify interacting partners of GATA-1.",
      "TBP (TATA box binding protein) has been identified as a GATA-1 interacting partner through the biotinylation tagging approach.",
      "NCoR (nuclear receptor corepressor) is an identified interacting partner of GATA-1 that forms a complex with it to repress transcription.",
      "HDAC1 (histone deacetylase 1), HDAC3 (histone deacetylase 3), and HDAC4 (histone deacetylase 4) have been identified as interacting partners of GATA-1 that repress transcription in complexes with GATA-1."
    ],
    "llama-7b_judge_raw": "1. TRUE: GATA-1 is indeed a transcription factor that plays a crucial role in the regulation of gene expression, particularly in the context of hematopoietic cell development, which includes processes such as differentiation, proliferation, and apoptosis.\n\n2. TRUE: The biotinylation tagging approach, also known as BioID or proximity labeling, is a method used to identify protein-protein interactions and would plausibly be used to discover interacting partners of a transcription factor like GATA-1.\n\n3. UNKNOWN: Without specific literature to confirm or refute the statement that TBP has been identified as a GATA-1 interacting partner through the biotinylation tagging approach, we cannot determine the truthfulness of this statement.\n\n4. TRUE: NCoR is known to interact with various transcription factors as a corepressor and it has been reported in the scientific literature to interact with GATA-1 to repress transcription.\n\n5. FALSE [correction]: HDAC1 and HDAC3 have been reported as GATA-1 interacting partners involved in repressing transcription. However, there isn't consistent evidence within the scientific literature to support that HDAC4 directly interacts with GATA-1, rather it is known to interact with other HDACs and corepressors. It's worth noting that the interactions between these proteins can be context-dependent and new findings might expand or clarify these relationships.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 1072,
    "user_query": "You MUST give a detailed answer to the following question: What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-7b_response": "TAF10 is a transcriptional co-activator that interacts with the GATA1 transcription factor, which is a key regulator of hematopoiesis and immune cell development. The interaction between TAF10 and GATA1 can lead to the activation of target genes involved in hematopoiesis and immune cell differentiation.\n\nIn particular, GATA1 binds to specific DNA sequences known as GATA boxes, which are found in the promoter regions of genes involved in hematopoiesis and immune cell development. When TAF10 interacts with GATA1, it helps to stabilize the GATA1-DNA complex and enhances the recruitment of other transcriptional co-activators, such as p300 and Brd4, to the GATA1-bound promoter. This leads to the formation of a transcriptional complex that is able to activate gene transcription and promote the differentiation of hematopoietic stem cells into mature immune cells.\n\nOverall, the interaction between TAF10 and GATA1 plays a crucial role in regulating hematopoiesis and immune cell development, and dysregulation of this interaction has been implicated in various hematological disorders and immune deficiency diseases.",
    "llama-7b_fact_raw": "1. TAF10 is a transcriptional co-activator that interacts with the GATA1 transcription factor.\n2. GATA1 is a key regulator of hematopoiesis and immune cell development.\n3. GATA1 binds to DNA sequences known as GATA boxes in the promoter regions of genes involved in hematopoiesis and immune cell development.\n4. TAF10 helps stabilize the GATA1-DNA complex and enhances the recruitment of other transcriptional co-activators.\n5. Dysregulation of the interaction between TAF10 and GATA1 has been implicated in various hematological disorders and immune deficiency diseases.",
    "llama-7b_fact": [
      "TAF10 is a transcriptional co-activator that interacts with the GATA1 transcription factor.",
      "GATA1 is a key regulator of hematopoiesis and immune cell development.",
      "GATA1 binds to DNA sequences known as GATA boxes in the promoter regions of genes involved in hematopoiesis and immune cell development.",
      "TAF10 helps stabilize the GATA1-DNA complex and enhances the recruitment of other transcriptional co-activators.",
      "Dysregulation of the interaction between TAF10 and GATA1 has been implicated in various hematological disorders and immune deficiency diseases."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN \n5. UNKNOWN\n\nThe first three statements are accurate representations of known scientific facts about the TAF10 co-activator and GATA1 transcription factor. Statement 4 and 5, although plausible, would require specific studies or evidence to confirm their accuracy, which is not provided in the context, so the veracity of these statements remains unknown without additional information.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1082,
    "user_query": "You MUST give a detailed answer to the following question: Are there any Decision support systems for chronic pain management ?",
    "llama-7b_response": "Yes, there are decision support systems for chronic pain management. These systems are designed to help healthcare providers and patients make informed decisions about the management of chronic pain.\n\nOne example of a decision support system for chronic pain management is the Pain Management Decision Support System (PM-DSS). PM-DSS is a web-based tool that provides clinicians with evidence-based recommendations for the management of chronic pain. The system includes a database of clinical guidelines, patient education materials, and other resources to support clinical decision-making.\n\nAnother example of a decision support system for chronic pain management is the Chronic Pain Management Decision Support System (CPMDSS). CPMDSS is a mobile app that provides patients with personalized recommendations for the management of chronic pain. The app includes a symptom checker, medication reminders, and other resources to support self-management of chronic pain.\n\nOverall, decision support systems for chronic pain management can help healthcare providers and patients make informed decisions about the management of chronic pain by providing evidence-based recommendations and personalized support.",
    "llama-7b_fact_raw": "1. There exist decision support systems designed to aid in the management of chronic pain.\n2. The Pain Management Decision Support System (PM-DSS) is a web-based tool that provides clinicians with evidence-based recommendations.\n3. PM-DSS includes a database that contains clinical guidelines and patient education materials.\n4. The Chronic Pain Management Decision Support System (CPMDSS) is a mobile app aimed at assisting patients with chronic pain management.\n5. CPMDSS features a symptom checker and medication reminders for its users.",
    "llama-7b_fact": [
      "There exist decision support systems designed to aid in the management of chronic pain.",
      "The Pain Management Decision Support System (PM-DSS) is a web-based tool that provides clinicians with evidence-based recommendations.",
      "PM-DSS includes a database that contains clinical guidelines and patient education materials.",
      "The Chronic Pain Management Decision Support System (CPMDSS) is a mobile app aimed at assisting patients with chronic pain management.",
      "CPMDSS features a symptom checker and medication reminders for its users."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The Chronic Pain Management Decision Support System (CPMDSS) is a fictional name; there is no widely recognized tool specifically by this name. However, there exist various decision support systems and mobile apps designed for chronic pain management that may have similar functionality.\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1149,
    "user_query": "You MUST give a detailed answer to the following question: Which is the subcellular localization of the protein angiogenin?",
    "llama-7b_response": "Angiogenin is a protein that plays a role in the process of angiogenesis, which is the formation of new blood vessels from pre-existing ones. The subcellular localization of angiogenin can vary depending on the cell type and the stage of the angiogenic process.\n\nIn general, angiogenin is found in the cytosol of cells, meaning it is present in the fluid inside the cell. However, during the early stages of angiogenesis, angiogenin can be found in the nucleus of endothelial cells, which are cells that line the inside of blood vessels.\n\nOnce angiogenesis is complete and new blood vessels have formed, angiogenin can be found in the extracellular space, which is the space outside of cells. It is thought that angiogenin may play a role in maintaining the integrity of newly formed blood vessels.\n\nOverall, the subcellular localization of angiogenin can vary depending on the cell type and the stage of the angiogenic process. It is present in the cytosol of cells during the early stages of angiogenesis and in the extracellular space once angiogenesis is complete.",
    "llama-7b_fact_raw": "1. Angiogenin plays a role in angiogenesis, which is the formation of new blood vessels from pre-existing ones.\n2. The subcellular localization of angiogenin varies depending on the cell type and the stage of the angiogenic process.\n3. Angiogenin is generally found in the cytosol of cells.\n4. During the early stages of angiogenesis, angiogenin can be localized in the nucleus of endothelial cells.\n5. Angiogenin can be found in the extracellular space after the completion of angiogenesis and the formation of new blood vessels.",
    "llama-7b_fact": [
      "Angiogenin plays a role in angiogenesis, which is the formation of new blood vessels from pre-existing ones.",
      "The subcellular localization of angiogenin varies depending on the cell type and the stage of the angiogenic process.",
      "Angiogenin is generally found in the cytosol of cells.",
      "During the early stages of angiogenesis, angiogenin can be localized in the nucleus of endothelial cells.",
      "Angiogenin can be found in the extracellular space after the completion of angiogenesis and the formation of new blood vessels."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Angiogenin can be found in the extracellular space but its presence is not limited to after the completion of angiogenesis. It can be secreted by cells and act on endothelial cells to promote angiogenesis at various stages of the process.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1161,
    "user_query": "You MUST give a detailed answer to the following question: How does ranolazine affect kinase signaling activation in the heart?",
    "llama-7b_response": "Ranolazine is a medication that is used to treat chronic angina, a type of chest pain that occurs when the blood flow to the muscles of the heart is reduced. It works by blocking the voltage-gated potassium channels in the heart, which helps to reduce the electrical activity in the heart and reduce the demand for oxygen in the muscles of the heart.\n\nIn terms of kinase signaling activation in the heart, ranolazine has been shown to inhibit the activity of several kinases, including AKT, ERK, and p38 MAPK. These kinases are involved in a variety of cellular processes, including cell survival, proliferation, and differentiation. By inhibiting the activity of these kinases, ranolazine may help to reduce the demand for oxygen in the muscles of the heart and reduce the frequency and severity of angina attacks.\n\nIt is worth noting that the exact mechanism by which ranolazine affects kinase signaling in the heart is not fully understood, and further research is needed to fully understand the effects of this medication on kinase signaling in the heart.",
    "llama-7b_fact_raw": "1. Ranolazine is used to treat chronic angina.\n2. Ranolazine works by blocking voltage-gated potassium channels in the heart.\n3. Blocking these channels helps to reduce the electrical activity in the heart.\n4. Ranolazine has been shown to inhibit the activity of several kinases including AKT, ERK, and p38 MAPK.\n5. The kinases affected by ranolazine are involved in cellular processes like cell survival, proliferation, and differentiation.",
    "llama-7b_fact": [
      "Ranolazine is used to treat chronic angina.",
      "Ranolazine works by blocking voltage-gated potassium channels in the heart.",
      "Blocking these channels helps to reduce the electrical activity in the heart.",
      "Ranolazine has been shown to inhibit the activity of several kinases including AKT, ERK, and p38 MAPK.",
      "The kinases affected by ranolazine are involved in cellular processes like cell survival, proliferation, and differentiation."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Ranolazine works by inhibiting the late phase of the inward sodium current in the heart, not by blocking voltage-gated potassium channels.\n3. FALSE [correction]: Reducing the late phase of the inward sodium current helps to decrease intracellular calcium levels and reduce the workload on the heart, which can help to control angina, not by reducing electrical activity through potassium channels.\n4. FALSE [correction]: While ranolazine can affect myocardial metabolism, there's no clear evidence that it inhibits the activity of kinases like AKT, ERK, and p38 MAPK as a primary mechanism of its anti-anginal effects.\n5. TRUE (though being true, this statement is irrelevant to the primary therapeutic action of ranolazine for angina as mentioned in the previous correction).",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1225,
    "user_query": "You MUST give a detailed answer to the following question: Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-7b_response": "Yes, the regulation of the VSR endonuclease is independent of the growth phase of bacteria.\n\nThe VSR endonuclease is a site-specific endonuclease that is involved in the integration of viral DNA into the bacterial genome. It has been shown to be regulated by a variety of factors, including the growth phase of the bacteria. For example, it has been shown that the activity of the VSR endonuclease is increased during the exponential phase of growth, and decreased during the stationary phase.\n\nHowever, it has also been shown that the regulation of the VSR endonuclease is independent of the growth phase of the bacteria. For example, it has been shown that the activity of the VSR endonuclease can be regulated by factors such as the concentration of Mg2+, the pH of the environment, and the presence of certain inhibitors. These factors can all affect the activity of the VSR endonuclease, regardless of the growth phase of the bacteria.\n\nTherefore, while the regulation of the VSR endonuclease may be influenced by the growth phase of the bacteria to some extent, it is not solely dependent on the growth phase and can be regulated by a variety of other factors as well.",
    "llama-7b_fact_raw": "1. The VSR endonuclease is a site-specific endonuclease involved in the integration of viral DNA into the bacterial genome.\n2. The activity of the VSR endonuclease increases during the exponential phase of bacterial growth.\n3. The activity of the VSR endonuclease decreases during the stationary phase of bacterial growth.\n4. The concentration of Mg2+ can regulate the activity of the VSR endonuclease.\n5. The pH of the environment and the presence of certain inhibitors can affect the activity of the VSR endonuclease regardless of the bacterial growth phase.",
    "llama-7b_fact": [
      "The VSR endonuclease is a site-specific endonuclease involved in the integration of viral DNA into the bacterial genome.",
      "The activity of the VSR endonuclease increases during the exponential phase of bacterial growth.",
      "The activity of the VSR endonuclease decreases during the stationary phase of bacterial growth.",
      "The concentration of Mg2+ can regulate the activity of the VSR endonuclease.",
      "The pH of the environment and the presence of certain inhibitors can affect the activity of the VSR endonuclease regardless of the bacterial growth phase."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The VSR endonuclease is not involved in the integration of viral DNA into the bacterial genome. VSR (Very Short Patch Repair) endonucleases are involved in DNA mismatch repair, specifically correcting T:G mismatches to the canonical A:T base pair in certain bacteria to correct errors that occur during DNA replication.\n2. UNKNOWN: The statement about the activity of VSR endonuclease increasing during the exponential phase is too vague without a specific scientific reference or context, as the regulation of enzyme activities can be complex and depends on various factors.\n3. UNKNOWN: Similar to statement 2, without specific context, it is unclear whether the activity of VSR endonuclease decreases during the stationary phase of bacterial growth as enzyme regulation can be complex.\n4. UNKNOWN: The effect of Mg2+ on VSR endonuclease activity could be true as magnesium ions are often required as cofactors for enzyme activity, but the statement is too vague without specific context regarding the VSR endonuclease.\n5. UNKNOWN: While it is generally true that environmental pH and the presence of inhibitors can affect enzyme activity, without specific context or scientific evidence about VSR endonuclease, the claim remains uncertain for this particular enzyme.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1233,
    "user_query": "You MUST give a detailed answer to the following question: What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-7b_response": "There are several computational tools available for the prediction of beta-barrel transmembrane proteins. Here are some of the most commonly used methods:\n\n1. TMHMM: TMHMM (Transmembrane Helices of Microbial Heme-containing proteins) is a widely used method for predicting transmembrane helices in proteins. It uses a hidden Markov model (HMM) to predict the location of transmembrane helices in proteins. TMHMM can also be used to predict beta-barrel proteins.\n2. beta-Barrel Predictor: The beta-Barrel Predictor is a web server that uses a machine learning approach to predict beta-barrel proteins. It uses a support vector machine (SVM) to classify proteins as beta-barrels or non-beta-barrels. The beta-Barrel Predictor has a high accuracy for predicting beta-barrel proteins.\n3. PSIPRED: PSIPRED (Protein Secondary Structure Prediction by Hidden Markov Models) is a web server that uses HMMs to predict the secondary structure of proteins. PSIPRED can be used to predict beta-barrel proteins by identifying the beta-strands that make up the beta-barrel.\n4. SCOP (Structural Classification of Proteins): SCOP (Structural Classification of Proteins) is a database and web server that classifies proteins based on their structural similarity. SCOP can be used to predict beta-barrel proteins by identifying proteins that have a beta-barrel structure.\n5. I-Tasser: I-Tasser is a web server that uses a combination of machine learning and bioinformatics methods to predict the structure and function of proteins. I-Tasser can be used to predict beta-barrel proteins by identifying the beta-strands that make up the beta-barrel.\n\nIn summary, there are several computational tools available for the prediction of beta-barrel transmembrane proteins, including TMHMM, beta-Barrel Predictor, PSIPRED, SCOP, and I-Tasser. These tools use different methods, such as HMMs, machine learning, and structural classification, to predict beta-",
    "llama-7b_fact_raw": "1. TMHMM is a computational method that uses a hidden Markov model to predict transmembrane helices in proteins and can be used to predict beta-barrel proteins.\n2. The beta-Barrel Predictor is a computational tool that utilizes a support vector machine to predict beta-barrel proteins.\n3. PSIPRED is a tool designed for protein secondary structure prediction using hidden Markov models and has the capability to predict beta-barrel proteins by identifying beta-strands.\n4. SCOP is a database and web server that classifies proteins based on structural similarity and can be utilized to predict beta-barrel proteins.\n5. I-Tasser is a web server that combines machine learning and bioinformatics to predict the structure and function of proteins, including the prediction of beta-barrel proteins.",
    "llama-7b_fact": [
      "TMHMM is a computational method that uses a hidden Markov model to predict transmembrane helices in proteins and can be used to predict beta-barrel proteins.",
      "The beta-Barrel Predictor is a computational tool that utilizes a support vector machine to predict beta-barrel proteins.",
      "PSIPRED is a tool designed for protein secondary structure prediction using hidden Markov models and has the capability to predict beta-barrel proteins by identifying beta-strands.",
      "SCOP is a database and web server that classifies proteins based on structural similarity and can be utilized to predict beta-barrel proteins.",
      "I-Tasser is a web server that combines machine learning and bioinformatics to predict the structure and function of proteins, including the prediction of beta-barrel proteins."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: TMHMM is a computational method that uses a hidden Markov model to predict transmembrane helices in proteins but it is designed for alpha-helical transmembrane proteins, not beta-barrel proteins.\n2. UNKNOWN: The correctness of this statement depends on the existence and features of a specific computational tool named \"beta-Barrel Predictor,\" which is not a widely recognized tool in literature as of my knowledge cutoff date. However, such a tool with that name may exist, or the statement may refer to a generic type of predictor which uses a support vector machine for beta-barrel proteins.\n3. FALSE [correction]: PSIPRED is designed for protein secondary structure prediction but it specifically predicts alpha-helices, beta-strands, and coils; it is not specifically designed to predict beta-barrel proteins, though identification of beta-strands could be indirectly useful in beta-barrel prediction.\n4. FALSE [correction]: SCOP is a database that classifies proteins into structural domains based on similarities in their structures; it does not predict protein structures nor specifically predict beta-barrel proteins.\n5. TRUE: I-TASSER is a web server for protein structure and function prediction that uses multiple methods, including threading, ab initio modeling, and machine learning. It can be used to predict the structure of proteins, including beta-barrel proteins, although it may not be specifically optimized for this protein class.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1251,
    "user_query": "You MUST give a detailed answer to the following question: Galassi classification is used for which disorder?",
    "llama-7b_response": "Galassi classification is used to classify congenital muscular dystrophies (CMDs), which are a group of inherited muscle disorders characterized by progressive muscle weakness and degeneration. The classification system was developed by Galassi et al. in 1998 and is based on clinical, genetic, and pathological features. There are three main categories of CMDs: Becker muscular dystrophy (BMD), Limb-girdle muscular dystrophy (LGMD), and Distal muscular dystrophy (DMD). Within each category, there are further subcategories based on specific genetic mutations and patterns of muscle involvement.",
    "llama-7b_fact_raw": "1. Galassi classification is used to classify congenital muscular dystrophies (CMDs).\n2. Congenital muscular dystrophies are characterized by progressive muscle weakness and degeneration.\n3. The Galassi classification system was developed in 1998 by Galassi et al.\n4. Becker muscular dystrophy (BMD), Limb-girdle muscular dystrophy (LGMD), and Distal muscular dystrophy (DMD) are the three main categories of CMDs under the Galassi classification.\n5. The Galassi classification includes subcategories based on specific genetic mutations and patterns of muscle involvement.",
    "llama-7b_fact": [
      "Galassi classification is used to classify congenital muscular dystrophies (CMDs).",
      "Congenital muscular dystrophies are characterized by progressive muscle weakness and degeneration.",
      "The Galassi classification system was developed in 1998 by Galassi et al.",
      "Becker muscular dystrophy (BMD), Limb-girdle muscular dystrophy (LGMD), and Distal muscular dystrophy (DMD) are the three main categories of CMDs under the Galassi classification.",
      "The Galassi classification includes subcategories based on specific genetic mutations and patterns of muscle involvement."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Galassi classification is used to classify cerebral cysts, not congenital muscular dystrophies (CMDs).\n2. TRUE\n3. UNKNOWN: There is no widely recognized classification system for congenital muscular dystrophies known as the Galassi classification, and I do not have information regarding a 1998 development of this system by Galassi et al. This statement possibly conflates information about cerebral cysts classification with the context of muscular dystrophies.\n4. FALSE [correction]: Becker muscular dystrophy (BMD), Limb-girdle muscular dystrophy (LGMD), and Distal muscular dystrophy (DMD) are separate types of muscular dystrophies, not categories under the Galassi classification, which pertains to cerebral cysts rather than CMDs.\n5. UNKNOWN: Since the Galassi classification does not apply to congenital muscular dystrophies, it is uncertain what this statement refers to. Congenital muscular dystrophies do have classifications based on genetic mutations and patterns of involvement, but this is unrelated to the Galassi classification.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1304,
    "user_query": "You MUST give a detailed answer to the following question: List common features of Shapiro syndrome",
    "llama-7b_response": "Shapiro syndrome is a rare genetic disorder that affects the body's ability to process amino acids, which are the building blocks of proteins. It is caused by a deficiency in the enzyme ornithine transcarbamylase (OTC), which is necessary for the breakdown of ornithine, an amino acid.\n\nHere are some common features of Shapiro syndrome:\n\n1. Hyperammonemia: This is a condition in which there is an abnormally high level of ammonia in the blood. Ammonia is a byproduct of the breakdown of ornithine, and it can build up to toxic levels in people with Shapiro syndrome.\n2. Liver dysfunction: The liver is responsible for breaking down ammonia and other toxins, so it is often affected in people with Shapiro syndrome. The liver may become enlarged and may not function properly, leading to a buildup of toxins in the blood.\n3. Intellectual disability: Intellectual disability is a common feature of Shapiro syndrome. This can range from mild to severe and may affect a person's ability to learn, communicate, and take care of themselves.\n4. Developmental delays: Children with Shapiro syndrome may experience delays in their physical and cognitive development. This can include delays in walking, talking, and other milestones.\n5. Behavioral problems: People with Shapiro syndrome may experience behavioral problems, such as aggression, irritability, and difficulty with social interactions.\n6. Eye abnormalities: Some people with Shapiro syndrome may have abnormalities in their eyes, such as cataracts, glaucoma, or nystagmus (involuntary movement of the eyes).\n7. Muscle weakness: Muscle weakness is a common feature of Shapiro syndrome, and it can affect the muscles in the arms, legs, and face. This can lead to difficulty with movement and coordination.\n8. Skin abnormalities: Some people with Shapiro syndrome may have skin abnormalities, such as acanthosis nigricans (a skin condition characterized by dark, thick, and velvety skin) or x",
    "llama-7b_fact_raw": "1. Shapiro syndrome is a genetic disorder that impacts the body's ability to process amino acids.\n2. The disorder is caused by a deficiency in the enzyme ornithine transcarbamylase (OTC).\n3. Hyperammonemia, an abnormal high level of ammonia in the blood, is a common feature of Shapiro syndrome.\n4. Liver dysfunction, including enlargement and impaired function, is often associated with Shapiro syndrome.\n5. Intellectual disability ranging from mild to severe is a common feature of Shapiro syndrome.",
    "llama-7b_fact": [
      "Shapiro syndrome is a genetic disorder that impacts the body's ability to process amino acids.",
      "The disorder is caused by a deficiency in the enzyme ornithine transcarbamylase (OTC).",
      "Hyperammonemia, an abnormal high level of ammonia in the blood, is a common feature of Shapiro syndrome.",
      "Liver dysfunction, including enlargement and impaired function, is often associated with Shapiro syndrome.",
      "Intellectual disability ranging from mild to severe is a common feature of Shapiro syndrome."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Shapiro syndrome is a rare neurologic disorder characterized by episodes of hypothermia, sweating, and agenesis of the corpus callosum, not an inability to process amino acids.\n2. FALSE [correction]: The enzyme deficiency causing a problem in processing amino acids, such as ornithine transcarbamylase deficiency, relates to urea cycle disorders, not Shapiro syndrome.\n3. FALSE [correction]: Hyperammonemia is typically associated with urea cycle disorders, not Shapiro syndrome.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1320,
    "user_query": "You MUST give a detailed answer to the following question: Which disease is linked to mutations within BRAG1?",
    "llama-7b_response": "BRAG1, also known as BRCA1-associated RING domain protein 1, is a protein that plays a role in the repair of damaged DNA. Mutations in the BRAG1 gene have been linked to the development of several types of cancer, including breast, ovarian, and prostate cancer.\n\nSpecifically, mutations in the BRAG1 gene have been found to be associated with an increased risk of developing hereditary breast and ovarian cancer syndrome (HBOC), which is a genetic disorder that increases the risk of developing breast and ovarian cancer. HBOC is caused by mutations in either the BRCA1 or BRCA2 genes, which are involved in the repair of damaged DNA.\n\nIn addition to HBOC, mutations in the BRAG1 gene have also been linked to the development of other types of cancer, including prostate cancer. Prostate cancer is the second leading cause of death from cancer among men in the United States.\n\nOverall, mutations in the BRAG1 gene have been found to be associated with an increased risk of developing several types of cancer, including breast, ovarian, and prostate cancer.",
    "llama-7b_fact_raw": "1. Mutations in the BRAG1 gene are linked to the development of several types of cancer.\n2. Hereditary breast and ovarian cancer syndrome (HBOC) is associated with mutations in the BRAG1 gene.\n3. HBOC increases the risk of developing breast and ovarian cancer and is caused by mutations in BRCA1 or BRCA2 genes.\n4. Mutations in the BRAG1 gene have also been linked to the development of prostate cancer.\n5. Prostate cancer is the second leading cause of death from cancer among men in the United States.",
    "llama-7b_fact": [
      "Mutations in the BRAG1 gene are linked to the development of several types of cancer.",
      "Hereditary breast and ovarian cancer syndrome (HBOC) is associated with mutations in the BRAG1 gene.",
      "HBOC increases the risk of developing breast and ovarian cancer and is caused by mutations in BRCA1 or BRCA2 genes.",
      "Mutations in the BRAG1 gene have also been linked to the development of prostate cancer.",
      "Prostate cancer is the second leading cause of death from cancer among men in the United States."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Mutations in the BRCA1 gene, not BRAG1, are linked to the development of several types of cancer.\n2. FALSE [correction]: Hereditary breast and ovarian cancer syndrome (HBOC) is associated with mutations in the BRCA1 and BRCA2 genes, not BRAG1.\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: Prostate cancer is the second most common cancer among men in the United States, but it is not the second leading cause of death from cancer among men; lung cancer is.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1362,
    "user_query": "You MUST give a detailed answer to the following question: Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-7b_response": "",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1374,
    "user_query": "You MUST give a detailed answer to the following question: Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-7b_response": "Adaptive mutagenesis, also known as stationary-phase mutagenesis, is a process by which bacteria, such as Bacillus subtilis, undergo genetic changes in response to environmental stress, such as a lack of nutrients. This process allows the bacteria to adapt and survive in the face of adverse conditions.\n\nThere are several mechanisms that underlie adaptive mutagenesis in B. subtilis:\n\n1. Mutator mutations: These are mutations that increase the frequency of mutations in the bacterial genome. The mutator phenotype is conferred by mutations in the mutS and mutL genes, which are involved in DNA mismatch repair. B. subtilis strains with a mutator phenotype have a higher frequency of spontaneous mutations and are more likely to undergo adaptive mutagenesis.\n2. Transposon mutagenesis: Transposons are mobile genetic elements that can insert themselves into the genome of B. subtilis. When transposons insert themselves into the genome, they can disrupt the function of nearby genes, leading to mutations. Transposon mutagenesis is a major mechanism of adaptive mutagenesis in B. subtilis.\n3. DNA damage response: B. subtilis responds to DNA damage by activating the DNA damage checkpoint, which delays cell division until the damage is repaired. If the damage is not repaired, the cell can undergo programmed cell death, or apoptosis, which can lead to the selection of cells with mutations that allow them to survive in the presence of DNA damage.\n4. Genetic recombination: Genetic recombination, or the exchange of genetic material between bacterial cells, can lead to the integration of new genetic elements into the genome, which can result in mutations. Genetic recombination is particularly important in B. subtilis during competence, a state in which the bacteria are able to take up extracellular DNA and use it as a source of genetic information.\n\nOverall, these mechanisms allow B. subtilis to undergo adaptive mutagenesis and evolve genetic changes that allow it to survive in the face of environmental stress.",
    "llama-7b_fact_raw": "1. Adaptive mutagenesis in B. subtilis is a process where the bacteria undergo genetic changes in response to environmental stress, such as nutrient scarcity.\n2. Mutator mutations that increase mutation frequency in B. subtilis are conferred by mutations in the mutS and mutL genes, which play a role in DNA mismatch repair.\n3. Transposon mutagenesis is a significant mechanism in B. subtilis, where mobile genetic elements insert into the genome and potentially disrupt gene function.\n4. B. subtilis activates a DNA damage checkpoint in response to DNA damage, which can lead to the selection of cells with survival mutations if the damage remains unrepaired.\n5. Genetic recombination in B. subtilis, especially during competence, can lead to the integration of new genetic material into the genome, resulting in mutations.",
    "llama-7b_fact": [
      "Adaptive mutagenesis in B. subtilis is a process where the bacteria undergo genetic changes in response to environmental stress, such as nutrient scarcity.",
      "Mutator mutations that increase mutation frequency in B. subtilis are conferred by mutations in the mutS and mutL genes, which play a role in DNA mismatch repair.",
      "Transposon mutagenesis is a significant mechanism in B. subtilis, where mobile genetic elements insert into the genome and potentially disrupt gene function.",
      "B. subtilis activates a DNA damage checkpoint in response to DNA damage, which can lead to the selection of cells with survival mutations if the damage remains unrepaired.",
      "Genetic recombination in B. subtilis, especially during competence, can lead to the integration of new genetic material into the genome, resulting in mutations."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Genetic recombination in B. subtilis, especially during competence, can lead to the integration of new genetic material into the genome, but this is not considered mutation. Recombination involves the exchange of genetic material between different DNA molecules, and it doesn't necessarily result in mutations, which are changes in the DNA sequence.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1399,
    "user_query": "You MUST give a detailed answer to the following question: What causes erucism?",
    "llama-7b_response": "Erucism, also known as goitrogenic hypothyroidism, is a condition caused by a deficiency of iodine in the diet, which leads to an enlargement of the thyroid gland (goiter) and an underactive thyroid gland (hypothyroidism).\n\nThe thyroid gland is located in the neck and is responsible for producing hormones that regulate metabolism, growth and development, and body temperature. Iodine is an essential nutrient that the thyroid gland needs to produce these hormones.\n\nWhen there is a deficiency of iodine in the diet, the thyroid gland tries to compensate by producing more thyroid hormones. However, this can lead to an enlargement of the thyroid gland (goiter) and an underactive thyroid gland (hypothyroidism). This condition is known as erucism.\n\nErucism can also be caused by consuming foods that contain goitrogens, which are compounds that interfere with the absorption of iodine in the body. These foods include cruciferous vegetables such as broccoli, cauliflower, cabbage, and Brussels sprouts.\n\nIn summary, erucism is caused by a deficiency of iodine in the diet, which leads to an enlargement of the thyroid gland (goiter) and an underactive thyroid gland (hypothyroidism). It can also be caused by consuming foods that contain goitrogens, which interfere with the absorption of iodine in the body.",
    "llama-7b_fact_raw": "1. Erucism is a condition caused by a deficiency of iodine in the diet.\n2. The condition leads to an enlargement of the thyroid gland, known as a goiter.\n3. It also results in an underactive thyroid gland, referred to as hypothyroidism.\n4. The thyroid gland needs iodine to produce hormones that regulate metabolism, growth and development, and body temperature.\n5. Goitrogens are compounds that can cause erucism by interfering with the absorption of iodine; they are found in cruciferous vegetables like broccoli, cauliflower, cabbage, and Brussels sprouts.",
    "llama-7b_fact": [
      "Erucism is a condition caused by a deficiency of iodine in the diet.",
      "The condition leads to an enlargement of the thyroid gland, known as a goiter.",
      "It also results in an underactive thyroid gland, referred to as hypothyroidism.",
      "The thyroid gland needs iodine to produce hormones that regulate metabolism, growth and development, and body temperature.",
      "Goitrogens are compounds that can cause erucism by interfering with the absorption of iodine; they are found in cruciferous vegetables like broccoli, cauliflower, cabbage, and Brussels sprouts."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Erucism is not a condition related to iodine deficiency; it is a reaction caused by contact with certain caterpillars. The condition caused by iodine deficiency is called iodine deficiency disorders.\n2. FALSE [correction]: The statement is about a condition caused by iodine deficiency, which would be a goiter, but it is not called erucism.\n3. TRUE: An underactive thyroid gland due to iodine deficiency is indeed referred to as hypothyroidism.\n4. TRUE: The thyroid gland does need iodine to produce hormones that regulate metabolism, growth and development, and body temperature.\n5. TRUE: Goitrogens are compounds that can interfere with the absorption of iodine and may contribute to goiter formation, although they are not the direct cause of erucism.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1413,
    "user_query": "You MUST give a detailed answer to the following question: What are the indications for hydrochlorothiazide?",
    "llama-7b_response": "Hydrochlorothiazide is a thiazide diuretic medication that is used to treat hypertension (high blood pressure) and edema (swelling) caused by various conditions, such as heart failure, liver disease, and kidney disease. It works by increasing the production of urine, which helps to remove excess fluid from the body. Hydrochlorothiazide is also used to treat hypokalemia (low potassium levels in the blood), which can occur as a side effect of certain diuretics or as a result of certain medical conditions. In addition, hydrochlorothiazide may be used to treat other conditions as determined by a healthcare provider.",
    "llama-7b_fact_raw": "1. Hydrochlorothiazide is used to treat hypertension (high blood pressure).\n2. Hydrochlorothiazide is prescribed for the treatment of edema (swelling) associated with heart failure, liver disease, and kidney disease.\n3. The mechanism of action for hydrochlorothiazide involves increasing the production of urine.\n4. Hydrochlorothiazide is employed in the treatment of hypokalemia (low potassium levels in the blood).\n5. Hydrochlorothiazide may be used to treat other conditions as determined by a healthcare provider.",
    "llama-7b_fact": [
      "Hydrochlorothiazide is used to treat hypertension (high blood pressure).",
      "Hydrochlorothiazide is prescribed for the treatment of edema (swelling) associated with heart failure, liver disease, and kidney disease.",
      "The mechanism of action for hydrochlorothiazide involves increasing the production of urine.",
      "Hydrochlorothiazide is employed in the treatment of hypokalemia (low potassium levels in the blood).",
      "Hydrochlorothiazide may be used to treat other conditions as determined by a healthcare provider."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Hydrochlorothiazide can cause hypokalemia as a side effect, not treat it.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1447,
    "user_query": "You MUST give a detailed answer to the following question: Has silicon been used in treatment of  incontinence ?",
    "llama-7b_response": "Yes, silicone has been used in the treatment of stress urinary incontinence (SUI) in women. Silicone is a synthetic substance that is often used in medical devices and implants because of its durability and biocompatibility.\n\nSilicone implants for SUI are designed to be placed in the vagina and act as a \"sling\" to support the urethra and prevent urine leakage. These implants are typically made of a soft, pliable silicone material that can be adjusted to fit the individual patient's anatomy.\n\nSilicone implants for SUI have been shown to be effective in reducing urine leakage and improving quality of life in women with SUI. However, like any medical device, there are potential risks and complications associated with their use, including infection, bleeding, and implant migration. It is important for patients to discuss the risks and benefits of silicone implants for SUI with their healthcare provider before making a decision about treatment.",
    "llama-7b_fact_raw": "1. Silicone has been used in the treatment of stress urinary incontinence (SUI) in women.\n2. Silicone is known for its durability and biocompatibility for use in medical devices and implants.\n3. Silicone implants are used in SUI treatments to support the urethra and prevent urine leakage.\n4. The implants for SUI are made of soft, pliable silicone material that can be adjusted to fit the patient's anatomy.\n5. Silicone implants for SUI can reduce urine leakage and improve quality of life but come with potential risks like infection, bleeding, and implant migration.",
    "llama-7b_fact": [
      "Silicone has been used in the treatment of stress urinary incontinence (SUI) in women.",
      "Silicone is known for its durability and biocompatibility for use in medical devices and implants.",
      "Silicone implants are used in SUI treatments to support the urethra and prevent urine leakage.",
      "The implants for SUI are made of soft, pliable silicone material that can be adjusted to fit the patient's anatomy.",
      "Silicone implants for SUI can reduce urine leakage and improve quality of life but come with potential risks like infection, bleeding, and implant migration."
    ],
    "llama-7b_judge_raw": "1. TRUE: Silicone has been used in the treatment of stress urinary incontinence (SUI) in women, often in the form of urethral bulking agents or other supportive implants.\n2. TRUE: Silicone is known for its durability and biocompatibility, making it a common choice for various medical devices and implants.\n3. TRUE: Silicone implants or bulking agents are indeed used in SUI treatments to provide additional support to the urethra to help prevent urine leakage.\n4. TRUE: Implants for SUI, such as urethral bulking agents, are generally made of soft, pliable silicone material that can conform to the patient's anatomy.\n5. TRUE: While silicone implants for SUI can reduce urine leakage and may improve the quality of life, they do come with potential risks such as infection, bleeding, and implant migration, which are known complications of such procedures.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "You MUST give a detailed answer to the following question: What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-7b_response": "The association between the moon cycle and rupture risk of intracranial aneurysms is a topic of ongoing research and debate. Some studies have suggested that there may be a correlation between the phases of the moon and the occurrence of intracranial aneurysm ruptures, while others have found no such association.\n\nIt is thought that the moon's gravitational pull may have an effect on the blood flow in the brain, which could potentially influence the rupture risk of an intracranial aneurysm. However, the exact mechanism by which this might occur is not well understood.\n\nSeveral studies have investigated the relationship between the moon cycle and intracranial aneurysm ruptures, with mixed results. Some studies have found that the risk of rupture may be higher during certain phases of the moon, such as the full moon or the new moon, while others have found no such association.\n\nFor example, a study published in the journal Neurology in 2012 found that the risk of intracranial aneurysm rupture was significantly higher during the full moon phase compared to other phases of the moon. However, another study published in the same journal in 2016 found no such association.\n\nIt is worth noting that these studies have limitations, such as small sample sizes and potential confounding factors, and more research is needed to determine the true association between the moon cycle and intracranial aneurysm ruptures.\n\nIn summary, the association between the moon cycle and rupture risk of intracranial aneurysms is a topic of ongoing research and debate. While some studies have suggested that there may be a correlation between the phases of the moon and the occurrence of intracranial aneurysm ruptures, others have found no such association. Further research is needed to better understand this relationship.",
    "llama-7b_fact_raw": "1. Some studies suggest a correlation between moon phases and the occurrence of intracranial aneurysm ruptures.\n2. The hypothesis for the association involves the moon's gravitational pull potentially affecting blood flow in the brain.\n3. Research on this topic has produced mixed results, with some studies indicating a higher risk during certain moon phases, like the full moon.\n4. A study published in the journal Neurology in 2012 found a higher risk of intracranial aneurysm rupture during the full moon.\n5. Another study in the same journal in 2016 did not find an association between the moon cycle and the risk of intracranial aneurysm rupture.",
    "llama-7b_fact": [
      "Some studies suggest a correlation between moon phases and the occurrence of intracranial aneurysm ruptures.",
      "The hypothesis for the association involves the moon's gravitational pull potentially affecting blood flow in the brain.",
      "Research on this topic has produced mixed results, with some studies indicating a higher risk during certain moon phases, like the full moon.",
      "A study published in the journal Neurology in 2012 found a higher risk of intracranial aneurysm rupture during the full moon.",
      "Another study in the same journal in 2016 did not find an association between the moon cycle and the risk of intracranial aneurysm rupture."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN (The statement may be true or false; however, without access to the archives of the journal Neurology or the specific study, we cannot verify the claim.)\n5. UNKNOWN (As with the previous statement, the truthfulness of this statement cannot be established without access to the specific study published in the journal Neurology in 2016.)",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1477,
    "user_query": "You MUST give a detailed answer to the following question: Does HuR protein regulate the splicing process?",
    "llama-7b_response": "Yes, HuR (ELAVL1) protein has been shown to regulate the splicing process.\n\nHuR is a RNA-binding protein that plays a crucial role in the regulation of gene expression at the post-transcriptional level. One of the key functions of HuR is to bind to unspliced or partially spliced pre-mRNAs and to promote their splicing by recruiting splicing factors and modulating their activity.\n\nHuR has been shown to interact with a variety of splicing factors, including SF2/ASF, SC35, and hnRNPA/B, and to regulate the splicing of a wide range of genes. For example, HuR has been shown to play a role in the splicing of tumor suppressor genes, such as p53 and retinoblastoma, as well as in the splicing of genes involved in cell proliferation, differentiation, and apoptosis.\n\nFurthermore, HuR has also been shown to regulate the splicing of microRNAs (miRNAs), which are small non-coding RNAs that play a crucial role in post-transcriptional gene regulation. HuR has been shown to bind to miRNA precursors and to promote their splicing, leading to the production of mature miRNAs that can regulate the expression of target genes.\n\nOverall, HuR is a key regulator of the splicing process and plays a crucial role in the regulation of gene expression at the post-transcriptional level.",
    "llama-7b_fact_raw": "1. HuR (ELAVL1) protein regulates the splicing process.\n2. HuR is a RNA-binding protein that is involved in the regulation of gene expression at the post-transcriptional level.\n3. HuR promotes splicing by recruiting splicing factors and modulating their activity.\n4. HuR interacts with splicing factors such as SF2/ASF, SC35, and hnRNPA/B.\n5. HuR is involved in the splicing of microRNAs (miRNAs) precursors, promoting the production of mature miRNAs.",
    "llama-7b_fact": [
      "HuR (ELAVL1) protein regulates the splicing process.",
      "HuR is a RNA-binding protein that is involved in the regulation of gene expression at the post-transcriptional level.",
      "HuR promotes splicing by recruiting splicing factors and modulating their activity.",
      "HuR interacts with splicing factors such as SF2/ASF, SC35, and hnRNPA/B.",
      "HuR is involved in the splicing of microRNAs (miRNAs) precursors, promoting the production of mature miRNAs."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: HuR (ELAVL1) protein is primarily known for regulating mRNA stability and translation at the post-transcriptional level, not the splicing process. \n2. TRUE\n3. FALSE [correction]: While HuR has been implicated in a variety of post-transcriptional regulatory processes, its role in promoting splicing by recruiting splicing factors is not well-established. If it does have a role in splicing, it would be indirect and not through the recruitment and modulation of splicing factor activity.\n4. TRUE: HuR is known to interact with a range of RNA-binding proteins and splicing factors, though the direct interactions with SF2/ASF, SC35, and hnRNPA/B would need to be supported by specific literature to affirm this statement.\n5. UNKNOWN: The involvement of HuR in microRNA (miRNA) processing is an area of ongoing research, and while there are studies suggesting that HuR might play a role in miRNA biogenesis, it is not well-established that it is involved in promoting the splicing of miRNA precursors to produce mature miRNAs. Without specific context or references, the statement's accuracy is uncertain.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1492,
    "user_query": "You MUST give a detailed answer to the following question: Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-7b_response": "The prothymosin alpha c-terminal peptide is a small protein fragment that is derived from the larger prothymosin alpha protein. The known functions of the prothymosin alpha c-terminal peptide include:\n\n1. Regulation of gene expression: The prothymosin alpha c-terminal peptide has been shown to regulate the expression of certain genes, including genes involved in immune function and inflammation.\n2. Modulation of immune responses: The prothymosin alpha c-terminal peptide has been shown to modulate immune responses, including the activation of T cells and the production of cytokines.\n3. Anti-inflammatory effects: The prothymosin alpha c-terminal peptide has been shown to have anti-inflammatory effects, including the inhibition of the production of certain pro-inflammatory cytokines.\n4. Neuroprotective effects: The prothymosin alpha c-terminal peptide has been shown to have neuroprotective effects, including the protection of neurons against oxidative stress and the promotion of neuronal survival.\n5. Anti-cancer effects: The prothymosin alpha c-terminal peptide has been shown to have anti-cancer effects, including the inhibition of cancer cell growth and the promotion of cancer cell death.\n\nOverall, the prothymosin alpha c-terminal peptide appears to have a wide range of potential therapeutic applications, including the treatment of inflammatory disorders, neurodegenerative diseases, and cancer. However, further research is needed to fully understand the mechanisms by which the prothymosin alpha c-terminal peptide exerts its effects and to determine its safety and efficacy as a therapeutic agent.",
    "llama-7b_fact_raw": "1. The prothymosin alpha c-terminal peptide regulates the expression of certain genes including those involved in immune function and inflammation.\n2. It modulates immune responses such as the activation of T cells and the production of cytokines.\n3. The prothymosin alpha c-terminal peptide has shown anti-inflammatory effects by inhibiting the production of certain pro-inflammatory cytokines.\n4. It has exhibited neuroprotective effects, including protecting neurons against oxidative stress and promoting neuronal survival.\n5. The peptide has anti-cancer properties that include inhibition of cancer cell growth and promotion of cancer cell death.",
    "llama-7b_fact": [
      "The prothymosin alpha c-terminal peptide regulates the expression of certain genes including those involved in immune function and inflammation.",
      "It modulates immune responses such as the activation of T cells and the production of cytokines.",
      "The prothymosin alpha c-terminal peptide has shown anti-inflammatory effects by inhibiting the production of certain pro-inflammatory cytokines.",
      "It has exhibited neuroprotective effects, including protecting neurons against oxidative stress and promoting neuronal survival.",
      "The peptide has anti-cancer properties that include inhibition of cancer cell growth and promotion of cancer cell death."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nBased on scientific understanding as of my knowledge cutoff in 2023, prothymosin alpha is known to play a role in regulating gene expression, modulating immune responses, and having anti-inflammatory effects. It has also been studied for neuroprotective and anti-cancer properties. However, please note that ongoing research may provide further insights or updates to these statements.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1516,
    "user_query": "You MUST give a detailed answer to the following question: Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-7b_response": "The peptide that plays a pivotal role in human cystatin C fibrillization is the C-terminal domain (CTD) of cystatin C.\n\nCystatin C is a cysteine protease inhibitor that plays a role in regulating various cellular processes, including protein folding, trafficking, and degradation. It is also involved in the regulation of the actin cytoskeleton and the maintenance of cellular homeostasis.\n\nFibrillization of cystatin C is a process in which the protein undergoes a series of structural changes that result in the formation of amyloid fibrils. These fibrils can accumulate in various tissues and organs, leading to a range of pathological conditions, including neurodegeneration, cardiovascular disease, and kidney dysfunction.\n\nThe CTD of cystatin C has been shown to play a pivotal role in the fibrillization process. The CTD is a highly conserved region of cystatin C that is involved in the regulation of various cellular processes, including protein folding, trafficking, and degradation. It is also involved in the regulation of the actin cytoskeleton and the maintenance of cellular homeostasis.\n\nStudies have shown that the CTD of cystatin C undergoes a series of structural changes during the fibrillization process, leading to the formation of amyloid fibrils. These fibrils can accumulate in various tissues and organs, leading to a range of pathological conditions, including neurodegeneration, cardiovascular disease, and kidney dysfunction.\n\nIn summary, the CTD of cystatin C plays a pivotal role in the fibrillization of cystatin C, which can lead to a range of pathological conditions. Understanding the mechanisms underlying cystatin C fibrillization is important for the development of therapeutic strategies to prevent or treat these conditions.",
    "llama-7b_fact_raw": "1. The C-terminal domain (CTD) of cystatin C plays a pivotal role in human cystatin C fibrillization.\n2. Cystatin C is a cysteine protease inhibitor involved in regulating protein folding, trafficking, and degradation.\n3. The fibrillization of cystatin C involves the protein undergoing structural changes to form amyloid fibrils.\n4. Amyloid fibrils from cystatin C fibrillization can accumulate in tissues and organs, leading to pathological conditions such as neurodegeneration, cardiovascular disease, and kidney dysfunction.\n5. The CTD of cystatin C is a highly conserved region that regulates various cellular processes, including the actin cytoskeleton and cellular homeostasis.",
    "llama-7b_fact": [
      "The C-terminal domain (CTD) of cystatin C plays a pivotal role in human cystatin C fibrillization.",
      "Cystatin C is a cysteine protease inhibitor involved in regulating protein folding, trafficking, and degradation.",
      "The fibrillization of cystatin C involves the protein undergoing structural changes to form amyloid fibrils.",
      "Amyloid fibrils from cystatin C fibrillization can accumulate in tissues and organs, leading to pathological conditions such as neurodegeneration, cardiovascular disease, and kidney dysfunction.",
      "The CTD of cystatin C is a highly conserved region that regulates various cellular processes, including the actin cytoskeleton and cellular homeostasis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The CTD (C-terminal domain) reference in regards to cystatin C relates specifically to its role in fibrillization, not necessarily to a regulatory role in various cellular processes such as the actin cytoskeleton and cellular homeostasis. These processes are typically regulated by a variety of proteins and signaling pathways, not specifically by the C-terminal domain of cystatin C.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1574,
    "user_query": "You MUST give a detailed answer to the following question: Does the concentration of protein HIF-1 increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-7b_response": "Yes, the concentration of protein HIF-1 (hypoxia-inducible factor 1 alpha) can increase after the administration of the cytoprotective prodrug amifostine (ethyol).\n\nHIF-1 is a transcription factor that plays a crucial role in the response of cells to hypoxia (low oxygen levels). It regulates the expression of genes involved in various cellular processes, including angiogenesis, metabolism, and cell survival.\n\nAmifostine (ethyol) is a cytoprotective prodrug that is administered to protect cells against the toxic effects of chemotherapy and radiation therapy. It is a water-soluble compound that is converted to a more stable form in cells, which can then be transported across the cell membrane and into the cytoplasm. Once inside the cell, amifostine can react with and detoxify reactive oxygen species (ROS) and other reactive nitrogen species (RNS) that are generated during chemotherapy and radiation therapy.\n\nThe effect of amifostine on the concentration of HIF-1 has been studied in various cell lines and in vivo models. In some studies, amifostine has been shown to increase the concentration of HIF-1 in response to hypoxia. This increase in HIF-1 can lead to the upregulation of genes involved in angiogenesis, metabolism, and cell survival, which can contribute to the cytoprotective effects of amifostine.\n\nIn summary, the concentration of protein HIF-1 can increase after the administration of the cytoprotective prodrug amifostine (ethyol) in response to hypoxia. This increase in HIF-1 can contribute to the cytoprotective effects of amifostine and may play a role in its ability to protect cells against the toxic effects of chemotherapy and radiation therapy.",
    "llama-7b_fact_raw": "1. The concentration of protein HIF-1 can increase after the administration of amifostine (ethyol).\n2. HIF-1 is a transcription factor involved in the cellular response to hypoxia.\n3. Amifostine is a cytoprotective prodrug used to protect cells from the toxic effects of chemotherapy and radiation therapy.\n4. In the cell, amifostine detoxifies reactive oxygen species and reactive nitrogen species created during chemotherapy and radiation therapy.\n5. Studies have shown that amifostine can upregulate genes involved in angiogenesis, metabolism, and cell survival via increased HIF-1 levels.",
    "llama-7b_fact": [
      "The concentration of protein HIF-1 can increase after the administration of amifostine (ethyol).",
      "HIF-1 is a transcription factor involved in the cellular response to hypoxia.",
      "Amifostine is a cytoprotective prodrug used to protect cells from the toxic effects of chemotherapy and radiation therapy.",
      "In the cell, amifostine detoxifies reactive oxygen species and reactive nitrogen species created during chemotherapy and radiation therapy.",
      "Studies have shown that amifostine can upregulate genes involved in angiogenesis, metabolism, and cell survival via increased HIF-1 levels."
    ],
    "llama-7b_judge_raw": "1. TRUE: The concentration of HIF-1 (Hypoxia-Inducible Factor 1-alpha) can indeed increase after the administration of amifostine, as one of the roles of HIF-1 is to help cells respond to hypoxia, and amifostine can affect cellular pathways that include hypoxia response.\n2. TRUE: HIF-1 is a transcription factor that is a key component in the cellular response to hypoxia. It helps the cell adapt to low oxygen conditions by activating the transcription of genes that help in adaptation and survival under such conditions.\n3. TRUE: Amifostine is a cytoprotective prodrug which means it is administered in an inactive form and converted to an active form within the body. It is used to reduce the damage to normal cells caused by chemotherapy and radiation therapy.\n4. TRUE: In its active form, amifostine works by scavenging reactive oxygen species (ROS) and possibly reactive nitrogen species (RNS), which are harmful byproducts increased during chemotherapy and radiation therapy that can damage DNA and cellular components.\n5. TRUE: Studies have suggested that amifostine has the potential to upregulate various genes involved in angiogenesis, metabolism, and cell survival, and this can include effects mediated by increased HIF-1 levels under certain conditions, such as hypoxia or oxidative stress.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1588,
    "user_query": "You MUST give a detailed answer to the following question: Which histone marks are deposited by Set7?",
    "llama-7b_response": "Set7 is a histone lysine methyltransferase that adds a methyl group to histone H3 at lysine 27 (H3K27) to repress transcription. In addition to H3K27, Set7 can also add methyl groups to histone H3 at lysine 36 (H3K36) and histone H4 at lysine 20 (H4K20) to repress transcription. These histone marks are often referred to as \"Set7 marks\" or \"Set7-specific marks.\"",
    "llama-7b_fact_raw": "1. Set7 is a histone lysine methyltransferase.\n2. Set7 adds a methyl group to histone H3 at lysine 27 (H3K27).\n3. The methylation of histone H3 at lysine 27 (H3K27) by Set7 is associated with repression of transcription.\n4. Set7 can also add methyl groups to histone H3 at lysine 36 (H3K36).\n5. Set7 is capable of methylating histone H4 at lysine 20 (H4K20).",
    "llama-7b_fact": [
      "Set7 is a histone lysine methyltransferase.",
      "Set7 adds a methyl group to histone H3 at lysine 27 (H3K27).",
      "The methylation of histone H3 at lysine 27 (H3K27) by Set7 is associated with repression of transcription.",
      "Set7 can also add methyl groups to histone H3 at lysine 36 (H3K36).",
      "Set7 is capable of methylating histone H4 at lysine 20 (H4K20)."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Set7 specifically adds a methyl group to histone H3 at lysine 4 (H3K4), not lysine 27 (H3K27).\n3. FALSE [correction]: The methylation of histone H3 at lysine 27 (H3K27) is associated with repression of transcription, but Set7 is not responsible for this modification. It is the EZH2 subunit of the PRC2 complex that typically mediates H3K27 methylation.\n4. FALSE [correction]: Set7/9 specifically methylates lysine 4 of histone H3 (H3K4) and does not methylate lysine 36 (H3K36).\n5. FALSE [correction]: Set7/9 specifically methylates lysine 4 of histone H3 (H3K4) and does not methylate histone H4 at lysine 20 (H4K20). Methylation of H4K20 is typically associated with other methyltransferases such as SUV420H1 and SUV420H2.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1620,
    "user_query": "You MUST give a detailed answer to the following question: How many disulfide bridges has the protein hepcidin got?",
    "llama-7b_response": "Hepcidin is a protein that plays a crucial role in the regulation of iron metabolism in the body. It is composed of two polypeptide chains, which are linked together by disulfide bridges. The exact number of disulfide bridges in hepcidin can vary depending on the species and the specific isoform of the protein. However, it is generally accepted that hepcidin contains between 4 and 6 disulfide bridges.",
    "llama-7b_fact_raw": "1. Hepcidin is a protein involved in the regulation of iron metabolism.\n2. Hepcidin is composed of two polypeptide chains.\n3. These polypeptide chains are linked together by disulfide bridges.\n4. The number of disulfide bridges in hepcidin can vary depending on the species.\n5. Hepcidin generally contains between 4 and 6 disulfide bridges.",
    "llama-7b_fact": [
      "Hepcidin is a protein involved in the regulation of iron metabolism.",
      "Hepcidin is composed of two polypeptide chains.",
      "These polypeptide chains are linked together by disulfide bridges.",
      "The number of disulfide bridges in hepcidin can vary depending on the species.",
      "Hepcidin generally contains between 4 and 6 disulfide bridges."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Hepcidin is composed of a single polypeptide chain.\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: Hepcidin contains 4 disulfide bridges.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1643,
    "user_query": "You MUST give a detailed answer to the following question: What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-7b_response": "The localization of the protein encoded by the gene DNAJC11 is not well understood. DNAJC11 is a member of the DNAJ (HSP40) family of chaperone proteins, which are involved in the folding, assembly, and transport of other proteins within the cell. While some members of the DNAJ family have been shown to localize to specific subcellular compartments, such as the endoplasmic reticulum or the mitochondria, the localization of DNAJC11 has not been extensively studied.\n\nIt is possible that DNAJC11 localizes to multiple subcellular compartments or that its localization is regulated in a tissue-specific or cell-specific manner. Further research is needed to determine the precise localization of DNAJC11 and the role it plays in the cell.",
    "llama-7b_fact_raw": "1. DNAJC11 is a gene that encodes for a protein.\n2. The protein encoded by DNAJC11 is a member of the DNAJ (HSP40) family of chaperone proteins.\n3. Chaperone proteins are involved in protein folding, assembly, and transport within the cell.\n4. The precise localization of the DNAJC11 protein within the cell is not well understood.\n5. Some members of the DNAJ family are known to localize to specific subcellular compartments, such as the endoplasmic reticulum or mitochondria.",
    "llama-7b_fact": [
      "DNAJC11 is a gene that encodes for a protein.",
      "The protein encoded by DNAJC11 is a member of the DNAJ (HSP40) family of chaperone proteins.",
      "Chaperone proteins are involved in protein folding, assembly, and transport within the cell.",
      "The precise localization of the DNAJC11 protein within the cell is not well understood.",
      "Some members of the DNAJ family are known to localize to specific subcellular compartments, such as the endoplasmic reticulum or mitochondria."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1655,
    "user_query": "You MUST give a detailed answer to the following question: Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-7b_response": "Ultraconserved elements (UCEs) are regions of the genome that are highly conserved across evolutionary time and are believed to be functionally important. UCEs are defined as regions of at least 200 nucleotides in length that are at least 100 times more conserved than the average genomic sequence.\n\nCopy number variants (CNVs) are variations in the number of copies of a particular genomic region. CNVs can arise through a variety of mechanisms, including duplications, deletions, and translocations.\n\nIt is possible that UCEs could be affected by CNVs, as CNVs can alter the copy number of UCEs and potentially affect their function. However, there is currently limited information on the relationship between UCEs and CNVs. Some studies have suggested that UCEs may be more likely to be affected by CNVs than other regions of the genome, but this has not been widely confirmed.\n\nIn summary, while it is possible that UCEs could be affected by CNVs, the relationship between UCEs and CNVs is not well understood and more research is needed to determine the extent to which UCEs are depleted among CNVs.",
    "llama-7b_fact_raw": "1. Ultraconserved elements (UCEs) are regions in the genome that are highly conserved across evolutionary time.\n2. UCEs are defined as regions of at least 200 nucleotides in length that are incredibly conserved, being at least 100 times more conserved than the average genomic sequence.\n3. Copy number variants (CNVs) are variations in the genome where the number of copies of a region varies due to mechanisms like duplications, deletions, and translocations.\n4. There is limited information on the relationship between UCEs and CNVs.\n5. Some studies have suggested that UCEs may be more affected by CNVs than other genomic regions, though this is not widely confirmed.",
    "llama-7b_fact": [
      "Ultraconserved elements (UCEs) are regions in the genome that are highly conserved across evolutionary time.",
      "UCEs are defined as regions of at least 200 nucleotides in length that are incredibly conserved, being at least 100 times more conserved than the average genomic sequence.",
      "Copy number variants (CNVs) are variations in the genome where the number of copies of a region varies due to mechanisms like duplications, deletions, and translocations.",
      "There is limited information on the relationship between UCEs and CNVs.",
      "Some studies have suggested that UCEs may be more affected by CNVs than other genomic regions, though this is not widely confirmed."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: UCEs are defined as regions of at least 200 nucleotides in length that are incredibly conserved, but they are not quantified as being at least 100 times more conserved than the average genomic sequence. The term \"ultraconserved\" does not specify a quantitative measure like being 100 times more conserved relative to other sequences; rather, it indicates that these elements are significantly more conserved than the rest of the genome across different species, sometimes showing 100% identity across diverse lineages.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1665,
    "user_query": "You MUST give a detailed answer to the following question: Which is the substrate of the haspin kinase during mitosis?",
    "llama-7b_response": "The haspin kinase is a serine/threonine kinase that plays a critical role in mitosis, the process by which cells divide and produce daughter cells. During mitosis, the haspin kinase is activated and phosphorylates a number of proteins, including tubulin, which is a key component of the mitotic spindle.\n\nThe substrate of the haspin kinase during mitosis is not a specific molecule or compound, but rather a wide range of proteins and other molecules that are phosphorylated by the enzyme. These include proteins involved in the regulation of cell division, such as cyclin-dependent kinases (CDKs), as well as proteins involved in the formation and maintenance of the mitotic spindle, such as tubulin.\n\nThe specific substrates of the haspin kinase during mitosis can vary depending on the stage of the cell cycle and the cell's needs. For example, during interphase, when the cell is not dividing, the haspin kinase may phosphorylate proteins involved in the regulation of gene expression and other cellular processes. During mitosis, however, the haspin kinase is primarily focused on phosphorylating proteins involved in the formation and maintenance of the mitotic spindle.\n\nOverall, the substrate of the haspin kinase during mitosis is a wide range of proteins and other molecules that are phosphorylated by the enzyme, and the specific substrates can vary depending on the stage of the cell cycle.",
    "llama-7b_fact_raw": "1. Haspin kinase is a serine/threonine kinase.\n2. Haspin kinase plays a critical role in mitosis.\n3. Haspin kinase phosphorylates a range of proteins during mitosis.\n4. Tubulin is one of the proteins phosphorylated by haspin kinase during mitosis.\n5. The substrates of haspin kinase can vary depending on the cell cycle stage.",
    "llama-7b_fact": [
      "Haspin kinase is a serine/threonine kinase.",
      "Haspin kinase plays a critical role in mitosis.",
      "Haspin kinase phosphorylates a range of proteins during mitosis.",
      "Tubulin is one of the proteins phosphorylated by haspin kinase during mitosis.",
      "The substrates of haspin kinase can vary depending on the cell cycle stage."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Haspin kinase specifically phosphorylates histone H3 at threonine 3 (H3T3ph) during mitosis, not a range of proteins.\n4. FALSE [correction]: Haspin kinase does not phosphorylate tubulin; it is known to specifically phosphorylate histone H3 on Thr3 during mitosis.\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1696,
    "user_query": "You MUST give a detailed answer to the following question: What is the mechanism of viroid replication?",
    "llama-7b_response": "Viroids are small infectious non-coding RNAs that replicate in the cytoplasm of host cells without the need for a complementary DNA template. The mechanism of viroid replication is different from that of viruses, which require a complementary DNA template to replicate.\n\nViroid replication begins when a viroid particle enters a host cell. The viroid particle is then endocytosed into the host cell and transported to the endoplasmic reticulum (ER). In the ER, the viroid particle is degraded into smaller fragments, which are then transported to the cis-Golgi apparatus.\n\nIn the cis-Golgi apparatus, the viroid fragments are reassembled into intact viroid particles. The reassembled viroid particles are then transported to the plasma membrane of the host cell, where they are released into the extracellular environment.\n\nOnce in the extracellular environment, the viroid particles can infect other host cells. The mechanism of viroid replication is not well understood, and further research is needed to fully understand the process.",
    "llama-7b_fact_raw": "1. Viroids are small infectious non-coding RNAs that replicate in the cytoplasm of host cells without a DNA template.\n2. The replication process of viroids is distinct from that of viruses, as viruses require a DNA template for replication.\n3. Viroid replication involves degradation into smaller fragments in the endoplasmic reticulum after initial endocytosis.\n4. Reassembly of viroid fragments into intact particles occurs in the cis-Golgi apparatus.\n5. The reassembled viroid particles are transported to the plasma membrane and released into the extracellular environment to infect other cells.",
    "llama-7b_fact": [
      "Viroids are small infectious non-coding RNAs that replicate in the cytoplasm of host cells without a DNA template.",
      "The replication process of viroids is distinct from that of viruses, as viruses require a DNA template for replication.",
      "Viroid replication involves degradation into smaller fragments in the endoplasmic reticulum after initial endocytosis.",
      "Reassembly of viroid fragments into intact particles occurs in the cis-Golgi apparatus.",
      "The reassembled viroid particles are transported to the plasma membrane and released into the extracellular environment to infect other cells."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Viruses may require either a DNA or an RNA template for replication depending on the type of virus, not exclusively a DNA template.\n3. FALSE [correction]: Viroid replication typically involves a rolling-circle mechanism taking place in the nucleus or chloroplast, not degradation in the endoplasmic reticulum after endocytosis.\n4. UNKNOWN: The reassembly location for viroids is not commonly specified as the cis-Golgi apparatus, and the details can vary depending on the type of viroid and the host cell.\n5. FALSE [correction]: Viroids usually do not form particles like viruses; they consist of naked RNA and typically spread to other cells through plant-to-plant contact or mechanical damage, not by being released into the extracellular environment and infecting other cells like viruses.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1723,
    "user_query": "You MUST give a detailed answer to the following question: Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-7b_response": "Fibronectin is a protein that is present in the extracellular matrix of many tissues and plays a role in cell-matrix interactions. It has been suggested that fibronectin may be a potential serum biomarker for Duchenne muscular dystrophy (DMD), a genetic disorder that causes progressive muscle degeneration and weakness.\n\nStudies have shown that fibronectin levels are increased in the serum of patients with DMD compared to healthy controls. This increase in fibronectin levels has been observed in both muscle biopsies and serum samples from patients with DMD.\n\nFurthermore, studies have also shown that fibronectin levels are increased in the serum of patients with other forms of muscular dystrophy, such as Becker muscular dystrophy (BMD) and limb-girdle muscular dystrophy (LGMD), which suggests that fibronectin may be a general marker for muscular dystrophy.\n\nHowever, it is worth noting that the relationship between fibronectin levels and muscular dystrophy is complex and not fully understood. Other factors, such as inflammation and fibrosis, may also contribute to the increase in fibronectin levels in the serum of patients with muscular dystrophy.\n\nIn conclusion, while fibronectin has been suggested as a potential serum biomarker for Duchenne muscular dystrophy, further research is needed to fully understand the relationship between fibronectin and muscular dystrophy.",
    "llama-7b_fact_raw": "1. Fibronectin is a protein that is present in the extracellular matrix and is involved in cell-matrix interactions.\n2. Fibronectin may be a potential serum biomarker for Duchenne muscular dystrophy (DMD), a genetic disorder.\n3. Studies have indicated that fibronectin levels are increased in the serum of patients with DMD when compared to healthy individuals.\n4. Increased fibronectin levels have also been observed in patients with other forms of muscular dystrophy, such as Becker muscular dystrophy (BMD) and limb-girdle muscular dystrophy (LGMD).\n5. The relationship between fibronectin levels and muscular dystrophy is complex and other factors like inflammation and fibrosis may influence fibronectin levels in serum.",
    "llama-7b_fact": [
      "Fibronectin is a protein that is present in the extracellular matrix and is involved in cell-matrix interactions.",
      "Fibronectin may be a potential serum biomarker for Duchenne muscular dystrophy (DMD), a genetic disorder.",
      "Studies have indicated that fibronectin levels are increased in the serum of patients with DMD when compared to healthy individuals.",
      "Increased fibronectin levels have also been observed in patients with other forms of muscular dystrophy, such as Becker muscular dystrophy (BMD) and limb-girdle muscular dystrophy (LGMD).",
      "The relationship between fibronectin levels and muscular dystrophy is complex and other factors like inflammation and fibrosis may influence fibronectin levels in serum."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE - However, I must note that this statement is based on research available until my knowledge cutoff date, and should research in the future provide new insights, this statement may need to be revisited. \n4. TRUE - As with the previous statement, this is based on the available research data until my knowledge cutoff date.\n5. TRUE - This statement is consistent with current understanding that the pathophysiology of muscular dystrophies is complex and involves multiple factors, including inflammation and fibrosis, which can affect protein levels such as fibronectin.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1763,
    "user_query": "You MUST give a detailed answer to the following question: Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-7b_response": "The DeepBlue epigenomic data server contains data from several major epigenome projects, including:\n\n1. The Encyclopedia of DNA Elements (ENCODE) project, which aims to identify and characterize all functional elements in the human genome, including regulatory elements such as enhancers and silencers.\n2. The Roadmap Epigenomics Project, which aims to create a comprehensive resource of epigenomic data for a variety of human tissues and cell types.\n3. The Epigenome Roadmap Project, which aims to create a comprehensive resource of epigenomic data for a variety of model organisms, including mouse and human.\n4. The 1000 Genomes Project, which aims to create a comprehensive resource of genomic data for a variety of human populations, including data on DNA methylation and other epigenetic marks.\n\nThese projects have generated a large amount of data on DNA methylation, histone modifications, and other epigenetic marks, which is available through the DeepBlue epigenomic data server.",
    "llama-7b_fact_raw": "1. The Encyclopedia of DNA Elements (ENCODE) project, which identifies and characterizes functional elements in the human genome, is included in the DeepBlue epigenomic data server.\n2. The Roadmap Epigenomics Project, focusing on creating a resource of epigenomic data for human tissues and cell types, contributes data to the DeepBlue epigenomic data server.\n3. Data from the Epigenome Roadmap Project, aiming to create epigenomic data resources for model organisms, is available on the DeepBlue epigenomic data server.\n4. The DeepBlue epigenomic data server houses data from the 1000 Genomes Project, which includes genomic information from various human populations.\n5. The DeepBlue epigenomic data server features information on DNA methylation, histone modifications, and other epigenetic marks from several major epigenome projects.",
    "llama-7b_fact": [
      "The Encyclopedia of DNA Elements (ENCODE) project, which identifies and characterizes functional elements in the human genome, is included in the DeepBlue epigenomic data server.",
      "The Roadmap Epigenomics Project, focusing on creating a resource of epigenomic data for human tissues and cell types, contributes data to the DeepBlue epigenomic data server.",
      "Data from the Epigenome Roadmap Project, aiming to create epigenomic data resources for model organisms, is available on the DeepBlue epigenomic data server.",
      "The DeepBlue epigenomic data server houses data from the 1000 Genomes Project, which includes genomic information from various human populations.",
      "The DeepBlue epigenomic data server features information on DNA methylation, histone modifications, and other epigenetic marks from several major epigenome projects."
    ],
    "llama-7b_judge_raw": "1. TRUE: The ENCODE project's aim is to identify functional elements in the human genome, and its data is indeed included in repositories such as the DeepBlue epigenomic data server.\n\n2. TRUE: The Roadmap Epigenomics Project does focus on creating a resource of epigenomic data for human tissues and cell types, and contributes data to epigenomic data repositories, including the DeepBlue epigenomic data server.\n\n3. FALSE [correction]: The name \"Epigenome Roadmap Project\" is possibly a confusion with the \"NIH Roadmap Epigenomics Mapping Consortium\" which focuses on human tissues and not model organisms. The correct statement should refer to how the Roadmap Epigenomics Project contributes human epigenomic data to the server and does not explicitly focus on model organisms.\n\n4. FALSE [correction]: While the DeepBlue epigenomic data server houses epigenomic data, the 1000 Genomes Project is primarily a catalogue of human genetic variation (genomic data), not epigenomic data. The 1000 Genomes data may not be housed on DeepBlue, which focuses on epigenomic information.\n\n5. TRUE: The DeepBlue epigenomic data server does indeed feature information on various epigenetic marks including DNA methylation and histone modifications, sourced from different epigenome projects.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1792,
    "user_query": "You MUST give a detailed answer to the following question: Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-7b_response": "One tool that employs self-organizing maps (SOMs) for analyzing synonymous codon usage is the program CodonOptimizer.\n\nCodonOptimizer is a bioinformatics tool that uses SOMs to analyze synonymous codon usage and identify optimal codon usage patterns for a given gene or set of genes. SOMs are a type of artificial neural network that can be used to map high-dimensional input data onto a lower-dimensional map, allowing for the visualization and analysis of complex patterns and relationships.\n\nIn the case of CodonOptimizer, the tool uses SOMs to analyze the codon usage patterns of a given gene or set of genes and identify patterns of codon usage that are optimal for a given host organism. The tool can then use this information to generate optimized codon usage tables that can be used to improve the efficiency and accuracy of gene expression in the host organism.\n\nOverall, CodonOptimizer is a useful tool for analyzing synonymous codon usage and identifying optimal codon usage patterns for a given gene or set of genes. Its use of SOMs allows for the visualization and analysis of complex patterns and relationships in the data, and can help to improve the efficiency and accuracy of gene expression in the host organism.",
    "llama-7b_fact_raw": "1. CodonOptimizer employs self-organizing maps (SOMs) for analyzing synonymous codon usage.\n2. CodonOptimizer is a bioinformatics tool designed to identify optimal codon usage patterns for genes.\n3. SOMs, used by CodonOptimizer, map high-dimensional data onto a lower-dimensional space for pattern visualization.\n4. The tool can generate optimized codon usage tables to improve gene expression efficiency in a host organism.\n5. Self-organizing maps (SOMs) are a type of artificial neural network used within CodonOptimizer.",
    "llama-7b_fact": [
      "CodonOptimizer employs self-organizing maps (SOMs) for analyzing synonymous codon usage.",
      "CodonOptimizer is a bioinformatics tool designed to identify optimal codon usage patterns for genes.",
      "SOMs, used by CodonOptimizer, map high-dimensional data onto a lower-dimensional space for pattern visualization.",
      "The tool can generate optimized codon usage tables to improve gene expression efficiency in a host organism.",
      "Self-organizing maps (SOMs) are a type of artificial neural network used within CodonOptimizer."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: Without additional context, it is unclear whether the bioinformatics tool CodonOptimizer specifically uses self-organizing maps (SOMs) for analyzing synonymous codon usage, as CodonOptimizer may refer to a hypothetical or specific software that is not commonly known.\n2. UNKNOWN: The description of CodonOptimizer as a bioinformatics tool designed to identify optimal codon usage patterns for genes is plausible, but whether this statement is true depends on the specific features of this particular tool.\n3. TRUE: SOMs are indeed known to map high-dimensional data onto a lower-dimensional space for pattern visualization and this is a common application of self-organizing maps in various fields including bioinformatics.\n4. UNKNOWN: The capability of generating optimized codon usage tables to improve gene expression efficiency in a host organism sounds like a reasonable function for a bioinformatics tool like CodonOptimizer, but its accuracy cannot be confirmed without specific information about the tool.\n5. TRUE: Self-organizing maps (SOMs) are a type of unsupervised artificial neural network that is used for various purposes, including pattern recognition which is relevant within the context of CodonOptimizer if it indeed utilizes SOMs.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1793,
    "user_query": "You MUST give a detailed answer to the following question: What is MINDY-1?",
    "llama-7b_response": "I'm sorry, but I am not familiar with any technology or device called \"MINDY-1.\" Can you provide more context or information about what you are referring to?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1810,
    "user_query": "You MUST give a detailed answer to the following question: Which software package is available for the analysis of conserved genomic loci?",
    "llama-7b_response": "There are several software packages available for the analysis of conserved genomic loci. Some of the most commonly used ones include:\n\n1. BLAST: BLAST (Basic Local Alignment Search Tool) is a widely used software tool for comparing nucleotide or protein sequences to a reference database. It can be used to identify regions of the genome that are highly conserved across different species.\n2. MEGA: MEGA (Molecular Evolutionary Genetics Analysis) is a software package for the analysis of molecular evolution. It can be used to perform phylogenetic analysis, identify conserved regions of the genome, and perform other molecular evolutionary analyses.\n3. PHYLIP: PHYLIP (Phylogeny Inference Package) is a software package for the analysis of phylogenetic trees. It can be used to construct phylogenetic trees based on conserved genomic loci and to perform other phylogenetic analyses.\n4. GENEious: GENEious is a software package for the analysis of gene expression data. It can be used to identify conserved regions of the genome that are associated with gene expression, and to perform other analyses of gene expression data.\n\nThese are just a few examples of the many software packages that are available for the analysis of conserved genomic loci. The choice of software package will depend on the specific goals of the analysis and the type of data that is available.",
    "llama-7b_fact_raw": "1. BLAST (Basic Local Alignment Search Tool) is used for comparing nucleotide or protein sequences to a reference database.\n2. MEGA (Molecular Evolutionary Genetics Analysis) is utilized for analysis in molecular evolution, including phylogenetic analysis and identification of conserved genomic regions.\n3. PHYLIP (Phylogeny Inference Package) is utilized for constructing phylogenetic trees and performing phylogenetic analyses based on conserved genomic loci.\n4. GENEious is a software package designed for the analysis of gene expression data, including the identification of conserved genomic regions related to gene expression.",
    "llama-7b_fact": [
      "BLAST (Basic Local Alignment Search Tool) is used for comparing nucleotide or protein sequences to a reference database.",
      "MEGA (Molecular Evolutionary Genetics Analysis) is utilized for analysis in molecular evolution, including phylogenetic analysis and identification of conserved genomic regions.",
      "PHYLIP (Phylogeny Inference Package) is utilized for constructing phylogenetic trees and performing phylogenetic analyses based on conserved genomic loci.",
      "GENEious is a software package designed for the analysis of gene expression data, including the identification of conserved genomic regions related to gene expression."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Geneious is a comprehensive suite of bioinformatics software for the analysis of molecular data, including sequence alignment, phylogenetics, primer design, molecular cloning, and more, rather than being specifically designed for the analysis of gene expression data.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1860,
    "user_query": "You MUST give a detailed answer to the following question: Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-7b_response": "Sure, here are three diseases associated with the PIEZO2 gene:\n\n1. Hereditary hemorrhagic telangiectasia (HHT): HHT is a genetic disorder that affects blood vessels, causing them to be abnormally fragile and prone to bleeding. The PIEZO2 gene has been implicated in the development of HHT, and mutations in this gene can increase the risk of developing the condition.\n2. Ehlers-Danlos syndrome (EDS): EDS is a group of genetic disorders that affect the connective tissues in the body, including the skin, joints, and blood vessels. The PIEZO2 gene has been implicated in the development of EDS, and mutations in this gene can increase the risk of developing the condition.\n3. Stickler syndrome: Stickler syndrome is a genetic disorder that affects the connective tissues in the body, including the eyes, joints, and bones. The PIEZO2 gene has been implicated in the development of Stickler syndrome, and mutations in this gene can increase the risk of developing the condition.",
    "llama-7b_fact_raw": "1. The PIEZO2 gene is associated with hereditary hemorrhagic telangiectasia (HHT).\n2. The PIEZO2 gene is implicated in the development of Ehlers-Danlos syndrome (EDS).\n3. Stickler syndrome is a genetic disorder associated with the PIEZO2 gene.",
    "llama-7b_fact": [
      "The PIEZO2 gene is associated with hereditary hemorrhagic telangiectasia (HHT).",
      "The PIEZO2 gene is implicated in the development of Ehlers-Danlos syndrome (EDS).",
      "Stickler syndrome is a genetic disorder associated with the PIEZO2 gene."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The PIEZO2 gene is not associated with hereditary hemorrhagic telangiectasia (HHT); HHT is often associated with mutations in genes such as ENG, ACVRL1, and SMAD4.\n2. FALSE [correction]: The PIEZO2 gene is associated with the sensation of touch and proprioception, not the development of Ehlers-Danlos syndrome (EDS). EDS is often associated with mutations in genes that encode proteins affecting collagen synthesis and structure, such as COL5A and COL3A.\n3. FALSE [correction]: Stickler syndrome is not associated with the PIEZO2 gene. It is usually associated with mutations in genes like COL2A1, COL11A1, and COL9A1, which are involved in the production of collagen.",
    "llama-7b_judge": [
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1867,
    "user_query": "You MUST give a detailed answer to the following question: What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-7b_response": "ERAP1 and ERAP2 are two members of the ER-associated degradation (ERAD) pathway, which is responsible for the recognition and removal of misfolded or damaged proteins from the endoplasmic reticulum (ER) in eukaryotic cells. The dimerization of ERAP1 and ERAP2 is an important step in the ERAD pathway, as it allows the two proteins to form a stable complex that can recognize and bind to misfolded proteins.\n\nThe ERAP1-ERAP2 dimerization promotes the recognition of misfolded proteins in several ways:\n\n1. Enhanced binding affinity: The dimerization of ERAP1 and ERAP2 leads to an increase in the binding affinity of the two proteins for misfolded proteins, allowing them to recognize and bind to a wider range of misfolded proteins.\n2. Increased specificity: The dimerization of ERAP1 and ERAP2 leads to an increase in the specificity of the ERAD pathway, as the two proteins can recognize and bind to a wider range of misfolded proteins.\n3. Improved efficiency: The dimerization of ERAP1 and ERAP2 leads to an increase in the efficiency of the ERAD pathway, as the two proteins can recognize and bind to a wider range of misfolded proteins.\n\nOverall, the ERAP1-ERAP2 dimerization is an important step in the ERAD pathway, as it allows the two proteins to form a stable complex that can recognize and bind to a wider range of misfolded proteins, improving the efficiency and specificity of the pathway.",
    "llama-7b_fact_raw": "1. ERAP1 and ERAP2 are involved in the endoplasmic reticulum-associated degradation (ERAD) pathway in eukaryotic cells.\n2. ERAP1-ERAP2 dimerization is an important step within the ERAD pathway.\n3. Dimerization enhances the binding affinity between ERAP1 and ERAP2 and misfolded proteins.\n4. The formation of the ERAP1-ERAP2 complex increases the specificity of the ERAD pathway towards misfolded proteins.\n5. Dimerization of ERAP1 and ERAP2 improves the efficiency of the ERAD pathway.",
    "llama-7b_fact": [
      "ERAP1 and ERAP2 are involved in the endoplasmic reticulum-associated degradation (ERAD) pathway in eukaryotic cells.",
      "ERAP1-ERAP2 dimerization is an important step within the ERAD pathway.",
      "Dimerization enhances the binding affinity between ERAP1 and ERAP2 and misfolded proteins.",
      "The formation of the ERAP1-ERAP2 complex increases the specificity of the ERAD pathway towards misfolded proteins.",
      "Dimerization of ERAP1 and ERAP2 improves the efficiency of the ERAD pathway."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: ERAP1 and ERAP2 are involved in trimming peptides for presentation on MHC class I molecules, not in the endoplasmic reticulum-associated degradation (ERAD) pathway.\n2. FALSE [correction]: There is currently no evidence to suggest that ERAP1 and ERAP2 dimerize as a function within the ERAD pathway or antigen presentation pathways.\n3. FALSE [correction]: Since ERAP1 and ERAP2 are not known to dimerize within the context of the ERAD pathway, the statement about dimerization enhancing the binding affinity between these proteins and misfolded proteins is incorrect.\n4. FALSE [correction]: The formation of the ERAP1-ERAP2 complex is not a recognized step in increasing the specificity of the ERAD pathway. They function in the context of antigen processing for MHC class I molecule presentation.\n5. FALSE [correction]: Dimerization of ERAP1 and ERAP2 is not a recognized mechanism that improves the efficiency of the ERAD pathway since their main function is associated with antigen processing.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1890,
    "user_query": "You MUST give a detailed answer to the following question: What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-7b_response": "R-spondin 1 and noggin are both proteins that play important roles in the development and maintenance of various tissues, including the gallbladder.\n\nR-spondin 1 is a member of the R-spondin family of proteins, which are secreted by cells and bind to specific receptors on the surface of other cells to regulate various physiological processes. In the case of the gallbladder, R-spondin 1 has been shown to play a role in the development and maturation of the epithelial cells that line the gallbladder. Specifically, R-spondin 1 has been shown to promote the proliferation and differentiation of these cells, which is important for the normal development of the gallbladder.\n\nNoggin, on the other hand, is a protein that is known to inhibit the activity of bone morphogenetic proteins (BMPs), which are signaling molecules that play a role in the development and maintenance of various tissues. In the gallbladder, noggin has been shown to inhibit the activity of BMPs, which may help to maintain the normal structure and function of the epithelial cells that line the gallbladder.\n\nIn summary, R-spondin 1 and noggin play important roles in the development and maintenance of the gallbladder. R-spondin 1 promotes the proliferation and differentiation of the epithelial cells that line the gallbladder, while noggin inhibits the activity of BMPs, which may help to maintain the normal structure and function of these cells.",
    "llama-7b_fact_raw": "1. R-spondin 1 is a protein that is involved in the development and maturation of epithelial cells in the gallbladder.\n2. R-spondin 1 facilitates the proliferation and differentiation of the epithelial cells lining the gallbladder.\n3. Noggin is a protein that inhibits the activity of bone morphogenetic proteins (BMPs).\n4. Bone morphogenetic proteins are signaling molecules involved in the development and maintenance of various tissues, including the gallbladder.\n5. Noggin's inhibition of BMPs may assist in maintaining the normal structure and function of the epithelial cells in the gallbladder.",
    "llama-7b_fact": [
      "R-spondin 1 is a protein that is involved in the development and maturation of epithelial cells in the gallbladder.",
      "R-spondin 1 facilitates the proliferation and differentiation of the epithelial cells lining the gallbladder.",
      "Noggin is a protein that inhibits the activity of bone morphogenetic proteins (BMPs).",
      "Bone morphogenetic proteins are signaling molecules involved in the development and maintenance of various tissues, including the gallbladder.",
      "Noggin's inhibition of BMPs may assist in maintaining the normal structure and function of the epithelial cells in the gallbladder."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: The statement is specific, and without additional context or a source to verify this information, it is difficult to assess its accuracy.\n2. UNKNOWN: This statement also details a specific biological function, which requires specialized knowledge or sources to verify.\n3. TRUE: Noggin is indeed a protein known to inhibit the activity of bone morphogenetic proteins (BMPs), which is consistent with established biological knowledge.\n4. TRUE: Bone morphogenetic proteins (BMPs) are signaling molecules that are known to play roles in the development and maintenance of various tissues, which can include the gallbladder among many others.\n5. UNKNOWN: While noggin does inhibit BMPs, which are involved in developmental processes, without specific evidence regarding its role in maintaining the normal structure and function of the epithelial cells in the gallbladder, it is difficult to verify the accuracy of this statement.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1937,
    "user_query": "You MUST give a detailed answer to the following question: Does NADPH oxidase 5 require any subunit for function?",
    "llama-7b_response": "Yes, NADPH oxidase 5 (NOX5) requires multiple subunits for its function. NOX5 is a member of the NADPH oxidase family, which is a group of enzymes that generate reactive oxygen species (ROS) from NADPH.\n\nNOX5 is composed of two structural subunits, p22phox and p40phox, and three accessory subunits, gp91phox, p67phox, and p47phox. The p22phox and p40phox subunits are required for the enzymatic activity of NOX5, while the gp91phox, p67phox, and p47phox subunits play important roles in the regulation and localization of NOX5.\n\nThe gp91phox subunit is involved in the recruitment of NOX5 to the plasma membrane, while the p67phox and p47phox subunits are required for the assembly of NOX5 into a functional enzyme complex. The p47phox subunit also plays a role in the regulation of NOX5 activity by interacting with the p22phox and p40phox subunits.\n\nThe absence of any of these subunits results in a loss of NOX5 activity, indicating that these subunits are required for the function of NOX5. Therefore, the answer to the question is \"Yes, NADPH oxidase 5 requires multiple subunits for its function.\"",
    "llama-7b_fact_raw": "1. NADPH oxidase 5 (NOX5) requires multiple subunits for its function.\n2. NOX5 is composed of two structural subunits: p22phox and p40phox.\n3. NOX5 has three accessory subunits: gp91phox, p67phox, and p47phox.\n4. The p22phox and p40phox subunits are essential for the enzymatic activity of NOX5.\n5. The absence of any of the subunits p22phox, p40phox, gp91phox, p67phox, or p47phox results in a loss of NOX5 activity.",
    "llama-7b_fact": [
      "NADPH oxidase 5 (NOX5) requires multiple subunits for its function.",
      "NOX5 is composed of two structural subunits: p22phox and p40phox.",
      "NOX5 has three accessory subunits: gp91phox, p67phox, and p47phox.",
      "The p22phox and p40phox subunits are essential for the enzymatic activity of NOX5.",
      "The absence of any of the subunits p22phox, p40phox, gp91phox, p67phox, or p47phox results in a loss of NOX5 activity."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: NADPH oxidase 5 (NOX5) does not require multiple subunits for its function; it is a calcium-dependent enzyme that functions independently.\n2. FALSE [correction]: NOX5 does not have structural subunits like p22phox and p40phox; these are subunits of other NOX enzymes such as NOX2.\n3. FALSE [correction]: NOX5 does not have accessory subunits gp91phox, p67phox, and p47phox; these are also components of the NOX2 complex, not NOX5.\n4. FALSE [correction]: Since NOX5 functions independently and does not require p22phox and p40phox subunits, the statement is incorrect.\n5. FALSE [correction]: Given that NOX5 is independent and the mentioned subunits are not part of its structure, their absence would not result in a loss of NOX5 activity.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1944,
    "user_query": "You MUST give a detailed answer to the following question: What is the connection between furin and hepcidin?",
    "llama-7b_response": "Furin and hepcidin are two different proteins that have distinct functions in the body.\n\nFurin is an enzyme that plays a role in the post-translational modification of other proteins. Specifically, it cleaves specific peptide bonds in other proteins, resulting in the formation of new peptides or proteins with different functions. Furin has been implicated in a variety of biological processes, including cell growth and differentiation, angiogenesis, and inflammation.\n\nHepcidin, on the other hand, is a hormone that plays a key role in regulating iron metabolism in the body. It is produced by hepatocytes in the liver and is released into the bloodstream, where it binds to iron and inhibits the absorption of iron from the gut. Hepcidin also regulates the storage of iron in various tissues, such as the liver and spleen.\n\nThe connection between furin and hepcidin is that both proteins are involved in iron metabolism. Furin has been shown to play a role in the regulation of hepcidin expression and activity. For example, studies have shown that furin can cleave a specific peptide within the hepcidin mRNA, leading to the production of a shorter, less active form of hepcidin. Conversely, hepcidin has been shown to inhibit the activity of furin, suggesting that the two proteins may interact in a feedback loop to regulate iron metabolism.\n\nOverall, while furin and hepcidin are two distinct proteins, they are both involved in the regulation of iron metabolism and have important roles in maintaining iron homeostasis in the body.",
    "llama-7b_fact_raw": "1. Furin is an enzyme that cleaves specific peptide bonds in other proteins during post-translational modification.\n2. Hepcidin is a hormone that regulates iron metabolism by inhibiting iron absorption from the gut and controlling iron storage in tissues.\n3. Furin has been implicated in biological processes such as cell growth, angiogenesis, and inflammation.\n4. Hepcidin is produced by hepatocytes in the liver and released into the bloodstream.\n5. Studies have indicated that furin can regulate the expression and activity of hepcidin, including the cleavage of hepcidin mRNA to produce a shorter form of the hormone.",
    "llama-7b_fact": [
      "Furin is an enzyme that cleaves specific peptide bonds in other proteins during post-translational modification.",
      "Hepcidin is a hormone that regulates iron metabolism by inhibiting iron absorption from the gut and controlling iron storage in tissues.",
      "Furin has been implicated in biological processes such as cell growth, angiogenesis, and inflammation.",
      "Hepcidin is produced by hepatocytes in the liver and released into the bloodstream.",
      "Studies have indicated that furin can regulate the expression and activity of hepcidin, including the cleavage of hepcidin mRNA to produce a shorter form of the hormone."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Furin is known to cleave proteins, not mRNA. It may play a role in the regulation of hepcidin, but not through the cleavage of hepcidin mRNA to produce a shorter form of the hormone. Hepcidin regulation is complex and involves multiple pathways and signals, but the specific mechanism involving furin, if any, would be at the protein level rather than mRNA.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1956,
    "user_query": "You MUST give a detailed answer to the following question: Which is the largest metabolic gene cluster in yeast?",
    "llama-7b_response": "The largest metabolic gene cluster in yeast is the pentose phosphate pathway (PPP). The PPP is a metabolic pathway that converts glucose, glyceraldehyde-3-phosphate (G3P), and pyruvate into ribose-5-phosphate and glyceraldehyde-3-phosphate, which are used in the synthesis of nucleic acids and other biomolecules. The PPP is composed of a series of enzymes that work together to convert glucose into ribose-5-phosphate and glyceraldehyde-3-phosphate. The PPP is one of the largest metabolic pathways in yeast, and it plays a crucial role in the synthesis of nucleic acids and other biomolecules.\n\nThe PPP is composed of several genes that are located on different chromosomes in the yeast genome. The genes that encode the enzymes of the PPP are clustered together in a region of the yeast genome that is known as the \"PPP region.\" The PPP region is one of the largest metabolic gene clusters in yeast, and it contains many genes that are involved in the synthesis of nucleic acids and other biomolecules.\n\nThe PPP region is composed of several genes that are involved in the synthesis of nucleic acids and other biomolecules. The genes that encode the enzymes of the PPP are clustered together in a region of the yeast genome that is known as the \"PPP region.\" The PPP region is one of the largest metabolic gene clusters in yeast, and it contains many genes that are involved in the synthesis of nucleic acids and other biomolecules.\n\nThe PPP region is composed of several genes that are involved in the synthesis of nucleic acids and other biomolecules. The genes that encode the enzymes of the PPP are clustered together in a region of the yeast genome that is known as the \"PPP region.\" The PPP region is one of the largest metabolic gene clusters in yeast, and it contains many genes that are involved in the synthesis of nucleic acids and other bi",
    "llama-7b_fact_raw": "1. The pentose phosphate pathway (PPP) is the largest metabolic gene cluster in yeast.\n2. The PPP converts glucose, glyceraldehyde-3-phosphate (G3P), and pyruvate into ribose-5-phosphate and glyceraldehyde-3-phosphate.\n3. The PPP plays a crucial role in the synthesis of nucleic acids and other biomolecules in yeast.\n4. The genes encoding the enzymes of the PPP are clustered in the yeast genome in a region referred to as the \"PPP region.\"\n5. The \"PPP region\" contains many genes involved in the synthesis of nucleic acids and other biomolecules.",
    "llama-7b_fact": [
      "The pentose phosphate pathway (PPP) is the largest metabolic gene cluster in yeast.",
      "The PPP converts glucose, glyceraldehyde-3-phosphate (G3P), and pyruvate into ribose-5-phosphate and glyceraldehyde-3-phosphate.",
      "The PPP plays a crucial role in the synthesis of nucleic acids and other biomolecules in yeast.",
      "The genes encoding the enzymes of the PPP are clustered in the yeast genome in a region referred to as the \"PPP region.\"",
      "The \"PPP region\" contains many genes involved in the synthesis of nucleic acids and other biomolecules."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The pentose phosphate pathway (PPP) is a metabolic pathway that operates in parallel with glycolysis, but it is not a gene cluster. The concept of a \"largest metabolic gene cluster\" is not standard terminology and is vague without specific genomic context.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The genes encoding the enzymes of the PPP are not necessarily clustered in a specific region referred to as the \"PPP region\" in the yeast genome. In yeast, genes can be dispersed throughout the genome.\n5. FALSE [correction]: While the PPP is involved in the synthesis of nucleic acids and other biomolecules, there is no specific \"PPP region\" that contains many genes for this synthesis. The genes involved in these processes are spread throughout the genome and are not confined to one particular region.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1967,
    "user_query": "You MUST give a detailed answer to the following question: What is the role of LIMT lncRNA?",
    "llama-7b_response": "The LIMT lncRNA (long non-coding RNA) is a non-coding RNA molecule that has been implicated in various biological processes, including cell differentiation, proliferation, and apoptosis. However, the precise role of LIMT lncRNA in these processes is not yet fully understood.\n\nRecent studies have suggested that LIMT lncRNA may play a role in regulating gene expression at the transcriptional level. For example, LIMT lncRNA has been shown to interact with transcription factors and modulate their activity, leading to changes in the expression of downstream target genes.\n\nAdditionally, LIMT lncRNA has been implicated in the regulation of cell proliferation and apoptosis. For example, overexpression of LIMT lncRNA has been shown to promote cell proliferation and inhibit apoptosis, while knockdown of LIMT lncRNA has been shown to inhibit cell proliferation and promote apoptosis.\n\nDespite these findings, the precise mechanisms by which LIMT lncRNA regulates gene expression and cellular processes are not yet fully understood. Further research is needed to elucidate the role of LIMT lncRNA in various biological processes and to determine its potential as a therapeutic target for various diseases.",
    "llama-7b_fact_raw": "1. LIMT lncRNA is a long non-coding RNA that has been implicated in cell differentiation, proliferation, and apoptosis.\n2. LIMT lncRNA may have a role in regulating gene expression at the transcriptional level.\n3. LIMT lncRNA has been shown to interact with transcription factors and influence their activity.\n4. Overexpression of LIMT lncRNA has been associated with increased cell proliferation and decreased apoptosis.\n5. The precise mechanisms by which LIMT lncRNA affects gene expression and cellular processes are not fully understood and require further research.",
    "llama-7b_fact": [
      "LIMT lncRNA is a long non-coding RNA that has been implicated in cell differentiation, proliferation, and apoptosis.",
      "LIMT lncRNA may have a role in regulating gene expression at the transcriptional level.",
      "LIMT lncRNA has been shown to interact with transcription factors and influence their activity.",
      "Overexpression of LIMT lncRNA has been associated with increased cell proliferation and decreased apoptosis.",
      "The precise mechanisms by which LIMT lncRNA affects gene expression and cellular processes are not fully understood and require further research."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nIt's important to note that without specific references to updated scientific literature, these answers are based on common characteristics of long non-coding RNAs (lncRNAs) like LIMT. LncRNAs are known to be involved in various cellular processes, including differentiation, proliferation, and apoptosis, and they can regulate gene expression at various levels, including transcriptional. They often interact with transcription factors and influence their activity, which can lead to changes in cell behavior such as proliferation and apoptosis. Lastly, the mechanisms by which specific lncRNAs affect gene expression can be complex and are frequently the subject of ongoing research, as implied in statement 5.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1984,
    "user_query": "You MUST give a detailed answer to the following question: Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-7b_response": "The R/Bioconductor package used for performing SNP enrichment analysis is called \"GREAT\".",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2015,
    "user_query": "You MUST give a detailed answer to the following question: Which are the key players on radial glial specification to ependymal cells?",
    "llama-7b_response": "Radial glial cells are a type of glial cell that play a crucial role in the development of the central nervous system, including the formation of the ependymal cells that line the ventricles of the brain. The process of radial glial specification to ependymal cells involves several key players and signaling pathways.\n\nOne of the key players in the specification of radial glial cells to ependymal cells is the Sonic hedgehog (Shh) signaling pathway. Shh is a protein that is expressed in the ventricular zone of the developing brain, where radial glial cells arise. Shh signaling promotes the proliferation and differentiation of radial glial cells into ependymal cells.\n\nAnother key player in the specification of radial glial cells to ependymal cells is the Bone Morphogenetic Protein (BMP) signaling pathway. BMP signaling inhibits the proliferation of radial glial cells and promotes their differentiation into ependymal cells.\n\nIn addition to Shh and BMP signaling, other signaling pathways, such as Wnt and Notch, also play a role in the specification of radial glial cells to ependymal cells. For example, Wnt signaling promotes the proliferation of radial glial cells, while Notch signaling inhibits their proliferation and promotes their differentiation into ependymal cells.\n\nOverall, the specification of radial glial cells to ependymal cells involves a complex interplay between several key players, including Shh, BMP, Wnt, and Notch signaling pathways. These signaling pathways work together to regulate the proliferation and differentiation of radial glial cells, ultimately leading to the formation of ependymal cells that line the ventricles of the brain.",
    "llama-7b_fact_raw": "1. Radial glial cells are involved in the development of the central nervous system and the formation of ependymal cells.\n2. The Sonic hedgehog (Shh) signaling pathway is a key player in the proliferation and differentiation of radial glial cells into ependymal cells.\n3. The Bone Morphogenetic Protein (BMP) signaling pathway inhibits the proliferation of radial glial cells and promotes their differentiation into ependymal cells.\n4. Wnt signaling is involved in the proliferation of radial glial cells.\n5. Notch signaling inhibits the proliferation of radial glial cells and promotes their differentiation into ependymal cells.",
    "llama-7b_fact": [
      "Radial glial cells are involved in the development of the central nervous system and the formation of ependymal cells.",
      "The Sonic hedgehog (Shh) signaling pathway is a key player in the proliferation and differentiation of radial glial cells into ependymal cells.",
      "The Bone Morphogenetic Protein (BMP) signaling pathway inhibits the proliferation of radial glial cells and promotes their differentiation into ependymal cells.",
      "Wnt signaling is involved in the proliferation of radial glial cells.",
      "Notch signaling inhibits the proliferation of radial glial cells and promotes their differentiation into ependymal cells."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Notch signaling promotes the proliferation of radial glial cells and regulates their differentiation. While it has a role in the fate decision of radial glial cells, it is generally associated with the maintenance of progenitor characteristics rather than promoting differentiation into ependymal cells.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2065,
    "user_query": "You MUST give a detailed answer to the following question: How are triple negative gliomas characterized?",
    "llama-7b_response": "Triple-negative breast cancer (TNBC) is a type of breast cancer that does not express estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). TNBC accounts for approximately 15-20% of all breast cancers and is more aggressive and difficult to treat than other types of breast cancer.\n\nTNBC is characterized by the absence of three key receptors on the surface of cancer cells: estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). The absence of these receptors makes TNBC resistant to hormonal therapies and targeted therapies that are commonly used to treat other types of breast cancer.\n\nTNBC is also characterized by the presence of certain genetic mutations, such as mutations in the BRCA1 and BRCA2 genes, which increase the risk of developing TNBC. Additionally, TNBC is often characterized by the presence of a specific pattern of gene expression, known as the basal-like subtype, which is associated with a particularly aggressive form of the disease.\n\nTNBC is typically diagnosed through a combination of imaging tests, such as mammography and ultrasound, and biopsy. Once diagnosed, TNBC is typically treated with a combination of chemotherapy, targeted therapies, and radiation therapy.",
    "llama-7b_fact_raw": "1. Triple-negative breast cancer (TNBC) does not express estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2.\n2. TNBC accounts for approximately 15-20% of all breast cancers.\n3. TNBC is usually more aggressive and difficult to treat than other types of breast cancer.\n4. Certain genetic mutations, including those in the BRCA1 and BRCA2 genes, are associated with an increased risk of developing TNBC.\n5. TNBC is commonly characterized by a pattern of gene expression known as the basal-like subtype.",
    "llama-7b_fact": [
      "Triple-negative breast cancer (TNBC) does not express estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2.",
      "TNBC accounts for approximately 15-20% of all breast cancers.",
      "TNBC is usually more aggressive and difficult to treat than other types of breast cancer.",
      "Certain genetic mutations, including those in the BRCA1 and BRCA2 genes, are associated with an increased risk of developing TNBC.",
      "TNBC is commonly characterized by a pattern of gene expression known as the basal-like subtype."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2069,
    "user_query": "You MUST give a detailed answer to the following question: What is TOPAZ1?",
    "llama-7b_response": "TOPAZ1 is a cryptographic algorithm used for encrypting and decrypting data. It is a stream cipher that uses a linear feedback shift register (LFSR) to generate a pseudorandom sequence of bits, which are then used to encrypt or decrypt the data. TOPAZ1 was developed by the National Security Agency (NSA) and is considered to be a strong encryption algorithm. It is often used in conjunction with other encryption algorithms to provide additional security.",
    "llama-7b_fact_raw": "1. TOPAZ1 is a cryptographic algorithm used for encrypting and decrypting data.\n2. It is a stream cipher type of cryptographic algorithm.\n3. TOPAZ1 uses a linear feedback shift register (LFSR) to generate a pseudorandom sequence of bits.\n4. The National Security Agency (NSA) developed TOPAZ1.\n5. TOPAZ1 is often used in conjunction with other encryption algorithms to enhance security.",
    "llama-7b_fact": [
      "TOPAZ1 is a cryptographic algorithm used for encrypting and decrypting data.",
      "It is a stream cipher type of cryptographic algorithm.",
      "TOPAZ1 uses a linear feedback shift register (LFSR) to generate a pseudorandom sequence of bits.",
      "The National Security Agency (NSA) developed TOPAZ1.",
      "TOPAZ1 is often used in conjunction with other encryption algorithms to enhance security."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: There's no widely recognized cryptographic algorithm known as TOPAZ1; however, it is possible that it could be a codename for an algorithm not publicly disclosed, or simply a fictional or incorrect name.\n2. UNKNOWN: Since TOPAZ1 is not a recognized cryptographic algorithm, it's unclear whether it would be a stream cipher.\n3. UNKNOWN: Without clear information on TOPAZ1, we cannot confirm whether it uses a linear feedback shift register (LFSR).\n4. UNKNOWN: The development of TOPAZ1, including whether the NSA is involved, cannot be confirmed for a non-recognized algorithm.\n5. UNKNOWN: The use of TOPAZ1 in conjunction with other encryption algorithms cannot be confirmed or denied based on the given information.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "You MUST give a detailed answer to the following question: Which gene controls the expression of GATA-1 isoforms?",
    "llama-7b_response": "The gene that controls the expression of GATA-1 isoforms is called GATA-1. GATA-1 is a transcription factor, which means it is a protein that regulates the expression of other genes by binding to specific DNA sequences. GATA-1 isoforms are different versions of the GATA-1 protein that result from alternative splicing, which is the removal or addition of non-coding regions to the mRNA transcript of the GATA-1 gene. The different isoforms can have different functions and may be expressed in different tissues or under different conditions.",
    "llama-7b_fact_raw": "1. The gene responsible for the expression of GATA-1 isoforms is called GATA-1.\n2. GATA-1 is a transcription factor, a type of protein that regulates gene expression.\n3. The production of GATA-1 isoforms is a result of alternative splicing of the mRNA transcript of the GATA-1 gene.\n4. Different GATA-1 isoforms may have distinct functions.\n5. GATA-1 isoforms may be expressed in various tissues or under varying conditions.",
    "llama-7b_fact": [
      "The gene responsible for the expression of GATA-1 isoforms is called GATA-1.",
      "GATA-1 is a transcription factor, a type of protein that regulates gene expression.",
      "The production of GATA-1 isoforms is a result of alternative splicing of the mRNA transcript of the GATA-1 gene.",
      "Different GATA-1 isoforms may have distinct functions.",
      "GATA-1 isoforms may be expressed in various tissues or under varying conditions."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nExplanation:\n1. The gene responsible for the expression of GATA-1 isoforms is indeed called GATA-1.\n2. GATA-1 is a transcription factor, which means it is involved in regulating gene expression.\n3. The production of different isoforms of a protein, including GATA-1, commonly occurs through alternative splicing of mRNA transcripts.\n4. It is generally true that different isoforms of a protein can have distinct, sometimes even opposing, functions.\n5. Isoforms of a gene product like GATA-1 can be expressed differentially in various tissues or under different conditions due to the regulatory elements controlling their expression.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "You MUST give a detailed answer to the following question: What is MIRA-seq?",
    "llama-7b_response": "MIRA-seq is a sequencing-based method for measuring the abundance of RNA molecules in a biological sample. It stands for \"multi-index RNA amplification sequencing\" and was developed by researchers at the Broad Institute of MIT and Harvard.\n\nThe MIRA-seq method is based on the principle of multiple displacement amplification (MDA), which is a technique used to increase the copy number of a specific RNA molecule in a sample. In MIRA-seq, MDA is used in combination with sequencing to measure the abundance of RNA molecules in a sample.\n\nThe MIRA-seq protocol involves the following steps:\n\n1. RNA isolation: The starting material for MIRA-seq is a biological sample containing RNA molecules. The sample is first isolated and purified to remove any contaminants.\n2. RNA fragmentation: The RNA molecules in the sample are fragmented into smaller pieces to make them more accessible to the MDA reaction.\n3. Multiple displacement amplification: MDA is used to increase the copy number of a specific RNA molecule in the sample. This is achieved by using a DNA polymerase enzyme to make multiple copies of the RNA molecule.\n4. Library preparation: The amplified RNA molecules are then used to prepare a library for sequencing. This involves fragmenting the RNA molecules further and attaching them to sequencing adapters.\n5. Sequencing: The prepared library is then sequenced using a high-throughput sequencing technology such as Illumina or PacBio.\n6. Data analysis: The sequencing data is analyzed to determine the abundance of each RNA molecule in the sample. This is typically done using a bioinformatics pipeline that involves mapping the sequencing reads to a reference genome, and then counting the number of reads that map to each RNA molecule.\n\nMIRA-seq has several advantages over other sequencing-based methods for measuring RNA abundance, including high sensitivity, specificity, and accuracy. It is particularly well-suited for measuring the abundance of low-abundance RNA molecules, as well as RNA molecules that are difficult to detect using other methods. MIRA-seq ha",
    "llama-7b_fact_raw": "1. MIRA-seq stands for \"multi-index RNA amplification sequencing.\"\n2. MIRA-seq was developed by researchers at the Broad Institute of MIT and Harvard.\n3. The MIRA-seq method utilizes multiple displacement amplification (MDA) to increase the copy number of specific RNA molecules in a sample.\n4. MIRA-seq involves several steps including RNA isolation, RNA fragmentation, MDA, library preparation, sequencing, and data analysis.\n5. MIRA-seq is designed for high sensitivity, specificity, and accuracy in measuring RNA abundance and is suitable for low-abundance and difficult-to-detect RNA molecules.",
    "llama-7b_fact": [
      "MIRA-seq stands for \"multi-index RNA amplification sequencing.\"",
      "MIRA-seq was developed by researchers at the Broad Institute of MIT and Harvard.",
      "The MIRA-seq method utilizes multiple displacement amplification (MDA) to increase the copy number of specific RNA molecules in a sample.",
      "MIRA-seq involves several steps including RNA isolation, RNA fragmentation, MDA, library preparation, sequencing, and data analysis.",
      "MIRA-seq is designed for high sensitivity, specificity, and accuracy in measuring RNA abundance and is suitable for low-abundance and difficult-to-detect RNA molecules."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: MIRA-seq stands for \"methylation-based inference of regulatory activity sequencing.\"\n2. TRUE\n3. FALSE [correction]: The MIRA-seq method does not utilize multiple displacement amplification (MDA), which is a DNA amplification technique. Instead, MIRA-seq is an RNA-sequencing method that infers gene regulatory activity by measuring RNA abundance and is based on capturing and sequencing methylated RNA.\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2108,
    "user_query": "You MUST give a detailed answer to the following question: What is the indication of ARCALYST?",
    "llama-7b_response": "ARCALYST (rilonacept) is a biologic medication that is used to treat cryopyrin-associated periodic syndromes (CAPS), such as Muckle-Wells syndrome (MWS) and neonatal-onset multisystem inflammatory disease (NOMID). CAPS are a group of rare autoinflammatory disorders that are characterized by recurrent episodes of inflammation, fever, and joint pain.\n\nARCALYST works by binding to a specific protein called interleukin-1 beta (IL-1), which is a key mediator of inflammation in these disorders. By binding to IL-1, ARCALYST helps to prevent the formation of active IL-1, which can reduce the frequency and severity of inflammatory episodes in patients with CAPS.\n\nARCALYST is administered as an injection under the skin (subcutaneously) once a month. It is typically used in combination with other medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids, to manage symptoms of CAPS. The efficacy and safety of ARCALYST have been studied in several clinical trials, and it has been shown to be effective in reducing the frequency and severity of inflammatory episodes in patients with CAPS.",
    "llama-7b_fact_raw": "1. ARCALYST (rilonacept) is used to treat cryopyrin-associated periodic syndromes (CAPS).\n2. Conditions such as Muckle-Wells syndrome (MWS) and neonatal-onset multisystem inflammatory disease (NOMID) are indications for ARCALYST.\n3. ARCALYST operates by binding to interleukin-1 beta (IL-1) to reduce inflammation.\n4. ARCALYST is administered subcutaneously once a month.\n5. Clinical trials have demonstrated the efficacy and safety of ARCALYST in reducing the frequency and severity of inflammatory episodes in patients with CAPS.",
    "llama-7b_fact": [
      "ARCALYST (rilonacept) is used to treat cryopyrin-associated periodic syndromes (CAPS).",
      "Conditions such as Muckle-Wells syndrome (MWS) and neonatal-onset multisystem inflammatory disease (NOMID) are indications for ARCALYST.",
      "ARCALYST operates by binding to interleukin-1 beta (IL-1) to reduce inflammation.",
      "ARCALYST is administered subcutaneously once a month.",
      "Clinical trials have demonstrated the efficacy and safety of ARCALYST in reducing the frequency and severity of inflammatory episodes in patients with CAPS."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: ARCALYST is typically administered by subcutaneous injection once weekly, not once a month.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2170,
    "user_query": "You MUST give a detailed answer to the following question: List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-7b_response": "Robertsonian translocation is a type of chromosomal rearrangement that involves the fusion of two acrocentric chromosomes. The human acrocentric chromosomes involved in Robertsonian translocation are chromosomes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2237,
    "user_query": "You MUST give a detailed answer to the following question: Which R package could be used for the identification of pediatric brain tumors?",
    "llama-7b_response": "There are several R packages that could be used for the identification of pediatric brain tumors, including:\n\n1. R/Bioconductor packages: The R/Bioconductor packages are a collection of tools for the analysis of high-throughput genomic data, including packages for the identification of pediatric brain tumors. Some examples of R/Bioconductor packages that could be used for this purpose include edgeR, DESeq2, and limma.\n2. R/Bioinformatics packages: The R/Bioinformatics packages are a collection of tools for the analysis of biological data, including packages for the identification of pediatric brain tumors. Some examples of R/Bioinformatics packages that could be used for this purpose include GROMACS, VMD, and PyMOL.\n3. R/Computational Biology packages: The R/Computational Biology packages are a collection of tools for the analysis of biological data, including packages for the identification of pediatric brain tumors. Some examples of R/Computational Biology packages that could be used for this purpose include GROMACS, VMD, and PyMOL.\n4. R/Machine Learning packages: The R/Machine Learning packages are a collection of tools for the analysis of biological data, including packages for the identification of pediatric brain tumors. Some examples of R/Machine Learning packages that could be used for this purpose include scikit-learn, TensorFlow, and Keras.\n5. R/Data Science packages: The R/Data Science packages are a collection of tools for the analysis of biological data, including packages for the identification of pediatric brain tumors. Some examples of R/Data Science packages that could be used for this purpose include scikit-learn, TensorFlow, and Keras.",
    "llama-7b_fact_raw": "1. R/Bioconductor packages like edgeR, DESeq2, and limma can be used for the identification of pediatric brain tumors.\n2. GROMACS, VMD, and PyMOL are mentioned as R/Bioinformatics packages for the analysis of biological data, including pediatric brain tumor identification.\n3. GROMACS and VMD appear to be duplicated as R/Computational Biology packages for identifying pediatric brain tumors.\n4. Scikit-learn, TensorFlow, and Keras are listed as R/Machine Learning packages suitable for pediatric brain tumor identification.\n5. Scikit-learn, TensorFlow, and Keras are also listed as part of R/Data Science packages for the same purpose of identifying pediatric brain tumors.",
    "llama-7b_fact": [
      "R/Bioconductor packages like edgeR, DESeq2, and limma can be used for the identification of pediatric brain tumors.",
      "GROMACS, VMD, and PyMOL are mentioned as R/Bioinformatics packages for the analysis of biological data, including pediatric brain tumor identification.",
      "GROMACS and VMD appear to be duplicated as R/Computational Biology packages for identifying pediatric brain tumors.",
      "Scikit-learn, TensorFlow, and Keras are listed as R/Machine Learning packages suitable for pediatric brain tumor identification.",
      "Scikit-learn, TensorFlow, and Keras are also listed as part of R/Data Science packages for the same purpose of identifying pediatric brain tumors."
    ],
    "llama-7b_judge_raw": "1. TRUE: R/Bioconductor packages like edgeR, DESeq2, and limma are indeed used for various types of biological data analysis, which can include the identification of pediatric brain tumors through gene expression analysis.\n2. FALSE [correction]: GROMACS, VMD, and PyMOL are not R/Bioinformatics packages. They are separate software tools used for molecular dynamics simulations and visualization, not directly associated with R or specifically used for pediatric brain tumor identification.\n3. FALSE [correction]: Since GROMACS and VMD are not R packages, the statement about them being duplicated as R/Computational Biology packages for identifying pediatric brain tumors is incorrect.\n4. FALSE [correction]: Scikit-learn, TensorFlow, and Keras are Python libraries for machine learning and not R packages. They can be used for tasks like pediatric brain tumor identification through the development of predictive models though they are separate from R.\n5. FALSE [correction]: Again, Scikit-learn, TensorFlow, and Keras are machine learning libraries for Python and not part of R/Data Science packages. They may be used alongside R in a broader data science workflow, but they are not R packages.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2246,
    "user_query": "You MUST give a detailed answer to the following question: Is NEMO a zinc finger protein?",
    "llama-7b_response": "No, NEMO (NF-B essential modulator) is not a zinc finger protein.\n\nZinc finger proteins are a class of transcription factors that contain zinc ions in their structure, which allows them to bind specifically to DNA sequences. Zinc finger proteins are known for their ability to recognize and bind to specific DNA sequences, which can then be used to regulate gene expression.\n\nNEMO, on the other hand, is a protein that plays a critical role in the regulation of the NF-B signaling pathway. NF-B is a transcription factor that regulates the expression of genes involved in immune and inflammatory responses. NEMO is a key regulator of the NF-B signaling pathway, and it acts as a kinase that phosphorylates and activates IB, leading to its degradation and the activation of NF-B.\n\nWhile NEMO does not contain zinc ions in its structure, it is an important regulator of the NF-B signaling pathway and plays a critical role in the regulation of immune and inflammatory responses.",
    "llama-7b_fact_raw": "1. NEMO (NF-B essential modulator) is not considered a zinc finger protein.\n2. Zinc finger proteins are transcription factors that contain zinc ions which help bind to DNA sequences.\n3. Zinc finger proteins are involved in regulating gene expression through DNA sequence recognition and binding.\n4. NEMO plays a critical role in regulating the NF-B signaling pathway.\n5. NEMO acts as a kinase that phosphorylates IB, leading to the activation of NF-B.",
    "llama-7b_fact": [
      "NEMO (NF-B essential modulator) is not considered a zinc finger protein.",
      "Zinc finger proteins are transcription factors that contain zinc ions which help bind to DNA sequences.",
      "Zinc finger proteins are involved in regulating gene expression through DNA sequence recognition and binding.",
      "NEMO plays a critical role in regulating the NF-B signaling pathway.",
      "NEMO acts as a kinase that phosphorylates IB, leading to the activation of NF-B."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: NEMO does not act as a kinase that phosphorylates IB; instead, it is part of the IKK complex, which contains the kinases (IKK and IKK) that phosphorylate IB, leading to the activation of NF-B.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2247,
    "user_query": "You MUST give a detailed answer to the following question: Does TFIIS affect nucleosome positioning?",
    "llama-7b_response": "Yes, TFIIS does affect nucleosome positioning. TFIIS is a general transcription factor that plays a crucial role in the initiation of RNA polymerase II transcription by unwinding the DNA double helix and positioning the RNA polymerase II holoenzyme at the transcription start site (TSS).\n\nDuring transcription, TFIIS interacts with the RNA polymerase II holoenzyme and helps to position the holoenzyme at the correct location on the DNA template. TFIIS also interacts with other transcription factors and cofactors, such as TFIIE and TFIIB, to facilitate the recruitment of these factors to the TSS.\n\nIn addition to its role in positioning the RNA polymerase II holoenzyme, TFIIS also plays a role in regulating nucleosome positioning. Nucleosomes are the basic units of chromatin, and they consist of DNA wrapped around a core of histone proteins. The positioning of nucleosomes on the DNA template can affect the accessibility of the DNA template to the RNA polymerase II holoenzyme and other transcription factors.\n\nTFIIS has been shown to interact with histone proteins and to affect the positioning of nucleosomes on the DNA template. For example, TFIIS has been shown to displace nucleosomes from the TSS and to promote the formation of a nucleosome-free region around the TSS. This nucleosome-free region is thought to facilitate the recruitment of the RNA polymerase II holoenzyme to the TSS and to promote the initiation of transcription.\n\nIn summary, TFIIS plays a crucial role in the initiation of RNA polymerase II transcription by positioning the RNA polymerase II holoenzyme at the correct location on the DNA template. TFIIS also plays a role in regulating nucleosome positioning, and has been shown to affect the positioning of nucleosomes around the TSS, promoting the formation of a nucleosome-free region that facilitates the initiation of transcription.",
    "llama-7b_fact_raw": "1. TFIIS is a general transcription factor that plays a role in the initiation of RNA polymerase II transcription.\n2. TFIIS assists in unwinding the DNA double helix during transcription.\n3. TFIIS helps position the RNA polymerase II holoenzyme at the transcription start site (TSS).\n4. TFIIS interacts with histone proteins and can affect nucleosome positioning on the DNA template.\n5. TFIIS can displace nucleosomes from the TSS to promote the formation of a nucleosome-free region.",
    "llama-7b_fact": [
      "TFIIS is a general transcription factor that plays a role in the initiation of RNA polymerase II transcription.",
      "TFIIS assists in unwinding the DNA double helix during transcription.",
      "TFIIS helps position the RNA polymerase II holoenzyme at the transcription start site (TSS).",
      "TFIIS interacts with histone proteins and can affect nucleosome positioning on the DNA template.",
      "TFIIS can displace nucleosomes from the TSS to promote the formation of a nucleosome-free region."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: TFIIS is not a general transcription factor but rather a transcription elongation factor that plays a role in the process of RNA polymerase II transcription elongation.\n2. FALSE [correction]: TFIIS does not assist in unwinding the DNA double helix during transcription; this task is performed by the RNA polymerase itself and other transcription factors.\n3. FALSE [correction]: TFIIS does not help position the RNA polymerase II holoenzyme at the transcription start site (TSS); this is the role of general transcription factors.\n4. UNKNOWN: The statement is vague as it is not well-established that TFIIS directly interacts with histone proteins to affect nucleosome positioning. TFIIS is known for its function in transcription elongation and cleavage of stalled RNA transcripts.\n5. UNKNOWN: The statement about TFIIS's role in nucleosome displacement from the TSS to promote a nucleosome-free region is not well-established or may pertain to other transcription factors or chromatin remodelers.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2262,
    "user_query": "You MUST give a detailed answer to the following question: Do origins of replication close to yeast centromeres fire early or late?",
    "llama-7b_response": "The question of whether origins of replication that are close to yeast centromeres fire early or late is a topic of ongoing research and debate in the field of genetics and molecular biology.\n\nIn general, origins of replication are regions on chromosomes where DNA replication begins. In eukaryotic cells, such as yeast, there are multiple origins of replication that are distributed along the length of each chromosome.\n\nIn yeast, the centromere is a specialized region of the chromosome that plays a crucial role in the proper separation of sister chromatids during cell division. It is thought that the proximity of origins of replication to centromeres may play a role in the regulation of DNA replication and the proper segregation of genetic material during cell division.\n\nSome studies have suggested that origins of replication that are close to yeast centromeres may fire earlier than origins that are further away from centromeres. This is based on the observation that origins that are closer to centromeres tend to initiate DNA replication earlier in the cell cycle than origins that are further away.\n\nOther studies, however, have suggested that the timing of DNA replication at origins of replication that are close to yeast centromeres may not be significantly different from origins that are further away.\n\nOverall, the question of whether origins of replication that are close to yeast centromeres fire early or late is a complex and active area of research, and the answer may depend on a variety of factors, including the specific strain of yeast being studied and the conditions under which the cells are grown.",
    "llama-7b_fact_raw": "1. In eukaryotic cells such as yeast, there are multiple origins of replication distributed along the length of each chromosome.\n2. The centromere is a specialized region of the chromosome crucial for the proper separation of sister chromatids during cell division in yeast.\n3. Some studies suggest that origins of replication near yeast centromeres may initiate DNA replication earlier than those further away.\n4. There is ongoing research and debate about the timing of DNA replication at origins near yeast centromeres.\n5. The timing of DNA replication at origins of replication close to yeast centromeres may be influenced by factors like the yeast strain and growth conditions.",
    "llama-7b_fact": [
      "In eukaryotic cells such as yeast, there are multiple origins of replication distributed along the length of each chromosome.",
      "The centromere is a specialized region of the chromosome crucial for the proper separation of sister chromatids during cell division in yeast.",
      "Some studies suggest that origins of replication near yeast centromeres may initiate DNA replication earlier than those further away.",
      "There is ongoing research and debate about the timing of DNA replication at origins near yeast centromeres.",
      "The timing of DNA replication at origins of replication close to yeast centromeres may be influenced by factors like the yeast strain and growth conditions."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided align with the current understanding of eukaryotic cell biology. Origins of replication are indeed distributed along chromosomes, the centromere is essential for chromosome separation, and it is recognized that the location can affect the timing of DNA replication. Current research does look into these aspects and acknowledges that various factors can influence the timing of DNA replication.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2268,
    "user_query": "You MUST give a detailed answer to the following question: Which are the properties of mammalian GA-sequences?",
    "llama-7b_response": "Mammalian GA-sequences are a type of non-coding RNA that have been identified in a wide range of mammalian tissues, including the brain, heart, liver, and skeletal muscle. They are characterized by a specific sequence motif, known as the GA-motif, which consists of two guanine (G) nucleotides followed by one adenine (A) nucleotide.\n\nIn addition to the GA-motif, mammalian GA-sequences have several other properties that distinguish them from other types of non-coding RNA. For example, they are typically longer in length than other non-coding RNAs, with lengths ranging from several hundred to several thousand nucleotides. They are also highly conserved across different mammalian species, which suggests that they play important functional roles in the cell.\n\nFurthermore, mammalian GA-sequences have been shown to be involved in a variety of biological processes, including regulation of gene expression, RNA splicing, and ribosome biogenesis. They have also been implicated in the development of certain diseases, such as cancer and neurodegenerative disorders.\n\nOverall, the properties of mammalian GA-sequences suggest that they are an important class of non-coding RNA that plays crucial roles in various biological processes and may be involved in the development of certain diseases. Further research is needed to fully understand the functions of these RNAs and their potential as therapeutic targets.",
    "llama-7b_fact_raw": "1. Mammalian GA-sequences are a type of non-coding RNA present in tissues such as the brain, heart, liver, and skeletal muscle.\n2. They contain a specific sequence motif known as the GA-motif, which comprises two guanine nucleotides followed by one adenine nucleotide.\n3. Mammalian GA-sequences are typically longer than other non-coding RNAs, ranging from several hundred to several thousand nucleotides in length.\n4. These GA-sequences are highly conserved across different mammalian species.\n5. Mammalian GA-sequences are involved in biological processes including gene expression regulation, RNA splicing, and ribosome biogenesis, and have been implicated in diseases like cancer and neurodegenerative disorders.",
    "llama-7b_fact": [
      "Mammalian GA-sequences are a type of non-coding RNA present in tissues such as the brain, heart, liver, and skeletal muscle.",
      "They contain a specific sequence motif known as the GA-motif, which comprises two guanine nucleotides followed by one adenine nucleotide.",
      "Mammalian GA-sequences are typically longer than other non-coding RNAs, ranging from several hundred to several thousand nucleotides in length.",
      "These GA-sequences are highly conserved across different mammalian species.",
      "Mammalian GA-sequences are involved in biological processes including gene expression regulation, RNA splicing, and ribosome biogenesis, and have been implicated in diseases like cancer and neurodegenerative disorders."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: The \"GA-motif\" is not specifically defined as comprising two guanine nucleotides followed by one adenine nucleotide. Generally, a motif would be referred to as a recognizable pattern, but GA does not specify the pattern without more context.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements regarding mammalian GA-sequences are quite specific and would require verification from a reliable scientific source to determine their accuracy. Without the necessary context or source data, it is not possible to provide a definitive answer to these statements. The details about GA-motifs, their conservation, length, and role in biology cannot be verified without more information.",
    "llama-7b_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2291,
    "user_query": "You MUST give a detailed answer to the following question: How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-7b_response": "The number of Groucho-related genes (GRG) contained in the mouse genome is currently unknown. Groucho is a transcriptional repressor that belongs to the Groucho family of proteins, which also includes Groucho-related proteins (Gro) and Groucho-like proteins (Gro-like). The Groucho family of proteins is involved in various cellular processes, including transcriptional regulation, development, and cell-cycle progression.\n\nThe mouse genome contains a total of approximately 20,000 protein-coding genes, and it is likely that some of these genes are members of the Groucho family. However, it is not possible to determine the exact number of Groucho-related genes in the mouse genome without a comprehensive study of the Groucho family in the mouse genome.\n\nTherefore, the answer to the question of how many Groucho-related genes are contained in the mouse genome is \"unknown.\" Further research is needed to determine the exact number of Groucho-related genes in the mouse genome.",
    "llama-7b_fact_raw": "1. The exact number of Groucho-related genes (GRG) in the mouse genome is unknown.\n2. Groucho is a transcriptional repressor in the Groucho family of proteins.\n3. The Groucho family of proteins includes Groucho-related proteins (Gro) and Groucho-like proteins (Gro-like).\n4. The Groucho family of proteins is involved in transcriptional regulation, development, and cell-cycle progression.\n5. The mouse genome contains approximately 20,000 protein-coding genes.",
    "llama-7b_fact": [
      "The exact number of Groucho-related genes (GRG) in the mouse genome is unknown.",
      "Groucho is a transcriptional repressor in the Groucho family of proteins.",
      "The Groucho family of proteins includes Groucho-related proteins (Gro) and Groucho-like proteins (Gro-like).",
      "The Groucho family of proteins is involved in transcriptional regulation, development, and cell-cycle progression.",
      "The mouse genome contains approximately 20,000 protein-coding genes."
    ],
    "llama-7b_judge_raw": "1. TRUE: The exact number of Groucho-related genes (GRG) could be unknown due to the complexity of the genome and the ongoing research in genetics.\n2. TRUE: Groucho is a well-known transcriptional repressor in the Groucho/TLE family of proteins.\n3. UNKNOWN: Without specific biological context or additional information, it's unclear what the statement refers to with Groucho-related proteins (Gro) and Groucho-like proteins (Gro-like), as the typical nomenclature refers to TLE or Groucho-related genes.\n4. TRUE: The Groucho family of proteins is indeed involved in transcriptional regulation, development, and cell-cycle progression among other biological processes.\n5. TRUE: The estimated number of protein-coding genes in the mouse genome is indeed around 20,000, although exact numbers may vary slightly as genomic research progresses.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2304,
    "user_query": "You MUST give a detailed answer to the following question: Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-7b_response": "The RNA polymerase II subunit that carries RNA cleavage activity is the C-terminal domain (CTD) of the largest subunit of RNA polymerase II. The CTD is a repeated sequence of approximately 20 amino acids that is located at the carboxy-terminal end of the largest subunit of RNA polymerase II. The CTD contains a serine residue that can be phosphorylated by the enzyme RNA polymerase II kinase, leading to the formation of a phosphoserine residue. This phosphoserine residue can then interact with the exonuclease activity of the RNase III enzyme, leading to the cleavage of RNA transcripts. The CTD is therefore an important component of the RNA cleavage activity of RNA polymerase II.",
    "llama-7b_fact_raw": "1. The C-terminal domain (CTD) of the largest subunit of RNA polymerase II carries RNA cleavage activity.\n2. The CTD is located at the carboxy-terminal end of the largest subunit of RNA polymerase II.\n3. The CTD is a repeated sequence consisting of approximately 20 amino acids.\n4. The CTD contains a serine residue that can be phosphorylated by RNA polymerase II kinase.\n5. This phosphoserine residue can interact with exonuclease activity of the RNase III enzyme, leading to RNA transcript cleavage.",
    "llama-7b_fact": [
      "The C-terminal domain (CTD) of the largest subunit of RNA polymerase II carries RNA cleavage activity.",
      "The CTD is located at the carboxy-terminal end of the largest subunit of RNA polymerase II.",
      "The CTD is a repeated sequence consisting of approximately 20 amino acids.",
      "The CTD contains a serine residue that can be phosphorylated by RNA polymerase II kinase.",
      "This phosphoserine residue can interact with exonuclease activity of the RNase III enzyme, leading to RNA transcript cleavage."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The C-terminal domain (CTD) of the largest subunit of RNA polymerase II does not carry RNA cleavage activity; it is involved in the processing of the pre-mRNA, among other functions.\n2. TRUE\n3. FALSE [correction]: The CTD is a repeated sequence consisting of seven amino acids (Y1S2P3T4S5P6S7) repeated many times (up to 52 times in humans).\n4. TRUE\n5. FALSE [correction]: While the CTD contains phosphoserine residues and can interact with various factors during transcription and RNA processing, the specific interaction with RNase III enzyme leading to RNA transcript cleavage as described is not a recognized function of the CTD. RNase III has other functions, often unrelated to the CTD.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2321,
    "user_query": "You MUST give a detailed answer to the following question: What is the genetic basis of Ohdo syndrome?",
    "llama-7b_response": "Ohdo syndrome is a rare genetic disorder that affects multiple systems in the body, including the skeletal, muscular, and cardiovascular systems. The genetic basis of Ohdo syndrome has been identified as a mutation in the COL11A1 gene.\n\nThe COL11A1 gene provides instructions for making a protein called type XI collagen, which is a component of the extracellular matrix, a complex network of proteins and other molecules that provides structural support to cells. Mutations in the COL11A1 gene lead to a deficiency of type XI collagen, which can cause the symptoms of Ohdo syndrome.\n\nThe COL11A1 gene is located on the long (q) arm of chromosome 12 at position 12q13.2. The mutation that causes Ohdo syndrome can occur in any of the three exons of the COL11A1 gene, but the most common mutation is a deletion of part of exon 3. This deletion results in a premature stop codon and a truncated form of the type XI collagen protein that is unable to perform its normal functions.\n\nThe symptoms of Ohdo syndrome result from the effects of the mutated type XI collagen protein on multiple systems in the body. For example, the mutated protein may affect the development and function of bones and muscles, leading to skeletal abnormalities and muscle weakness. It may also affect the function of the heart and blood vessels, leading to cardiovascular problems.\n\nIn summary, the genetic basis of Ohdo syndrome is a mutation in the COL11A1 gene that leads to a deficiency of type XI collagen and the symptoms of the disorder. The mutation can occur in any of the three exons of the COL11A1 gene, but the most common mutation is a deletion of part of exon 3. The symptoms of Ohdo syndrome result from the effects of the mutated type XI collagen protein on multiple systems in the body.",
    "llama-7b_fact_raw": "1. Ohdo syndrome is a genetic disorder caused by mutations in the COL11A1 gene.\n2. The COL11A1 gene provides instructions for the production of type XI collagen.\n3. A deficiency of type XI collagen due to mutations in the COL11A1 gene leads to the symptoms of Ohdo syndrome.\n4. The COL11A1 gene is located on the long arm of chromosome 12 at position 12q13.2.\n5. The most common mutation in the COL11A1 gene related to Ohdo syndrome is a deletion of part of exon 3.",
    "llama-7b_fact": [
      "Ohdo syndrome is a genetic disorder caused by mutations in the COL11A1 gene.",
      "The COL11A1 gene provides instructions for the production of type XI collagen.",
      "A deficiency of type XI collagen due to mutations in the COL11A1 gene leads to the symptoms of Ohdo syndrome.",
      "The COL11A1 gene is located on the long arm of chromosome 12 at position 12q13.2.",
      "The most common mutation in the COL11A1 gene related to Ohdo syndrome is a deletion of part of exon 3."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Ohdo syndrome is a genetic disorder, but it is not typically caused by mutations in the COL11A1 gene. It is instead associated with mutations in several genes, including KAT6B (also known as qkf), MED12, and others.\n2. TRUE\n3. FALSE [correction]: The symptoms of Ohdo syndrome are not typically associated with a deficiency of type XI collagen due to mutations in the COL11A1 gene. As Ohdo syndrome is not typically connected to COL11A1 mutations, the symptoms are generally not related to type XI collagen deficiency.\n4. TRUE\n5. FALSE [correction]: Since the COL11A1 gene is not typically related to Ohdo syndrome, the statement about the most common mutation in the COL11A1 gene related to Ohdo syndrome being a deletion of part of exon 3 is incorrect. The specific common mutations associated with Ohdo syndrome would depend on the specific gene that is affected, such as KAT6B or MED12, not COL11A1.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2331,
    "user_query": "You MUST give a detailed answer to the following question: Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-7b_response": "The R/Bioconductor package for the analysis of psychiatric disease genes is called \"PsychiatricGWAS\". This package provides tools for the analysis of genome-wide association studies (GWAS) of psychiatric diseases, such as schizophrenia, bipolar disorder, and major depressive disorder.\n\nThe PsychiatricGWAS package provides functions for the following tasks:\n\n1. Loading and preprocessing of GWAS data: The package provides functions for loading and preprocessing of GWAS data, including imputing missing genotype data and correcting for population structure.\n2. Association analysis: The package provides functions for performing association analysis, including testing for association between genetic variants and psychiatric traits or diseases.\n3. Gene set analysis: The package provides functions for performing gene set analysis, including testing for enrichment of genetic variants in gene sets associated with psychiatric traits or diseases.\n4. Pathway analysis: The package provides functions for performing pathway analysis, including testing for enrichment of genetic variants in pathways associated with psychiatric traits or diseases.\n\nOverall, the PsychiatricGWAS package provides a comprehensive set of tools for the analysis of genetic data in psychiatric disease research.",
    "llama-7b_fact_raw": "1. The \"PsychiatricGWAS\" is an R/Bioconductor package developed for the analysis of psychiatric disease genes.\n2. The PsychiatricGWAS package is used in the analysis of genome-wide association studies (GWAS) of psychiatric diseases.\n3. Psychiatric diseases that the package targets for GWAS analysis include schizophrenia, bipolar disorder, and major depressive disorder.\n4. The package offers functions for loading and preprocessing of GWAS data, including imputing missing genotype data and correcting for population structure.\n5. It provides tools for association analysis, gene set analysis, and pathway analysis related to psychiatric diseases.",
    "llama-7b_fact": [
      "The \"PsychiatricGWAS\" is an R/Bioconductor package developed for the analysis of psychiatric disease genes.",
      "The PsychiatricGWAS package is used in the analysis of genome-wide association studies (GWAS) of psychiatric diseases.",
      "Psychiatric diseases that the package targets for GWAS analysis include schizophrenia, bipolar disorder, and major depressive disorder.",
      "The package offers functions for loading and preprocessing of GWAS data, including imputing missing genotype data and correcting for population structure.",
      "It provides tools for association analysis, gene set analysis, and pathway analysis related to psychiatric diseases."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: \"PsychiatricGWAS\" is not recognized as a specific R/Bioconductor package. Instead, there are general R/Bioconductor packages designed for the analysis of genome-wide association studies, but they are not named \"PsychiatricGWAS.\"\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nIt is important to note that while there are several packages in R/Bioconductor for analyzing GWAS data, without specific information on a package named \"PsychiatricGWAS,\" we cannot confirm the truth of statements 2 through 5 related to its functionality or the diseases it targets.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2360,
    "user_query": "You MUST give a detailed answer to the following question: Describe swirl sign in intracerebral hemorrhage.",
    "llama-7b_response": "A swirl sign in intracerebral hemorrhage is a characteristic imaging finding on computed tomography (CT) or magnetic resonance imaging (MRI) scans of the brain. It is a sign of intracerebral hemorrhage, which is a type of stroke caused by bleeding in the brain.\n\nThe swirl sign is characterized by a swirling pattern of blood within the affected hemisphere of the brain. This pattern is caused by the movement of blood within the hemorrhage, which can cause the blood to flow in a circular pattern. The swirl sign is typically seen on CT or MRI scans of the brain, and it can be a useful tool for diagnosing intracerebral hemorrhage.\n\nThe swirl sign is not specific to intracerebral hemorrhage, and it can also be seen in other conditions that cause bleeding in the brain, such as subarachnoid hemorrhage, which is a type of stroke caused by bleeding in the subarachnoid space around the brain. However, the presence of the swirl sign in combination with other symptoms and imaging findings is highly suggestive of intracerebral hemorrhage.\n\nIn summary, the swirl sign is a characteristic imaging finding in intracerebral hemorrhage, and it is caused by the movement of blood within the hemorrhage. It is typically seen on CT or MRI scans of the brain and can be a useful tool for diagnosing intracerebral hemorrhage.",
    "llama-7b_fact_raw": "1. A swirl sign is an imaging finding on computed tomography (CT) or magnetic resonance imaging (MRI) scans.\n2. The swirl sign is indicative of intracerebral hemorrhage, a type of stroke caused by bleeding in the brain.\n3. The swirl sign is characterized by a pattern of blood that appears to swirl within the hemisphere of the brain affected by the hemorrhage.\n4. This imaging sign can be useful in diagnosing intracerebral hemorrhage.\n5. While the swirl sign can also be seen in other conditions with brain bleeding, such as subarachnoid hemorrhage, its presence in conjunction with other symptoms and findings supports the diagnosis of intracerebral hemorrhage.",
    "llama-7b_fact": [
      "A swirl sign is an imaging finding on computed tomography (CT) or magnetic resonance imaging (MRI) scans.",
      "The swirl sign is indicative of intracerebral hemorrhage, a type of stroke caused by bleeding in the brain.",
      "The swirl sign is characterized by a pattern of blood that appears to swirl within the hemisphere of the brain affected by the hemorrhage.",
      "This imaging sign can be useful in diagnosing intracerebral hemorrhage.",
      "While the swirl sign can also be seen in other conditions with brain bleeding, such as subarachnoid hemorrhage, its presence in conjunction with other symptoms and findings supports the diagnosis of intracerebral hemorrhage."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The swirl sign is specifically associated with intracerebral hemorrhage and not typically seen in other types of bleeding such as subarachnoid hemorrhage.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2392,
    "user_query": "You MUST give a detailed answer to the following question: What induces Arabidopsis ROF1 expression?",
    "llama-7b_response": "Arabidopsis ROF1 is a transcription factor that plays a crucial role in the response of plants to various stresses, including drought, salt, and temperature stress. ROF1 expression is regulated by a variety of factors, including abiotic and biotic stresses, hormones, and signaling molecules.\n\nOne of the key inducers of ROF1 expression is abscisic acid (ABA), a phytohormone that plays a central role in the response of plants to drought stress. ABA binds to and activates several ABA receptors, including the ABSCISIC ACID INSENSITIVE3 (ABI3) and ABSCISIC ACID INSENSITIVE2 (ABI2) proteins, which in turn activate downstream signaling pathways that lead to the expression of ROF1 and other drought-responsive genes.\n\nAnother inducer of ROF1 expression is salicylic acid (SA), a plant hormone that plays a key role in the response to pathogens and other biotic stresses. Like ABA, SA activates the ABI3 and ABI2 receptors, leading to the expression of ROF1 and other defense genes.\n\nROF1 expression can also be induced by various stress-related signaling molecules, such as jasmonic acid (JA) and ethylene. JA, for example, is a signaling molecule that plays a central role in the response to pathogens and other biotic stresses, and it has been shown to induce ROF1 expression in Arabidopsis thaliana.\n\nIn summary, ROF1 expression is induced by a variety of factors, including abiotic and biotic stresses, hormones, and signaling molecules. These inducers activate downstream signaling pathways that lead to the expression of ROF1 and other drought-responsive genes.",
    "llama-7b_fact_raw": "1. Arabidopsis ROF1 is a transcription factor involved in plant responses to drought, salt, and temperature stress.\n2. Abscisic acid (ABA), a phytohormone associated with drought stress response, is an inducer of ROF1 expression in plants.\n3. Salicylic acid (SA), a plant hormone related to biotic stress response, can activate pathways leading to the expression of ROF1.\n4. Jasmonic acid (JA) is a signaling molecule that plays a role in the response to biotic stresses and induces ROF1 expression in Arabidopsis thaliana.\n5. ROF1 expression is regulated by various factors including abiotic and biotic stresses, hormones, and signaling molecules.",
    "llama-7b_fact": [
      "Arabidopsis ROF1 is a transcription factor involved in plant responses to drought, salt, and temperature stress.",
      "Abscisic acid (ABA), a phytohormone associated with drought stress response, is an inducer of ROF1 expression in plants.",
      "Salicylic acid (SA), a plant hormone related to biotic stress response, can activate pathways leading to the expression of ROF1.",
      "Jasmonic acid (JA) is a signaling molecule that plays a role in the response to biotic stresses and induces ROF1 expression in Arabidopsis thaliana.",
      "ROF1 expression is regulated by various factors including abiotic and biotic stresses, hormones, and signaling molecules."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nThe correctness of statements 1-4 requires specific knowledge or research on the ROF1 gene in Arabidopsis thaliana and its regulation by various stress conditions and phytohormones. Without access to the current scientific literature on this topic, I cannot verify these statements. However, statement 5 is generally true for many genes in plants, including genes like ROF1 that are involved in stress responses; their expression is often regulated by various factors, which can include abiotic stresses (like drought and temperature), biotic stresses (such as pathogen attack), and different hormones and signaling molecules.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2398,
    "user_query": "You MUST give a detailed answer to the following question: What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-7b_response": "Hereditary renal amyloidosis is a condition caused by the accumulation of abnormal protein deposits in the kidneys. The most common protein that causes hereditary renal amyloidosis is called transthyretin (TTR). TTR is a plasma protein that is normally involved in transporting thyroid hormones and retinol (vitamin A) throughout the body. In hereditary renal amyloidosis, mutations in the TTR gene lead to the production of abnormal TTR protein that accumulates in the kidneys, causing damage and eventually leading to kidney failure.",
    "llama-7b_fact_raw": "1. The most common protein that causes hereditary renal amyloidosis is transthyretin (TTR).\n2. Transthyretin (TTR) is a plasma protein involved in transporting thyroid hormones and retinol (vitamin A).\n3. Mutations in the TTR gene lead to the production of abnormal TTR protein.\n4. The abnormal TTR protein can accumulate in the kidneys in cases of hereditary renal amyloidosis.\n5. Accumulation of abnormal TTR protein in the kidneys can cause damage that may lead to kidney failure.",
    "llama-7b_fact": [
      "The most common protein that causes hereditary renal amyloidosis is transthyretin (TTR).",
      "Transthyretin (TTR) is a plasma protein involved in transporting thyroid hormones and retinol (vitamin A).",
      "Mutations in the TTR gene lead to the production of abnormal TTR protein.",
      "The abnormal TTR protein can accumulate in the kidneys in cases of hereditary renal amyloidosis.",
      "Accumulation of abnormal TTR protein in the kidneys can cause damage that may lead to kidney failure."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The most common protein that causes hereditary renal amyloidosis is not transthyretin (TTR), but rather fibrinogen A alpha-chain in most cases.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2407,
    "user_query": "You MUST give a detailed answer to the following question: Has the proteome of mice hippocampus been analysed?",
    "llama-7b_response": "Yes, the proteome of mice hippocampus has been analyzed. The proteome is the complete set of proteins expressed by an organism or a cell at a particular time or under specific conditions. The hippocampus is a critical brain region involved in learning, memory, and emotional regulation, and its proteome has been extensively studied in various experimental models, including mice.\n\nSeveral large-scale proteomic studies have been conducted to identify and characterize the proteins expressed in the mouse hippocampus. These studies have used a variety of techniques, including two-dimensional gel electrophoresis, mass spectrometry, and bioinformatics analysis, to identify and quantify thousands of proteins in the hippocampus.\n\nFor example, a study published in the journal Molecular and Cellular Proteomics in 2006 used two-dimensional gel electrophoresis and mass spectrometry to identify and quantify over 1,000 proteins in the mouse hippocampus. Another study published in the journal Proteomics in 2008 used a similar approach to identify and quantify over 2,000 proteins in the hippocampus of mice.\n\nThese studies have provided a wealth of information about the proteins expressed in the mouse hippocampus and have helped to elucidate the molecular mechanisms underlying learning, memory, and other cognitive processes. They have also identified potential biomarkers and targets for the treatment of neurological disorders, such as Alzheimer's disease and epilepsy.",
    "llama-7b_fact_raw": "1. The proteome of mice hippocampus has been analyzed.\n2. Proteomics studies have used techniques such as two-dimensional gel electrophoresis and mass spectrometry for analysis.\n3. A study published in the journal Molecular and Cellular Proteomics in 2006 identified and quantified over 1,000 proteins in the mouse hippocampus.\n4. Another study, published in Proteomics in 2008, identified and quantified over 2,000 proteins in the mouse hippocampus.\n5. Proteomic studies of the mouse hippocampus have contributed to understanding cognitive processes and identifying potential neurological disorder treatments.",
    "llama-7b_fact": [
      "The proteome of mice hippocampus has been analyzed.",
      "Proteomics studies have used techniques such as two-dimensional gel electrophoresis and mass spectrometry for analysis.",
      "A study published in the journal Molecular and Cellular Proteomics in 2006 identified and quantified over 1,000 proteins in the mouse hippocampus.",
      "Another study, published in Proteomics in 2008, identified and quantified over 2,000 proteins in the mouse hippocampus.",
      "Proteomic studies of the mouse hippocampus have contributed to understanding cognitive processes and identifying potential neurological disorder treatments."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThese statements generally align with typical scientific research approaches and findings within the field of proteomics. Proteomics studies often analyze specific tissues like the hippocampus, use techniques like 2D gel electrophoresis and mass spectrometry, focus on identifying and quantifying proteins, and aim at understanding biological processes relevant to health and disease. While the exact numbers and years of publication mentioned in statements 3 and 4 without specific citations cannot be confirmed here, they are plausible claims given the nature of proteomics research.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "You MUST give a detailed answer to the following question: Are mouse chromosomes acrocentric?",
    "llama-7b_response": "Yes, mouse chromosomes are acrocentric. Acrocentric chromosomes are a type of chromosome that have their centromeres (the point at which the two arms of the chromosome are attached) located towards the ends of the chromosome, rather than in the middle. This is in contrast to metacentric chromosomes, which have their centromeres in the middle of the chromosome.\n\nMouse chromosomes are numbered from 1 to 20, with the exception of the X and Y chromosomes, which are designated as chromosome 17 and chromosome 18, respectively. The centromeres of mouse chromosomes are located at different positions along the length of the chromosomes. For example, the centromere of chromosome 1 is located near the middle of the chromosome, while the centromere of chromosome 19 is located towards the end of the chromosome.\n\nOverall, the arrangement of the centromeres on mouse chromosomes is consistent with the classification of acrocentric chromosomes.",
    "llama-7b_fact_raw": "1. Mouse chromosomes are classified as acrocentric.\n2. Acrocentric chromosomes have their centromeres located towards the ends of the chromosome.\n3. Metacentric chromosomes have their centromeres located in the middle of the chromosome.\n4. Mouse chromosomes are numbered from 1 to 20, not including the sex chromosomes.\n5. The X and Y chromosomes in mice are designated as chromosome 17 and chromosome 18, respectively.",
    "llama-7b_fact": [
      "Mouse chromosomes are classified as acrocentric.",
      "Acrocentric chromosomes have their centromeres located towards the ends of the chromosome.",
      "Metacentric chromosomes have their centromeres located in the middle of the chromosome.",
      "Mouse chromosomes are numbered from 1 to 20, not including the sex chromosomes.",
      "The X and Y chromosomes in mice are designated as chromosome 17 and chromosome 18, respectively."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: In mice, the X and Y chromosomes are not designated as chromosome 17 and chromosome 18. Instead, they are referred to simply as the X and Y chromosomes without any numerical designation. Chromosomes 1 to 19 are the autosomes, and the 20th is not numbered since it refers to the sex chromosomes X and Y.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2417,
    "user_query": "You MUST give a detailed answer to the following question: Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-7b_response": "There are several small interfering RNA (siRNA) based drugs that are currently in clinical trials for the treatment of pancreatic cancer. One such drug is AT-1212, which is being developed by Alnylam Pharmaceuticals. AT-1212 is an RNA interference (RNAi) therapeutic that uses a single-stranded RNA molecule to silence the expression of a specific gene that is believed to play a role in the development and progression of pancreatic cancer.\n\nAnother siRNA-based drug that is being studied for the treatment of pancreatic cancer is ON-01910, which is being developed by OncoNeb. ON-01910 is an RNAi therapeutic that uses a double-stranded RNA molecule to silence the expression of a specific gene that is believed to play a role in the development and progression of pancreatic cancer.\n\nBoth AT-1212 and ON-01910 are still in the early stages of clinical development and have not yet been approved for use in the treatment of pancreatic cancer. However, they have shown promising results in preclinical studies and are being closely watched by the medical community as potential new treatments for this deadly disease.",
    "llama-7b_fact_raw": "1. AT-1212 is a small interfering RNA (siRNA) based drug in clinical trials for the treatment of pancreatic cancer.\n2. Alnylam Pharmaceuticals is developing AT-1212 as an RNA interference (RNAi) therapeutic.\n3. AT-1212 uses a single-stranded RNA molecule to silence the expression of a specific gene related to pancreatic cancer.\n4. ON-01910 is another siRNA-based drug in clinical trials for treating pancreatic cancer.\n5. ON-01910 is being developed by OncoNeb and utilizes a double-stranded RNA molecule for gene silencing.",
    "llama-7b_fact": [
      "AT-1212 is a small interfering RNA (siRNA) based drug in clinical trials for the treatment of pancreatic cancer.",
      "Alnylam Pharmaceuticals is developing AT-1212 as an RNA interference (RNAi) therapeutic.",
      "AT-1212 uses a single-stranded RNA molecule to silence the expression of a specific gene related to pancreatic cancer.",
      "ON-01910 is another siRNA-based drug in clinical trials for treating pancreatic cancer.",
      "ON-01910 is being developed by OncoNeb and utilizes a double-stranded RNA molecule for gene silencing."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: siRNA-based drugs typically use double-stranded RNA molecules to silence the expression of a specific gene, not single-stranded RNA molecules.\n4. UNKNOWN\n5. UNKNOWN\n\nNote: The specific companies developing AT-1212 and ON-01910, their targets, and their stages of clinical trials would need to be verified with the latest scientific literature or regulatory filings to provide a true or false statement. The mechanism of siRNAs as double-stranded molecules is based on general knowledge about RNA interference technology.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2419,
    "user_query": "You MUST give a detailed answer to the following question: What is the HPG pore?",
    "llama-7b_response": "I'm sorry, but I am not familiar with the term \"HPG pore.\" Could you please provide more context or information about what you are referring to?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2472,
    "user_query": "You MUST give a detailed answer to the following question: What is the 959 Nematode Genomes initiative?",
    "llama-7b_response": "The 959 Nematode Genomes initiative is a large-scale project aimed at sequencing and analyzing the genomes of 959 species of roundworms, also known as nematodes. Nematodes are a diverse group of organisms that include parasitic worms, plant-feeding nematodes, and free-living soil-dwelling nematodes.\n\nThe goal of the 959 Nematode Genomes initiative is to create a comprehensive resource of nematode genomes that will provide insights into the evolution, ecology, and biology of these organisms. By sequencing and analyzing the genomes of a wide range of nematode species, researchers hope to gain a better understanding of the genetic basis of nematode traits, such as their ability to cause disease in humans and animals, their interactions with other organisms, and their role in nutrient cycling in soil.\n\nThe 959 Nematode Genomes initiative is a collaborative effort between researchers from around the world, and is supported by a number of funding agencies and organizations. The sequencing and analysis of the nematode genomes is being carried out using a combination of next-generation sequencing technologies and bioinformatics tools.\n\nOverall, the 959 Nematode Genomes initiative has the potential to provide significant insights into the biology and evolution of nematodes, and could have implications for a wide range of fields, including medicine, agriculture, and ecology.",
    "llama-7b_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of roundworms.\n2. Nematodes include parasitic worms, plant-feeding nematodes, and free-living soil-dwelling nematodes.\n3. The initiative seeks to provide insights into nematodes' evolution, ecology, and biology.\n4. The 959 Nematode Genomes initiative is supported by multiple funding agencies and organizations.\n5. The initiative utilizes next-generation sequencing technologies and bioinformatics tools for genome analysis.",
    "llama-7b_fact": [
      "The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of roundworms.",
      "Nematodes include parasitic worms, plant-feeding nematodes, and free-living soil-dwelling nematodes.",
      "The initiative seeks to provide insights into nematodes' evolution, ecology, and biology.",
      "The 959 Nematode Genomes initiative is supported by multiple funding agencies and organizations.",
      "The initiative utilizes next-generation sequencing technologies and bioinformatics tools for genome analysis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE - Although without specific details on which agencies and organizations, this statement is generally what can be expected from large scientific initiatives. \n5. TRUE - This is a reasonable assumption given that next-generation sequencing technologies and bioinformatics tools are standard in modern genomics research. However, without specific details about the initiative's methods, the complete accuracy of this statement cannot be confirmed.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "You MUST give a detailed answer to the following question: Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-7b_response": "There are several R packages that have been developed for analyzing Non-invasive prenatal testing (NIPT) data. Some of the most popular ones include:\n\n1. NIPTAnalytics: This package provides tools for analyzing NIPT data, including tools for imputation, quality control, and statistical analysis.\n2. NIPT-R: This package provides a range of tools for analyzing NIPT data, including tools for imputation, quality control, and statistical analysis.\n3. NIPTAnalytics: This package provides tools for analyzing NIPT data, including tools for imputation, quality control, and statistical analysis.\n4. NIPT-R: This package provides a range of tools for analyzing NIPT data, including tools for imputation, quality control, and statistical analysis.\n5. NIPTAnalytics: This package provides tools for analyzing NIPT data, including tools for imputation, quality control, and statistical analysis.\n6. NIPT-R: This package provides a range of tools for analyzing NIPT data, including tools for imputation, quality control, and statistical analysis.\n7. NIPTAnalytics: This package provides tools for analyzing NIPT data, including tools for imputation, quality control, and statistical analysis.\n8. NIPT-R: This package provides a range of tools for analyzing NIPT data, including tools for imputation, quality control, and statistical analysis.\n9. NIPTAnalytics: This package provides tools for analyzing NIPT data, including tools for imputation, quality control, and statistical analysis.\n10. NIPT-R: This package provides a range of tools for analyzing NIPT data, including tools for imputation, quality control, and statistical analysis.",
    "llama-7b_fact_raw": "1. NIPTAnalytics is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.\n2. NIPT-R is another R package developed for analyzing Non-invasive prenatal testing (NIPT) data.\n3. Both NIPTAnalytics and NIPT-R packages offer tools for imputation related to NIPT data analysis.\n4. Both NIPTAnalytics and NIPT-R packages provide tools for quality control in NIPT data analysis.\n5. Statistical analysis tools for NIPT data are included in both NIPTAnalytics and NIPT-R packages.",
    "llama-7b_fact": [
      "NIPTAnalytics is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.",
      "NIPT-R is another R package developed for analyzing Non-invasive prenatal testing (NIPT) data.",
      "Both NIPTAnalytics and NIPT-R packages offer tools for imputation related to NIPT data analysis.",
      "Both NIPTAnalytics and NIPT-R packages provide tools for quality control in NIPT data analysis.",
      "Statistical analysis tools for NIPT data are included in both NIPTAnalytics and NIPT-R packages."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: Without specific evidence or references, it is not possible to verify if NIPTAnalytics is an R package for analyzing Non-invasive prenatal testing (NIPT) data.\n2. UNKNOWN: Similarly, without more information or a source confirming the existence of an R package named NIPT-R developed for analyzing NIPT data, it is not possible to verify the truthfulness of the statement.\n3. UNKNOWN: Without further details or documentation outlining the features of these R packages, it's not possible to determine if both NIPTAnalytics and NIPT-R offer tools for imputation in relation to NIPT data analysis.\n4. UNKNOWN: In the absence of specific details regarding the functions included in the NIPTAnalytics and NIPT-R packages, it's unclear whether they provide tools for quality control in NIPT data analysis.\n5. UNKNOWN: The statement regarding the inclusion of statistical analysis tools for NIPT data in both NIPTAnalytics and NIPT-R packages cannot be verified without additional information or access to the software documentation or published materials describing their features.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2560,
    "user_query": "You MUST give a detailed answer to the following question: Describe Achenbachs syndrome.",
    "llama-7b_response": "Achenbach's syndrome, also known as Achenbach's sign or Achenbach's test, is a physical examination maneuver used to assess the integrity of the cervical spinal nerve roots. It is named after the German neurologist Friedrich Achenbach, who first described the syndrome in 1891.\n\nThe maneuver involves applying pressure to the skin overlying the cervical spine, typically at the C6-C7 or C7-T1 levels, while the patient is asked to turn their head to the opposite side. If the nerve root is intact, the patient will experience pain, paresthesia (abnormal sensations such as tingling or numbness), or weakness in the arm or hand on the affected side. If the nerve root is compressed or damaged, these symptoms will be elicited.\n\nAchenbach's syndrome is often used as a diagnostic tool for conditions that affect the cervical spine, such as cervical disc herniation, cervical spinal stenosis, or cervical radiculopathy. It can also be used to evaluate the effectiveness of treatments for these conditions, such as surgery or physical therapy. However, it should be noted that Achenbach's syndrome is not a definitive diagnostic test and should be used in conjunction with other diagnostic tests and clinical examination findings.",
    "llama-7b_fact_raw": "1. Achenbach's syndrome is a physical examination maneuver used to assess the integrity of the cervical spinal nerve roots.\n2. The syndrome is named after Friedrich Achenbach, the German neurologist who first described it in 1891.\n3. The Achenbach's syndrome maneuver involves applying pressure to the skin over the cervical spine while the patient turns their head to the opposite side.\n4. Achenbach's syndrome is used as a diagnostic tool for conditions such as cervical disc herniation, cervical spinal stenosis, or cervical radiculopathy.\n5. Pain, paresthesia, or weakness in the arm or hand indicates that the cervical spinal nerve root is intact, while eliciting these symptoms may indicate compression or damage to the nerve root.",
    "llama-7b_fact": [
      "Achenbach's syndrome is a physical examination maneuver used to assess the integrity of the cervical spinal nerve roots.",
      "The syndrome is named after Friedrich Achenbach, the German neurologist who first described it in 1891.",
      "The Achenbach's syndrome maneuver involves applying pressure to the skin over the cervical spine while the patient turns their head to the opposite side.",
      "Achenbach's syndrome is used as a diagnostic tool for conditions such as cervical disc herniation, cervical spinal stenosis, or cervical radiculopathy.",
      "Pain, paresthesia, or weakness in the arm or hand indicates that the cervical spinal nerve root is intact, while eliciting these symptoms may indicate compression or damage to the nerve root."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Achenbach's syndrome is not a physical examination maneuver; it is a condition where patients experience sudden, unexplained bruising in the hand.\n2. TRUE\n3. FALSE [correction]: This statement incorrectly describes Achenbach's syndrome as a physical maneuver. Achenbach's syndrome involves spontaneous bruising, not an assessment of the cervical spinal nerve roots.\n4. FALSE [correction]: Achenbach's syndrome is not used as a diagnostic tool for spinal conditions. It is characterized by self-limiting episodes of bleeding into the skin of the hands.\n5. FALSE [correction]: Pain, paresthesia, or weakness in the arm or hand indicating the integrity of the cervical spinal nerve root is not relevant to Achenbach's syndrome, as it is not related to the cervical spine but to the hands.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2581,
    "user_query": "You MUST give a detailed answer to the following question: Which algorithm is used for detection of long repeat expansions?",
    "llama-7b_response": "There are several algorithms that can be used for the detection of long repeat expansions, but one of the most commonly used algorithms is the \"sliding window\" approach.\n\nIn this approach, a sliding window is used to scan the DNA sequence for the presence of the repeat expansion. The window is moved along the DNA sequence one nucleotide at a time, and for each nucleotide in the window, the number of repeats is counted. If the number of repeats exceeds a certain threshold, then the repeat expansion is detected.\n\nAnother algorithm that can be used for the detection of long repeat expansions is the \"dynamic programming\" approach. In this approach, a matrix is used to keep track of the number of repeats at each position in the DNA sequence. The matrix is initialized with zeros, and then the number of repeats is incremented for each nucleotide in the window. If the number of repeats exceeds a certain threshold, then the repeat expansion is detected.\n\nBoth of these algorithms have their own advantages and disadvantages, and the choice of algorithm will depend on the specific requirements of the application.",
    "llama-7b_fact_raw": "1. The \"sliding window\" approach is an algorithm used for detecting long repeat expansions in DNA sequences.\n2. In the sliding window approach, the window scans the DNA sequence and counts the number of repeats for each nucleotide.\n3. A repeat expansion is detected by the sliding window approach when the number of repeats exceeds a certain threshold.\n4. The \"dynamic programming\" approach is another algorithm used for detection of long repeat expansions.\n5. In the dynamic programming approach, a matrix is utilized to track the number of repeats at each position in the DNA sequence.",
    "llama-7b_fact": [
      "The \"sliding window\" approach is an algorithm used for detecting long repeat expansions in DNA sequences.",
      "In the sliding window approach, the window scans the DNA sequence and counts the number of repeats for each nucleotide.",
      "A repeat expansion is detected by the sliding window approach when the number of repeats exceeds a certain threshold.",
      "The \"dynamic programming\" approach is another algorithm used for detection of long repeat expansions.",
      "In the dynamic programming approach, a matrix is utilized to track the number of repeats at each position in the DNA sequence."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: In the sliding window approach, the window scans the DNA sequence, but it does not count the number of repeats for each individual nucleotide. It typically looks for patterns or motifs that repeat consecutively.\n3. TRUE\n4. UNKNOWN: Without more context about how \"dynamic programming\" is applied, it is not possible to confirm whether it is used for the detection of long repeat expansions in DNA sequences.\n5. FALSE [correction]: Dynamic programming does utilize a matrix, but the matrix is generally used to align sequences, find similarities, and track optimal alignment scores, not explicitly to track the number of repeats at each position in the DNA sequence. This statement oversimplifies the use of dynamic programming and attributes an incorrect functionality in the context given.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2582,
    "user_query": "You MUST give a detailed answer to the following question: Which brain tumors does neuroligin-3 promote?",
    "llama-7b_response": "Neuroligin-3 is a protein that plays a role in the development and function of the nervous system. It has been shown to promote the growth of certain types of brain tumors, specifically gliomas.\n\nGliomas are a type of brain tumor that arise from glial cells, which are supportive cells in the brain. There are several subtypes of gliomas, including astrocytomas, oligodendrogliomas, and ependymomas. Neuroligin-3 has been found to promote the growth of astrocytomas and oligodendrogliomas, which are two of the most common types of gliomas.\n\nNeuroligin-3 works by promoting the survival and proliferation of glioma cells. It does this by interacting with N-methyl-D-aspartate (NMDA) receptors on the surface of glioma cells. Activation of NMDA receptors can lead to an increase in intracellular calcium levels, which can promote the growth and survival of glioma cells. By interacting with NMDA receptors, neuroligin-3 can enhance the activity of these receptors and promote the growth of glioma cells.\n\nIt is worth noting that the role of neuroligin-3 in gliomas is complex and not fully understood. Further research is needed to fully understand the mechanisms by which neuroligin-3 promotes the growth of gliomas.",
    "llama-7b_fact_raw": "1. Neuroligin-3 is a protein involved in the development and function of the nervous system.\n2. Neuroligin-3 promotes the growth of certain brain tumors, specifically gliomas.\n3. Gliomas are a type of brain tumor that originate from glial cells.\n4. Neuroligin-3 is found to promote the growth of astrocytomas and oligodendrogliomas, subtypes of gliomas.\n5. Neuroligin-3 enhances the activity of N-methyl-D-aspartate (NMDA) receptors on glioma cells, which can increase intracellular calcium levels that promote tumor growth and survival.",
    "llama-7b_fact": [
      "Neuroligin-3 is a protein involved in the development and function of the nervous system.",
      "Neuroligin-3 promotes the growth of certain brain tumors, specifically gliomas.",
      "Gliomas are a type of brain tumor that originate from glial cells.",
      "Neuroligin-3 is found to promote the growth of astrocytomas and oligodendrogliomas, subtypes of gliomas.",
      "Neuroligin-3 enhances the activity of N-methyl-D-aspartate (NMDA) receptors on glioma cells, which can increase intracellular calcium levels that promote tumor growth and survival."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nIt is important to note that the details provided in statements 2, 4, and 5 are specific and would require verification from current scientific research to confirm their accuracy. Given that this information could be subject to new findings, they are considered true based on the context provided, but actual scientific literature should be consulted for the most up-to-date information.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2586,
    "user_query": "You MUST give a detailed answer to the following question: What is the approximate size of gas vesicles?",
    "llama-7b_response": "Gas vacuoles, also known as gas vesicles, are small, gas-filled organelles found in some bacteria and archaea. Their size can vary depending on the species and environmental conditions, but they are typically on the order of 1-100 nm in diameter. In some cases, gas vacuoles can reach up to several micrometers in size, but this is relatively rare. It's worth noting that the size of gas vacuoles can be influenced by factors such as nutrient availability, temperature, and pH, which can affect their growth and development.",
    "llama-7b_fact_raw": "1. Gas vesicles, also referred to as gas vacuoles, are found in some bacteria and archaea.\n2. The typical diameter range for gas vesicles is about 1-100 nanometers.\n3. In certain cases, gas vesicles can reach sizes of several micrometers.\n4. The size of gas vesicles can vary based on species and environmental conditions.\n5. Factors such as nutrient availability, temperature, and pH can influence the size of gas vesicles.",
    "llama-7b_fact": [
      "Gas vesicles, also referred to as gas vacuoles, are found in some bacteria and archaea.",
      "The typical diameter range for gas vesicles is about 1-100 nanometers.",
      "In certain cases, gas vesicles can reach sizes of several micrometers.",
      "The size of gas vesicles can vary based on species and environmental conditions.",
      "Factors such as nutrient availability, temperature, and pH can influence the size of gas vesicles."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The typical diameter for gas vesicles is about 45-200 nanometers.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2589,
    "user_query": "You MUST give a detailed answer to the following question: List BET proteins.",
    "llama-7b_response": "BET (Bromodomain and Extra-terminal domain) proteins are a family of epigenetic regulators that play a crucial role in the regulation of gene expression. BET proteins are characterized by the presence of two distinct domains: the bromodomain, which recognizes acetylated lysine residues, and the extra-terminal (ET) domain, which is involved in protein-protein interactions and transcriptional regulation.\n\nHere is a non-exhaustive list of BET proteins:\n\n1. BRD2 (Bromodomain-containing protein 2)\n2. BRD3 (Bromodomain-containing protein 3)\n3. BRD4 (Bromodomain-containing protein 4)\n4. BAP1 (Bromodomain-associated protein 1)\n5. BAP3 (Bromodomain-associated protein 3)\n6. BAP2 (Bromodomain-associated protein 2)\n7. BAP4 (Bromodomain-associated protein 4)\n8. BAP5 (Bromodomain-associated protein 5)\n9. BAP6 (Bromodomain-associated protein 6)\n10. BAP7 (Bromodomain-associated protein 7)\n11. BAP8 (Bromodomain-associated protein 8)\n12. BAP9 (Bromodomain-associated protein 9)\n13. BAP10 (Bromodomain-associated protein 10)\n14. BAP11 (Bromodomain-associated protein 11)\n15. BAP12 (Bromodomain-associated protein 12)\n16. BAP13 (Bromodomain-associated protein 13)\n17. BAP14 (Bromodomain-associated protein 14)\n18. BAP15 (Bromodomain-associated protein 15)\n19. BAP16 (Bromodomain-associated protein 16)\n20.",
    "llama-7b_fact_raw": "1. BET proteins are epigenetic regulators involved in gene expression regulation.\n2. BET proteins contain two domains: the bromodomain and the extra-terminal domain.\n3. BRD2 is a member of the BET protein family.\n4. BRD3 is a member of the BET protein family.\n5. BRD4 is a member of the BET protein family.",
    "llama-7b_fact": [
      "BET proteins are epigenetic regulators involved in gene expression regulation.",
      "BET proteins contain two domains: the bromodomain and the extra-terminal domain.",
      "BRD2 is a member of the BET protein family.",
      "BRD3 is a member of the BET protein family.",
      "BRD4 is a member of the BET protein family."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2610,
    "user_query": "You MUST give a detailed answer to the following question: Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-7b_response": "There are several algorithms that have been developed for the prediction of protein subcellular localization using deep learning, including:\n\n1. Convolutional Neural Networks (CNNs): These are a type of deep learning algorithm that have been used to predict protein subcellular localization by analyzing the amino acid sequence of the protein.\n2. Recurrent Neural Networks (RNNs): These are a type of deep learning algorithm that have been used to predict protein subcellular localization by analyzing the amino acid sequence of the protein and taking into account the context in which the protein is found in the cell.\n3. Autoencoders: These are a type of deep learning algorithm that have been used to predict protein subcellular localization by learning to reconstruct the protein from its amino acid sequence, and then using this reconstruction to predict the subcellular location of the protein.\n4. Generative Adversarial Networks (GANs): These are a type of deep learning algorithm that have been used to predict protein subcellular localization by training two neural networks, one generative and one discriminative, to predict the subcellular location of the protein.\n5. Transformers: These are a type of deep learning algorithm that have been used to predict protein subcellular localization by using a self-attention mechanism to analyze the amino acid sequence of the protein and take into account the context in which the protein is found in the cell.",
    "llama-7b_fact_raw": "1. Convolutional Neural Networks (CNNs) have been used to predict protein subcellular localization based on amino acid sequences.\n2. Recurrent Neural Networks (RNNs) have been utilized for predicting protein subcellular localization by considering the context of proteins in cells.\n3. Autoencoders have been applied to predict protein subcellular localization by reconstructing proteins from their amino acid sequences.\n4. Generative Adversarial Networks (GANs) have been employed for predicting protein subcellular localization through the training of generative and discriminative neural networks.\n5. Transformers have been used to predict protein subcellular localization by employing self-attention mechanisms to analyze amino acid sequences within their cellular context.",
    "llama-7b_fact": [
      "Convolutional Neural Networks (CNNs) have been used to predict protein subcellular localization based on amino acid sequences.",
      "Recurrent Neural Networks (RNNs) have been utilized for predicting protein subcellular localization by considering the context of proteins in cells.",
      "Autoencoders have been applied to predict protein subcellular localization by reconstructing proteins from their amino acid sequences.",
      "Generative Adversarial Networks (GANs) have been employed for predicting protein subcellular localization through the training of generative and discriminative neural networks.",
      "Transformers have been used to predict protein subcellular localization by employing self-attention mechanisms to analyze amino acid sequences within their cellular context."
    ],
    "llama-7b_judge_raw": "1. TRUE: Convolutional Neural Networks (CNNs) have indeed been used to predict protein subcellular localization based on amino acid sequences due to their ability to extract features from sequential data.\n2. TRUE: Recurrent Neural Networks (RNNs) are well-suited for sequence-based tasks and have been used for predicting protein subcellular localization by considering the sequential context of amino acids.\n3. UNKNOWN: Autoencoders are generally used for unsupervised learning tasks such as dimensionality reduction and feature learning. While they could theoretically be used for reconstructing amino acid sequences, there is not enough information to confirm their specific application in predicting protein subcellular localization in this context.\n4. UNKNOWN: Generative Adversarial Networks (GANs) are a class of neural network architectures used for generative modeling. They could be applied to a wide range of problems, including potentially protein subcellular localization, but without specific information, it's unclear if they have been employed for this purpose.\n5. TRUE: Transformers, which use self-attention mechanisms, have been utilized for various sequence-based tasks including those in bioinformatics like predicting protein structures and functions, which could include subcellular localization.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2634,
    "user_query": "You MUST give a detailed answer to the following question: What is MULTOVL?",
    "llama-7b_response": "I'm sorry, but I am not familiar with the term \"MULTOVL.\" Without more context or information, it is difficult for me to provide a detailed answer. Could you please provide more information or clarify your question?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2660,
    "user_query": "You MUST give a detailed answer to the following question: Can GDF15 be a biomarker for metformin treatment?",
    "llama-7b_response": "GDF15 (Growth Differentiation Factor 15) is a protein that has been studied as a potential biomarker for various conditions, including aging, cancer, and cardiovascular disease. However, its role as a biomarker for metformin treatment has not been well established.\n\nGDF15 is known to be involved in the regulation of glucose metabolism and insulin sensitivity. Some studies have suggested that GDF15 levels may be elevated in individuals with type 2 diabetes, and that metformin treatment may decrease GDF15 levels. However, other studies have found conflicting results, and the relationship between GDF15 and metformin treatment is not yet fully understood.\n\nTherefore, while GDF15 has been studied as a potential biomarker for metformin treatment, its role in this regard is not yet well established. Further research is needed to clarify the relationship between GDF15 and metformin treatment, and to determine whether GDF15 can be used as a reliable biomarker for metformin efficacy.",
    "llama-7b_fact_raw": "1. GDF15 is a protein studied as a potential biomarker for various conditions including aging, cancer, and cardiovascular disease.\n2. GDF15 is involved in the regulation of glucose metabolism and insulin sensitivity.\n3. Some studies suggest that GDF15 levels may be elevated in individuals with type 2 diabetes.\n4. There are studies that suggest metformin treatment may decrease GDF15 levels.\n5. The role of GDF15 as a biomarker for metformin treatment is not yet well established and requires further research.",
    "llama-7b_fact": [
      "GDF15 is a protein studied as a potential biomarker for various conditions including aging, cancer, and cardiovascular disease.",
      "GDF15 is involved in the regulation of glucose metabolism and insulin sensitivity.",
      "Some studies suggest that GDF15 levels may be elevated in individuals with type 2 diabetes.",
      "There are studies that suggest metformin treatment may decrease GDF15 levels.",
      "The role of GDF15 as a biomarker for metformin treatment is not yet well established and requires further research."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: There are studies that suggest metformin treatment may increase GDF15 levels.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2664,
    "user_query": "You MUST give a detailed answer to the following question: Is recursive splicing more common in short introns?",
    "llama-7b_response": "Recursive splicing is more common in short introns.\n\nRecursive splicing occurs when an intron is spliced out of an RNA transcript multiple times, resulting in multiple copies of the intron being present in the final transcript. This phenomenon is more likely to occur in short introns because they are more likely to be spliced out of the transcript multiple times due to their smaller size.\n\nShort introns are more likely to be spliced out of the transcript because they are more likely to interfere with the correct splicing of the coding exons. This is because short introns are more likely to be located in the vicinity of coding exons, which increases the likelihood of the intron being spliced out of the transcript.\n\nIn addition, short introns are more likely to be spliced out of the transcript because they are more likely to contain regulatory elements that can affect the splicing of the coding exons. For example, short introns may contain splicing enhancers or silencers that can affect the splicing of the coding exons, leading to the intron being spliced out of the transcript.\n\nOverall, short introns are more likely to be spliced out of the transcript, which increases the likelihood of recursive splicing occurring. This is because short introns are more likely to be located in the vicinity of coding exons and contain regulatory elements that can affect the splicing of the coding exons.",
    "llama-7b_fact_raw": "1. Recursive splicing is the process where an intron is spliced out of an RNA transcript multiple times.\n2. Recursive splicing is more likely to occur in short introns than in longer ones.\n3. Short introns are more likely to be spliced out of RNA transcripts multiple times due to their smaller size.\n4. Short introns commonly reside in close proximity to coding exons, which can increase the likelihood of them being spliced out.\n5. Short introns may contain splicing enhancers or silencers that can influence the splicing of coding exons.",
    "llama-7b_fact": [
      "Recursive splicing is the process where an intron is spliced out of an RNA transcript multiple times.",
      "Recursive splicing is more likely to occur in short introns than in longer ones.",
      "Short introns are more likely to be spliced out of RNA transcripts multiple times due to their smaller size.",
      "Short introns commonly reside in close proximity to coding exons, which can increase the likelihood of them being spliced out.",
      "Short introns may contain splicing enhancers or silencers that can influence the splicing of coding exons."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Recursive splicing is a process where a long intron is removed in multiple steps through the use of internal splice sites within the intron, not by splicing out the intron multiple times.\n2. FALSE [correction]: Recursive splicing is more likely to occur in longer introns because they might contain recursive splice sites, which are necessary for the process to occur.\n3. FALSE [correction]: This statement is based on the incorrect premise that short introns are more likely to undergo recursive splicing. Recursive splicing typically involves longer introns.\n4. TRUE: Short introns often do reside close to coding exons, which could affect their splicing due to proximity to regulatory elements.\n5. TRUE: Short introns may indeed contain elements such as splicing enhancers or silencers that influence splicing, though this is true for introns of various lengths and not exclusive to short introns.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2679,
    "user_query": "You MUST give a detailed answer to the following question: What is the TALE-iD method used for?",
    "llama-7b_response": "The TALE-iD (Transcription Activator-Like Effector-based IDentification) method is a bioinformatics tool used for the identification of transcription factor binding sites (TFBS) in DNA sequences.\n\nTranscription factors (TFs) are proteins that regulate gene expression by binding to specific sequences in the promoter or enhancer regions of target genes. The binding of TFs to these sequences plays a crucial role in the regulation of gene expression, and the identification of TFBS is an important step in understanding gene regulation.\n\nThe TALE-iD method is based on the use of Transcription Activator-Like Effector (TALE) proteins, which are DNA-binding proteins that can be programmed to recognize specific DNA sequences. TALE-iD uses TALE proteins to identify TFBS in a given DNA sequence by measuring the binding affinity of TALE proteins for different regions of the DNA sequence.\n\nThe TALE-iD method works by designing TALE proteins that recognize specific TFBS, and then using these TALE proteins to bind to the DNA sequence of interest. The binding affinity of the TALE proteins for different regions of the DNA sequence is then measured, and the regions with the highest binding affinity are identified as TFBS.\n\nThe TALE-iD method has several advantages over other methods for the identification of TFBS, including its high specificity and sensitivity, as well as its ability to identify TFBS in complex genomic regions. The method has been used to identify TFBS in a variety of organisms, including bacteria, yeast, and mammals, and has been applied to a wide range of research areas, including gene regulation, epigenetics, and drug discovery.\n\nOverall, the TALE-iD method is a powerful tool for the identification of TFBS in DNA sequences, and has the potential to contribute to our understanding of gene regulation and the development of new therapeutics.",
    "llama-7b_fact_raw": "1. The TALE-iD method is used for the identification of transcription factor binding sites in DNA sequences.\n2. Transcription factors regulate gene expression by binding to specific sequences in promoter or enhancer regions of target genes.\n3. TALE-iD is based on the use of Transcription Activator-Like Effector proteins, which are programmed to recognize specific DNA sequences.\n4. TALE-iD uses the binding affinity of TALE proteins for different regions of DNA to identify transcription factor binding sites.\n5. The TALE-iD method has been applied to a wide range of research areas, including gene regulation, epigenetics, and drug discovery.",
    "llama-7b_fact": [
      "The TALE-iD method is used for the identification of transcription factor binding sites in DNA sequences.",
      "Transcription factors regulate gene expression by binding to specific sequences in promoter or enhancer regions of target genes.",
      "TALE-iD is based on the use of Transcription Activator-Like Effector proteins, which are programmed to recognize specific DNA sequences.",
      "TALE-iD uses the binding affinity of TALE proteins for different regions of DNA to identify transcription factor binding sites.",
      "The TALE-iD method has been applied to a wide range of research areas, including gene regulation, epigenetics, and drug discovery."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nIt's important to note that while the statements regarding the TALE-iD method appear accurate based on common scientific understanding, the applicability of the method to a \"wide range of research areas\" in statement 5 is a general statement that is likely true; however, specifics would depend on the prevalent research and publications available up to the cutoff knowledge date. The exact range of applications could be more detailed with additional context, but the given statement is generally correct in the context of biological research.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2747,
    "user_query": "You MUST give a detailed answer to the following question: Which Lisp framework has been developed for image processing?",
    "llama-7b_response": "There are several Lisp frameworks that have been developed for image processing, including:\n\n1. Common Lisp Object System (CLOS)\n2. Lisp Image Processing System (LIPS)\n3. Lisp Machine Image Processing System (LMIPS)\n4. Common Lisp Image Processing (CLIP)\n5. Lisp Machine Image Processing (LMIP)\n\nIt is worth noting that these frameworks are not specific to image processing and can be used for a variety of tasks, including natural language processing, data analysis, and more.",
    "llama-7b_fact_raw": "1. The Common Lisp Object System (CLOS) is a framework that has been developed and can be used for image processing.\n2. The Lisp Image Processing System (LIPS) is a framework that has been developed for image processing.\n3. The Lisp Machine Image Processing System (LMIPS) is a framework that has been developed for image processing.\n4. Common Lisp Image Processing (CLIP) is a framework that has been developed for image processing.\n5. Lisp Machine Image Processing (LMIP) is a framework that has been developed for image processing.",
    "llama-7b_fact": [
      "The Common Lisp Object System (CLOS) is a framework that has been developed and can be used for image processing.",
      "The Lisp Image Processing System (LIPS) is a framework that has been developed for image processing.",
      "The Lisp Machine Image Processing System (LMIPS) is a framework that has been developed for image processing.",
      "Common Lisp Image Processing (CLIP) is a framework that has been developed for image processing.",
      "Lisp Machine Image Processing (LMIP) is a framework that has been developed for image processing."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: While CLOS (Common Lisp Object System) is an object-oriented programming system for the programming language Common Lisp, there's no direct evidence that CLOS itself is a framework specifically developed for image processing. However, it could be used as part of such a framework.\n\n2. FALSE [correction]: As of my last update in 2023, there is no well-known or widely recognized framework named Lisp Image Processing System (LIPS) specifically developed for image processing. However, Lisp is a family of programming languages that could potentially be used to create an image processing system, but LIPS does not appear to be a standard term or recognized framework in this domain.\n\n3. FALSE [correction]: There is no well-known or widely recognized framework named Lisp Machine Image Processing System (LMIPS) developed for image processing.\n\n4. UNKNOWN: I don't have up-to-date information to confirm the existence of a framework called Common Lisp Image Processing (CLIP) specifically developed for image processing. CLIP is not a widely recognized acronym in the domain of image processing as per the knowledge available up to 2023.\n\n5. UNKNOWN: I don't have up-to-date information about a framework called Lisp Machine Image Processing (LMIP). The term is not widely recognized in the context of image processing frameworks as of my last update.",
    "llama-7b_judge": [
      "unknown",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2759,
    "user_query": "You MUST give a detailed answer to the following question: How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-7b_response": "There are approximately 5,000 genes in the genome of Saccharomyces cerevisiae, also known as baker's yeast. It is believed that the majority of these genes are the result of an ancient whole genome duplication event that occurred approximately 100 million years ago. This event resulted in the duplication of the ancestral yeast genome, leading to the formation of two identical copies of each gene. Over time, many of these duplicate genes have become functionally distinct or have lost their original function, leading to the diversification of the S. cerevisiae genome.",
    "llama-7b_fact_raw": "1. The genome of Saccharomyces cerevisiae contains approximately 5,000 genes.\n2. The majority of the genes in the genome of Saccharomyces cerevisiae are the result of an ancient whole genome duplication.\n3. The ancient whole genome duplication event in Saccharomyces cerevisiae occurred approximately 100 million years ago.\n4. The genome duplication in Saccharomyces cerevisiae resulted in two identical copies of each gene.\n5. Over time, duplicate genes in the Saccharomyces cerevisiae genome have diverged functionally or lost their original function.",
    "llama-7b_fact": [
      "The genome of Saccharomyces cerevisiae contains approximately 5,000 genes.",
      "The majority of the genes in the genome of Saccharomyces cerevisiae are the result of an ancient whole genome duplication.",
      "The ancient whole genome duplication event in Saccharomyces cerevisiae occurred approximately 100 million years ago.",
      "The genome duplication in Saccharomyces cerevisiae resulted in two identical copies of each gene.",
      "Over time, duplicate genes in the Saccharomyces cerevisiae genome have diverged functionally or lost their original function."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The ancient whole genome duplication event in Saccharomyces cerevisiae is estimated to have occurred about 100-150 million years ago, with scientific sources varying on the exact timeframe.\n4. FALSE [correction]: The genome duplication in Saccharomyces cerevisiae initially resulted in two identical copies of each gene, but these copies have since evolved and are not necessarily identical anymore.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2763,
    "user_query": "You MUST give a detailed answer to the following question: Which complex is bound by estrogen-related receptor  (Esrrb)?",
    "llama-7b_response": "Estrogen-related receptor  (Esrrb) is a member of the nuclear receptor superfamily of transcription factors. It is a ligand-activated transcription factor that plays a role in the regulation of gene expression in response to estrogen and other steroid hormones.\n\nEsrrb is known to be bound by a variety of compounds, including steroid hormones such as estrogen and androgens, as well as non-steroidal compounds such as tamoxifen and raloxifene. These compounds act as ligands for Esrrb, binding to specific domains on the receptor and activating its transcriptional activity.\n\nEsrrb is expressed in a variety of tissues, including the breast, where it plays a role in the regulation of gene expression in response to estrogen. It has been shown to be involved in the development and progression of breast cancer, and may be a target for the development of new therapeutic strategies for the treatment of this disease.\n\nIn summary, Esrrb is bound by a variety of compounds, including steroid hormones and non-steroidal compounds, and plays a role in the regulation of gene expression in response to estrogen and other steroid hormones. It is expressed in a variety of tissues, including the breast, and may be a target for the development of new therapeutic strategies for the treatment of breast cancer.",
    "llama-7b_fact_raw": "1. Estrogen-related receptor  (Esrrb) is a member of the nuclear receptor superfamily of transcription factors.\n2. Esrrb functions as a ligand-activated transcription factor in the regulation of gene expression.\n3. Compounds that bind to Esrrb include steroid hormones such as estrogen and androgens, as well as non-steroidal compounds like tamoxifen and raloxifene.\n4. Esrrb is expressed in various tissues, including breast tissue.\n5. Esrrb has been implicated in the development and progression of breast cancer.",
    "llama-7b_fact": [
      "Estrogen-related receptor  (Esrrb) is a member of the nuclear receptor superfamily of transcription factors.",
      "Esrrb functions as a ligand-activated transcription factor in the regulation of gene expression.",
      "Compounds that bind to Esrrb include steroid hormones such as estrogen and androgens, as well as non-steroidal compounds like tamoxifen and raloxifene.",
      "Esrrb is expressed in various tissues, including breast tissue.",
      "Esrrb has been implicated in the development and progression of breast cancer."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Estrogen-related receptor  (Esrrb) is considered an orphan receptor and does not have any known natural ligands, unlike other receptors that bind with steroid hormones. It is regulated by transcriptional coregulators rather than by ligand binding.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2842,
    "user_query": "You MUST give a detailed answer to the following question: What is the role of ZCCHC17?",
    "llama-7b_response": "ZCCHC17, also known as zinc finger CCCH-type zinc finger protein 17, is a protein that plays a crucial role in various cellular processes. The exact function of ZCCHC17 is not fully understood, but it is believed to be involved in the regulation of gene expression.\n\nZCCHC17 is a zinc finger protein, which means it contains multiple zinc ions bound to amino acid side chains in its structure. These zinc ions play a crucial role in the protein's ability to bind to DNA and other molecules. ZCCHC17 contains several zinc finger domains, which allow it to recognize specific DNA sequences and bind to them.\n\nOne of the main functions of ZCCHC17 is to act as a transcription factor, which means it can bind to specific DNA sequences and regulate the expression of genes. Studies have shown that ZCCHC17 can bind to promoter regions of genes and enhance their transcription. This suggests that ZCCHC17 may play a role in the regulation of gene expression in a variety of cells and tissues.\n\nIn addition to its role in transcription, ZCCHC17 has also been implicated in other cellular processes. For example, studies have shown that ZCCHC17 can interact with other proteins and modulate their activity. This suggests that ZCCHC17 may play a role in the regulation of signaling pathways and other cellular processes.\n\nOverall, while the exact function of ZCCHC17 is not fully understood, it is clear that it plays a crucial role in various cellular processes. Further research is needed to fully elucidate the role of ZCCHC17 in the regulation of gene expression and other cellular processes.",
    "llama-7b_fact_raw": "1. ZCCHC17, also known as zinc finger CCCH-type zinc finger protein 17, is a protein.\n2. ZCCHC17 is believed to be involved in the regulation of gene expression.\n3. ZCCHC17 contains multiple zinc ions that contribute to its ability to bind to DNA.\n4. ZCCHC17 can act as a transcription factor by binding to specific DNA sequences to regulate gene expression.\n5. ZCCHC17 may interact with other proteins and modulate their activity, suggesting a role in regulating signaling pathways.",
    "llama-7b_fact": [
      "ZCCHC17, also known as zinc finger CCCH-type zinc finger protein 17, is a protein.",
      "ZCCHC17 is believed to be involved in the regulation of gene expression.",
      "ZCCHC17 contains multiple zinc ions that contribute to its ability to bind to DNA.",
      "ZCCHC17 can act as a transcription factor by binding to specific DNA sequences to regulate gene expression.",
      "ZCCHC17 may interact with other proteins and modulate their activity, suggesting a role in regulating signaling pathways."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: ZCCHC17 contains zinc finger motifs, which typically coordinate zinc ions, but a statement that it contains \"multiple zinc ions\" is imprecise without specifying the number of zinc finger motifs in the protein that could bind zinc ions.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2861,
    "user_query": "You MUST give a detailed answer to the following question: Which proteins form the nuclear pore basket in human cells?",
    "llama-7b_response": "The nuclear pore basket, also known as the nuclear pore complex (NPC), is a large protein structure that forms a selective barrier between the nucleus and the cytoplasm of eukaryotic cells. The NPC is composed of multiple copies of a large number of different proteins, and the exact composition of these proteins can vary between different organisms and even between different cell types within the same organism.\n\nIn human cells, the NPC is composed of a number of different proteins, including:\n\n1. Nup107-160: These proteins make up the outer ring of the NPC and are responsible for forming the selective barrier between the nucleus and the cytoplasm.\n2. Nup153: This protein forms part of the inner ring of the NPC and is involved in the transport of molecules through the pore.\n3. Nup214: This protein is involved in the assembly of the NPC and is required for its proper function.\n4. Nup93: This protein forms part of the inner ring of the NPC and is involved in the transport of molecules through the pore.\n5. Nup188: This protein is involved in the assembly of the NPC and is required for its proper function.\n\nThese are just a few examples of the proteins that make up the nuclear pore basket in human cells. There are many other proteins that are also involved in the formation and function of the NPC, and the exact composition of the NPC can vary depending on the cell type and the organism.",
    "llama-7b_fact_raw": "1. The nuclear pore complex (NPC) forms a selective barrier between the nucleus and the cytoplasm in eukaryotic cells.\n2. Nup107-160 proteins make up the outer ring of the NPC in human cells.\n3. Nup153 is a protein that forms part of the inner ring of the NPC in human cells and is involved in the transport of molecules.\n4. Nup214 is a protein involved in the assembly of the NPC in human cells.\n5. Nup93 is part of the inner ring of the NPC in human cells and aids in molecule transport through the pore.",
    "llama-7b_fact": [
      "The nuclear pore complex (NPC) forms a selective barrier between the nucleus and the cytoplasm in eukaryotic cells.",
      "Nup107-160 proteins make up the outer ring of the NPC in human cells.",
      "Nup153 is a protein that forms part of the inner ring of the NPC in human cells and is involved in the transport of molecules.",
      "Nup214 is a protein involved in the assembly of the NPC in human cells.",
      "Nup93 is part of the inner ring of the NPC in human cells and aids in molecule transport through the pore."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Nup153 is a component associated with the nuclear basket structure of the NPC in human cells and plays a role in nuclear transport but is not part of the inner ring.\n4. FALSE [correction]: Nup214 is not directly involved in the assembly of the NPC in human cells. It is part of the cytoplasmic filaments of the NPC and is involved in the export of mRNA and other processes.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2919,
    "user_query": "You MUST give a detailed answer to the following question: What type of topoisomerase inhibitor is gepotidacin?",
    "llama-7b_response": "Gepotidacin is a topoisomerase II inhibitor.",
    "llama-7b_fact_raw": "1. Gepotidacin is an inhibitor of topoisomerase II.",
    "llama-7b_fact": [
      "Gepotidacin is an inhibitor of topoisomerase II."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Gepotidacin is not an inhibitor of topoisomerase II; it is an inhibitor of bacterial topoisomerase IV and DNA gyrase (topoisomerase II enzymes in bacteria), which are different from human topoisomerase II enzymes.",
    "llama-7b_judge": [
      "false"
    ]
  },
  {
    "id": 2943,
    "user_query": "You MUST give a detailed answer to the following question: Describe Canvas SPW",
    "llama-7b_response": "I'm sorry, but I'm not sure what you mean by \"Canvas SPW.\" Could you please provide more context or clarify your question?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2960,
    "user_query": "You MUST give a detailed answer to the following question: List STING agonists.",
    "llama-7b_response": "STING (Stimulator of Interferon Genes) is a protein that plays a crucial role in the innate immune response to viral infections. STING agonists are compounds or agents that stimulate the activity of STING and enhance the immune response against viral infections. Here are some examples of STING agonists:\n\n1. Cyclic di-GMP (c-di-GMP): c-di-GMP is a bacterial second messenger that regulates various cellular processes, including virulence and host-pathogen interactions. STING agonists such as c-di-GMP have been shown to enhance the immune response against viral infections by activating STING.\n2. Cyclic dinucleotides: Cyclic dinucleotides are a class of small molecules that mimic c-di-GMP. They have been shown to activate STING and enhance the immune response against viral infections.\n3. Cyclic di-GMP mimetics: Cyclic di-GMP mimetics are synthetic compounds that mimic the activity of c-di-GMP. They have been shown to activate STING and enhance the immune response against viral infections.\n4. CpG oligonucleotides: CpG oligonucleotides are synthetic nucleic acids that contain unmethylated CpG dinucleotides. They have been shown to activate STING and enhance the immune response against viral infections.\n5. Poly I:C: Poly I:C is a synthetic analog of double-stranded RNA. It has been shown to activate STING and enhance the immune response against viral infections.\n\nThese are just a few examples of STING agonists. There are many other compounds and agents that have been shown to activate STING and enhance the immune response against viral infections.",
    "llama-7b_fact_raw": "1. Cyclic di-GMP (c-di-GMP) is an example of a STING agonist that can activate STING and enhance the immune response against viral infections.\n2. Cyclic dinucleotides are a class of small molecules capable of activating STING.\n3. Synthetic compounds known as cyclic di-GMP mimetics mimic the activity of c-di-GMP and activate STING.\n4. CpG oligonucleotides are synthetic nucleic acids that include unmethylated CpG dinucleotides and can activate STING.\n5. Poly I:C, a synthetic analog of double-stranded RNA, can activate STING and is categorized as a STING agonist.",
    "llama-7b_fact": [
      "Cyclic di-GMP (c-di-GMP) is an example of a STING agonist that can activate STING and enhance the immune response against viral infections.",
      "Cyclic dinucleotides are a class of small molecules capable of activating STING.",
      "Synthetic compounds known as cyclic di-GMP mimetics mimic the activity of c-di-GMP and activate STING.",
      "CpG oligonucleotides are synthetic nucleic acids that include unmethylated CpG dinucleotides and can activate STING.",
      "Poly I:C, a synthetic analog of double-stranded RNA, can activate STING and is categorized as a STING agonist."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Cyclic di-GMP (c-di-GMP) is actually an example of a bacterial second messenger and is not known as a STING agonist. STING agonists are typically cyclic dinucleotides, but c-di-GMP itself specifically does not activate STING to enhance immune response against viral infections.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: CpG oligonucleotides are known for their ability to activate Toll-like receptor 9 (TLR9), not STING. They include unmethylated CpG motifs that mimic bacterial DNA, leading to an immune response.\n5. FALSE [correction]: Poly I:C is a synthetic analog of double-stranded RNA and is known to activate TLR3 and the RIG-I like receptor pathways, not directly the STING pathway. It's not categorized as a STING agonist.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2964,
    "user_query": "You MUST give a detailed answer to the following question: Describe SLIC-CAGE",
    "llama-7b_response": "SLIC-CAGE is an acronym that stands for \"Slice-based Layer-wise Integrated Channel Attention and Graph Convolutional Encoder.\" It is a deep learning model that is used for natural language processing (NLP) tasks, such as text classification and sentiment analysis.\n\nThe SLIC-CAGE model is composed of several layers, each of which performs a specific task. The first layer in the model is called the \"Slice-based Layer-wise Integrated Channel Attention\" layer. This layer uses attention mechanisms to focus on different parts of the input text when making predictions.\n\nThe next layer in the SLIC-CAGE model is called the \"Graph Convolutional Encoder.\" This layer uses graph convolutional networks (GCNs) to process the input text as a graph, where each node in the graph represents a word or a subword in the text, and the edges between the nodes represent the relationships between the words.\n\nThe final layer in the SLIC-CAGE model is a classification layer, which uses a softmax function to produce a probability distribution over the possible classes or labels that the input text could belong to.\n\nOverall, the SLIC-CAGE model is a powerful tool for NLP tasks, as it is able to process text as both a sequence of words and as a graph, and it can use attention mechanisms to focus on important parts of the input text when making predictions.",
    "llama-7b_fact_raw": "1. SLIC-CAGE stands for \"Slice-based Layer-wise Integrated Channel Attention and Graph Convolutional Encoder.\"\n2. The SLIC-CAGE model is used for natural language processing tasks such as text classification and sentiment analysis.\n3. The first layer in the SLIC-CAGE model uses attention mechanisms to focus on different parts of the input text.\n4. The SLIC-CAGE model includes a \"Graph Convolutional Encoder\" layer that processes text as a graph, where nodes represent words or subwords.\n5. The SLIC-CAGE model uses a softmax function in its classification layer to produce a probability distribution over potential classes or labels.",
    "llama-7b_fact": [
      "SLIC-CAGE stands for \"Slice-based Layer-wise Integrated Channel Attention and Graph Convolutional Encoder.\"",
      "The SLIC-CAGE model is used for natural language processing tasks such as text classification and sentiment analysis.",
      "The first layer in the SLIC-CAGE model uses attention mechanisms to focus on different parts of the input text.",
      "The SLIC-CAGE model includes a \"Graph Convolutional Encoder\" layer that processes text as a graph, where nodes represent words or subwords.",
      "The SLIC-CAGE model uses a softmax function in its classification layer to produce a probability distribution over potential classes or labels."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE (In most models used for classification tasks, including those in natural language processing, a softmax function is typically used in the final layer to produce a probability distribution over classes or labels. This is a common practice and not necessarily specific to the SLIC-CAGE model. However, without specific details about the SLIC-CAGE model, it is still unknown whether this model follows the same structure.)",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2978,
    "user_query": "You MUST give a detailed answer to the following question: What are the roles of LEM-3?",
    "llama-7b_response": "LEM-3 (Lymphoid Enhancer-Binding Factor 3) is a transcription factor that plays a crucial role in the development and function of the immune system. It is a member of the LEF/TCF (Lymphoid Enhancer-Binding Factor/Transcriptional Coactivator with PDZ-binding motif) family of proteins, which are involved in the regulation of gene expression.\n\nThe main roles of LEM-3 in the immune system are:\n\n1. Regulation of B cell development: LEM-3 is essential for the development of B cells, which are a type of immune cell that produces antibodies to protect against infections. It regulates the expression of genes involved in B cell development and activation.\n2. Regulation of T cell development: LEM-3 also plays a role in the development of T cells, which are a type of immune cell that helps coordinate the immune response. It regulates the expression of genes involved in T cell development and activation.\n3. Regulation of immune response: LEM-3 is involved in the regulation of the immune response to infections and inflammation. It regulates the expression of genes involved in the production of immune cells, the activation of immune responses, and the regulation of inflammation.\n4. Regulation of stem cell function: LEM-3 is also involved in the regulation of stem cell function. It regulates the self-renewal and differentiation of hematopoietic stem cells, which are stem cells that give rise to immune cells.\n\nIn summary, LEM-3 plays a crucial role in the development and function of the immune system by regulating the expression of genes involved in B cell, T cell, and immune response development, as well as stem cell function.",
    "llama-7b_fact_raw": "1. LEM-3 (Lymphoid Enhancer-Binding Factor 3) is a transcription factor that is important for immune system development and function.\n2. It is part of the LEF/TCF family of proteins, which are involved in gene expression regulation.\n3. LEM-3 is essential for the development and activation of B cells, immune cells responsible for producing antibodies.\n4. LEM-3 plays a role in T cell development, another type of immune cell involved in coordinating the immune response.\n5. LEM-3 regulates gene expression related to immune responses, including the production and activation of immune cells and inflammation control.",
    "llama-7b_fact": [
      "LEM-3 (Lymphoid Enhancer-Binding Factor 3) is a transcription factor that is important for immune system development and function.",
      "It is part of the LEF/TCF family of proteins, which are involved in gene expression regulation.",
      "LEM-3 is essential for the development and activation of B cells, immune cells responsible for producing antibodies.",
      "LEM-3 plays a role in T cell development, another type of immune cell involved in coordinating the immune response.",
      "LEM-3 regulates gene expression related to immune responses, including the production and activation of immune cells and inflammation control."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: The name LEM-3 does not correspond to a well-known transcription factor involved in immune system development, making it difficult to verify the accuracy of the statement without additional context. Lymphoid Enhancer-Binding Factor is usually known as LEF-1.\n2. TRUE: LEF/TCF family of proteins, which includes LEF-1, is indeed involved in gene expression regulation, particularly in the Wnt signaling pathway.\n3. UNKNOWN: Without clarification on whether LEM-3 is a misnomer for LEF-1 or a different protein altogether, it is difficult to determine the validity of the statement concerning B cell development and antibody production.\n4. UNKNOWN: Similar to statement 3, without clear identification of LEM-3, it is not possible to confirm its role in T cell development.\n5. UNKNOWN: While members of the LEF/TCF family are involved in gene expression related to the immune system, the exact nature of LEM-3's role in regulating immune responses remains unclear due to the ambiguous designation of \"LEM-3.\"",
    "llama-7b_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2992,
    "user_query": "You MUST give a detailed answer to the following question: List the releases of tmVar",
    "llama-7b_response": "I'm sorry, but I cannot provide a detailed answer to your question as it is not clear what you are asking. Could you please provide more context or clarify your question?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3018,
    "user_query": "You MUST give a detailed answer to the following question: Which is the database of somatic mutations in normal cells?",
    "llama-7b_response": "The database of somatic mutations in normal cells is called the Cancer Genome Atlas (TCGA). It is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI), both part of the National Institutes of Health (NIH). The TCGA project aims to comprehensively characterize the genomic changes that occur in various types of cancer, with the goal of improving our understanding of cancer biology and identifying potential targets for cancer treatment.\n\nThe TCGA project has generated a vast amount of data on somatic mutations in normal cells, including whole-exome sequencing (WES) and whole-genome sequencing (WGS) data for a large number of cancer tissue samples. This data is publicly available and can be accessed through the TCGA Data Portal, which provides a range of tools and resources for analyzing and interpreting the data.\n\nThe TCGA data has been used to identify recurrent somatic mutations in various types of cancer, as well as to study the genomic changes that occur during cancer development and progression. The data has also been used to identify potential therapeutic targets and to develop new cancer treatments. Overall, the TCGA project has made significant contributions to our understanding of cancer genomics and has the potential to improve the diagnosis, treatment, and prevention of cancer.",
    "llama-7b_fact_raw": "1. The Cancer Genome Atlas (TCGA) is a database of somatic mutations in normal cells.\n2. The TCGA is a collaborative project between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).\n3. The goal of the TCGA project is to characterize the genomic changes in various types of cancer to improve understanding and treatment.\n4. The TCGA project includes whole-exome sequencing (WES) and whole-genome sequencing (WGS) data.\n5. The data from TCGA is publicly accessible through the TCGA Data Portal.",
    "llama-7b_fact": [
      "The Cancer Genome Atlas (TCGA) is a database of somatic mutations in normal cells.",
      "The TCGA is a collaborative project between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).",
      "The goal of the TCGA project is to characterize the genomic changes in various types of cancer to improve understanding and treatment.",
      "The TCGA project includes whole-exome sequencing (WES) and whole-genome sequencing (WGS) data.",
      "The data from TCGA is publicly accessible through the TCGA Data Portal."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Cancer Genome Atlas (TCGA) is a database of somatic mutations in cancer cells, not normal cells.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3037,
    "user_query": "You MUST give a detailed answer to the following question: Are there graph kernel libraries available implemented in JAVA?",
    "llama-7b_response": "Yes, there are several graph kernel libraries available implemented in Java. Some of the popular ones include:\n\n1. Jena: Jena is a Java framework for building Semantic Web and Linked Data applications. It provides a set of libraries for working with RDF and OWL ontologies, as well as a SPARQL query engine. Jena also has support for graph kernels through the use of the Sesame library.\n2. Sesame: Sesame is a Java library for working with RDF and OWL ontologies. It provides a SPARQL query engine and support for graph kernels through the use of the Jena framework.\n3. Apache Jena: Apache Jena is a Java framework for building Semantic Web and Linked Data applications. It provides a set of libraries for working with RDF and OWL ontologies, as well as a SPARQL query engine. Jena also has support for graph kernels through the use of the Sesame library.\n4. OpenCog: OpenCog is a Java-based platform for building intelligent applications. It provides a set of libraries for working with knowledge graphs and has support for graph kernels through the use of the Sesame library.\n\nThese are just a few examples of the many graph kernel libraries available implemented in Java.",
    "llama-7b_fact_raw": "1. Jena is a Java framework for building Semantic Web and Linked Data applications that supports graph kernels through the use of the Sesame library.\n2. Sesame is a Java library that works with RDF and OWL ontologies and supports graph kernels through the use of the Jena framework.\n3. Apache Jena is a Java framework, similar to Jena, for building Semantic Web and Linked Data applications with support for graph kernels.\n4. OpenCog is a Java-based platform for building intelligent applications and supports graph kernels.\n5. These libraries provide a SPARQL query engine as part of their functionalities.",
    "llama-7b_fact": [
      "Jena is a Java framework for building Semantic Web and Linked Data applications that supports graph kernels through the use of the Sesame library.",
      "Sesame is a Java library that works with RDF and OWL ontologies and supports graph kernels through the use of the Jena framework.",
      "Apache Jena is a Java framework, similar to Jena, for building Semantic Web and Linked Data applications with support for graph kernels.",
      "OpenCog is a Java-based platform for building intelligent applications and supports graph kernels.",
      "These libraries provide a SPARQL query engine as part of their functionalities."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Jena is a Java framework for building Semantic Web and Linked Data applications. However, it does not use the Sesame library; instead, it is a distinct project that also provides an RDF (Resource Description Framework) API.\n2. FALSE [correction]: Sesame is indeed a Java library that was used for processing RDF data, but it does not rely on Jena for graph kernel support. Sesame and Jena are separate projects, and Sesame has now been succeeded by RDF4J.\n3. TRUE: Apache Jena, also known simply as Jena, is a Java framework for building Semantic Web and Linked Data applications, supporting graph data models.\n4. FALSE [correction]: OpenCog is not Java-based; it is mainly developed in C++ and Scheme, and it is used for artificial intelligence research rather than specifically for Semantic Web or Linked Data applications.\n5. TRUE: Both Jena and Sesame (now RDF4J) provide a SPARQL query engine as part of their functionalities for querying RDF data.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3045,
    "user_query": "You MUST give a detailed answer to the following question: List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-7b_response": "Sure, here are the four advances integrated into the SHERLOCKv2 platform:\n\n1. Machine learning algorithms: SHERLOCKv2 uses machine learning algorithms to analyze and interpret medical images, such as X-rays, CT scans, and MRI scans. These algorithms can detect and diagnose a wide range of medical conditions, including cancer, cardiovascular disease, and neurological disorders.\n2. Artificial intelligence: SHERLOCKv2 is an example of artificial intelligence (AI) in healthcare. AI refers to the ability of computers and machines to perform tasks that typically require human intelligence, such as learning, problem-solving, and decision-making. In the case of SHERLOCKv2, AI is used to analyze medical images and provide accurate diagnoses.\n3. Computer vision: SHERLOCKv2 uses computer vision technology to analyze medical images. Computer vision is the ability of computers and machines to interpret and understand visual information, such as images and videos. In the case of SHERLOCKv2, computer vision is used to analyze X-rays, CT scans, and MRI scans to detect and diagnose medical conditions.\n4. Deep learning: SHERLOCKv2 uses deep learning, a type of machine learning algorithm, to analyze medical images. Deep learning is a subset of machine learning that involves training artificial neural networks to learn from large amounts of data. In the case of SHERLOCKv2, deep learning is used to analyze medical images and provide accurate diagnoses.",
    "llama-7b_fact_raw": "1. SHERLOCKv2 uses machine learning algorithms to analyze and interpret medical images.\n2. SHERLOCKv2 is an application of artificial intelligence in healthcare, particularly in the analysis of medical images for diagnosis.\n3. The platform utilizes computer vision technology to understand and interpret visual information from medical images such as X-rays, CT scans, and MRI scans.\n4. Deep learning, as a subset of machine learning, is used within SHERLOCKv2 for analyzing medical images.",
    "llama-7b_fact": [
      "SHERLOCKv2 uses machine learning algorithms to analyze and interpret medical images.",
      "SHERLOCKv2 is an application of artificial intelligence in healthcare, particularly in the analysis of medical images for diagnosis.",
      "The platform utilizes computer vision technology to understand and interpret visual information from medical images such as X-rays, CT scans, and MRI scans.",
      "Deep learning, as a subset of machine learning, is used within SHERLOCKv2 for analyzing medical images."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nWithout specific context or details regarding a platform called \"SHERLOCKv2,\" it is not possible to determine the veracity of these statements. These statements could potentially apply to a hypothetical or real software platform designed for medical image analysis, but without further information, their truth cannot be ascertained.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3078,
    "user_query": "You MUST give a detailed answer to the following question: Describe the bartender algorithm",
    "llama-7b_response": "The bartender algorithm is a heuristic algorithm used in the traveling salesman problem (TSP) to find near-optimal solutions to the problem. The algorithm is based on the idea of having a bartender who serves drinks to a group of customers, where the goal is to minimize the total distance traveled by the bartender while serving all the customers.\n\nThe algorithm works as follows:\n\n1. Start with an initial solution, which is a tour that visits all the cities in the TSP problem.\n2. For each city in the tour, calculate the distance between the city and all other cities in the tour.\n3. Select the city with the highest distance from the other cities as the next city to be visited.\n4. Repeat steps 2 and 3 until all cities have been visited.\n\nThe bartender algorithm is a local search algorithm, which means that it only considers the immediate neighborhood of the current solution when making decisions. This makes the algorithm computationally efficient, but it may not find the optimal solution to the TSP problem.\n\nThe bartender algorithm has been shown to be effective in solving small to medium-sized TSP problems, and it is often used as a baseline algorithm for comparing the performance of other TSP-solving algorithms.",
    "llama-7b_fact_raw": "1. The bartender algorithm is used in the traveling salesman problem to find near-optimal solutions.\n2. The goal of the algorithm is to minimize the total distance traveled while serving all customers.\n3. The initial step of the bartender algorithm is to start with a tour that visits all the cities in the problem.\n4. The algorithm identifies the city with the highest distance from other cities as the next to visit in the sequence.\n5. The bartender algorithm has been shown to be effective in solving small to medium-sized traveling salesman problems.",
    "llama-7b_fact": [
      "The bartender algorithm is used in the traveling salesman problem to find near-optimal solutions.",
      "The goal of the algorithm is to minimize the total distance traveled while serving all customers.",
      "The initial step of the bartender algorithm is to start with a tour that visits all the cities in the problem.",
      "The algorithm identifies the city with the highest distance from other cities as the next to visit in the sequence.",
      "The bartender algorithm has been shown to be effective in solving small to medium-sized traveling salesman problems."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The correct term is the \"nearest neighbor algorithm,\" not the \"bartender algorithm,\" which is used in the traveling salesman problem to find near-optimal solutions.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The nearest neighbor algorithm selects the nearest unvisited city as the next city to visit, not necessarily the city with the highest distance from other cities.\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3100,
    "user_query": "You MUST give a detailed answer to the following question: Which web-based pedigree editors are available?",
    "llama-7b_response": "There are several web-based pedigree editors available, including:\n\n1. Geni: Geni is a popular web-based genealogy platform that allows users to create and manage their family trees online. It offers a range of features, including the ability to collaborate with others on your tree, add photos and stories, and connect with other users who are researching the same ancestors.\n2. MyHeritage: MyHeritage is a comprehensive genealogy platform that offers a range of features, including a web-based pedigree editor. Users can create and manage their family trees, add photos and documents, and connect with other users who are researching the same ancestors.\n3. Ancestry: Ancestry is a popular genealogy platform that offers a range of features, including a web-based pedigree editor. Users can create and manage their family trees, add photos and documents, and connect with other users who are researching the same ancestors.\n4. WeRelate: WeRelate is a web-based genealogy platform that allows users to create and manage their family trees online. It offers a range of features, including the ability to collaborate with others on your tree, add photos and stories, and connect with other users who are researching the same ancestors.\n5. WikiTree: WikiTree is a collaborative genealogy platform that allows users to create and manage their family trees online. It offers a range of features, including the ability to collaborate with others on your tree, add photos and stories, and connect with other users who are researching the same ancestors.\n\nThese are just a few examples of the many web-based pedigree editors available. Each platform offers different features and benefits, so it's worth exploring a few to find the one that best suits your needs.",
    "llama-7b_fact_raw": "1. Geni is a web-based genealogy platform that allows users to create and manage their family trees.\n2. MyHeritage offers a web-based pedigree editor as part of its genealogy platform.\n3. Ancestry provides a web-based pedigree editor for users to create and manage their family trees.\n4. WeRelate is a web-based genealogy platform that includes features for tree collaboration, photo and story additions, and connecting with others.\n5. WikiTree is a collaborative genealogy platform that offers users the ability to manage their family trees online.",
    "llama-7b_fact": [
      "Geni is a web-based genealogy platform that allows users to create and manage their family trees.",
      "MyHeritage offers a web-based pedigree editor as part of its genealogy platform.",
      "Ancestry provides a web-based pedigree editor for users to create and manage their family trees.",
      "WeRelate is a web-based genealogy platform that includes features for tree collaboration, photo and story additions, and connecting with others.",
      "WikiTree is a collaborative genealogy platform that offers users the ability to manage their family trees online."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3107,
    "user_query": "You MUST give a detailed answer to the following question: Which curated databases exist for spider-venom toxins?",
    "llama-7b_response": "There are several curated databases that exist for spider venom toxins. Here are some of the most notable ones:\n\n1. Spider Toxin Database (STD): The Spider Toxin Database is a comprehensive resource for spider venom toxins. It provides information on the chemical structure, biological activity, and pharmacological effects of spider venom toxins. The database includes information on toxins from a wide range of spider species, including venomous and non-venomous spiders.\n2. Australian Spider Venom Database (ASVD): The Australian Spider Venom Database is a comprehensive resource for spider venom toxins from Australian spiders. It provides information on the chemical structure, biological activity, and pharmacological effects of spider venom toxins. The database includes information on toxins from a wide range of spider species, including venomous and non-venomous spiders.\n3. World Spider Catalog (WSC): The World Spider Catalog is a comprehensive resource for spider species, including information on their venom toxins. It provides information on the chemical structure, biological activity, and pharmacological effects of spider venom toxins. The database includes information on toxins from a wide range of spider species, including venomous and non-venomous spiders.\n4. Spider Venom Database (SVDB): The Spider Venom Database is a comprehensive resource for spider venom toxins. It provides information on the chemical structure, biological activity, and pharmacological effects of spider venom toxins. The database includes information on toxins from a wide range of spider species, including venomous and non-venomous spiders.\n\nThese databases are valuable resources for researchers studying spider venom toxins, and they provide a wealth of information on the chemical structure, biological activity, and pharmacological effects of spider venom toxins.",
    "llama-7b_fact_raw": "1. The Spider Toxin Database (STD) is a curated database that provides information on the chemical structure, biological activity, and pharmacological effects of spider venom toxins, covering a wide range of spider species.\n2. The Australian Spider Venom Database (ASVD) is a resource that focuses on spider venom toxins from Australian spiders and includes information on the chemical structure, biological activity, and pharmacological effects.\n3. The World Spider Catalog (WSC) provides resources for spider species information, including their venom toxins, offering details on chemical structure, biological activity, and pharmacological effects.\n4. The Spider Venom Database (SVDB) is a comprehensive resource for information regarding spider venom toxins from a wide range of spider species, including both venomous and non-venomous spiders.",
    "llama-7b_fact": [
      "The Spider Toxin Database (STD) is a curated database that provides information on the chemical structure, biological activity, and pharmacological effects of spider venom toxins, covering a wide range of spider species.",
      "The Australian Spider Venom Database (ASVD) is a resource that focuses on spider venom toxins from Australian spiders and includes information on the chemical structure, biological activity, and pharmacological effects.",
      "The World Spider Catalog (WSC) provides resources for spider species information, including their venom toxins, offering details on chemical structure, biological activity, and pharmacological effects.",
      "The Spider Venom Database (SVDB) is a comprehensive resource for information regarding spider venom toxins from a wide range of spider species, including both venomous and non-venomous spiders."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The World Spider Catalog (WSC) provides resources for taxonomic information on spiders, not specifically information about their venom toxins, chemical structures, biological activity, or pharmacological effects.\n4. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3111,
    "user_query": "You MUST give a detailed answer to the following question: Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-7b_response": "Axitinib is a medication that is used to treat certain types of cancer, including pancreatic cancer. It is a type of drug called a tyrosine kinase inhibitor, which works by blocking the action of certain proteins that help cancer cells grow and divide.\n\nThere have been several studies that have looked at the use of axitinib in patients with pancreatic cancer. While some of these studies have suggested that axitinib may be able to slow the growth of the cancer and improve survival, the results have been mixed and more research is needed to confirm these findings.\n\nFor example, one study published in the Journal of Clinical Oncology in 2017 found that patients with advanced pancreatic cancer who received axitinib had a longer survival rate compared to those who received standard chemotherapy. However, another study published in the Journal of the National Cancer Institute in 2018 found that axitinib did not improve overall survival in patients with advanced pancreatic cancer.\n\nIt's also worth noting that the use of axitinib in pancreatic cancer is still considered experimental and is not yet widely used as a standard treatment option. More research is needed to fully understand the benefits and risks of using this medication in patients with pancreatic cancer.",
    "llama-7b_fact_raw": "1. Axitinib is a medication used to treat certain types of cancer, including pancreatic cancer.\n2. Axitinib is a tyrosine kinase inhibitor, which blocks the action of proteins that help cancer cells grow and divide.\n3. Some studies on axitinib in pancreatic cancer patients have suggested it may slow cancer growth and improve survival, but results are mixed.\n4. A study published in the Journal of Clinical Oncology in 2017 indicated that axitinib might lead to a longer survival rate in advanced pancreatic cancer patients compared to standard chemotherapy.\n5. Another study published in the Journal of the National Cancer Institute in 2018 found that axitinib did not improve overall survival in patients with advanced pancreatic cancer.",
    "llama-7b_fact": [
      "Axitinib is a medication used to treat certain types of cancer, including pancreatic cancer.",
      "Axitinib is a tyrosine kinase inhibitor, which blocks the action of proteins that help cancer cells grow and divide.",
      "Some studies on axitinib in pancreatic cancer patients have suggested it may slow cancer growth and improve survival, but results are mixed.",
      "A study published in the Journal of Clinical Oncology in 2017 indicated that axitinib might lead to a longer survival rate in advanced pancreatic cancer patients compared to standard chemotherapy.",
      "Another study published in the Journal of the National Cancer Institute in 2018 found that axitinib did not improve overall survival in patients with advanced pancreatic cancer."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Axitinib is used to treat advanced renal cell carcinoma and not typically used for pancreatic cancer.\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: Without specific details of the study, it's not possible to confirm this statement, and since axitinib is not typically used for pancreatic cancer, the statement is likely incorrect.\n5. FALSE [correction]: Similar to the previous statement, given axitinib is not typically indicated for pancreatic cancer, this statement regarding a study in the Journal of the National Cancer Institute is likely inaccurate for this medication.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 3113,
    "user_query": "You MUST give a detailed answer to the following question: Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-7b_response": "MLP (Myosin-Light-Chain-Phosphatase) is a protein that plays a crucial role in regulating the dynamics of F-actin, a component of the cytoskeleton. The cytoskeleton is a network of proteins that provides structural support to cells and helps them maintain their shape. F-actin is a key component of the cytoskeleton, and its dynamics are tightly regulated by a variety of proteins.\n\nOne way in which MLP regulates F-actin dynamics is through its interaction with the Arp2/3 complex. The Arp2/3 complex is a protein complex that is responsible for nucleating the formation of new F-actin filaments. MLP interacts with the Arp2/3 complex and helps to regulate its activity, which in turn affects the dynamics of F-actin.\n\nAnother way in which MLP regulates F-actin dynamics is through its interaction with myosin motors. Myosin motors are proteins that move along F-actin filaments and use their energy to generate force. MLP interacts with myosin motors and helps to regulate their activity, which in turn affects the dynamics of F-actin.\n\nOverall, MLP regulates F-actin dynamics through its interactions with the Arp2/3 complex and myosin motors. These interactions help to regulate the formation and breakdown of F-actin filaments, which in turn affects the overall dynamics of the cytoskeleton.",
    "llama-7b_fact_raw": "1. MLP interacts with the Arp2/3 complex to regulate F-actin dynamics.\n2. The Arp2/3 complex is responsible for nucleating the formation of new F-actin filaments.\n3. MLP interacts with myosin motors to regulate F-actin dynamics.\n4. Myosin motors move along F-actin filaments and generate force.\n5. The regulation of the Arp2/3 complex and myosin motors by MLP affects the formation and breakdown of F-actin filaments.",
    "llama-7b_fact": [
      "MLP interacts with the Arp2/3 complex to regulate F-actin dynamics.",
      "The Arp2/3 complex is responsible for nucleating the formation of new F-actin filaments.",
      "MLP interacts with myosin motors to regulate F-actin dynamics.",
      "Myosin motors move along F-actin filaments and generate force.",
      "The regulation of the Arp2/3 complex and myosin motors by MLP affects the formation and breakdown of F-actin filaments."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN\n\nThe truth value of statements 1, 3, and 5 depends on specific scientific findings, and without additional context or references, it is impossible to confirm the accuracy of those statements. The field of cellular biology is vast, and while MLP (Mylip/Myosin regulatory light chain interacting protein) could indeed interact with the Arp2/3 complex and myosin motors, providing a definite answer would require access to specific scientific studies or data that detail these interactions.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3125,
    "user_query": "You MUST give a detailed answer to the following question: How many pseudokinases are there in the human kinome?",
    "llama-7b_response": "There are 53 pseudokinases in the human kinome.",
    "llama-7b_fact_raw": "1. There are 53 pseudokinases in the human kinome.",
    "llama-7b_fact": [
      "There are 53 pseudokinases in the human kinome."
    ],
    "llama-7b_judge_raw": "UNKNOWN\n\nThe specificity of the number \"53\" for the count of pseudokinases in the human kinome cannot be verified without access to up-to-date scientific research and literature. The number of pseudokinases identified in the human kinome can vary based on new discoveries and advancements in genomics and proteomics. Therefore, without current information or the specific context from which this statement is taken, the truth value of this statement is unknown.",
    "llama-7b_judge": [
      "unknown"
    ]
  },
  {
    "id": 3139,
    "user_query": "You MUST give a detailed answer to the following question: List 3 apoE mimetics.",
    "llama-7b_response": "ApoE (apolipoprotein E) is a protein that plays an important role in the transport and metabolism of lipids in the blood. It is a major protein component of high-density lipoproteins (HDL), which are known as the \"good cholesterol\" because they help to remove cholesterol from the bloodstream and prevent it from building up in the arteries.\n\nThere are three main forms of apoE: apoE2, apoE3, and apoE4. ApoE2 and apoE3 are considered \"beneficial\" forms of the protein because they are associated with a lower risk of cardiovascular disease. ApoE4, on the other hand, is considered \"detrimental\" because it is associated with an increased risk of cardiovascular disease and Alzheimer's disease.\n\nOne way to mimic the beneficial effects of apoE is to increase the levels of HDL cholesterol in the blood. This can be done through a healthy diet and regular exercise, as well as through the use of certain medications. Another way to mimic the beneficial effects of apoE is to consume foods or supplements that contain compounds that are similar to apoE. These compounds are known as apoE mimetics.\n\nHere are three examples of apoE mimetics:\n\n1. Omega-3 fatty acids: Omega-3 fatty acids, such as EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), are essential fatty acids that are important for heart health. They have been shown to increase HDL cholesterol levels and reduce the risk of cardiovascular disease. Omega-3 fatty acids can be found in fatty fish, such as salmon and sardines, as well as in supplements.\n2. Resveratrol: Resveratrol is a compound that is found in certain plants, including grapes, berries, and peanuts. It has been shown to have a number of health benefits, including reducing inflammation and improving cardiovascular health. Resveratrol has also been shown to increase HDL cholesterol levels and reduce the risk of cardiovasc",
    "llama-7b_fact_raw": "1. ApoE (apolipoprotein E) plays a role in the transport and metabolism of lipids in the blood.\n2. HDL cholesterol, also known as \"good cholesterol,\" helps to remove cholesterol from the bloodstream.\n3. There are three main forms of apoE: apoE2, apoE3, and apoE4.\n4. ApoE4 is associated with an increased risk of cardiovascular disease and Alzheimer's disease.\n5. Omega-3 fatty acids, such as EPA and DHA, are considered apoE mimetics that can increase HDL cholesterol levels and reduce the risk of cardiovascular disease.",
    "llama-7b_fact": [
      "ApoE (apolipoprotein E) plays a role in the transport and metabolism of lipids in the blood.",
      "HDL cholesterol, also known as \"good cholesterol,\" helps to remove cholesterol from the bloodstream.",
      "There are three main forms of apoE: apoE2, apoE3, and apoE4.",
      "ApoE4 is associated with an increased risk of cardiovascular disease and Alzheimer's disease.",
      "Omega-3 fatty acids, such as EPA and DHA, are considered apoE mimetics that can increase HDL cholesterol levels and reduce the risk of cardiovascular disease."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Omega-3 fatty acids, such as EPA and DHA, are not considered apoE mimetics. However, they can increase HDL cholesterol levels and reduce the risk of cardiovascular disease.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3140,
    "user_query": "You MUST give a detailed answer to the following question: What are there sex differences in SAMHD1 activity?",
    "llama-7b_response": "Sex differences in SAMHD1 activity have not been extensively studied, but there is some evidence to suggest that there may be differences in SAMHD1 activity between males and females.\n\nSAMHD1 is an important regulator of the HIV-1 life cycle, as it has been shown to inhibit HIV-1 replication by depleting the intracellular pool of deoxynucleoside triphosphates (dNTPs), which are required for HIV-1 reverse transcription. SAMHD1 is primarily expressed in immune cells, such as CD4+ T cells and macrophages, and its activity is thought to be regulated by post-translational modifications, such as phosphorylation and ubiquitination.\n\nA study published in 2018 found that SAMHD1 activity was higher in female compared to male mice, which was associated with higher levels of HIV-1 replication in female mice. However, it is worth noting that this study used a mouse model of HIV-1 infection, and the results may not be directly applicable to humans.\n\nAnother study published in 2020 found that SAMHD1 activity was lower in CD4+ T cells from HIV-1-infected women compared to HIV-1-infected men, which was associated with higher levels of HIV-1 replication in women. However, this study also used a mouse model of HIV-1 infection, and the results may not be directly applicable to humans.\n\nOverall, while there is some evidence to suggest that there may be differences in SAMHD1 activity between males and females, further research is needed to fully understand the role of SAMHD1 in HIV-1 replication and to determine if there are sex differences in SAMHD1 activity in humans.",
    "llama-7b_fact_raw": "1. SAMHD1 is known to inhibit HIV-1 replication by depleting the intracellular pool of deoxynucleoside triphosphates (dNTPs).\n2. SAMHD1 is primarily expressed in immune cells, including CD4+ T cells and macrophages.\n3. A 2018 study indicated SAMHD1 activity was higher in female mice compared to male mice, and this was associated with higher levels of HIV-1 replication in female mice.\n4. A 2020 study found that SAMHD1 activity was lower in CD4+ T cells from HIV-1-infected women compared to HIV-1-infected men, resulting in higher levels of HIV-1 replication in women.\n5. The studies mentioned used mouse models of HIV-1 infection, implying that their results may not be directly applicable to humans.",
    "llama-7b_fact": [
      "SAMHD1 is known to inhibit HIV-1 replication by depleting the intracellular pool of deoxynucleoside triphosphates (dNTPs).",
      "SAMHD1 is primarily expressed in immune cells, including CD4+ T cells and macrophages.",
      "A 2018 study indicated SAMHD1 activity was higher in female mice compared to male mice, and this was associated with higher levels of HIV-1 replication in female mice.",
      "A 2020 study found that SAMHD1 activity was lower in CD4+ T cells from HIV-1-infected women compared to HIV-1-infected men, resulting in higher levels of HIV-1 replication in women.",
      "The studies mentioned used mouse models of HIV-1 infection, implying that their results may not be directly applicable to humans."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: A 2018 study indicating SAMHD1 activity was higher in females compared to males would imply lower levels of HIV-1 replication in female mice, not higher, because SAMHD1 inhibits HIV-1 replication by depleting dNTPs.\n4. UNKNOWN: Without the specific details of the 2020 study, it's not possible to confirm the accuracy of this statement. Results from studies need to be evaluated in the context of the full report to confirm their findings.\n5. TRUE: Mouse models are commonly used in scientific research but do not always mimic human biology exactly; therefore, results may not be directly applicable to humans.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3205,
    "user_query": "You MUST give a detailed answer to the following question: Does RUNX2 inhibit astrocyte differentiation?",
    "llama-7b_response": "Yes, RUNX2 has been shown to inhibit astrocyte differentiation.\n\nRUNX2 is a transcription factor that plays a crucial role in the regulation of gene expression during the differentiation of various cell types, including astrocytes. Studies have shown that RUNX2 can inhibit astrocyte differentiation by suppressing the expression of genes involved in the astrocyte lineage.\n\nFor example, a study published in the journal Molecular and Cellular Biology in 2005 found that RUNX2 inhibited the differentiation of neural stem cells into astrocytes by suppressing the expression of genes involved in the astrocyte lineage. The study also found that overexpression of RUNX2 in astrocytes led to the upregulation of genes involved in the oligodendrocyte lineage, indicating that RUNX2 can also affect the differentiation of other cell types.\n\nAdditionally, a study published in the journal Glia in 2012 found that RUNX2 inhibited astrocyte differentiation by suppressing the expression of genes involved in the Wnt signaling pathway, which is a key pathway in the regulation of astrocyte development.\n\nOverall, these studies suggest that RUNX2 can inhibit astrocyte differentiation by suppressing the expression of genes involved in the astrocyte lineage and the Wnt signaling pathway.",
    "llama-7b_fact_raw": "1. RUNX2 is known to inhibit astrocyte differentiation.\n2. RUNX2 functions as a transcription factor that regulates gene expression.\n3. A study in the journal Molecular and Cellular Biology in 2005 indicated that RUNX2 inhibits the differentiation of neural stem cells into astrocytes.\n4. The 2005 study found that overexpression of RUNX2 resulted in upregulation of genes involved in the oligodendrocyte lineage.\n5. A study in the journal Glia in 2012 reported that RUNX2 suppresses the expression of genes in the Wnt signaling pathway, which influences astrocyte development.",
    "llama-7b_fact": [
      "RUNX2 is known to inhibit astrocyte differentiation.",
      "RUNX2 functions as a transcription factor that regulates gene expression.",
      "A study in the journal Molecular and Cellular Biology in 2005 indicated that RUNX2 inhibits the differentiation of neural stem cells into astrocytes.",
      "The 2005 study found that overexpression of RUNX2 resulted in upregulation of genes involved in the oligodendrocyte lineage.",
      "A study in the journal Glia in 2012 reported that RUNX2 suppresses the expression of genes in the Wnt signaling pathway, which influences astrocyte development."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: Without specific context or reference to research, it's unclear whether RUNX2 inhibits astrocyte differentiation as its role may vary depending on the cellular context and the presence of other signaling factors.\n\n2. TRUE: RUNX2 is indeed a transcription factor that regulates gene expression, particularly in the context of bone development.\n\n3. UNKNOWN: To confirm the truth of this statement, the specific article from the journal Molecular and Cellular Biology in 2005 would need to be reviewed. Without access to this study, the impact of RUNX2 on the differentiation of neural stem cells into astrocytes cannot be verified.\n\n4. UNKNOWN: Similar to the above statement, the accuracy of this statement would require verification from the specific 2005 study, which cannot be determined without reviewing the actual research.\n\n5. UNKNOWN: The details of the study in the journal Glia in 2012 must be verified by reviewing the article itself to confirm whether RUNX2 suppresses the expression of genes in the Wnt signaling pathway affecting astrocyte development.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3209,
    "user_query": "You MUST give a detailed answer to the following question: Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-7b_response": "The Cobb-Stainsby excision arthroplasty is a surgical procedure used to treat osteoarthritis of the knee. It involves the removal of a wedge-shaped portion of the articular cartilage from the femoral condyle and the tibial plateau, along with the underlying bone. The goal of the procedure is to relieve pain and improve joint function.\n\nThe Cobb-Stainsby excision arthroplasty is typically performed on the knee joint, specifically on the femoral condyle and the tibial plateau. The procedure is typically performed arthroscopically, which means that it is done through small incisions and using specialized instruments that allow the surgeon to visualize and operate on the joint through these incisions.\n\nThe specific location of the incisions for the Cobb-Stainsby excision arthroplasty will depend on the individual patient and the surgeon's preferred approach. However, in general, the incisions are made on the front (anterior) or back (posterior) of the knee, depending on the location of the damaged cartilage. The surgeon will use these incisions to access the joint and remove the damaged cartilage and underlying bone.\n\nOverall, the Cobb-Stainsby excision arthroplasty is typically performed on the knee joint, specifically on the femoral condyle and the tibial plateau. The procedure is typically performed arthroscopically, which means that it is done through small incisions and using specialized instruments that allow the surgeon to visualize and operate on the joint through these incisions. The specific location of the incisions will depend on the individual patient and the surgeon's preferred approach.",
    "llama-7b_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is a surgical procedure used to treat osteoarthritis of the knee.\n2. The procedure involves the removal of a wedge-shaped portion of the articular cartilage from the femoral condyle and the tibial plateau, along with underlying bone.\n3. The goal of the Cobb-Stainsby excision arthroplasty is to relieve pain and improve joint function.\n4. The Cobb-Stainsby excision arthroplasty is typically performed arthroscopically.\n5. The incisions for the procedure are generally made on the anterior or posterior of the knee.",
    "llama-7b_fact": [
      "The Cobb-Stainsby excision arthroplasty is a surgical procedure used to treat osteoarthritis of the knee.",
      "The procedure involves the removal of a wedge-shaped portion of the articular cartilage from the femoral condyle and the tibial plateau, along with underlying bone.",
      "The goal of the Cobb-Stainsby excision arthroplasty is to relieve pain and improve joint function.",
      "The Cobb-Stainsby excision arthroplasty is typically performed arthroscopically.",
      "The incisions for the procedure are generally made on the anterior or posterior of the knee."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is a surgical procedure used for the management of painful and/or unstable floppy foot due to paralytic conditions, not specifically for osteoarthritis of the knee.\n2. FALSE [correction]: The Cobb-Stainsby excision arthroplasty does not involve the removal of a wedge-shaped portion of the articular cartilage from the femoral condyle and the tibial plateau. It usually involves the excision of part of the peroneal tendons and the elongation or transfer of tendons to stabilize the foot.\n3. TRUE: The goal of the Cobb-Stainsby excision arthroplasty is to relieve pain and improve the function of the foot.\n4. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is not typically performed arthroscopically as it is a surgical procedure related to the foot and not the knee.\n5. UNKNOWN: The statement is vague regarding the specific surgical procedure mentioned earlier. Incisions for the Cobb-Stainsby excision arthroplasty would be around the foot or ankle, not necessarily on the anterior or posterior of the knee. However, without specific details on the incision locations for this procedure, the accuracy of this statement cannot be evaluated.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3243,
    "user_query": "You MUST give a detailed answer to the following question: Does GRHL2 over-expression lead to EMT?",
    "llama-7b_response": "Yes, GRHL2 over-expression has been shown to lead to epithelial-to-mesenchymal transition (EMT) in various cell types.\n\nEpithelial-to-mesenchymal transition (EMT) is a process by which epithelial cells lose their cell-cell adhesion and acquire a mesenchymal phenotype, characterized by the loss of cell-cell adhesion, the upregulation of mesenchymal genes, and the acquisition of a migratory and invasive phenotype.\n\nGRHL2, also known as E-cadherin repressor 2, is a transcription factor that regulates the expression of genes involved in cell-cell adhesion and epithelial differentiation. Over-expression of GRHL2 has been shown to downregulate the expression of E-cadherin, a key protein involved in cell-cell adhesion, and upregulate the expression of mesenchymal genes, leading to EMT in various cell types.\n\nFor example, in breast cancer cells, over-expression of GRHL2 has been shown to downregulate the expression of E-cadherin and upregulate the expression of mesenchymal genes, leading to EMT and increased invasiveness. Similarly, in lung cancer cells, over-expression of GRHL2 has been shown to downregulate the expression of E-cadherin and upregulate the expression of mesenchymal genes, leading to EMT and increased migration and invasion.\n\nTherefore, GRHL2 over-expression has been shown to lead to EMT in various cell types, by downregulating the expression of E-cadherin and upregulating the expression of mesenchymal genes.",
    "llama-7b_fact_raw": "1. GRHL2 over-expression can lead to epithelial-to-mesenchymal transition (EMT) in various cell types.\n2. Epithelial-to-mesenchymal transition is characterized by loss of cell-cell adhesion and acquisition of a mesenchymal phenotype.\n3. GRHL2 (Grainyhead-like 2) is a transcription factor that can regulate genes involved in cell adhesion and epithelial differentiation.\n4. Over-expression of GRHL2 is known to downregulate the expression of E-cadherin, which is crucial for cell-cell adhesion.\n5. In breast and lung cancer cells, GRHL2 over-expression has been demonstrated to promote EMT by upregulating mesenchymal gene expression and increasing cell invasiveness and migration.",
    "llama-7b_fact": [
      "GRHL2 over-expression can lead to epithelial-to-mesenchymal transition (EMT) in various cell types.",
      "Epithelial-to-mesenchymal transition is characterized by loss of cell-cell adhesion and acquisition of a mesenchymal phenotype.",
      "GRHL2 (Grainyhead-like 2) is a transcription factor that can regulate genes involved in cell adhesion and epithelial differentiation.",
      "Over-expression of GRHL2 is known to downregulate the expression of E-cadherin, which is crucial for cell-cell adhesion.",
      "In breast and lung cancer cells, GRHL2 over-expression has been demonstrated to promote EMT by upregulating mesenchymal gene expression and increasing cell invasiveness and migration."
    ],
    "llama-7b_judge_raw": "1. TRUE: GRHL2 (Grainyhead-like 2) over-expression has been reported to be involved in the epithelial-to-mesenchymal transition (EMT) process in various cell types.\n\n2. TRUE: EMT is characterized by the loss of cell-cell adhesion and the acquisition of a mesenchymal phenotype, which includes changes such as increased motility.\n\n3. TRUE: GRHL2 is a transcription factor that plays a role in the regulation of genes involved in maintaining cell adhesion and epithelial differentiation.\n\n4. FALSE [correction]: Over-expression of GRHL2 is typically associated with the upregulation of E-cadherin expression, not downregulation. GRHL2 is generally considered to maintain epithelial characteristics and prevent EMT by preserving cell-cell adhesion through E-cadherin expression.\n\n5. FALSE [correction]: Given the previous correction, this statement would generally be considered false, as GRHL2 over-expression would not be expected to promote EMT. Instead, GRHL2 usually acts to suppress EMT by maintaining the expression of epithelial markers such as E-cadherin. However, this statement could be context-dependent, and exceptions may exist in complex biological systems like cancer cells, so without specific research data to reference, this statement is challenging to assess with certainty.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3254,
    "user_query": "You MUST give a detailed answer to the following question: Which T-UCRs have been implicated in lung cancer?",
    "llama-7b_response": "There are several T-UCRs that have been implicated in lung cancer. These include:\n\n1. TNF-alpha (Tumor Necrosis Factor-alpha): TNF-alpha is a pro-inflammatory cytokine that has been implicated in the development of several types of cancer, including lung cancer.\n2. Interleukin-1 beta (IL-1 beta): IL-1 beta is another pro-inflammatory cytokine that has been implicated in the development of lung cancer.\n3. Interleukin-6 (IL-6): IL-6 is a cytokine that has been implicated in the development of several types of cancer, including lung cancer.\n4. Interleukin-8 (IL-8): IL-8 is a cytokine that has been implicated in the development of several types of cancer, including lung cancer.\n5. Interleukin-12 (IL-12): IL-12 is a cytokine that has been implicated in the development of several types of cancer, including lung cancer.\n6. Interleukin-18 (IL-18): IL-18 is a cytokine that has been implicated in the development of several types of cancer, including lung cancer.\n7. Interleukin-23 (IL-23): IL-23 is a cytokine that has been implicated in the development of several types of cancer, including lung cancer.\n8. Interleukin-27 (IL-27): IL-27 is a cytokine that has been implicated in the development of several types of cancer, including lung cancer.\n9. Interleukin-35 (IL-35): IL-35 is a cytokine that has been implicated in the development of several types of cancer, including lung cancer.\n10. Interleukin-36 (IL-36): IL-36 is a cytokine that has been implicated in the development of several types of cancer, including lung cancer.\n11. Interleukin-38 (IL-38): IL-38 is a cytokine that has been implicated in the development of several types of cancer, including lung cancer.\n12. Interleukin-40",
    "llama-7b_fact_raw": "1. TNF-alpha is a cytokine that has been implicated in the development of lung cancer.\n2. Interleukin-1 beta is a cytokine that has been implicated in the development of lung cancer.\n3. Interleukin-6 has been implicated in the development of lung cancer.\n4. Interleukin-8 has been implicated in the development of lung cancer.\n5. Interleukin-12 has been implicated in the development of lung cancer.",
    "llama-7b_fact": [
      "TNF-alpha is a cytokine that has been implicated in the development of lung cancer.",
      "Interleukin-1 beta is a cytokine that has been implicated in the development of lung cancer.",
      "Interleukin-6 has been implicated in the development of lung cancer.",
      "Interleukin-8 has been implicated in the development of lung cancer.",
      "Interleukin-12 has been implicated in the development of lung cancer."
    ],
    "llama-7b_judge_raw": "1. TRUE: TNF-alpha (Tumor Necrosis Factor-alpha) is a cytokine that has been implicated in various inflammatory processes and diseases including the potential to contribute to the development and progression of lung cancer.\n2. TRUE: Interleukin-1 beta (IL-1) is a pro-inflammatory cytokine that has been implicated in various inflammatory and autoimmune diseases, and it has been studied for its role in tumorigenesis including lung cancer.\n3. TRUE: Interleukin-6 (IL-6) is a cytokine known for its role in the immune response and has been implicated in the pathogenesis of several types of cancer, including lung cancer.\n4. TRUE: Interleukin-8 (IL-8) is a chemokine that has been implicated in inflammation and has also been associated with the promotion of angiogenesis and metastasis in lung cancer.\n5. TRUE: Although Interleukin-12 (IL-12) generally has anti-tumor properties, its role in cancer is complex, and under certain conditions, it may be implicated in the promotion of the immune environment that can contribute to lung cancer development. However, due to its primary association with anti-tumor responses, this statement may be somewhat controversial and context-dependent.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3268,
    "user_query": "You MUST give a detailed answer to the following question: What is known about the orphan receptor GPR151?",
    "llama-7b_response": "GPR151, also known as G protein-coupled receptor 151, is an orphan receptor that belongs to the G protein-coupled receptor (GPCR) family. GPCRs are a large family of transmembrane proteins that play a crucial role in various physiological processes, including signal transduction, cellular communication, and the regulation of various physiological responses.\n\nGPR151 is primarily expressed in the brain, particularly in the hippocampus and cerebral cortex, and has been implicated in various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. However, the precise function of GPR151 and its role in these disorders is not well understood.\n\nSeveral studies have suggested that GPR151 may play a role in the regulation of neurotransmitter release, particularly dopamine and serotonin, in the brain. For example, GPR151 has been shown to modulate the activity of dopamine D2 receptors, which are important regulators of dopamine release in the brain. Additionally, GPR151 has been implicated in the regulation of glutamate release, which is the primary excitatory neurotransmitter in the brain.\n\nFurther research is needed to fully understand the function of GPR151 and its potential as a therapeutic target for various neurological and psychiatric disorders.",
    "llama-7b_fact_raw": "1. GPR151 is known as G protein-coupled receptor 151.\n2. GPR151 is a member of the G protein-coupled receptor (GPCR) family.\n3. GPR151 is primarily expressed in the brain, specifically in the hippocampus and cerebral cortex.\n4. GPR151 has been implicated in neurological and psychiatric disorders such as Alzheimer's disease, Parkinson's disease, and schizophrenia.\n5. There is research suggesting that GPR151 may influence the regulation of neurotransmitter release, including dopamine and serotonin, in the brain.",
    "llama-7b_fact": [
      "GPR151 is known as G protein-coupled receptor 151.",
      "GPR151 is a member of the G protein-coupled receptor (GPCR) family.",
      "GPR151 is primarily expressed in the brain, specifically in the hippocampus and cerebral cortex.",
      "GPR151 has been implicated in neurological and psychiatric disorders such as Alzheimer's disease, Parkinson's disease, and schizophrenia.",
      "There is research suggesting that GPR151 may influence the regulation of neurotransmitter release, including dopamine and serotonin, in the brain."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nEach of the statements is consistent with the common scientific knowledge regarding G protein-coupled receptors (GPCRs) like GPR151, which are indeed implicated in various brain functions and disorders. However, for the most up-to-date and specific research findings, one would need to consult the latest scientific studies.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3285,
    "user_query": "You MUST give a detailed answer to the following question: List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-7b_response": "The Fluzone intradermal quadrivalent vaccine contains attenuated live viruses of four strains of influenza:\n\n1. A/Michigan/45/2015 (H1N1)pdm09-like virus\n2. A/Texas/50/2012 (H3N2) virus\n3. B/Massachusetts/2/2012-like virus (B/Yamagata lineage)\n4. B/Phuket/3073/2013-like virus (B/Victoria lineage)",
    "llama-7b_fact_raw": "1. The Fluzone intradermal quadrivalent vaccine contains an attenuated live virus strain A/Michigan/45/2015 (H1N1)pdm09-like virus.\n2. The Fluzone intradermal quadrivalent vaccine contains an attenuated live virus strain A/Texas/50/2012 (H3N2) virus.\n3. The Fluzone intradermal quadrivalent vaccine contains an attenuated live virus strain B/Massachusetts/2/2012-like virus (B/Yamagata lineage).\n4. The Fluzone intradermal quadrivalent vaccine contains an attenuated live virus strain B/Phuket/3073/2013-like virus (B/Victoria lineage).",
    "llama-7b_fact": [
      "The Fluzone intradermal quadrivalent vaccine contains an attenuated live virus strain A/Michigan/45/2015 (H1N1)pdm09-like virus.",
      "The Fluzone intradermal quadrivalent vaccine contains an attenuated live virus strain A/Texas/50/2012 (H3N2) virus.",
      "The Fluzone intradermal quadrivalent vaccine contains an attenuated live virus strain B/Massachusetts/2/2012-like virus (B/Yamagata lineage).",
      "The Fluzone intradermal quadrivalent vaccine contains an attenuated live virus strain B/Phuket/3073/2013-like virus (B/Victoria lineage)."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine contains an inactivated virus strain A/Michigan/45/2015 (H1N1)pdm09-like virus.\n2. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine contains an inactivated virus strain A/Texas/50/2012 (H3N2) virus.\n3. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine contains an inactivated virus strain B/Massachusetts/2/2012-like virus (B/Yamagata lineage).\n4. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine contains an inactivated virus strain B/Phuket/3073/2013-like virus (B/Victoria lineage).\n\nThe specific virus strains in Fluzone's vaccine can vary by year to match the predicted circulating strains, and while the strains listed may be part of some year's formulation, the Fluzone vaccines do not contain live attenuated viruses, but rather inactivated ones. Furthermore, the exact strains included in the vaccine change annually based on the recommendations of the World Health Organization (WHO) and other health authorities.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3345,
    "user_query": "You MUST give a detailed answer to the following question: Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-7b_response": "The TNFR2 gene, also known as the tumor necrosis factor receptor 2 gene, is located on chromosome 6p21.3 and encodes for a protein that is a key component of the tumor necrosis factor (TNF) receptor superfamily. TNF is a cytokine that plays a central role in the immune system and is involved in the regulation of inflammation, cell growth, and apoptosis (programmed cell death).\n\nSystemic lupus erythematosus (SLE) is an autoimmune disorder that is characterized by the production of autoantibodies and the formation of immune complexes that deposit in various tissues and organs, leading to inflammation, tissue damage, and organ dysfunction. The exact cause of SLE is not fully understood, but it is believed to involve a combination of genetic and environmental factors.\n\nStudies have identified several genetic variants that are associated with an increased risk of developing SLE. One of these variants is a single-nucleotide polymorphism (SNP) located in the promoter region of the TNFR2 gene. This SNP, known as rs763780, has been found to be associated with an increased risk of developing SLE in several studies.\n\nIn summary, the TNFR2 gene is genetically associated with SLE, and a specific SNP located in the promoter region of the gene, rs763780, has been found to be associated with an increased risk of developing the disease.",
    "llama-7b_fact_raw": "1. The TNFR2 gene is located on chromosome 6p21.3.\n2. The TNFR2 gene encodes for a protein that is part of the tumor necrosis factor receptor superfamily.\n3. Systemic lupus erythematosus (SLE) is characterized by the production of autoantibodies and the formation of immune complexes.\n4. Genetic and environmental factors are believed to contribute to the cause of SLE.\n5. A single-nucleotide polymorphism (SNP) in the promoter region of the TNFR2 gene, known as rs763780, is associated with an increased risk of developing SLE.",
    "llama-7b_fact": [
      "The TNFR2 gene is located on chromosome 6p21.3.",
      "The TNFR2 gene encodes for a protein that is part of the tumor necrosis factor receptor superfamily.",
      "Systemic lupus erythematosus (SLE) is characterized by the production of autoantibodies and the formation of immune complexes.",
      "Genetic and environmental factors are believed to contribute to the cause of SLE.",
      "A single-nucleotide polymorphism (SNP) in the promoter region of the TNFR2 gene, known as rs763780, is associated with an increased risk of developing SLE."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe association of specific single-nucleotide polymorphisms with diseases such as SLE can be complex and is subject to ongoing research. Without information about the latest findings concerning the TNFR2 gene and its variants like rs763780, the association with SLE cannot be confirmed or denied.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3353,
    "user_query": "You MUST give a detailed answer to the following question: Is there a vaccine for peanut allergy?",
    "llama-7b_response": "Yes, there is a vaccine for peanut allergy.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3365,
    "user_query": "You MUST give a detailed answer to the following question: What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-7b_response": "The mouse Fxy gene is located on the X chromosome, which is one of the two sex chromosomes in mammals. In mammals, females have two X chromosomes (XX) and males have one X and one Y chromosome (XY). The X chromosome is known to contain a higher number of genes than the Y chromosome, and many of these genes are involved in the development and function of the female reproductive system.\n\nThe position of the Fxy gene on the X chromosome is particularly interesting because it is located in a region that contains several other genes involved in spermatogenesis, the process by which sperm are produced. This suggests that the Fxy gene may play a role in spermatogenesis, either directly or by regulating the expression of other genes in the region.\n\nFurthermore, the Fxy gene is located in a region of the X chromosome that is known to be subject to X-chromosome inactivation, a process by which one of the two X chromosomes in females is randomly silenced in each cell. This process is thought to help balance the expression of genes on the X chromosome and prevent the accumulation of excessive amounts of X-linked genes. It is possible that the Fxy gene is subject to X-chromosome inactivation, which could have implications for its expression and function in different tissues and cell types.\n\nOverall, the chromosomal position of the Fxy gene on the X chromosome and its proximity to other genes involved in spermatogenesis and X-chromosome inactivation make it a particularly interesting gene for further study.",
    "llama-7b_fact_raw": "1. The mouse Fxy gene is located on the X chromosome.\n2. In mammals, females usually have two X chromosomes, while males have one X and one Y chromosome.\n3. The X chromosome contains a higher number of genes than the Y chromosome.\n4. The Fxy gene is located in a region linked with genes involved in spermatogenesis.\n5. The Fxy gene is in a region subject to X-chromosome inactivation, a process where one X chromosome in females is randomly silenced in each cell.",
    "llama-7b_fact": [
      "The mouse Fxy gene is located on the X chromosome.",
      "In mammals, females usually have two X chromosomes, while males have one X and one Y chromosome.",
      "The X chromosome contains a higher number of genes than the Y chromosome.",
      "The Fxy gene is located in a region linked with genes involved in spermatogenesis.",
      "The Fxy gene is in a region subject to X-chromosome inactivation, a process where one X chromosome in females is randomly silenced in each cell."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The Fxy gene (also known as FXYD domain-containing ion transport regulator 2 (FXYD2)), if referring to the gene family that includes FXYD2, is not specifically linked with genes involved in spermatogenesis. Spermatogenesis-related genes are primarily located on the Y chromosome, although there are some related genes on other chromosomes.\n5. UNKNOWN\n\nNote: The correctness of statements 1 and 5 regarding the Fxy gene is unclear without specific scientific reference or context, as the nomenclature might differ and gene function or localization might vary between mice and humans or be subject to newly discovered research. Moreover, 'Fxy' itself doesn't specifically refer to a known gene, and it could be a hypothetical designation. The statement regarding X-chromosome inactivation (5) is a general feature of X chromosomes in mammals but cannot be confirmed as true or false for the Fxy gene without specific information.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3397,
    "user_query": "You MUST give a detailed answer to the following question: What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-7b_response": "Methiumpropyl-EDTA sequencing (MPE-seq) is a method used to sequence RNA molecules. The method is based on the fact that RNA molecules can bind to Methiumpropyl-EDTA (MPE) molecules with high affinity and specificity.\n\nThe MPE-seq method involves the following steps:\n\n1. The RNA molecules of interest are incubated with MPE molecules.\n2. The RNA-MPE complexes are then separated from the unbound RNA and MPE molecules using a technique such as chromatography or gel electrophoresis.\n3. The RNA-MPE complexes are then denatured to separate the RNA from the MPE molecules.\n4. The denatured RNA-MPE complexes are then incubated with a DNA polymerase and nucleotides.\n5. The DNA polymerase adds nucleotides to the RNA-MPE complexes, extending the RNA molecules.\n6. The extended RNA molecules are then separated from the unextended RNA and MPE molecules using a technique such as chromatography or gel electrophoresis.\n7. The extended RNA molecules are then sequenced to determine the sequence of the RNA molecules.\n\nThe basis of the MPE-seq method is that the RNA molecules bind to the MPE molecules with high affinity and specificity, allowing for the separation of the RNA molecules from the unbound RNA and MPE molecules. The method is then used to determine the sequence of the RNA molecules by sequencing the extended RNA molecules.",
    "llama-7b_fact_raw": "1. Methidiumpropyl-EDTA sequencing (MPE-seq) is used to sequence RNA molecules.\n2. RNA molecules can bind to Methidiumpropyl-EDTA (MPE) molecules with high affinity and specificity.\n3. The MPE-seq method includes an incubation step where RNA molecules of interest are incubated with MPE molecules.\n4. The RNA-MPE complexes are separated from unbound RNA and MPE molecules using techniques such as chromatography or gel electrophoresis.\n5. After separation and denaturation, the RNA-MPE complexes are incubated with a DNA polymerase and nucleotides for the extension of RNA molecules.",
    "llama-7b_fact": [
      "Methidiumpropyl-EDTA sequencing (MPE-seq) is used to sequence RNA molecules.",
      "RNA molecules can bind to Methidiumpropyl-EDTA (MPE) molecules with high affinity and specificity.",
      "The MPE-seq method includes an incubation step where RNA molecules of interest are incubated with MPE molecules.",
      "The RNA-MPE complexes are separated from unbound RNA and MPE molecules using techniques such as chromatography or gel electrophoresis.",
      "After separation and denaturation, the RNA-MPE complexes are incubated with a DNA polymerase and nucleotides for the extension of RNA molecules."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Methidiumpropyl-EDTA sequencing (MPE-seq) is used to sequence DNA molecules, not RNA.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: After separation, the DNA-MPE complexes (not RNA) would typically be subjected to a process of amplification or sequencing rather than incubation with a DNA polymerase and nucleotides for the extension of RNA molecules since MPE-seq is about sequencing DNA, not extending RNA.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3400,
    "user_query": "You MUST give a detailed answer to the following question: Which programming language has been used for implementing GWAR?",
    "llama-7b_response": "I'm sorry, but I am not aware of any programming language called \"GWAR\" that has been used for implementing anything. Could you please provide more context or clarify your question?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3406,
    "user_query": "You MUST give a detailed answer to the following question: Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-7b_response": "Yes, xaliproden has been shown to improve the prognosis of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.\n\nXaliproden is a medication that belongs to a class of drugs called selective serotonin and norepinephrine reuptake inhibitors (SNRIs). It is thought to work by increasing the levels of certain chemicals in the brain, such as serotonin and norepinephrine, which may help to improve symptoms of ALS.\n\nSeveral studies have investigated the use of xaliproden in patients with ALS. One study, published in the journal Neurology, found that patients who took xaliproden had a slower decline in their ability to perform daily activities compared to those who did not take the medication. Another study, published in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, found that patients who took xaliproden had a longer survival time compared to those who did not take the medication.\n\nWhile these studies suggest that xaliproden may improve the prognosis of ALS, more research is needed to confirm these findings and to fully understand the potential benefits and risks of using this medication in patients with this condition.",
    "llama-7b_fact_raw": "1. Xaliproden has been demonstrated to improve prognosis in patients with amyotrophic lateral sclerosis (ALS).\n2. Xaliproden is classified as a selective serotonin and norepinephrine reuptake inhibitor (SNRI).\n3. One study published in the journal Neurology indicated that ALS patients taking xaliproden experienced a slower decline in the ability to perform daily activities.\n4. Another study published in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration showed that ALS patients on xaliproden had longer survival times.\n5. Further research is necessary to corroborate the benefits and understand the risks of using xaliproden for ALS treatment.",
    "llama-7b_fact": [
      "Xaliproden has been demonstrated to improve prognosis in patients with amyotrophic lateral sclerosis (ALS).",
      "Xaliproden is classified as a selective serotonin and norepinephrine reuptake inhibitor (SNRI).",
      "One study published in the journal Neurology indicated that ALS patients taking xaliproden experienced a slower decline in the ability to perform daily activities.",
      "Another study published in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration showed that ALS patients on xaliproden had longer survival times.",
      "Further research is necessary to corroborate the benefits and understand the risks of using xaliproden for ALS treatment."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: The statement's accuracy depends on specific research findings, which are not provided in the context. While there may have been studies investigating xaliproden's effects on ALS prognosis, without access to those studies it's not possible to definitively verify the accuracy of the statement.\n2. FALSE [correction]: Xaliproden is not classified as an SNRI. It is an experimental drug that was being studied for its potential neuroprotective and neurotrophic effects.\n3. UNKNOWN: Whether this statement is true or false would require verification from the specific study in the journal Neurology. Without that information, the accuracy of the statement cannot be determined.\n4. UNKNOWN: Similar to the previous statement, this one would require verification from the study mentioned, and without access to the study in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, the truthfulness of the statement cannot be established.\n5. TRUE: In the context of medical research, especially concerning experimental treatments, further research is typically required to confirm benefits and understand risks, making this statement generally true.",
    "llama-7b_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3410,
    "user_query": "You MUST give a detailed answer to the following question: In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-7b_response": "In the case of the LiPS-A3S line, the transgenes are inserted into the X chromosome.",
    "llama-7b_fact_raw": "1. In the LiPS-A3S line, transgenes are inserted into the X chromosome.",
    "llama-7b_fact": [
      "In the LiPS-A3S line, transgenes are inserted into the X chromosome."
    ],
    "llama-7b_judge_raw": "UNKNOWN\n\n[Without additional context or specific information regarding the \"LiPS-A3S line,\" it is not possible to accurately determine the veracity of the statement.]",
    "llama-7b_judge": [
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "You MUST give a detailed answer to the following question: Which tool exist for predicting drug synergy with deep learning?",
    "llama-7b_response": "There are several tools available for predicting drug synergy using deep learning, including:\n\n1. DeepDrug: This is a deep learning-based method for predicting drug synergy and toxicity. It uses a convolutional neural network (CNN) to analyze the chemical structure of drugs and predict their potential toxicity and synergy with other drugs.\n2. DS-Net: DS-Net is a deep learning-based method for predicting drug synergy and toxicity. It uses a neural network to analyze the chemical structure of drugs and predict their potential toxicity and synergy with other drugs.\n3. ChemNet: ChemNet is a deep learning-based method for predicting drug synergy and toxicity. It uses a neural network to analyze the chemical structure of drugs and predict their potential toxicity and synergy with other drugs.\n4. DrugSyn: DrugSyn is a deep learning-based method for predicting drug synergy and toxicity. It uses a neural network to analyze the chemical structure of drugs and predict their potential toxicity and synergy with other drugs.\n\nThese are just a few examples of the many tools available for predicting drug synergy using deep learning.",
    "llama-7b_fact_raw": "1. DeepDrug is a tool that applies deep learning to predict drug synergy and toxicity and uses convolutional neural networks.\n2. DS-Net is another deep learning-based method intended for predicting drug synergy and toxicity.\n3. ChemNet is a deep learning approach designed to predict drug synergy and toxicity through the analysis of chemical structures.\n4. DrugSyn employs deep learning to predict the synergy and toxicity of drugs, analyzing their chemical structures for this purpose.\n5. Each of the mentioned toolsDeepDrug, DS-Net, ChemNet, and DrugSynrely on neural networks to analyze the chemical structure of drugs to make predictions about their synergies and toxicities.",
    "llama-7b_fact": [
      "DeepDrug is a tool that applies deep learning to predict drug synergy and toxicity and uses convolutional neural networks.",
      "DS-Net is another deep learning-based method intended for predicting drug synergy and toxicity.",
      "ChemNet is a deep learning approach designed to predict drug synergy and toxicity through the analysis of chemical structures.",
      "DrugSyn employs deep learning to predict the synergy and toxicity of drugs, analyzing their chemical structures for this purpose.",
      "Each of the mentioned toolsDeepDrug, DS-Net, ChemNet, and DrugSynrely on neural networks to analyze the chemical structure of drugs to make predictions about their synergies and toxicities."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: ChemNet is a deep learning approach designed to predict chemical properties and activities directly from the raw 2D representation of chemical structures, not specifically for drug synergy and toxicity.\n4. UNKNOWN\n5. FALSE [correction]: Not all mentioned tools specifically analyze the chemical structure of drugs for predicting their synergies and toxicities. ChemNet, for example, is designed to predict chemical properties and activities in general. Additionally, without further information about DS-Net and DrugSyn, it cannot be confirmed that they analyze chemical structures.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3433,
    "user_query": "You MUST give a detailed answer to the following question: Which cloud-based platform has been developed for comparing GWAS?",
    "llama-7b_response": "There are several cloud-based platforms that have been developed for comparing genome-wide association studies (GWAS). Some examples include:\n\n1. The National Center for Biotechnology Information's (NCBI) dbGaP (Database of Genotypes and Phenotypes): dbGaP is a public database that provides access to genotype and phenotype data from large-scale genetic studies, including GWAS.\n2. The National Institutes of Health's (NIH) National Center for Biotechnology Information's (NCBI) Gene Expression Omnibus (GEO): GEO is a public database that provides access to gene expression data from a variety of sources, including GWAS.\n3. The European Bioinformatics Institute's (EBI) ArrayExpress: ArrayExpress is a public database that provides access to gene expression data from microarray experiments, including GWAS.\n4. The Wellcome Sanger Institute's GWAS Catalog: The GWAS Catalog is a public database that provides access to summary-level data from large-scale GWAS studies.\n\nThese are just a few examples of cloud-based platforms that have been developed for comparing GWAS data. There are many others, and the choice of platform will depend on the specific needs and goals of the researcher.",
    "llama-7b_fact_raw": "1. The NCBI's dbGaP provides access to genotype and phenotype data from large-scale genetic studies, including GWAS.\n2. NIH's NCBI Gene Expression Omnibus (GEO) is a public database accessing gene expression data, including from GWAS.\n3. EBI's ArrayExpress is a public database offering access to gene expression data from microarray experiments, including GWAS.\n4. The Wellcome Sanger Institute's GWAS Catalog provides access to summary-level data from large-scale GWAS studies.\n5. The choice of a cloud-based platform for comparing GWAS data depends on the specific needs and goals of the researcher.",
    "llama-7b_fact": [
      "The NCBI's dbGaP provides access to genotype and phenotype data from large-scale genetic studies, including GWAS.",
      "NIH's NCBI Gene Expression Omnibus (GEO) is a public database accessing gene expression data, including from GWAS.",
      "EBI's ArrayExpress is a public database offering access to gene expression data from microarray experiments, including GWAS.",
      "The Wellcome Sanger Institute's GWAS Catalog provides access to summary-level data from large-scale GWAS studies.",
      "The choice of a cloud-based platform for comparing GWAS data depends on the specific needs and goals of the researcher."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: NIH's NCBI Gene Expression Omnibus (GEO) is a public database for accessing gene expression data, but not specifically from GWAS.\n3. FALSE [correction]: EBI's ArrayExpress is a public database offering access to gene expression data from microarray experiments, but GWAS data is not the focus of ArrayExpress.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3434,
    "user_query": "You MUST give a detailed answer to the following question: Can CMB305 be used against sarcomas?",
    "llama-7b_response": "CMB305 is a monoclonal antibody that targets the CD19 antigen, which is expressed on the surface of B-cells, including malignant B-cells in various B-cell malignancies such as chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).\n\nSarcomas are a diverse group of malignant tumors that arise from the mesenchymal tissues, such as bone, cartilage, fat, muscle, and connective tissue. These tumors do not express CD19 antigen on their surface, so CMB305 would not be effective against sarcomas.\n\nHowever, there are other monoclonal antibodies that target different antigens expressed on the surface of sarcoma cells, such as bevacizumab (Avastin), which targets vascular endothelial growth factor (VEGF), and pazopanib (Votrient), which targets vascular endothelial growth factor receptor (VEGFR). These antibodies may be used in combination with chemotherapy or other targeted therapies to treat sarcomas.",
    "llama-7b_fact_raw": "1. CMB305 is a monoclonal antibody that targets the CD19 antigen.\n2. The CD19 antigen is expressed on the surface of B-cells, including malignant B-cells in various B-cell malignancies.\n3. Chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL) are examples of B-cell malignancies.\n4. Sarcomas are malignant tumors that arise from mesenchymal tissues and do not express the CD19 antigen.\n5. CMB305 would not be effective against sarcomas because they do not have the CD19 antigen.",
    "llama-7b_fact": [
      "CMB305 is a monoclonal antibody that targets the CD19 antigen.",
      "The CD19 antigen is expressed on the surface of B-cells, including malignant B-cells in various B-cell malignancies.",
      "Chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL) are examples of B-cell malignancies.",
      "Sarcomas are malignant tumors that arise from mesenchymal tissues and do not express the CD19 antigen.",
      "CMB305 would not be effective against sarcomas because they do not have the CD19 antigen."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3461,
    "user_query": "You MUST give a detailed answer to the following question: What are manifestations of the Saint's Triad?",
    "llama-7b_response": "The manifestations of the Saint's Triad refer to the various ways in which the three aspects of the divine - the Father, the Son, and the Holy Spirit - are revealed or made known to humanity. These manifestations can take many different forms, depending on the religious tradition or belief system in question.\n\nIn Christianity, for example, the manifestations of the Saint's Triad can be seen in the life, teachings, death, and resurrection of Jesus Christ, who is believed to be the Son of God. The Holy Spirit is also present in the form of the Church, which is seen as the body of Christ on earth.\n\nIn Hinduism, the manifestations of the Saint's Triad can be seen in the trinity of Brahma, Vishnu, and Shiva, who are the creator, preserver, and destroyer of the universe, respectively.\n\nIn Buddhism, the manifestations of the Saint's Triad can be seen in the three jewels of Buddhism: the Buddha, the Dharma (the teachings of the Buddha), and the Sangha (the community of Buddhist practitioners).\n\nOverall, the manifestations of the Saint's Triad can be seen as the various ways in which the divine is made known to humanity, and can take many different forms depending on the religious tradition or belief system in question.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3470,
    "user_query": "You MUST give a detailed answer to the following question: Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-7b_response": "Yes, overexpression of LY6K has been associated with better prognosis for non-small cell lung cancer (NSCLC) patients.\n\nLY6K, also known as galectin-9, is a protein that plays a role in cell-cell and cell-matrix interactions. It has been found to be overexpressed in various types of cancer, including NSCLC.\n\nSeveral studies have investigated the prognostic significance of LY6K expression in NSCLC. One study, published in the Journal of Thoracic Oncology, analyzed the expression of LY6K and other biomarkers in a cohort of NSCLC patients and found that high LY6K expression was associated with better overall survival and disease-free survival.\n\nAnother study, published in the Journal of Clinical Oncology, analyzed the expression of LY6K and other biomarkers in a large cohort of NSCLC patients and found that high LY6K expression was associated with improved overall survival and progression-free survival.\n\nThese findings suggest that overexpression of LY6K may be a favorable prognostic factor for NSCLC patients. However, further research is needed to confirm these findings and to better understand the role of LY6K in the development and progression of NSCLC.",
    "llama-7b_fact_raw": "1. Overexpression of LY6K is associated with better prognosis for non-small cell lung cancer (NSCLC) patients.\n2. LY6K is a protein that participates in cell-cell and cell-matrix interactions.\n3. High LY6K expression was found to be correlated with better overall survival in NSCLC patients as reported in the Journal of Thoracic Oncology.\n4. According to a study in the Journal of Clinical Oncology, high LY6K expression was linked to improved progression-free survival in NSCLC patients.\n5. LY6K is referred to as galectin-9 in some biomedical contexts.",
    "llama-7b_fact": [
      "Overexpression of LY6K is associated with better prognosis for non-small cell lung cancer (NSCLC) patients.",
      "LY6K is a protein that participates in cell-cell and cell-matrix interactions.",
      "High LY6K expression was found to be correlated with better overall survival in NSCLC patients as reported in the Journal of Thoracic Oncology.",
      "According to a study in the Journal of Clinical Oncology, high LY6K expression was linked to improved progression-free survival in NSCLC patients.",
      "LY6K is referred to as galectin-9 in some biomedical contexts."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Overexpression of LY6K is generally associated with a poorer prognosis for non-small cell lung cancer (NSCLC) patients.\n2. TRUE\n3. FALSE [correction]: High LY6K expression is usually associated with poorer overall survival in NSCLC patients. Unless a specific study with different findings is referenced, the general consensus should be considered.\n4. UNKNOWN: This statement would require verification from the specific study referenced. The outcome might vary depending on the study design and findings.\n5. FALSE [correction]: LY6K (Lymphocyte Antigen 6 Complex, Locus K) is not the same as galectin-9. Galectin-9 is a different protein altogether that can be involved in immune processes within the body.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3473,
    "user_query": "You MUST give a detailed answer to the following question: List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-7b_response": "Cdk targets that are dephosphorylated during cytokinesis include:\n\n1. Cyclin B1: Cyclin B1 is dephosphorylated by Cdk1 during cytokinesis, allowing it to be degraded by the ubiquitin-proteasome pathway.\n2. Plk1: Plk1 is dephosphorylated by Cdk1 during cytokinesis, allowing it to be inactivated and degraded by the proteasome.\n3. Aurora B: Aurora B is dephosphorylated by Cdk1 during cytokinesis, allowing it to be inactivated and degraded by the proteasome.\n4. Borealin: Borealin is dephosphorylated by Cdk1 during cytokinesis, allowing it to be inactivated and degraded by the proteasome.\n5. Mid1: Mid1 is dephosphorylated by Cdk1 during cytokinesis, allowing it to be inactivated and degraded by the proteasome.",
    "llama-7b_fact_raw": "1. Cyclin B1 is dephosphorylated by Cdk1 during cytokinesis.\n2. Plk1 is dephosphorylated by Cdk1 during cytokinesis.\n3. Aurora B is dephosphorylated by Cdk1 during cytokinesis.\n4. Borealin is dephosphorylated by Cdk1 during cytokinesis.\n5. Mid1 is dephosphorylated by Cdk1 during cytokinesis.",
    "llama-7b_fact": [
      "Cyclin B1 is dephosphorylated by Cdk1 during cytokinesis.",
      "Plk1 is dephosphorylated by Cdk1 during cytokinesis.",
      "Aurora B is dephosphorylated by Cdk1 during cytokinesis.",
      "Borealin is dephosphorylated by Cdk1 during cytokinesis.",
      "Mid1 is dephosphorylated by Cdk1 during cytokinesis."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Cyclin B1 is not dephosphorylated by Cdk1 during cytokinesis. Instead, Cyclin B1 is targeted for degradation during the mitotic exit.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nNote: While Cdk1 (Cyclin-dependent kinase 1) is involved in cell cycle regulation, the phosphorylation state of proteins such as Plk1, Aurora B, Borealin, and Mid1 during cytokinesis is more complex, often involving various kinases and phosphatases. The specific regulatory mechanisms can vary and are subject to ongoing research. Without more detailed context, it's not possible to confidently confirm the phosphorylation states of these proteins in relation to Cdk1 during cytokinesis.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3508,
    "user_query": "You MUST give a detailed answer to the following question: What is Xanamem?",
    "llama-7b_response": "Xanamem is a medication that is used to treat Alzheimer's disease. It is a type of drug called a cholinesterase inhibitor, which works by increasing the levels of a chemical called acetylcholine in the brain. Acetylcholine is a neurotransmitter that is important for memory and cognitive function.\n\nXanamem is different from other cholinesterase inhibitors in that it is a prodrug, which means that it must be converted into its active form in the body before it can be effective. This conversion is catalyzed by an enzyme called butyrylcholinesterase, which is found in high levels in the brain. By inhibiting this enzyme, Xanamem is able to increase the levels of acetylcholine for a longer period of time, which can improve memory and cognitive function in people with Alzheimer's disease.\n\nXanamem is typically taken as a pill or a liquid, and the dosage and frequency of administration will depend on the individual patient and their response to the medication. Side effects of Xanamem may include nausea, diarrhea, and constipation, and it is important for patients to report any side effects to their healthcare provider.",
    "llama-7b_fact_raw": "1. Xanamem is a medication used to treat Alzheimer's disease.\n2. Xanamem belongs to a class of drugs called cholinesterase inhibitors.\n3. Cholinesterase inhibitors, such as Xanamem, work by increasing levels of the neurotransmitter acetylcholine in the brain.\n4. Xanamem is a prodrug, requiring conversion into its active form by an enzyme called butyrylcholinesterase.\n5. Side effects of Xanamem may include nausea, diarrhea, and constipation.",
    "llama-7b_fact": [
      "Xanamem is a medication used to treat Alzheimer's disease.",
      "Xanamem belongs to a class of drugs called cholinesterase inhibitors.",
      "Cholinesterase inhibitors, such as Xanamem, work by increasing levels of the neurotransmitter acetylcholine in the brain.",
      "Xanamem is a prodrug, requiring conversion into its active form by an enzyme called butyrylcholinesterase.",
      "Side effects of Xanamem may include nausea, diarrhea, and constipation."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: Without specific and updated information about a medication named Xanamem, it is impossible to confirm or deny its use in treating Alzheimer's disease.\n2. UNKNOWN: Since the status of Xanamem is not confirmed, it cannot be stated definitively whether it belongs to the class of cholinesterase inhibitors.\n3. TRUE: Cholinesterase inhibitors work by increasing levels of acetylcholine in the brain, which is generally true for this class of drugs.\n4. UNKNOWN: Without specific information about Xanamem, it cannot be determined if it is a prodrug or how it is metabolically activated.\n5. UNKNOWN: Without specific knowledge of Xanamem, its side effects cannot be confirmed or denied. The side effects listed are, however, commonly associated with cholinesterase inhibitors.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3520,
    "user_query": "You MUST give a detailed answer to the following question: What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-7b_response": "The Hof1-Cyk3 interaction plays a critical role in regulating the cellular response to oxidative stress in yeast. Hof1 is a ubiquitin-conjugating enzyme that adds ubiquitin molecules to proteins, marking them for degradation by the proteasome. Cyk3 is a member of the cytochrome c oxidase complex, which is responsible for generating ATP through the oxidation of molecular oxygen.\n\nDuring oxidative stress, the activity of the cytochrome c oxidase complex is inhibited, leading to the accumulation of reactive oxygen species (ROS) within the mitochondria. The Hof1-Cyk3 interaction plays a key role in sensing this increase in ROS and activating the cellular response to oxidative stress.\n\nWhen the Hof1-Cyk3 interaction is disrupted, the cellular response to oxidative stress is impaired, leading to increased sensitivity to oxidative stress and cell death. Conversely, overexpression of Hof1 or Cyk3 leads to increased resistance to oxidative stress, suggesting that the Hof1-Cyk3 interaction plays a critical role in regulating the cellular response to oxidative stress in yeast.\n\nOverall, the Hof1-Cyk3 interaction plays a crucial role in regulating the cellular response to oxidative stress in yeast by sensing the accumulation of ROS within the mitochondria and activating the cellular response to oxidative stress. Disruption of the Hof1-Cyk3 interaction leads to increased sensitivity to oxidative stress and cell death, while overexpression of Hof1 or Cyk3 leads to increased resistance to oxidative stress, suggesting that the Hof1-Cyk3 interaction plays a critical role in regulating the cellular response to oxidative stress in yeast.",
    "llama-7b_fact_raw": "1. The Hof1-Cyk3 interaction in yeast is involved in regulating the cellular response to oxidative stress.\n2. Hof1 is a ubiquitin-conjugating enzyme that tags proteins for degradation in yeast.\n3. Cyk3 is part of the cytochrome c oxidase complex, which is important for ATP generation in yeast.\n4. Disruption of the Hof1-Cyk3 interaction impairs yeast cells' response to oxidative stress, resulting in increased sensitivity to oxidative stress and cell death.\n5. Overexpression of Hof1 or Cyk3 in yeast increases resistance to oxidative stress.",
    "llama-7b_fact": [
      "The Hof1-Cyk3 interaction in yeast is involved in regulating the cellular response to oxidative stress.",
      "Hof1 is a ubiquitin-conjugating enzyme that tags proteins for degradation in yeast.",
      "Cyk3 is part of the cytochrome c oxidase complex, which is important for ATP generation in yeast.",
      "Disruption of the Hof1-Cyk3 interaction impairs yeast cells' response to oxidative stress, resulting in increased sensitivity to oxidative stress and cell death.",
      "Overexpression of Hof1 or Cyk3 in yeast increases resistance to oxidative stress."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: The Hof1-Cyk3 interaction is known to be involved in cytokinesis in yeast, but there is no specific information provided in your prompt about its role in regulating the cellular response to oxidative stress. Without additional context, it's impossible to determine the truthfulness of this statement.\n2. FALSE [correction]: Hof1 is not a ubiquitin-conjugating enzyme. It is actually involved in cytokinesis, for example, it interacts with Rho1 to promote actomyosin ring contraction during cytokinesis in Saccharomyces cerevisiae.\n3. FALSE [correction]: Cyk3 is not part of the cytochrome c oxidase complex. It is a protein involved in the process of cytokinesis. The cytochrome c oxidase complex is a separate entity that is involved in the electron transport chain, essential for ATP synthesis.\n4. UNKNOWN: While disruptions in proteins involved in cellular processes such as cytokinesis might have downstream effects on a cells response to stress, without specific scientific evidence or clarification, it is unclear if disrupting the Hof1-Cyk3 interaction impairs oxidative stress responses in yeast.\n5. UNKNOWN: Overexpression of certain proteins can confer resistance to oxidative stress in some contexts, but without data or a specific reference to the Hof1 and Cyk3 proteins' overexpression effect on oxidative stress resistance, the claim's validity is undetermined.",
    "llama-7b_judge": [
      "unknown",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3598,
    "user_query": "You MUST give a detailed answer to the following question: Which T-UCRs have been implicated in gastric cancer?",
    "llama-7b_response": "There are several T-UCRs that have been implicated in gastric cancer. These include:\n\n1. TNF-alpha: TNF-alpha is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. It has been shown to promote cell proliferation, angiogenesis, and invasion in gastric cancer cells.\n2. IL-1beta: IL-1beta is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. It has been shown to promote cell proliferation, angiogenesis, and invasion in gastric cancer cells.\n3. IL-6: IL-6 is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. It has been shown to promote cell proliferation, angiogenesis, and invasion in gastric cancer cells.\n4. IL-8: IL-8 is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. It has been shown to promote cell proliferation, angiogenesis, and invasion in gastric cancer cells.\n5. IL-12: IL-12 is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. It has been shown to promote cell proliferation, angiogenesis, and invasion in gastric cancer cells.\n6. IL-18: IL-18 is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. It has been shown to promote cell proliferation, angiogenesis, and invasion in gastric cancer cells.\n7. IFN-gamma: IFN-gamma is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. It has been shown to promote cell proliferation, angiogenesis, and invasion in gastric cancer cells.\n8. TGF-beta: TGF-beta is a cytokine that has been implicated in the development of gastric cancer. It has been shown to promote cell proliferation, angiogenesis, and",
    "llama-7b_fact_raw": "1. TNF-alpha is a cytokine implicated in the development of gastric cancer and is known to promote cell proliferation, angiogenesis, and invasion in gastric cancer cells.\n2. IL-1beta has been implicated in gastric cancer development and promotes cell proliferation, angiogenesis, and invasion in gastric cancer cells.\n3. IL-6 is a cytokine that is implicated in the promotion of gastric cancer.\n4. IL-8 has been implicated in gastric cancer development and is associated with cell proliferation, angiogenesis, and invasion in gastric cancer cells.\n5. IL-12 has been shown to be involved in the development of gastric cancer, promoting cell proliferation, angiogenesis, and invasion.\n\n(Note: It seems there may be a misunderstanding in the provided answer, as T-UCRs (Transcribed-Ultraconserved Regions) do not correspond to the cytokines listed in the answer. Cytokines like TNF-alpha, IL-1beta, IL-6, IL-8, IL-12, and others are not T-UCRs. If the context was to list actual T-UCRs implicated in gastric cancer, the provided answer does not accurately address that. Instead, it incorrectly lists cytokines as T-UCRs. However, the factual statements listed above are valid for cytokines that have been implicated in gastric cancer, as per the information provided in the answer.)",
    "llama-7b_fact": [
      "TNF-alpha is a cytokine implicated in the development of gastric cancer and is known to promote cell proliferation, angiogenesis, and invasion in gastric cancer cells.",
      "IL-1beta has been implicated in gastric cancer development and promotes cell proliferation, angiogenesis, and invasion in gastric cancer cells.",
      "IL-6 is a cytokine that is implicated in the promotion of gastric cancer.",
      "IL-8 has been implicated in gastric cancer development and is associated with cell proliferation, angiogenesis, and invasion in gastric cancer cells.",
      "IL-12 has been shown to be involved in the development of gastric cancer, promoting cell proliferation, angiogenesis, and invasion.",
      "ote: It seems there may be a misunderstanding in the provided answer, as T-UCRs (Transcribed-Ultraconserved Regions) do not correspond to the cytokines listed in the answer. Cytokines like TNF-alpha, IL-1beta, IL-6, IL-8, IL-12, and others are not T-UCRs. If the context was to list actual T-UCRs implicated in gastric cancer, the provided answer does not accurately address that. Instead, it incorrectly lists cytokines as T-UCRs. However, the factual statements listed above are valid for cytokines that have been implicated in gastric cancer, as per the information provided in the answer.)"
    ],
    "llama-7b_judge_raw": "1. TRUE - TNF-alpha is a cytokine known to be involved in various pro-inflammatory processes and has been implicated in the development of several cancer types, including gastric cancer, where it can promote cell proliferation, angiogenesis, and invasion.\n2. TRUE - IL-1beta is another pro-inflammatory cytokine that can contribute to tumorigenesis by promoting similar processes such as cell proliferation, angiogenesis, and invasion, which are involved in gastric cancer development.\n3. TRUE - IL-6 is a cytokine that plays a significant role in the immune response and has also been implicated in the promotion of gastric cancer through various mechanisms including inflammation, cell survival, and angiogenesis.\n4. TRUE - IL-8 is a chemokine associated with inflammatory responses and has been implicated in promoting tumorigenesis, including cell proliferation, angiogenesis, and invasion in gastric cancer.\n5. FALSE [correction]: While IL-12 does play a role in the immune system, it is typically associated with anti-tumorigenic activities, as it stimulates the immune system to attack tumor cells. Thus, it would not be promoting cell proliferation, angiogenesis, and invasion in the context of cancer but rather would be expected to help inhibit these processes.\n6. UNKNOWN - This statement appears to be more of a note regarding a potential misunderstanding about T-UCRs (Transcribed-Ultraconserved Regions) and cytokines. It does not present a clear factual statement that can be labeled true or false. It clarifies that T-UCRs are distinct from cytokines and should not be confused with the cytokines listed previously.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3607,
    "user_query": "You MUST give a detailed answer to the following question: What is the Lupus Severity Index (LSI)?",
    "llama-7b_response": "The Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease that affects various body systems, including the skin, joints, kidneys, heart, and lungs. The LSI was developed in the 1970s and is based on a combination of clinical and laboratory criteria.\n\nThe LSI is calculated based on the presence and severity of various SLE manifestations, such as malar rash (a butterfly-shaped rash on the cheeks), photosensitivity, discoid rash (a red, scaly rash on the skin), arthritis, nephritis (inflammation of the kidneys), and hematologic abnormalities (such as anemia or thrombocytopenia). The score ranges from 0 to 4, with higher scores indicating more severe disease.\n\nThe LSI is widely used in clinical practice and research to assess the disease activity and response to treatment in patients with SLE. It is also used to monitor the progression of the disease over time and to identify patients who may be at risk of disease flares or organ damage.\n\nIn summary, the Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease that affects various body systems. It is based on a combination of clinical and laboratory criteria and is calculated based on the presence and severity of various SLE manifestations. The score ranges from 0 to 4, with higher scores indicating more severe disease. The LSI is widely used in clinical practice and research to assess the disease activity and response to treatment in patients with SLE and to monitor the progression of the disease over time.",
    "llama-7b_fact_raw": "1. The Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE).\n2. The LSI was developed in the 1970s.\n3. The LSI score ranges from 0 to 4, with higher scores indicating a more severe disease state.\n4. The LSI uses clinical and laboratory criteria to assess various SLE manifestations including malar rash, photosensitivity, discoid rash, arthritis, nephritis, and hematologic abnormalities.\n5. The LSI is used in both clinical practice and research to assess disease activity, response to treatment, progression, and risk of disease flares or organ damage in patients with SLE.",
    "llama-7b_fact": [
      "The Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE).",
      "The LSI was developed in the 1970s.",
      "The LSI score ranges from 0 to 4, with higher scores indicating a more severe disease state.",
      "The LSI uses clinical and laboratory criteria to assess various SLE manifestations including malar rash, photosensitivity, discoid rash, arthritis, nephritis, and hematologic abnormalities.",
      "The LSI is used in both clinical practice and research to assess disease activity, response to treatment, progression, and risk of disease flares or organ damage in patients with SLE."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: It is unknown when the Lupus Severity Index (LSI) was specifically developed; the description lacks the precise timeline of its development. Moreover, standard tools for measuring disease activity in SLE include the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and the British Isles Lupus Assessment Group (BILAG) index, which were developed in the 1980s and 1990s respectively.\n3. FALSE [correction]: Standard indices like the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score ranges from 0 to 105, not 0 to 4, with higher scores indicating a more severe disease state. There might be a confusion with another scale or an unestablished tool specific to a certain study or clinical practice.\n4. TRUE (assuming the LSI is a valid tool, this statement would be true as these are common SLE manifestations considered in disease assessments.)\n5. TRUE (assuming the LSI is a valid and established tool, it would likely be used for such purposes as described, much like other disease activity indices.)",
    "llama-7b_judge": [
      "true",
      "unknown",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3615,
    "user_query": "You MUST give a detailed answer to the following question: Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-7b_response": "De novo mutations are genetic changes that occur for the first time in an individual and are not inherited from the parents. ZSWIM6 is a gene that has been implicated in several human disorders, and some of these disorders may be caused by de novo mutations in this gene.\n\nOne disorder associated with de novo mutations in ZSWIM6 is autism spectrum disorder (ASD). ASD is a neurodevelopmental disorder characterized by social impairments, communication difficulties, and repetitive behaviors. Studies have identified mutations in ZSWIM6 as a risk factor for ASD, suggesting that de novo mutations in this gene may contribute to the development of this disorder.\n\nAnother disorder associated with de novo mutations in ZSWIM6 is intellectual disability (ID). ID is a condition characterized by significant impairments in cognitive abilities and adaptive skills, and it can range from mild to severe. Studies have identified mutations in ZSWIM6 as a risk factor for ID, suggesting that de novo mutations in this gene may contribute to the development of this disorder.\n\nIt's worth noting that these are just a few examples of disorders associated with de novo mutations in ZSWIM6, and further research is needed to fully understand the role of this gene in human health and disease.",
    "llama-7b_fact_raw": "1. De novo mutations are genetic changes that are not inherited from the parents.\n2. ZSWIM6 is a gene that has been associated with several human disorders.\n3. Autism spectrum disorder (ASD) may be caused by de novo mutations in ZSWIM6.\n4. Mutations in ZSWIM6 are identified as a risk factor for autism spectrum disorder.\n5. Intellectual disability (ID) is associated with de novo mutations in ZSWIM6, with mutations in the gene as a risk factor for this condition.",
    "llama-7b_fact": [
      "De novo mutations are genetic changes that are not inherited from the parents.",
      "ZSWIM6 is a gene that has been associated with several human disorders.",
      "Autism spectrum disorder (ASD) may be caused by de novo mutations in ZSWIM6.",
      "Mutations in ZSWIM6 are identified as a risk factor for autism spectrum disorder.",
      "Intellectual disability (ID) is associated with de novo mutations in ZSWIM6, with mutations in the gene as a risk factor for this condition."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE: De novo mutations in the ZSWIM6 gene have been implicated in ASD.\n4. TRUE: Mutations in ZSWIM6 are indeed identified as a possible risk factor for autism spectrum disorder.\n5. TRUE: Intellectual disability (ID) is one of the conditions that can be associated with de novo mutations in ZSWIM6, making mutations in the gene a risk factor.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3626,
    "user_query": "You MUST give a detailed answer to the following question: Which disease can be classified using the Koos Classification?",
    "llama-7b_response": "The Koos Classification is a system for classifying diseases of the foot and ankle. It was developed by Dr. Cornelis Koos, a Dutch orthopedic surgeon, and is used to categorize foot and ankle disorders based on their etiology, anatomy, and pathology.\n\nThe Koos Classification system includes several categories of foot and ankle disorders, including:\n\n1. Neuropathic foot: This category includes disorders that affect the nerves of the foot and ankle, such as neuropathy, Charcot foot, and diabetic foot ulcers.\n2. Arthritic foot: This category includes disorders that affect the joints of the foot and ankle, such as osteoarthritis, rheumatoid arthritis, and gout.\n3. Mechanical foot: This category includes disorders that affect the bones, muscles, and tendons of the foot and ankle, such as bunions, hammertoes, and Achilles tendinitis.\n4. Traumatic foot: This category includes disorders that result from trauma to the foot and ankle, such as fractures, dislocations, and crush injuries.\n5. Infectious foot: This category includes disorders that are caused by infection, such as bacterial, fungal, and viral infections.\n\nIn summary, the Koos Classification system can be used to classify a wide range of foot and ankle disorders, including neuropathic, arthritic, mechanical, traumatic, and infectious disorders.",
    "llama-7b_fact_raw": "1. The Koos Classification is a system used for classifying diseases of the foot and ankle.\n2. Dr. Cornelis Koos, a Dutch orthopedic surgeon, developed the Koos Classification system.\n3. The Koos Classification includes a neuropathic foot category, covering disorders like neuropathy and diabetic foot ulcers.\n4. Arthritic disorders such as osteoarthritis and rheumatoid arthritis in the foot and ankle are classified under the arthritic foot category in the Koos Classification.\n5. The Koos Classification categorizes traumatic foot disorders, including conditions like fractures and dislocations of the foot and ankle.",
    "llama-7b_fact": [
      "The Koos Classification is a system used for classifying diseases of the foot and ankle.",
      "Dr. Cornelis Koos, a Dutch orthopedic surgeon, developed the Koos Classification system.",
      "The Koos Classification includes a neuropathic foot category, covering disorders like neuropathy and diabetic foot ulcers.",
      "Arthritic disorders such as osteoarthritis and rheumatoid arthritis in the foot and ankle are classified under the arthritic foot category in the Koos Classification.",
      "The Koos Classification categorizes traumatic foot disorders, including conditions like fractures and dislocations of the foot and ankle."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Koos Classification is a system used for classifying pediatric cerebellar tumors, not diseases of the foot and ankle.\n2. FALSE [correction]: Dr. Cornelis Koos, a Dutch neurosurgeon, is associated with the classification of pediatric cerebellar tumors, not an orthopedic classification system.\n3. FALSE [correction]: Since the Koos Classification pertains to pediatric cerebellar tumors, it would not include a neuropathic foot category. This category might be found in a classification system for foot and ankle disorders, but not in the Koos Classification.\n4. FALSE [correction]: As the Koos Classification is related to cerebellar tumors, it would not have an arthritic foot category which would pertain to foot and ankle disorders.\n5. FALSE [correction]: The Koos Classification does not concern traumatic foot disorders, which involve fractures and dislocations of the foot and ankle; it is for grading cerebellar tumors in pediatrics.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3628,
    "user_query": "You MUST give a detailed answer to the following question: What are the in vivo effects of AZD8601?",
    "llama-7b_response": "AZD8601, also known as AT-1212, is a selective and potent agonist of the AT-1 receptor, which is a subtype of the angiotensin II type 1 receptor (AT-1 receptor). The AT-1 receptor is a G protein-coupled receptor that plays a key role in the regulation of blood pressure and cardiovascular function.\n\nIn vivo studies have shown that AZD8601 has potent and selective agonist activity at the AT-1 receptor, with little to no activity at other receptors, including the AT-2 and AT-3 receptors. This selective activity makes AZD8601 a useful tool for studying the physiological and pharmacological effects of the AT-1 receptor.\n\nIn vivo studies have also shown that AZD8601 has potent and dose-dependent effects on blood pressure and cardiovascular function. For example, acute administration of AZD8601 to rats has been shown to increase mean arterial pressure, heart rate, and cardiac output, while decreasing systemic vascular resistance. These effects are thought to be mediated by the activation of the AT-1 receptor and the subsequent activation of downstream signaling pathways, including the renin-angiotensin-aldosterone system (RAAS).\n\nIn addition to its effects on blood pressure and cardiovascular function, AZD8601 has also been shown to have effects on other physiological systems. For example, acute administration of AZD8601 to rats has been shown to increase glomerular filtration rate and renal blood flow, while decreasing sodium and water retention. These effects are thought to be mediated by the activation of the AT-1 receptor and the subsequent activation of downstream signaling pathways, including the RAAS.\n\nOverall, the in vivo effects of AZD8601 are thought to be mediated by the activation of the AT-1 receptor and the subsequent activation of downstream signaling pathways, including the RAAS. These effects include the regulation of blood pressure and cardiovascular function, as well as effect",
    "llama-7b_fact_raw": "1. AZD8601 is a selective and potent agonist of the AT-1 receptor.\n2. The AT-1 receptor is part of the renin-angiotensin-aldosterone system and plays a key role in blood pressure and cardiovascular function regulation.\n3. AZD8601 has little to no activity at other angiotensin receptors such as AT-2 and AT-3 receptors.\n4. Acute administration of AZD8601 in rats increased mean arterial pressure, heart rate, and cardiac output, while decreasing systemic vascular resistance.\n5. AZD8601 also affected renal function by increasing glomerular filtration rate and renal blood flow, and decreasing sodium and water retention in rats.",
    "llama-7b_fact": [
      "AZD8601 is a selective and potent agonist of the AT-1 receptor.",
      "The AT-1 receptor is part of the renin-angiotensin-aldosterone system and plays a key role in blood pressure and cardiovascular function regulation.",
      "AZD8601 has little to no activity at other angiotensin receptors such as AT-2 and AT-3 receptors.",
      "Acute administration of AZD8601 in rats increased mean arterial pressure, heart rate, and cardiac output, while decreasing systemic vascular resistance.",
      "AZD8601 also affected renal function by increasing glomerular filtration rate and renal blood flow, and decreasing sodium and water retention in rats."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: AZD8601 is not a selective and potent agonist of the AT-1 receptor. AZD8601 is an mRNA-based therapy designed to produce vascular endothelial growth factor A (VEGF-A) in the body to aid in the regeneration of vascular tissue.\n2. TRUE\n3. UNKNOWN  Without specific information about AZD8601s activity at other angiotensin receptors, it is not possible to verify this statement.\n4. UNKNOWN  The effects of AZD8601 on blood pressure, heart rate, cardiac output, and systemic vascular resistance are not provided with this context, and therefore the statement cannot be confirmed or denied.\n5. UNKNOWN  Similarly, the effects of AZD8601 on renal function and parameters such as glomerular filtration rate, renal blood flow, and sodium and water retention in rats are not specified in the provided context.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3640,
    "user_query": "You MUST give a detailed answer to the following question: How are SAHFS created?",
    "llama-7b_response": "SAHFS (Secure Access to Healthcare Facilities and Services) are created through a process that involves several key steps:\n\n1. Identification of healthcare facilities and services: The first step in creating a SAHFS is to identify the healthcare facilities and services that are to be included in the agreement. This may involve consulting with relevant government agencies, non-governmental organizations, and other stakeholders to determine which facilities and services are most in need of support.\n2. Negotiation and signing of the agreement: Once the list of healthcare facilities and services has been established, the next step is to negotiate and sign a SAHFS agreement with the government of the country in question. This agreement should outline the terms and conditions of the support provided by the donor country, including the amount and duration of the funding, as well as any specific conditions or requirements that must be met in order to receive support.\n3. Implementation of the agreement: Once the agreement has been signed, the donor country must work with the government of the recipient country to implement the agreement. This may involve providing technical assistance and support to help the recipient country develop the necessary infrastructure and capacity to effectively manage and deliver healthcare services.\n4. Monitoring and evaluation of the agreement: It is important for both the donor country and the recipient country to monitor and evaluate the progress of the SAHFS agreement to ensure that it is being implemented effectively and that the intended outcomes are being achieved. This may involve conducting regular reviews and assessments, as well as collecting and analyzing data on the impact of the support provided.\n\nOverall, the process of creating a SAHFS involves a collaborative effort between the donor country and the recipient country, with a focus on identifying the most pressing healthcare needs and working together to develop and implement a plan to address those needs.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3672,
    "user_query": "You MUST give a detailed answer to the following question: What is the function of the PDZ domain in SATB1?",
    "llama-7b_response": "The PDZ domain is a protein interaction domain found in many proteins, including the transcription factor SATB1 (Special AT-rich sequence-binding protein 1). The function of the PDZ domain in SATB1 is to mediate protein-protein interactions with other proteins.\n\nThe PDZ domain in SATB1 specifically binds to other proteins that contain a PDZ-binding motif, which is a specific sequence of amino acids. The PDZ domain in SATB1 interacts with a variety of proteins, including other transcription factors, cytoskeletal proteins, and scaffolding proteins.\n\nOne of the key functions of the PDZ domain in SATB1 is to regulate the localization and activity of SATB1. By interacting with other proteins, the PDZ domain in SATB1 can target SATB1 to specific subcellular locations, such as the nucleus or the cytoplasm. Additionally, the PDZ domain in SATB1 can modulate the activity of SATB1 by recruiting other proteins that regulate its transcriptional activity.\n\nOverall, the PDZ domain in SATB1 plays a crucial role in regulating the function of SATB1 by mediating protein-protein interactions with other proteins.",
    "llama-7b_fact_raw": "1. The PDZ domain is a protein interaction domain that mediates protein-protein interactions.\n2. SATB1 stands for Special AT-rich sequence-binding protein 1 and contains a PDZ domain.\n3. The PDZ domain in SATB1 binds to other proteins that have a PDZ-binding motif.\n4. The PDZ domain in SATB1 helps in regulating the localization and activity of SATB1 within the cell.\n5. The PDZ domain can influence the transcriptional activity of SATB1 by recruiting proteins that affect its function.",
    "llama-7b_fact": [
      "The PDZ domain is a protein interaction domain that mediates protein-protein interactions.",
      "SATB1 stands for Special AT-rich sequence-binding protein 1 and contains a PDZ domain.",
      "The PDZ domain in SATB1 binds to other proteins that have a PDZ-binding motif.",
      "The PDZ domain in SATB1 helps in regulating the localization and activity of SATB1 within the cell.",
      "The PDZ domain can influence the transcriptional activity of SATB1 by recruiting proteins that affect its function."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: SATB1 stands for Special AT-rich sequence-binding protein 1, but it does not contain a PDZ domain.\n3. FALSE [correction]: Since SATB1 does not contain a PDZ domain, it does not bind to other proteins through a PDZ domain.\n4. FALSE [correction]: Because the PDZ domain is not a part of SATB1, it does not directly help in regulating the localization and activity of SATB1 within the cell.\n5. FALSE [correction]: As SATB1 does not contain a PDZ domain, a PDZ domain cannot influence the transcriptional activity of SATB1 through recruitment of proteins.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3678,
    "user_query": "You MUST give a detailed answer to the following question: What is the basis of the BLISS technique?",
    "llama-7b_response": "The BLISS technique is based on the principles of classical conditioning and operant conditioning.\n\nClassical conditioning is a learning process in which an association is made between a naturally occurring stimulus (the \"unconditioned stimulus\") and a previously neutral stimulus (the \"conditioned stimulus\"). The conditioned stimulus then elicits the same response as the unconditioned stimulus.\n\nOperant conditioning is a learning process in which behavior is modified by its consequences. Positive reinforcement increases the likelihood of the behavior occurring again, while negative reinforcement decreases the likelihood of the behavior occurring again. Punishment decreases the likelihood of the behavior occurring again.\n\nThe BLISS technique uses both classical conditioning and operant conditioning to help individuals with insomnia associate their bed and bedroom with relaxation and sleep. The technique involves the following steps:\n\n1. Bedtime routine: Establish a consistent bedtime routine that includes relaxing activities, such as reading a book or taking a warm bath, before going to bed.\n2. Bed association: Associate the bed and bedroom with relaxation and sleep by spending time in the bed and bedroom only for sleeping and sex. Avoid other activities, such as watching TV or working, in the bed and bedroom.\n3. Low stimulus environment: Create a low stimulus environment in the bed and bedroom by minimizing noise, light, and other distractions.\n4. Sleep-promoting cues: Use sleep-promoting cues, such as lavender essential oil or white noise, to signal to the brain that it is time to sleep.\n5. Sleep onset associations: Use classical conditioning to associate the bed and bedroom with sleep by associating the bed and bedroom with relaxation and sleep. This can be done by using positive reinforcement, such as giving oneself a reward (e.g., a glass of milk) when they get into bed and stay there until they fall asleep.\n\nBy using the BLISS technique, individuals with insomnia can learn to associate their bed and bedroom with relaxation and sleep, which can help them fall asleep faster and sleep more soundly.",
    "llama-7b_fact_raw": "1. The BLISS technique utilizes the principles of classical conditioning and operant conditioning.\n2. Classical conditioning involves an association between a naturally occurring stimulus and a previously neutral stimulus.\n3. Operant conditioning involves modifying behavior by its consequences, including reinforcement and punishment.\n4. The BLISS technique aims to help individuals with insomnia associate their bed and bedroom with relaxation and sleep.\n5. The technique includes establishing a consistent bedtime routine and creating a low stimulus environment.",
    "llama-7b_fact": [
      "The BLISS technique utilizes the principles of classical conditioning and operant conditioning.",
      "Classical conditioning involves an association between a naturally occurring stimulus and a previously neutral stimulus.",
      "Operant conditioning involves modifying behavior by its consequences, including reinforcement and punishment.",
      "The BLISS technique aims to help individuals with insomnia associate their bed and bedroom with relaxation and sleep.",
      "The technique includes establishing a consistent bedtime routine and creating a low stimulus environment."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN (The statement could be true or false depending on what the BLISS technique specifically entails, but there is not enough information provided to determine the accuracy of the statement. BLISS is not a universally recognized acronym in psychological literature, and without further context on what BLISS stands for, a true or false determination cannot be made.)\n2. TRUE\n3. TRUE\n4. UNKNOWN (As the BLISS technique is not clearly defined in general psychological literature, it is not possible to confirm whether this statement is true or false without additional context.)\n5. UNKNOWN (Similar to the previous statement, without specific information about what the BLISS technique is or detailed knowledge about its components, the truthfulness of this statement cannot be determined.)",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3679,
    "user_query": "You MUST give a detailed answer to the following question: List 3 NK3R antagonists.",
    "llama-7b_response": "NK3 receptors are G protein-coupled receptors that play a role in the regulation of neurotransmitter release in the nervous system. They are activated by the neurokinin-3 (NK3) peptide and are involved in a variety of physiological processes, including pain perception, inflammation, and cardiovascular function.\n\nThere are several NK3 receptor antagonists that have been developed as potential therapeutic agents. Here are three examples:\n\n1. L-733060: L-733060 is a potent and selective NK3 receptor antagonist that has been used in a number of preclinical studies to investigate the role of NK3 receptors in various physiological processes. It has been shown to block the effects of the NK3 peptide on neurotransmitter release and to have analgesic and anti-inflammatory effects in animal models.\n2. AT-1212: AT-1212 is another selective NK3 receptor antagonist that has been investigated for its potential therapeutic applications. It has been shown to block the effects of the NK3 peptide on neurotransmitter release and to have analgesic and anti-inflammatory effects in animal models.\n3. SB-612125: SB-612125 is a potent and selective NK3 receptor antagonist that has been used in a number of preclinical studies to investigate the role of NK3 receptors in various physiological processes. It has been shown to block the effects of the NK3 peptide on neurotransmitter release and to have analgesic and anti-inflammatory effects in animal models.",
    "llama-7b_fact_raw": "1. L-733060 is a selective NK3 receptor antagonist used in preclinical studies.\n2. AT-1212 is a selective NK3 receptor antagonist researched for therapeutic applications.\n3. SB-612125 is a selective NK3 receptor antagonist that has been involved in preclinical studies.\n4. NK3 receptors are G protein-coupled receptors related to neurotransmitter release regulation in the nervous system.\n5. NK3 receptors are activated by the neurokinin-3 (NK3) peptide.",
    "llama-7b_fact": [
      "L-733060 is a selective NK3 receptor antagonist used in preclinical studies.",
      "AT-1212 is a selective NK3 receptor antagonist researched for therapeutic applications.",
      "SB-612125 is a selective NK3 receptor antagonist that has been involved in preclinical studies.",
      "NK3 receptors are G protein-coupled receptors related to neurotransmitter release regulation in the nervous system.",
      "NK3 receptors are activated by the neurokinin-3 (NK3) peptide."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The name AT-1212 does not correspond to any known NK3 receptor antagonist; the statement is likely incorrect, but without additional context, a specific correction can't be provided.\n3. UNKNOWN (SB-612111 is a NK3 receptor antagonist, but there is no available information on SB-612125)\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3691,
    "user_query": "You MUST give a detailed answer to the following question: Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-7b_response": "The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is known as AT-1212. It was developed by the Japanese pharmaceutical company Astellas Pharma and was initially studied for its potential use in the treatment of type 2 diabetes. AT-1212 works by binding to the ghrelin receptor (GHS-R1a) and inhibiting the activity of ghrelin, which is a hormone that is released by the stomach and plays a role in regulating hunger and appetite.\n\nAT-1212 has been studied in a number of clinical trials, including a phase 2b trial in which it was shown to be effective in reducing body weight and improving glycemic control in overweight or obese individuals with type 2 diabetes. However, the development of AT-1212 has been discontinued due to concerns about its safety profile, including an increased risk of cardiovascular events in some patients.\n\nIt's worth noting that there are other oral ghrelin receptor inverse agonists that have been developed and are currently being studied for potential use in the treatment of various conditions, including type 2 diabetes, obesity, and other metabolic disorders. However, AT-1212 was the first such drug to be profiled in healthy subjects, and it paved the way for further research in this area.",
    "llama-7b_fact_raw": "1. AT-1212 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.\n2. The drug AT-1212 was developed by Astellas Pharma, a Japanese pharmaceutical company.\n3. AT-1212's mechanism of action involves binding to the ghrelin receptor and inhibiting the activity of ghrelin, a hormone involved in regulating hunger and appetite.\n4. In a phase 2b clinical trial, AT-1212 was found to be effective in reducing body weight and improving glycemic control in overweight or obese individuals with type 2 diabetes.\n5. The development of AT-1212 has been discontinued due to safety concerns, including an increased risk of cardiovascular events.",
    "llama-7b_fact": [
      "AT-1212 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
      "The drug AT-1212 was developed by Astellas Pharma, a Japanese pharmaceutical company.",
      "AT-1212's mechanism of action involves binding to the ghrelin receptor and inhibiting the activity of ghrelin, a hormone involved in regulating hunger and appetite.",
      "In a phase 2b clinical trial, AT-1212 was found to be effective in reducing body weight and improving glycemic control in overweight or obese individuals with type 2 diabetes.",
      "The development of AT-1212 has been discontinued due to safety concerns, including an increased risk of cardiovascular events."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE (assuming that AT-1212 is indeed an inverse agonist, which by definition would bind to the ghrelin receptor and inhibit the activity of ghrelin.)\n4. UNKNOWN\n5. UNKNOWN\n\nThe validity of statements regarding AT-1212's development, clinical trials, and potential discontinuation due to safety concerns would require specific and current information about the drug's status and history. As this information is not provided, the truthfulness of these statements cannot be evaluated without additional context or research.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3693,
    "user_query": "You MUST give a detailed answer to the following question: What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-7b_response": "Vaxchora is a vaccine that is approved for the prevention of cholera caused by the serogroup O1 in individuals 18 years of age and older. The vaccine is administered as a single-dose intramuscular injection.\n\nStudies have shown that Vaxchora provides protective efficacy against moderate to severe cholera. A randomized, double-blind, placebo-controlled trial conducted in Bangladesh found that Vaxchora was effective in preventing symptomatic cholera caused by serogroup O1. The vaccine was found to be 66% effective in preventing symptomatic cholera, with a lower bound of the 95% confidence interval of 45%.\n\nAnother randomized, double-blind, placebo-controlled trial conducted in Haiti also found that Vaxchora was effective in preventing symptomatic cholera caused by serogroup O1. The vaccine was found to be 71% effective in preventing symptomatic cholera, with a lower bound of the 95% confidence interval of 56%.\n\nThese studies suggest that Vaxchora provides protective efficacy against moderate to severe cholera caused by serogroup O1. However, it is worth noting that the efficacy of the vaccine may vary depending on factors such as the serogroup of the cholera strain, the age and immune status of the vaccine recipient, and the environment in which the vaccine is used.",
    "llama-7b_fact_raw": "1. Vaxchora is approved for preventing cholera caused by serogroup O1 in individuals 18 years and older.\n2. Vaxchora is administered as a single-dose intramuscular injection.\n3. A study in Bangladesh reported that Vaxchora was 66% effective in preventing symptomatic cholera, with a 95% confidence interval lower bound of 45%.\n4. A study in Haiti reported that Vaxchora was 71% effective in preventing symptomatic cholera, with a 95% confidence interval lower bound of 56%.\n5. The protective efficacy of Vaxchora against moderate to severe cholera may vary based on factors such as cholera strain serogroup, age, immune status, and environmental conditions.",
    "llama-7b_fact": [
      "Vaxchora is approved for preventing cholera caused by serogroup O1 in individuals 18 years and older.",
      "Vaxchora is administered as a single-dose intramuscular injection.",
      "A study in Bangladesh reported that Vaxchora was 66% effective in preventing symptomatic cholera, with a 95% confidence interval lower bound of 45%.",
      "A study in Haiti reported that Vaxchora was 71% effective in preventing symptomatic cholera, with a 95% confidence interval lower bound of 56%.",
      "The protective efficacy of Vaxchora against moderate to severe cholera may vary based on factors such as cholera strain serogroup, age, immune status, and environmental conditions."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Vaxchora is administered as a single-dose oral vaccine, not an intramuscular injection.\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3716,
    "user_query": "You MUST give a detailed answer to the following question: Which was the first cholera vaccine approved in the US?",
    "llama-7b_response": "The first cholera vaccine approved in the US was Dukoral, which was approved by the US Food and Drug Administration (FDA) in 2005. Dukoral is a live, attenuated oral vaccine that is made from a strain of cholera bacteria that has been weakened through a process called attenuation. The vaccine is administered in a single dose and provides protection against cholera for up to 2 years. Dukoral is approved for use in adults and children over the age of 1 year and is recommended for use in travelers to areas where cholera is common.",
    "llama-7b_fact_raw": "1. Dukoral was the first cholera vaccine approved in the US.\n2. The US Food and Drug Administration (FDA) approved Dukoral in 2005.\n3. Dukoral is a live, attenuated oral vaccine for cholera.\n4. Dukoral provides protection against cholera for up to 2 years.\n5. Dukoral is approved for use in adults and children over the age of 1 year.",
    "llama-7b_fact": [
      "Dukoral was the first cholera vaccine approved in the US.",
      "The US Food and Drug Administration (FDA) approved Dukoral in 2005.",
      "Dukoral is a live, attenuated oral vaccine for cholera.",
      "Dukoral provides protection against cholera for up to 2 years.",
      "Dukoral is approved for use in adults and children over the age of 1 year."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Dukoral was not the first cholera vaccine approved in the US. Vaxchora, not Dukoral, was the first cholera vaccine approved by the FDA for use in the United States.\n2. FALSE [correction]: The US Food and Drug Administration (FDA) did not approve Dukoral. Dukoral is approved and used in other countries but not in the United States where Vaxchora is approved instead.\n3. TRUE\n4. FALSE [correction]: Dukoral provides protection against cholera for about two years in adults and six months in children, with a booster dose recommended for continuous protection.\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3737,
    "user_query": "You MUST give a detailed answer to the following question: Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-7b_response": "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is the autoimmune regulator (AIRE) gene. CVID is a primary immunodeficiency disorder characterized by a reduced ability to produce immunoglobulins, which are proteins that help fight infections. The AIRE gene provides instructions for making a protein that is involved in the regulation of the immune system. Mutations in the AIRE gene can lead to reduced production of immunoglobulins and the symptoms of CVID.",
    "llama-7b_fact_raw": "1. The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is a mutation in the autoimmune regulator (AIRE) gene.\n2. CVID is characterized by a reduced ability to produce immunoglobulins.\n3. Immunoglobulins are proteins that help fight infections.\n4. The AIRE gene is involved in the regulation of the immune system.\n5. Mutations in the AIRE gene can lead to the symptoms of CVID.",
    "llama-7b_fact": [
      "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is a mutation in the autoimmune regulator (AIRE) gene.",
      "CVID is characterized by a reduced ability to produce immunoglobulins.",
      "Immunoglobulins are proteins that help fight infections.",
      "The AIRE gene is involved in the regulation of the immune system.",
      "Mutations in the AIRE gene can lead to the symptoms of CVID."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The most common genetic cause of common variable immunodeficiency (CVID) in Europeans is not a mutation in the autoimmune regulator (AIRE) gene, but rather mutations in genes like TNFRSF13B (which encodes TACI), and less frequently, ICOS or others. The AIRE gene is associated with Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED), not CVID.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Mutations in the AIRE gene are not typically associated with CVID; instead, they lead to a different condition known as Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED). Mutations associated with CVID symptoms are generally found in other genes.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3743,
    "user_query": "You MUST give a detailed answer to the following question: Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-7b_response": "The IFIT1 gene, also known as Interferon, alpha-inducible protein 18, plays a role in the immune response against viral infections. It is a type III interferon, which means it is produced by cells in response to viral infection and regulates the expression of genes involved in the antiviral response.\n\nIn the context of Systemic Lupus Erythematosus (SLE), there is some evidence to suggest that IFIT1 may play a role in the pathogenesis of the disease. SLE is an autoimmune disorder in which the immune system attacks the body's own tissues, leading to inflammation and damage to various organs and systems.\n\nOne study published in the journal Arthritis & Rheumatology in 2018 found that individuals with SLE had lower levels of IFIT1 expression in their peripheral blood mononuclear cells (PBMCs) compared to healthy controls. This suggests that IFIT1 may be involved in the regulation of the immune response in SLE and may play a role in the development of the disease.\n\nAnother study published in the journal PLoS One in 2019 found that IFIT1 was downregulated in SLE patients with active disease compared to those with inactive disease. This suggests that IFIT1 may be a potential biomarker for disease activity in SLE.\n\nOverall, while more research is needed to fully understand the role of IFIT1 in SLE, there is some evidence to suggest that it may play a role in the regulation of the immune response and may be involved in the pathogenesis of the disease.",
    "llama-7b_fact_raw": "1. The IFIT1 gene, also known as Interferon, alpha-inducible protein 18, is involved in the immune response to viral infections.\n2. IFIT1 is a type III interferon that is produced in response to viral infections and regulates the expression of genes involved in the antiviral response.\n3. Systemic Lupus Erythematosus (SLE) is an autoimmune disorder where the immune system attacks the body's own tissues.\n4. A study published in Arthritis & Rheumatology in 2018 indicated that individuals with SLE had lower levels of IFIT1 expression in their PBMCs compared to healthy controls.\n5. Research published in PLoS One in 2019 found that IFIT1 was downregulated in SLE patients with active disease versus those with inactive disease, suggesting its potential as a biomarker for disease activity.",
    "llama-7b_fact": [
      "The IFIT1 gene, also known as Interferon, alpha-inducible protein 18, is involved in the immune response to viral infections.",
      "IFIT1 is a type III interferon that is produced in response to viral infections and regulates the expression of genes involved in the antiviral response.",
      "Systemic Lupus Erythematosus (SLE) is an autoimmune disorder where the immune system attacks the body's own tissues.",
      "A study published in Arthritis & Rheumatology in 2018 indicated that individuals with SLE had lower levels of IFIT1 expression in their PBMCs compared to healthy controls.",
      "Research published in PLoS One in 2019 found that IFIT1 was downregulated in SLE patients with active disease versus those with inactive disease, suggesting its potential as a biomarker for disease activity."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: IFIT1 is not a type III interferon but is a gene that is induced by interferons, including type I, which are produced in response to viral infections and are involved in the antiviral response.\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3752,
    "user_query": "You MUST give a detailed answer to the following question: What is the use of the Liverpool Elbow Score?",
    "llama-7b_response": "The Liverpool Elbow Score (LES) is a clinical scoring system used to assess the severity of elbow osteoarthritis. It was developed by a team of researchers at the University of Liverpool in the United Kingdom and was first published in the Journal of the American Academy of Orthopaedic Surgeons in 2010.\n\nThe LES is based on a combination of patient-reported symptoms and physical examination findings, and it has been shown to be a reliable and valid tool for assessing the severity of elbow osteoarthritis. The score ranges from 0 to 100, with higher scores indicating more severe disease.\n\nThe LES can be used in a variety of clinical settings, including primary care, orthopedic clinics, and rheumatology clinics. It can be used to monitor the progression of elbow osteoarthritis over time, to assess the effectiveness of treatment, and to identify patients who may benefit from surgical intervention.\n\nIn addition to its use in clinical practice, the LES has also been used in research studies to evaluate the effectiveness of various treatments for elbow osteoarthritis, such as medications, injections, and surgical interventions.\n\nOverall, the Liverpool Elbow Score is a useful tool for clinicians to assess the severity of elbow osteoarthritis and to guide treatment decisions.",
    "llama-7b_fact_raw": "1. The Liverpool Elbow Score (LES) is used to assess the severity of elbow osteoarthritis.\n2. The LES was developed by researchers at the University of Liverpool in the United Kingdom.\n3. The tool was first published in the Journal of the American Academy of Orthopaedic Surgeons in 2010.\n4. The score ranges from 0 to 100, with higher scores indicating more severe disease.\n5. The LES is useful for monitoring progression, assessing treatment effectiveness, and making surgical intervention decisions.",
    "llama-7b_fact": [
      "The Liverpool Elbow Score (LES) is used to assess the severity of elbow osteoarthritis.",
      "The LES was developed by researchers at the University of Liverpool in the United Kingdom.",
      "The tool was first published in the Journal of the American Academy of Orthopaedic Surgeons in 2010.",
      "The score ranges from 0 to 100, with higher scores indicating more severe disease.",
      "The LES is useful for monitoring progression, assessing treatment effectiveness, and making surgical intervention decisions."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Liverpool Elbow Score (LES) is used to assess the outcome after elbow surgery, not specifically the severity of elbow osteoarthritis.\n2. TRUE\n3. UNKNOWN: Without access to the specific publication history of the LES, the journal and year of its first publication can't be confirmed.\n4. UNKNOWN: The precise scale and interpretation of the LES are not given in the statement, and need to be verified with the actual scoring system.\n5. TRUE: The LES, like many clinical assessment tools, is generally used for monitoring progression, assessing treatment effectiveness, and informing decisions regarding surgical interventions, although the specific uses can vary depending on the score or index.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3763,
    "user_query": "You MUST give a detailed answer to the following question: Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-7b_response": "The 100,000 Genomes Project is a UK-based initiative that aims to sequence 100,000 whole genomes from patients with a range of diseases, including cancer. As part of this project, efforts have been made to sequence genomes of patients with sarcoma, a type of cancer that affects the soft tissues and bones.\n\nSarcomas are rare cancers, and the 100,000 Genomes Project has sequenced the genomes of over 100 patients with sarcoma. The sequencing data has been used to identify genetic mutations that are specific to sarcoma, and to develop new diagnostic tools and treatments for the disease.\n\nOne of the key findings from the 100,000 Genomes Project's efforts on sarcoma is the identification of specific genetic mutations that are common in different subtypes of sarcoma. For example, the project has identified mutations in the PIK3CA gene as being common in gastrointestinal stromal tumors (GISTs), a type of sarcoma that affects the digestive system. This information has helped clinicians to develop more targeted treatments for GISTs, and has also helped to improve the accuracy of diagnostic tests for the disease.\n\nIn addition to identifying genetic mutations, the 100,000 Genomes Project has also helped to improve our understanding of the biology of sarcoma. By sequencing the genomes of patients with sarcoma, researchers have been able to identify patterns of gene expression that are specific to different subtypes of the disease. This information has helped to develop new diagnostic tools and treatments for sarcoma, and has also helped to improve our understanding of how the disease develops and progresses.\n\nOverall, the 100,000 Genomes Project's efforts on sarcoma have made a significant contribution to our understanding of this rare and complex disease. By sequencing the genomes of patients with sarcoma, the project has identified specific genetic mutations that are common in different subtypes of the disease, and has helped to develop new diagnostic tools and treatments for sarcoma. These efforts have also helped to improve our understanding of the biology",
    "llama-7b_fact_raw": "1. The 100,000 Genomes Project is a UK-based initiative aimed at sequencing 100,000 whole genomes from patients with various diseases including cancer.\n2. The project has sequenced genomes of over 100 patients with sarcoma.\n3. Genetic mutations specific to sarcoma, such as mutations in the PIK3CA gene, have been identified through the project's sequencing efforts, particularly in gastrointestinal stromal tumors (GISTs).\n4. The 100,000 Genomes Project has contributed to the development of more targeted treatments for subtypes of sarcoma like GISTs.\n5. Research from the project has led to improved diagnostic tools and a better understanding of the biology and progression of sarcoma.",
    "llama-7b_fact": [
      "The 100,000 Genomes Project is a UK-based initiative aimed at sequencing 100,000 whole genomes from patients with various diseases including cancer.",
      "The project has sequenced genomes of over 100 patients with sarcoma.",
      "Genetic mutations specific to sarcoma, such as mutations in the PIK3CA gene, have been identified through the project's sequencing efforts, particularly in gastrointestinal stromal tumors (GISTs).",
      "The 100,000 Genomes Project has contributed to the development of more targeted treatments for subtypes of sarcoma like GISTs.",
      "Research from the project has led to improved diagnostic tools and a better understanding of the biology and progression of sarcoma."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE (PIK3CA mutations are found in a variety of tumor types, including GISTs, and it's reasonable to assume that such common mutations would be identified in a large-scale project like the 100,000 Genomes Project.)\n4. TRUE (Large genomic projects often contribute to targeted treatment development by providing insights into molecular subtypes of diseases.)\n5. TRUE (Research from large-scale genomic projects like the 100,000 Genomes Project generally leads to improvements in diagnostics and understanding of disease biology and progression.)",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3777,
    "user_query": "You MUST give a detailed answer to the following question: Does protein ALEX1 contain armadillo repeats?",
    "llama-7b_response": "Yes, protein ALEX1 contains armadillo repeats.",
    "llama-7b_fact_raw": "1. Protein ALEX1 contains armadillo repeats.",
    "llama-7b_fact": [
      "Protein ALEX1 contains armadillo repeats."
    ],
    "llama-7b_judge_raw": "UNKNOWN",
    "llama-7b_judge": [
      "unknown"
    ]
  },
  {
    "id": 3789,
    "user_query": "You MUST give a detailed answer to the following question: List enzymes that removes histone modifications.",
    "llama-7b_response": "There are several enzymes that remove histone modifications, including:\n\n1. Histone deacetylases (HDACs): HDACs remove acetyl groups from histone tails, leading to a more compact chromatin structure and the repression of gene expression.\n2. Histone lysine methyltransferases (KMTs): KMTs add methyl groups to histone lysine residues, leading to the repression of gene expression.\n3. Histone lysine demethylases (KDMs): KDMs remove methyl groups from histone lysine residues, leading to the activation of gene expression.\n4. Histone lysine acetyltransferases (KATs): KATs add acetyl groups to histone tails, leading to the activation of gene expression.\n5. Histone lysine methyltransferases (KMTs): KMTs add methyl groups to histone lysine residues, leading to the repression of gene expression.\n6. Histone lysine demethylases (KDMs): KDMs remove methyl groups from histone lysine residues, leading to the activation of gene expression.\n7. Histone lysine acetyltransferases (KATs): KATs add acetyl groups to histone tails, leading to the activation of gene expression.\n8. Histone lysine methyltransferases (KMTs): KMTs add methyl groups to histone lysine residues, leading to the repression of gene expression.\n9. Histone lysine demethylases (KDMs): KDMs remove methyl groups from histone lysine residues, leading to the activation of gene expression.\n10. Histone lysine acetyltransferases (KATs): KATs add acetyl groups to histone tails, leading to the activation of gene expression.\n11. Histone lysine methyltransferases (KMTs): KMTs add methyl groups to histone lysine residues, leading to the repression of gene expression.\n12. Histone lysine demethylases (KDMs): KDM",
    "llama-7b_fact_raw": "1. Histone deacetylases (HDACs) are enzymes that remove acetyl groups from histone tails.\n2. Histone lysine demethylases (KDMs) are enzymes that remove methyl groups from histone lysine residues.\n   \nThe answer contains repetitive information, so there are only two distinct and verifiable factual statements provided.",
    "llama-7b_fact": [
      "Histone deacetylases (HDACs) are enzymes that remove acetyl groups from histone tails.",
      "Histone lysine demethylases (KDMs) are enzymes that remove methyl groups from histone lysine residues.",
      "e answer contains repetitive information, so there are only two distinct and verifiable factual statements provided."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3806,
    "user_query": "You MUST give a detailed answer to the following question: Does head ct increase brain tumor risk?",
    "llama-7b_response": "The relationship between head CT scans and brain tumor risk is complex and has been the subject of much research and debate.\n\nOn one hand, head CT scans are an important tool for diagnosing and monitoring brain tumors. They can help identify tumors at an early stage, when they are more likely to be treatable, and can also be used to monitor the effectiveness of treatment.\n\nOn the other hand, there is some evidence to suggest that repeated exposure to radiation from CT scans may increase the risk of developing a brain tumor. This is particularly true for children and young adults, whose brains are still growing and may be more sensitive to the effects of radiation.\n\nStudies have found that the risk of developing a brain tumor increases with the number of CT scans a person has undergone. However, it is worth noting that the risk is still relatively low, and most people who undergo CT scans do not go on to develop a brain tumor.\n\nIn summary, while head CT scans are an important tool for diagnosing and monitoring brain tumors, there is some evidence to suggest that repeated exposure to radiation from CT scans may increase the risk of developing a brain tumor. However, the risk is still relatively low, and most people who undergo CT scans do not go on to develop a brain tumor.",
    "llama-7b_fact_raw": "1. Head CT scans are used for diagnosing and monitoring brain tumors.\n2. There is evidence suggesting that repeated exposure to radiation from CT scans could increase the risk of developing a brain tumor.\n3. Children and young adults may have a higher risk of developing brain tumors from CT scans due to their still-developing brains.\n4. The risk of developing a brain tumor rises with the number of CT scans a person has.\n5. Despite the risk increase, the probability remains relatively low that a person will develop a brain tumor after undergoing CT scans.",
    "llama-7b_fact": [
      "Head CT scans are used for diagnosing and monitoring brain tumors.",
      "There is evidence suggesting that repeated exposure to radiation from CT scans could increase the risk of developing a brain tumor.",
      "Children and young adults may have a higher risk of developing brain tumors from CT scans due to their still-developing brains.",
      "The risk of developing a brain tumor rises with the number of CT scans a person has.",
      "Despite the risk increase, the probability remains relatively low that a person will develop a brain tumor after undergoing CT scans."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "You MUST give a detailed answer to the following question: Which type of pluripotency is Otx2 associated with?",
    "llama-7b_response": "Otx2 is associated with transcriptional pluripotency.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3815,
    "user_query": "You MUST give a detailed answer to the following question: How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-7b_response": "The number of DNaseI hypersensitive sites (DHS) that mark the murine beta globin locus region is not a fixed or easily quantifiable number, as the number of DHS can vary depending on the experimental conditions and the method used to identify them.\n\nDNaseI hypersensitive sites are regions of the genome that are more susceptible to DNA cleavage by the enzyme DNaseI, indicating that these regions are more accessible to the enzyme and are therefore likely to be in closer proximity to the surface of the nucleus or the nuclear membrane.\n\nThe beta globin locus region is a region of the genome that contains genes involved in the production of beta globin proteins, which are a type of hemoglobin. The beta globin locus region is located on chromosome 16 in mammals, and it contains several genes that are involved in the production of different types of beta globin proteins.\n\nThe number of DHS that mark the beta globin locus region can vary depending on the experimental conditions and the method used to identify them. For example, some studies have used DNaseI hypersensitive site mapping to identify DHS in the beta globin locus region, while other studies have used other methods, such as chromatin immunoprecipitation followed by sequencing (ChIP-seq), to identify DHS in this region.\n\nIn general, the beta globin locus region is known to contain several DHS, which are thought to play a role in the regulation of gene expression in this region. However, the exact number of DHS that mark the beta globin locus region is not a fixed or easily quantifiable number, and can vary depending on the experimental conditions and the method used to identify them.",
    "llama-7b_fact_raw": "1. The number of DNaseI hypersensitive sites (DHS) marking the murine beta globin locus region varies and is not a fixed quantity.\n2. DNaseI hypersensitive sites are regions more susceptible to cleavage by the enzyme DNaseI, indicating higher accessibility.\n3. The beta globin locus region contains genes involved in the production of beta globin proteins which are part of hemoglobin.\n4. The beta globin locus is located on chromosome 16 in mammals.\n5. Methods used to identify DHS in the beta globin locus region include DNaseI hypersensitive site mapping and chromatin immunoprecipitation followed by sequencing (ChIP-seq).",
    "llama-7b_fact": [
      "The number of DNaseI hypersensitive sites (DHS) marking the murine beta globin locus region varies and is not a fixed quantity.",
      "DNaseI hypersensitive sites are regions more susceptible to cleavage by the enzyme DNaseI, indicating higher accessibility.",
      "The beta globin locus region contains genes involved in the production of beta globin proteins which are part of hemoglobin.",
      "The beta globin locus is located on chromosome 16 in mammals.",
      "Methods used to identify DHS in the beta globin locus region include DNaseI hypersensitive site mapping and chromatin immunoprecipitation followed by sequencing (ChIP-seq)."
    ],
    "llama-7b_judge_raw": "1. TRUE: The number of DNaseI hypersensitive sites (DHS) marking a region such as the murine beta globin locus can indeed vary due to factors such as cell type and developmental stage, making it not a fixed quantity.\n\n2. TRUE: DNaseI hypersensitive sites are indeed regions that are more susceptible to cleavage by the enzyme DNaseI, which is commonly associated with higher accessibility of the chromatin, reflective of active regulatory regions.\n\n3. TRUE: The beta globin locus contains genes involved in the production of beta globin chains which are indeed a part of hemoglobin, important for oxygen transport in the blood.\n\n4. FALSE [correction]: The beta globin locus is actually located on chromosome 11 in humans and on chromosome 7 in mice. The locus varies depending on the species; chromosome 16 is incorrect for both humans and mice in the context of beta globin genes.\n\n5. TRUE: Techniques such as DNaseI hypersensitive site mapping and chromatin immunoprecipitation followed by sequencing (ChIP-seq) are commonly used to identify regions of open chromatin, including DNaseI hypersensitive sites, which can provide insight into gene regulation, including at the beta globin locus.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3822,
    "user_query": "You MUST give a detailed answer to the following question: List as many European influenza vaccines as possible.",
    "llama-7b_response": "There are several European influenza vaccines available, including:\n\n1. Fluarix: This is an inactivated influenza vaccine that is manufactured by GlaxoSmithKline (GSK). It is approved for use in adults and children aged 3 years and older.\n2. FluLaval: This is an inactivated influenza vaccine that is manufactured by Sanofi Pasteur. It is approved for use in adults and children aged 6 months and older.\n3. Fluarix Quadrivalent: This is an inactivated influenza vaccine that is manufactured by GSK. It is approved for use in adults and children aged 3 years and older.\n4. Fluarix Tetravalent: This is an inactivated influenza vaccine that is manufactured by GSK. It is approved for use in adults and children aged 3 years and older.\n5. Fluzone: This is an inactivated influenza vaccine that is manufactured by Sanofi Pasteur. It is approved for use in adults and children aged 6 months and older.\n6. Fluzone High-Dose: This is an inactivated influenza vaccine that is manufactured by Sanofi Pasteur. It is approved for use in adults aged 65 years and older.\n7. Fluad: This is an inactivated influenza vaccine that is manufactured by Novartis. It is approved for use in adults aged 65 years and older.\n8. FluMist: This is a live attenuated influenza vaccine (LAIV) that is manufactured by MedImmune. It is approved for use in healthy children and adults aged 2-49 years old who are not pregnant.\n9. Afluria: This is an inactivated influenza vaccine that is manufactured by Seqirus. It is approved for use in adults and children aged 18 years and older.\n10. Afluria Quadrivalent: This is an inactivated influenza vaccine that is manufactured by Seqirus. It is approved for use in adults and children aged 18 years and older.",
    "llama-7b_fact_raw": "1. Fluarix is an inactivated influenza vaccine manufactured by GlaxoSmithKline approved for use in individuals aged 3 years and older.\n2. FluLaval is an inactivated influenza vaccine manufactured by Sanofi Pasteur approved for use in individuals aged 6 months and older.\n3. Fluzone is an inactivated influenza vaccine produced by Sanofi Pasteur approved for use in individuals aged 6 months and older.\n4. Fluzone High-Dose is an inactivated influenza vaccine designed for use in adults aged 65 years and over, and is manufactured by Sanofi Pasteur.\n5. FluMist is a live attenuated influenza vaccine intended for healthy individuals aged 2-49 years who are not pregnant and is manufactured by MedImmune.",
    "llama-7b_fact": [
      "Fluarix is an inactivated influenza vaccine manufactured by GlaxoSmithKline approved for use in individuals aged 3 years and older.",
      "FluLaval is an inactivated influenza vaccine manufactured by Sanofi Pasteur approved for use in individuals aged 6 months and older.",
      "Fluzone is an inactivated influenza vaccine produced by Sanofi Pasteur approved for use in individuals aged 6 months and older.",
      "Fluzone High-Dose is an inactivated influenza vaccine designed for use in adults aged 65 years and over, and is manufactured by Sanofi Pasteur.",
      "FluMist is a live attenuated influenza vaccine intended for healthy individuals aged 2-49 years who are not pregnant and is manufactured by MedImmune."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: FluLaval is an inactivated influenza vaccine manufactured by GlaxoSmithKline approved for use in individuals aged 6 months and older.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3832,
    "user_query": "You MUST give a detailed answer to the following question: Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-7b_response": "The Paramyxovirus geneome is segmented, negative-sense RNA.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3869,
    "user_query": "You MUST give a detailed answer to the following question: Roflumilast Cream is effective for which disease?",
    "llama-7b_response": "Roflumilast cream is a medication that is used to treat a specific type of lung disease called chronic obstructive pulmonary disease (COPD). COPD is a group of lung diseases that include chronic bronchitis and emphysema. Roflumilast cream works by reducing inflammation in the lungs and improving lung function in people with COPD. It is not effective for treating any other diseases.",
    "llama-7b_fact_raw": "1. Roflumilast cream is used to treat chronic obstructive pulmonary disease (COPD).\n2. COPD is a group of lung diseases that includes chronic bronchitis and emphysema.\n3. Roflumilast cream works by reducing inflammation in the lungs.\n4. Roflumilast cream helps to improve lung function in people with COPD.\n5. Roflumilast cream is not effective for treating diseases other than COPD.",
    "llama-7b_fact": [
      "Roflumilast cream is used to treat chronic obstructive pulmonary disease (COPD).",
      "COPD is a group of lung diseases that includes chronic bronchitis and emphysema.",
      "Roflumilast cream works by reducing inflammation in the lungs.",
      "Roflumilast cream helps to improve lung function in people with COPD.",
      "Roflumilast cream is not effective for treating diseases other than COPD."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Roflumilast is available in tablet form and used orally to treat chronic obstructive pulmonary disease (COPD); however, it is not formulated as a cream for this purpose.\n2. TRUE\n3. FALSE [correction]: Roflumilast works by reducing inflammation in the lungs when taken orally as a tablet. If there is a cream form, it would not be typical for treating COPD, as the condition requires systemic treatment rather than topical.\n4. TRUE (provided the statement is referring to the oral tablet form of roflumilast as the cream form would be incorrect)\n5. FALSE [correction]: Although roflumilast is primarily used for COPD, it is being studied for potential effectiveness in treating other diseases, such as psoriasis, and it is not accurate to claim categorically that it is not effective for any other diseases. Additionally, categorically stating it is not effective for treating any diseases other than COPD would require comprehensive knowledge of all possible diseases and the efficacy of roflumilast for those conditions, which is beyond current scientific conclusions.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3885,
    "user_query": "You MUST give a detailed answer to the following question: Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-7b_response": "There are several tools that have been developed for identifying and visualizing ncRNA promoters. Here are some of the most commonly used ones:\n\n1. RNAhybrid: RNAhybrid is a web-based tool that uses a hybridization-based approach to identify promoter regions in ncRNAs. It can be used to identify promoters in both known and novel ncRNAs.\n2. MatInspector: MatInspector is a web-based tool that uses a machine learning approach to identify promoter regions in ncRNAs. It can be used to identify promoters in both known and novel ncRNAs.\n3. RNAprom: RNAprom is a web-based tool that uses a hybridization-based approach to identify promoter regions in ncRNAs. It can be used to identify promoters in both known and novel ncRNAs.\n4. PromoterFinder: PromoterFinder is a web-based tool that uses a hybridization-based approach to identify promoter regions in ncRNAs. It can be used to identify promoters in both known and novel ncRNAs.\n5. PROMO: PROMO is a web-based tool that uses a machine learning approach to identify promoter regions in ncRNAs. It can be used to identify promoters in both known and novel ncRNAs.\n\nThese tools can be useful for identifying and visualizing ncRNA promoters, but the specific tool used will depend on the research question and the type of ncRNA being studied.",
    "llama-7b_fact_raw": "1. RNAhybrid is a tool designed to identify promoter regions in ncRNAs using a hybridization-based approach.\n2. MatInspector utilizes a machine learning approach to identify promoter regions within ncRNAs.\n3. RNAprom is a web-based tool that identifies ncRNA promoter regions through a hybridization-based approach.\n4. PromoterFinder also identifies ncRNA promoter regions using a hybridization-based methodology.\n5. PROMO employs a machine learning strategy to identify promoter regions in ncRNAs.",
    "llama-7b_fact": [
      "RNAhybrid is a tool designed to identify promoter regions in ncRNAs using a hybridization-based approach.",
      "MatInspector utilizes a machine learning approach to identify promoter regions within ncRNAs.",
      "RNAprom is a web-based tool that identifies ncRNA promoter regions through a hybridization-based approach.",
      "PromoterFinder also identifies ncRNA promoter regions using a hybridization-based methodology.",
      "PROMO employs a machine learning strategy to identify promoter regions in ncRNAs."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: RNAhybrid is designed to find the minimum free energy hybridization of a long and a short RNA, not specifically to identify promoter regions in ncRNAs.\n2. FALSE [correction]: MatInspector is a software tool that identifies transcription factor binding sites using a library of position weight matrices, not specifically for finding promoter regions within ncRNAs using machine learning.\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: PROMO is a tool that predicts transcription factor binding sites in DNA sequences, not specifically employing a machine learning strategy to identify promoter regions in ncRNAs.",
    "llama-7b_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3918,
    "user_query": "You MUST give a detailed answer to the following question: List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-7b_response": "The SWIM tool is a web-based tool that uses machine learning algorithms to analyze gene expression data and identify genes that are differentially expressed in different types of cancer, including glioblastoma. The tool has identified a number of genes that are down-regulated in glioblastoma, including:\n\n1. PTEN: PTEN is a tumor suppressor gene that plays a role in regulating cell growth and division. It has been found to be down-regulated in a number of cancers, including glioblastoma.\n2. CDKN2A: CDKN2A is a tumor suppressor gene that encodes a protein that regulates cell cycle progression. It has been found to be down-regulated in a number of cancers, including glioblastoma.\n3. TP53: TP53 is a tumor suppressor gene that encodes a protein that plays a role in regulating cell growth and division. It has been found to be down-regulated in a number of cancers, including glioblastoma.\n4. CDKN1A: CDKN1A is a tumor suppressor gene that encodes a protein that regulates cell cycle progression. It has been found to be down-regulated in a number of cancers, including glioblastoma.\n5. RB1: RB1 is a tumor suppressor gene that encodes a protein that plays a role in regulating cell growth and division. It has been found to be down-regulated in a number of cancers, including glioblastoma.\n\nThese are just a few examples of the genes that SWIM tool has identified as being down-regulated in glioblastoma. The tool can also identify other genes that are differentially expressed in glioblastoma and other types of cancer.",
    "llama-7b_fact_raw": "1. The SWIM tool has identified the PTEN gene as down-regulated in glioblastoma.\n2. The SWIM tool has identified the CDKN2A gene as down-regulated in glioblastoma.\n3. The SWIM tool has identified the TP53 gene as down-regulated in glioblastoma.\n4. The SWIM tool has identified the CDKN1A gene as down-regulated in glioblastoma.\n5. The SWIM tool has identified the RB1 gene as down-regulated in glioblastoma.",
    "llama-7b_fact": [
      "The SWIM tool has identified the PTEN gene as down-regulated in glioblastoma.",
      "The SWIM tool has identified the CDKN2A gene as down-regulated in glioblastoma.",
      "The SWIM tool has identified the TP53 gene as down-regulated in glioblastoma.",
      "The SWIM tool has identified the CDKN1A gene as down-regulated in glioblastoma.",
      "The SWIM tool has identified the RB1 gene as down-regulated in glioblastoma."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nExplanation: Without specific information or data results from the SWIM (Subnetworks Weighted Integrative Method) tool regarding the regulation of the PTEN, CDKN2A, TP53, CDKN1A, and RB1 genes in glioblastoma, it is impossible to determine the veracity of these statements. The SWIM tool is a bioinformatics method utilized for identifying cancer-related genes and pathways, but without the actual output or a citation from a study using the SWIM tool, the regulation status of these genes in glioblastoma remains unknown based on the provided statements.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "You MUST give a detailed answer to the following question: Which R packages have been developed for studying TADs?",
    "llama-7b_response": "There are several R packages that have been developed for studying TADs (Topologically Associating Domains). Here are some of the most popular ones:\n\n1. TADMatrix: This is a package for visualizing and analyzing TADs in single-cell RNA sequencing (scRNA-seq) data. It allows users to visualize and compare TADs between different cell types, and to identify TADs that are enriched for specific genes or functional annotations.\n2. TADProfiler: This is a package for analyzing TADs in bulk RNA sequencing (RNA-seq) data. It allows users to identify TADs based on gene expression data, and to compare TADs between different samples or conditions.\n3. TADTree: This is a package for visualizing and analyzing TADs in scRNA-seq data. It allows users to visualize TADs as a tree structure, and to identify TADs that are enriched for specific genes or functional annotations.\n4. TADView: This is a package for visualizing and analyzing TADs in bulk RNA sequencing (RNA-seq) data. It allows users to visualize TADs as a heatmap, and to identify TADs that are enriched for specific genes or functional annotations.\n5. TADAnalyzer: This is a package for analyzing TADs in bulk RNA sequencing (RNA-seq) data. It allows users to identify TADs based on gene expression data, and to compare TADs between different samples or conditions.\n\nThese packages provide a range of tools for studying TADs, including visualization, analysis, and comparison of TADs between different samples or conditions. They can be used to identify TADs that are enriched for specific genes or functional annotations, and to gain insights into the organization of the genome in different cell types or tissues.",
    "llama-7b_fact_raw": "1. TADMatrix is an R package developed to visualize and analyze Topologically Associating Domains (TADs) in single-cell RNA sequencing data.\n2. TADProfiler is an R package designed to analyze TADs in bulk RNA sequencing data.\n3. TADTree is an R package that visualizes TADs as a tree structure in single-cell RNA sequencing data.\n4. TADView is an R package for visualizing TADs as a heatmap in bulk RNA sequencing data.\n5. TADAnalyzer is an R package for analyzing TADs in bulk RNA sequencing data, with capabilities to compare TADs between different samples or conditions.",
    "llama-7b_fact": [
      "TADMatrix is an R package developed to visualize and analyze Topologically Associating Domains (TADs) in single-cell RNA sequencing data.",
      "TADProfiler is an R package designed to analyze TADs in bulk RNA sequencing data.",
      "TADTree is an R package that visualizes TADs as a tree structure in single-cell RNA sequencing data.",
      "TADView is an R package for visualizing TADs as a heatmap in bulk RNA sequencing data.",
      "TADAnalyzer is an R package for analyzing TADs in bulk RNA sequencing data, with capabilities to compare TADs between different samples or conditions."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: TADMatrix is an R package developed to visualize and analyze Topologically Associating Domains (TADs) in Hi-C data, not single-cell RNA sequencing data.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe accuracy of some statements regarding specialized R packages such as TADProfiler, TADTree, TADView, and TADAnalyzer cannot be verified without specific knowledge about these packages or access to current information on them. My training data includes information up until early 2023, and these packages may have been developed or defined after that. It is also possible that these packages might not exist, or their functionalities are different than described. Therefore, the truth value of statements 2, 3, 4, and 5 is unknown without further research into these specific R packages.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3927,
    "user_query": "You MUST give a detailed answer to the following question: Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-7b_response": "The bioconductor tool that has been developed for accessing bacterial regulatory networks is called \"BioNetGen\".\n\nBioNetGen is a bioconductor package that allows users to model, analyze, and simulate regulatory networks in a variety of organisms, including bacteria. It provides a range of tools for building and analyzing regulatory networks, including tools for importing and exporting data in a variety of formats, as well as tools for visualizing and analyzing the networks.\n\nOne of the key features of BioNetGen is its ability to handle large and complex regulatory networks. It can handle networks with thousands of genes and interactions, and it can also handle networks with multiple types of interactions, such as positive and negative regulation.\n\nBioNetGen is widely used in the field of systems biology and bioinformatics, and it has been applied to a variety of organisms, including bacteria. It has been used to study the regulation of gene expression in a variety of bacterial species, including Escherichia coli and Bacillus subtilis.\n\nOverall, BioNetGen is a powerful tool for accessing and analyzing bacterial regulatory networks, and it is an important resource for researchers in the field of systems biology and bioinformatics.",
    "llama-7b_fact_raw": "1. BioNetGen is a bioconductor tool developed for accessing bacterial regulatory networks.\n2. BioNetGen includes tools for building and analyzing regulatory networks.\n3. The package allows for the import and export of data in various formats.\n4. BioNetGen can model networks with thousands of genes and interactions, including both positive and negative regulation.\n5. BioNetGen has been used in studies involving Escherichia coli and Bacillus subtilis regulatory networks.",
    "llama-7b_fact": [
      "BioNetGen is a bioconductor tool developed for accessing bacterial regulatory networks.",
      "BioNetGen includes tools for building and analyzing regulatory networks.",
      "The package allows for the import and export of data in various formats.",
      "BioNetGen can model networks with thousands of genes and interactions, including both positive and negative regulation.",
      "BioNetGen has been used in studies involving Escherichia coli and Bacillus subtilis regulatory networks."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: BioNetGen is not a bioconductor tool, it is a software for rule-based modeling of biochemical systems, not specifically for accessing bacterial regulatory networks.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3933,
    "user_query": "You MUST give a detailed answer to the following question: What are the end products of the shikimate pathway?",
    "llama-7b_response": "",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3936,
    "user_query": "You MUST give a detailed answer to the following question: Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-7b_response": "Yes, cabergoline is used for the treatment of Nelson's syndrome.\n\nNelson's syndrome is a rare condition that occurs in patients with a history of prolactinoma, a benign tumor of the pituitary gland that secretes high levels of the hormone prolactin. Nelson's syndrome is characterized by the development of macroprolactinoma, a type of prolactinoma that secretes large amounts of prolactin, leading to symptoms such as galactorrhea (milk production), amenorrhea (absence of menstrual periods), and erectile dysfunction.\n\nCabergoline is a dopamine agonist that is used to treat prolactinoma by lowering the levels of prolactin in the blood. It is also effective in treating Nelson's syndrome by reducing the size of the macroprolactinoma and improving symptoms such as galactorrhea, amenorrhea, and erectile dysfunction.\n\nIn addition to its use in treating Nelson's syndrome, cabergoline is also used to treat other conditions such as Parkinson's disease and hyperprolactinemia (high levels of prolactin in the blood).",
    "llama-7b_fact_raw": "1. Cabergoline is used for the treatment of Nelson's syndrome.\n2. Nelson's syndrome is characterized by the development of macroprolactinoma.\n3. Symptoms of Nelson's syndrome may include galactorrhea, amenorrhea, and erectile dysfunction.\n4. Cabergoline functions as a dopamine agonist.\n5. Cabergoline is also used to treat Parkinson's disease and hyperprolactinemia.",
    "llama-7b_fact": [
      "Cabergoline is used for the treatment of Nelson's syndrome.",
      "Nelson's syndrome is characterized by the development of macroprolactinoma.",
      "Symptoms of Nelson's syndrome may include galactorrhea, amenorrhea, and erectile dysfunction.",
      "Cabergoline functions as a dopamine agonist.",
      "Cabergoline is also used to treat Parkinson's disease and hyperprolactinemia."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Cabergoline is not used for the treatment of Nelson's syndrome. It is used for the treatment of hyperprolactinemia and Parkinson's disease. Nelson's syndrome involves the growth of a pituitary adenoma post-adrenalectomy for Cushing's disease and is not treated with cabergoline.\n2. FALSE [correction]: Nelson's syndrome is characterized by the development of an ACTH-secreting pituitary adenoma after bilateral adrenalectomy for Cushing's disease, not a macroprolactinoma.\n3. FALSE [correction]: Symptoms of Nelson's syndrome typically include skin hyperpigmentation, headaches, and visual disturbances due to enlarging pituitary tumor mass. Galactorrhea, amenorrhea, and erectile dysfunction are symptoms associated with hyperprolactinemia, not Nelson's syndrome.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3939,
    "user_query": "You MUST give a detailed answer to the following question: What is the main manifestation of Liebenberg syndrome?",
    "llama-7b_response": "Liebenberg syndrome is a rare genetic disorder caused by mutations in the PIK3CD gene, which encodes for a subunit of the phosphatidylinositol 3-kinase (PI3K) enzyme. The PI3K enzyme plays a crucial role in regulating various cellular processes, including cell growth, survival, and metabolism.\n\nThe main manifestation of Liebenberg syndrome is a combination of congenital abnormalities, including:\n\n1. Developmental delay: Children with Liebenberg syndrome may experience delays in physical and cognitive development.\n2. Microcephaly: Infants with Liebenberg syndrome may have abnormally small heads (microcephaly) due to abnormal brain development.\n3. Facial dysmorphism: Children with Liebenberg syndrome may have distinctive facial features, such as a broad forehead, widely spaced eyes, and a flattened nasal bridge.\n4. Skeletal abnormalities: Individuals with Liebenberg syndrome may have abnormalities in the development of bones and cartilage, leading to skeletal abnormalities such as short limbs, abnormal curvature of the spine (scoliosis), and joint contractures.\n5. Heart defects: Liebenberg syndrome is often associated with congenital heart defects, such as patent ductus arteriosus (PDA), atrial septal defect (ASD), and ventricular septal defect (VSD).\n6. Gastrointestinal abnormalities: Children with Liebenberg syndrome may have abnormalities in the development of the gastrointestinal tract, leading to feeding difficulties and gastrointestinal problems.\n7. Genitourinary abnormalities: Liebenberg syndrome is also associated with genitourinary abnormalities, such as hypospadias (a congenital abnormality of the urethra) and undescended testicles (cryptorchidism).\n\nOverall, Liebenberg syndrome is characterized by a combination of congenital abnormalities, including developmental delay, microcephaly, facial dysmorphism, skeletal abnormalities, heart defect",
    "llama-7b_fact_raw": "1. Liebenberg syndrome is caused by mutations in the PIK3CD gene.\n2. Liebenberg syndrome leads to developmental delays in children.\n3. Microcephaly is an abnormal condition associated with Liebenberg syndrome.\n4. Individuals with Liebenberg syndrome can have distinctive facial features such as a broad forehead, widely spaced eyes, and a flattened nasal bridge.\n5. Congenital heart defects, such as patent ductus arteriosus (PDA), atrial septal defect (ASD), and ventricular septal defect (VSD), are associated with Liebenberg syndrome.",
    "llama-7b_fact": [
      "Liebenberg syndrome is caused by mutations in the PIK3CD gene.",
      "Liebenberg syndrome leads to developmental delays in children.",
      "Microcephaly is an abnormal condition associated with Liebenberg syndrome.",
      "Individuals with Liebenberg syndrome can have distinctive facial features such as a broad forehead, widely spaced eyes, and a flattened nasal bridge.",
      "Congenital heart defects, such as patent ductus arteriosus (PDA), atrial septal defect (ASD), and ventricular septal defect (VSD), are associated with Liebenberg syndrome."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Liebenberg syndrome, also known as brachydactyly-elbow wrist dysplasia syndrome, is typically caused by mutations in the PITX1 gene, not the PIK3CD gene.\n2. UNKNOWN: There isn't enough specific information provided to determine whether Liebenberg syndrome leads to developmental delays in children. Generally speaking, Liebenberg syndrome primarily affects limb development.\n3. FALSE [correction]: Microcephaly, which is a condition where a baby's head is significantly smaller than expected, is not typically associated with Liebenberg syndrome. Liebenberg syndrome is more commonly associated with abnormalities in the development of the arms and hands.\n4. UNKNOWN: There is limited information available on the specifics of facial features associated with Liebenberg syndrome, so without additional context or reference to source material, it's difficult to verify the accuracy of this statement.\n5. FALSE [correction]: There is no established direct association between congenital heart defects and Liebenberg syndrome. Liebenberg syndrome primarily affects the skeletal development of the arms. Congenital heart defects like PDA, ASD, and VSD are typically associated with other genetic conditions.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3977,
    "user_query": "You MUST give a detailed answer to the following question: List orally bioavailable MPS1 kinase inhibitors",
    "llama-7b_response": "Sure, here are some orally bioavailable MPS1 kinase inhibitors:\n\n1. AT-1212 - This is a small molecule inhibitor of MPS1 that has shown efficacy in preclinical models of cancer. It has been tested in Phase I clinical trials for the treatment of solid tumors.\n2. PF-04217903 - This is another small molecule inhibitor of MPS1 that has shown efficacy in preclinical models of cancer. It has been tested in Phase I clinical trials for the treatment of solid tumors.\n3. GSK2879552 - This is a small molecule inhibitor of MPS1 that has shown efficacy in preclinical models of cancer. It has been tested in Phase I clinical trials for the treatment of solid tumors.\n4. TAK-901 - This is a small molecule inhibitor of MPS1 that has shown efficacy in preclinical models of cancer. It has been tested in Phase I clinical trials for the treatment of solid tumors.\n5. AT-9283 - This is a small molecule inhibitor of MPS1 that has shown efficacy in preclinical models of cancer. It has been tested in Phase I clinical trials for the treatment of solid tumors.\n\nThese are just a few examples of orally bioavailable MPS1 kinase inhibitors that have been studied in clinical trials. However, it's worth noting that the development of MPS1 inhibitors as cancer therapeutics is a relatively new and active area of research, so there may be additional compounds that have not yet been tested in clinical trials.",
    "llama-7b_fact_raw": "1. AT-1212 is an orally bioavailable MPS1 kinase inhibitor that has been tested in Phase I clinical trials for the treatment of solid tumors.\n2. PF-04217903 is an orally bioavailable MPS1 kinase inhibitor that has been tested in Phase I clinical trials for the treatment of solid tumors.\n3. GSK2879552 is an orally bioavailable MPS1 kinase inhibitor that has been tested in Phase I clinical trials for the treatment of solid tumors.\n4. TAK-901 is an orally bioavailable MPS1 kinase inhibitor that has been tested in Phase I clinical trials for the treatment of solid tumors.\n5. AT-9283 is an orally bioavailable MPS1 kinase inhibitor that has been tested in Phase I clinical trials for the treatment of solid tumors.",
    "llama-7b_fact": [
      "AT-1212 is an orally bioavailable MPS1 kinase inhibitor that has been tested in Phase I clinical trials for the treatment of solid tumors.",
      "PF-04217903 is an orally bioavailable MPS1 kinase inhibitor that has been tested in Phase I clinical trials for the treatment of solid tumors.",
      "GSK2879552 is an orally bioavailable MPS1 kinase inhibitor that has been tested in Phase I clinical trials for the treatment of solid tumors.",
      "TAK-901 is an orally bioavailable MPS1 kinase inhibitor that has been tested in Phase I clinical trials for the treatment of solid tumors.",
      "AT-9283 is an orally bioavailable MPS1 kinase inhibitor that has been tested in Phase I clinical trials for the treatment of solid tumors."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: GSK2879552 is not an MPS1 kinase inhibitor; it is a lysine-specific demethylase 1 (LSD1) inhibitor.\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific references to clinical trial databases or research publications, it is not possible to verify the statements related to AT-1212, PF-04217903, TAK-901, or AT-9283 regarding their properties or clinical trial phases. However, GSK2879552 is recognized as an LSD1 inhibitor, which suggests the statement about it being an MPS1 kinase inhibitor is inaccurate.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4031,
    "user_query": "You MUST give a detailed answer to the following question: Was golimumab tested for diabetes?",
    "llama-7b_response": "Golimumab, also known by the trade name Simponi, is a medication that is used to treat several autoimmune disorders, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It is a monoclonal antibody that works by blocking the activity of a protein called tumor necrosis factor-alpha (TNF-alpha), which is involved in the inflammatory response.\n\nAs of my knowledge cutoff date of September 2021, golimumab had not been specifically tested or approved for the treatment of diabetes. However, it is possible that there may be ongoing research or clinical trials investigating the use of golimumab for diabetes or related conditions. I would recommend consulting with a healthcare professional or conducting further research to obtain the most up-to-date information on the use of golimumab for diabetes.",
    "llama-7b_fact_raw": "1. Golimumab is used to treat autoimmune disorders, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.\n2. It functions as a monoclonal antibody that blocks the activity of tumor necrosis factor-alpha (TNF-alpha).\n3. As of September 2021, golimumab had not been tested or approved for the treatment of diabetes.",
    "llama-7b_fact": [
      "Golimumab is used to treat autoimmune disorders, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.",
      "It functions as a monoclonal antibody that blocks the activity of tumor necrosis factor-alpha (TNF-alpha).",
      "As of September 2021, golimumab had not been tested or approved for the treatment of diabetes."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4055,
    "user_query": "You MUST give a detailed answer to the following question: Is progeria caused by an autosomal recessive gene?",
    "llama-7b_response": "Yes, progeria is caused by an autosomal recessive gene.\n\nProgeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is a rare genetic disorder that causes premature aging in children. It is caused by a mutation in the LMNA gene, which is located on chromosome 1q21. The LMNA gene provides instructions for making a protein called lamin A, which is a key component of the nuclear lamina, a structural framework that helps to maintain the shape of the nucleus in cells.\n\nIn progeria, the mutation in the LMNA gene leads to the production of a defective form of lamin A, which accumulates in the cells and causes them to age prematurely. This accumulation of defective lamin A protein is what leads to the characteristic features of progeria, such as hair loss, aged-looking skin, stiff joints, and an increased risk of heart disease and other age-related conditions.\n\nThe LMNA gene is inherited in an autosomal recessive manner, which means that a child must inherit two copies of the mutated gene (one from each parent) in order to develop progeria. If a child only inherits one copy of the mutated gene, they will be a carrier of the condition but will not show any symptoms themselves. However, if the child inherits two copies of the mutated gene, they will develop progeria.\n\nIn summary, progeria is caused by an autosomal recessive gene mutation in the LMNA gene, which leads to the production of a defective form of lamin A protein that causes premature aging in children.",
    "llama-7b_fact_raw": "1. Progeria is also known as Hutchinson-Gilford progeria syndrome (HGPS).\n2. The genetic disorder progeria is caused by a mutation in the LMNA gene located on chromosome 1q21.\n3. The LMNA gene is responsible for making lamin A, a structural protein for the nuclear lamina in cells.\n4. A defective form of lamin A protein accumulates in cells in individuals with progeria, leading to premature aging.\n5. The LMNA gene is inherited in an autosomal recessive manner, meaning a child must inherit two copies of the mutated gene to develop progeria.",
    "llama-7b_fact": [
      "Progeria is also known as Hutchinson-Gilford progeria syndrome (HGPS).",
      "The genetic disorder progeria is caused by a mutation in the LMNA gene located on chromosome 1q21.",
      "The LMNA gene is responsible for making lamin A, a structural protein for the nuclear lamina in cells.",
      "A defective form of lamin A protein accumulates in cells in individuals with progeria, leading to premature aging.",
      "The LMNA gene is inherited in an autosomal recessive manner, meaning a child must inherit two copies of the mutated gene to develop progeria."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The LMNA gene mutation that causes progeria is typically not inherited, but a new (de novo) mutation that occurs during the early stages of development. Progeria follows an autosomal dominant pattern whereby a single copy of the mutated gene in each cell is sufficient to cause the disorder.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 4082,
    "user_query": "You MUST give a detailed answer to the following question: What are common variants at 12q14 and 12q24 associated with?",
    "llama-7b_response": "Common variants at 12q14 and 12q24 have been associated with various traits and diseases. Here are some examples:\n\n1. 12q14:\n\t* Variants at this locus have been associated with risk of type 2 diabetes, obesity, and cardiovascular disease.\n\t* One of the most well-known genes at this locus is TCF7L1, which encodes a transcription factor involved in Wnt signaling. Variants in TCF7L1 have been associated with increased risk of type 2 diabetes and obesity.\n2. 12q24:\n\t* Variants at this locus have been associated with risk of Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.\n\t* One of the most well-known genes at this locus is APOE, which encodes a protein involved in lipid metabolism and transport. Variants in APOE have been associated with increased risk of Alzheimer's disease and other neurodegenerative disorders.",
    "llama-7b_fact_raw": "1. Variants at locus 12q14 have been associated with an increased risk of type 2 diabetes, obesity, and cardiovascular disease.\n2. The gene TCF7L1, located at the 12q14 locus, encodes a transcription factor involved in Wnt signaling and has been associated with an increased risk of type 2 diabetes and obesity.\n3. Variants at locus 12q24 have been associated with an increased risk of Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.\n4. The gene APOE, located at the 12q24 locus, encodes a protein that plays a role in lipid metabolism and transport and has been associated with an increased risk of Alzheimer's disease and other neurodegenerative disorders.",
    "llama-7b_fact": [
      "Variants at locus 12q14 have been associated with an increased risk of type 2 diabetes, obesity, and cardiovascular disease.",
      "The gene TCF7L1, located at the 12q14 locus, encodes a transcription factor involved in Wnt signaling and has been associated with an increased risk of type 2 diabetes and obesity.",
      "Variants at locus 12q24 have been associated with an increased risk of Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.",
      "The gene APOE, located at the 12q24 locus, encodes a protein that plays a role in lipid metabolism and transport and has been associated with an increased risk of Alzheimer's disease and other neurodegenerative disorders."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The transcription factor encoded by TCF7L2, not TCF7L1, plays a role in Wnt signaling and has been associated with an increased risk of type 2 diabetes and obesity.\n3. TRUE\n4. FALSE [correction]: The APOE gene is located on chromosome 19, not at the 12q24 locus. It encodes a protein that plays a role in lipid metabolism and transport and has been associated with an increased risk of Alzheimer's disease and other neurodegenerative disorders.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 4096,
    "user_query": "You MUST give a detailed answer to the following question: Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-7b_response": "The Roundabout (Robo) receptors are G protein-coupled receptors that are involved in various cellular processes, including cell-cell adhesion, migration, and differentiation. The ligands of the Roundabout receptors are proteins or peptides that bind to the extracellular domain of the receptor and activate its intracellular signaling pathways.\n\nThere are several known ligands of the Roundabout receptors, including:\n\n1. Robo1: Robo1 is the most well-studied ligand of the Roundabout receptors. It is a transmembrane protein that is expressed on the surface of various cell types, including neurons, glia, and epithelial cells. Robo1 binds to the Roundabout receptors on neighboring cells and promotes cell-cell adhesion and migration.\n2. Robo2: Robo2 is a transmembrane protein that is expressed on the surface of various cell types, including neurons, glia, and epithelial cells. Like Robo1, Robo2 binds to the Roundabout receptors on neighboring cells and promotes cell-cell adhesion and migration.\n3. Robo3: Robo3 is a transmembrane protein that is expressed on the surface of various cell types, including neurons, glia, and epithelial cells. Like Robo1 and Robo2, Robo3 binds to the Roundabout receptors on neighboring cells and promotes cell-cell adhesion and migration.\n4. Robo4: Robo4 is a transmembrane protein that is expressed on the surface of various cell types, including neurons, glia, and epithelial cells. Like Robo1, Robo2, and Robo3, Robo4 binds to the Roundabout receptors on neighboring cells and promotes cell-cell adhesion and migration.\n5. Robo5: Robo5 is a transmembrane protein that is expressed on the surface of various cell types, including neurons, glia, and epithelial cells. Like Robo1, Robo2, Robo3, and Robo4, Robo5 binds to the Roundabout receptors on neighboring cells and promotes cell-cell adhesion",
    "llama-7b_fact_raw": "1. Roundabout (Robo) receptors are G protein-coupled receptors.\n2. Ligands of the Roundabout receptors are proteins or peptides that bind to their extracellular domain.\n3. Robo1, a ligand for Roundabout receptors, is a transmembrane protein expressed on various cell types.\n4. Robo2, like Robo1, serves as a ligand for Roundabout receptors and is involved in cell-cell adhesion and migration.\n5. Robo3 and Robo4 are transmembrane proteins that bind to Roundabout receptors and are involved in similar cellular processes as Robo1 and Robo2.",
    "llama-7b_fact": [
      "Roundabout (Robo) receptors are G protein-coupled receptors.",
      "Ligands of the Roundabout receptors are proteins or peptides that bind to their extracellular domain.",
      "Robo1, a ligand for Roundabout receptors, is a transmembrane protein expressed on various cell types.",
      "Robo2, like Robo1, serves as a ligand for Roundabout receptors and is involved in cell-cell adhesion and migration.",
      "Robo3 and Robo4 are transmembrane proteins that bind to Roundabout receptors and are involved in similar cellular processes as Robo1 and Robo2."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Roundabout (Robo) receptors are not G protein-coupled receptors; they are a family of single-pass transmembrane receptors.\n2. TRUE\n3. FALSE [correction]: Robo1 is not a ligand for Roundabout receptors; it is a member of the Roundabout receptor family itself.\n4. FALSE [correction]: Robo2, like Robo1, is not a ligand for Roundabout receptors; it is another member of the Roundabout receptor family and is involved in processes such as axon guidance and neuronal migration.\n5. FALSE [correction]: Robo3 and Robo4 are members of the Roundabout receptor family, not ligands that bind to Roundabout receptors. They are involved in various biological processes related to axon guidance and vascular development, respectively.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 4112,
    "user_query": "You MUST give a detailed answer to the following question: Is there a role for TFII-I in megakaryopoiesis?",
    "llama-7b_response": "Yes, there is a role for TFII-I in megakaryopoiesis. TFII-I is a transcription factor that plays an important role in the regulation of gene expression during the process of megakaryopoiesis.\n\nMegakaryopoiesis is the process by which megakaryocytes, which are specialized bone marrow cells that produce platelets, are formed. This process involves the proliferation and differentiation of hematopoietic stem cells into megakaryocytes.\n\nTFII-I is a key transcription factor that is involved in the regulation of gene expression during megakaryopoiesis. It binds to specific DNA sequences known as TFII-I elements, which are located upstream of genes that are specifically expressed in megakaryocytes.\n\nTFII-I has been shown to play a crucial role in the regulation of gene expression during megakaryopoiesis. For example, studies have shown that TFII-I is required for the expression of genes that are specifically expressed in megakaryocytes, such as genes that encode proteins involved in platelet production.\n\nIn addition, TFII-I has also been shown to play a role in the differentiation of hematopoietic stem cells into megakaryocytes. For example, studies have shown that TFII-I is required for the proliferation and differentiation of hematopoietic stem cells into megakaryocytes in vitro.\n\nOverall, TFII-I plays an important role in the regulation of gene expression and differentiation during megakaryopoiesis.",
    "llama-7b_fact_raw": "1. TFII-I is a transcription factor that plays an important role in the regulation of gene expression during megakaryopoiesis.\n2. Megakaryopoiesis is the process by which megakaryocytes are formed from hematopoietic stem cells in the bone marrow.\n3. TFII-I binds to specific DNA sequences called TFII-I elements, which are located upstream of megakaryocyte-specific genes.\n4. TFII-I is required for the expression of genes specifically expressed in megakaryocytes, such as those involved in platelet production.\n5. Studies have indicated that TFII-I is necessary for the proliferation and differentiation of hematopoietic stem cells into megakaryocytes in vitro.",
    "llama-7b_fact": [
      "TFII-I is a transcription factor that plays an important role in the regulation of gene expression during megakaryopoiesis.",
      "Megakaryopoiesis is the process by which megakaryocytes are formed from hematopoietic stem cells in the bone marrow.",
      "TFII-I binds to specific DNA sequences called TFII-I elements, which are located upstream of megakaryocyte-specific genes.",
      "TFII-I is required for the expression of genes specifically expressed in megakaryocytes, such as those involved in platelet production.",
      "Studies have indicated that TFII-I is necessary for the proliferation and differentiation of hematopoietic stem cells into megakaryocytes in vitro."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: TFII-I does bind to specific DNA sequences, but they are not called \"TFII-I elements\". It recognizes and binds to specific DNA sequences known as Initiator elements (Inr) and E-boxes.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 4145,
    "user_query": "You MUST give a detailed answer to the following question: Is atenolol metabolized by CYP2D6?",
    "llama-7b_response": "Yes, atenolol is metabolized by CYP2D6. Atenolol is a beta-blocker medication that is used to treat hypertension and angina pectoris. It works by blocking the action of certain natural substances in your body, such as norepinephrine, on the heart and blood vessels.\n\nCYP2D6 is an enzyme that is responsible for the metabolism of many medications, including atenolol. The metabolism of atenolol by CYP2D6 results in the formation of several metabolites, which are then excreted from the body.\n\nThe metabolism of atenolol by CYP2D6 can be affected by genetic variations in the CYP2D6 gene. Some people may have reduced activity of the CYP2D6 enzyme, which can result in reduced metabolism of atenolol and an increased risk of side effects. Conversely, some people may have increased activity of the CYP2D6 enzyme, which can result in increased metabolism of atenolol and a reduced effectiveness of the medication.\n\nIn summary, atenolol is metabolized by CYP2D6, and the metabolism of atenolol by CYP2D6 can be affected by genetic variations in the CYP2D6 gene.",
    "llama-7b_fact_raw": "1. Atenolol is metabolized by the enzyme CYP2D6.\n2. Atenolol is a medication used to treat hypertension and angina pectoris.\n3. CYP2D6 is responsible for the metabolism of many medications, including atenolol.\n4. Genetic variations in the CYP2D6 gene can affect the metabolism of atenolol.\n5. Variations in CYP2D6 enzyme activity can lead to differences in the metabolism of atenolol, which can influence the risk of side effects or medication effectiveness.",
    "llama-7b_fact": [
      "Atenolol is metabolized by the enzyme CYP2D6.",
      "Atenolol is a medication used to treat hypertension and angina pectoris.",
      "CYP2D6 is responsible for the metabolism of many medications, including atenolol.",
      "Genetic variations in the CYP2D6 gene can affect the metabolism of atenolol.",
      "Variations in CYP2D6 enzyme activity can lead to differences in the metabolism of atenolol, which can influence the risk of side effects or medication effectiveness."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Atenolol is not significantly metabolized by the liver and thus is not affected by the enzyme CYP2D6. It is excreted primarily unchanged in the urine.\n2. TRUE\n3. FALSE [correction]: CYP2D6 is indeed responsible for the metabolism of many medications, but not atenolol.\n4. FALSE [correction]: Since atenolol is not metabolized by CYP2D6, genetic variations in the CYP2D6 gene would not affect the metabolism of atenolol.\n5. FALSE [correction]: Since atenolol is not metabolized by CYP2D6, variations in CYP2D6 enzyme activity would not lead to differences in the metabolism of atenolol. However, differences in kidney function can influence the clearance of atenolol, which in turn can affect the risk of side effects or medication effectiveness.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 4158,
    "user_query": "You MUST give a detailed answer to the following question: List versions of ExpansionHunter",
    "llama-7b_response": "I apologize, but I am unable to provide a detailed answer to your question as I am not aware of any specific versions of ExpansionHunter. Could you please provide more context or clarify your question?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 4164,
    "user_query": "You MUST give a detailed answer to the following question: What is the role of Adamts18 in hormone receptor signaling?",
    "llama-7b_response": "Adamts18, also known as aggrecanase-1, is an enzyme that degrades the proteoglycan aggrecan, which is a major component of cartilage. Adamts18 has been shown to play a role in the regulation of hormone receptor signaling by affecting the expression and activity of hormone receptors.\n\nIn particular, Adamts18 has been shown to regulate the expression of estrogen receptors (ERs) and androgen receptors (ARs) in breast cancer cells. Studies have shown that Adamts18 can promote the degradation of ERs and ARs, leading to a decrease in their expression and activity. This, in turn, can reduce the ability of these hormone receptors to bind to their hormone ligands and activate downstream signaling pathways.\n\nAdditionally, Adamts18 has been shown to regulate the expression of other genes involved in hormone receptor signaling, such as those encoding for transcription factors and signaling molecules. For example, Adamts18 has been shown to regulate the expression of p53, a tumor suppressor protein that plays a role in the regulation of hormone receptor signaling.\n\nOverall, the role of Adamts18 in hormone receptor signaling is complex and involves both the regulation of hormone receptor expression and activity, as well as the regulation of the expression of other genes involved in hormone receptor signaling.",
    "llama-7b_fact_raw": "1. Adamts18 is an enzyme that degrades aggrecan, a major component of cartilage.\n2. Adamts18 influences the regulation of hormone receptor signaling by affecting hormone receptor expression and activity.\n3. Adamts18 can regulate the expression of estrogen receptors and androgen receptors in breast cancer cells.\n4. The enzyme can promote the degradation of estrogen receptors and androgen receptors, leading to a decrease in expression and activity.\n5. Adamts18 has been shown to regulate the expression of the tumor suppressor protein p53, which plays a role in hormone receptor signaling.",
    "llama-7b_fact": [
      "Adamts18 is an enzyme that degrades aggrecan, a major component of cartilage.",
      "Adamts18 influences the regulation of hormone receptor signaling by affecting hormone receptor expression and activity.",
      "Adamts18 can regulate the expression of estrogen receptors and androgen receptors in breast cancer cells.",
      "The enzyme can promote the degradation of estrogen receptors and androgen receptors, leading to a decrease in expression and activity.",
      "Adamts18 has been shown to regulate the expression of the tumor suppressor protein p53, which plays a role in hormone receptor signaling."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: ADAMTS18 is an enzyme that is part of the ADAMTS (A Disintegrin And Metalloproteinase with Thrombospondin Motifs) family, but there is no strong evidence that it degrades aggrecan specifically. Aggrecan is primarily degraded by enzymes such as ADAMTS4 and ADAMTS5.\n2. UNKNOWN: The role of ADAMTS18 in hormone receptor signaling regulation has not been well established or widely recognized in scientific literature, making this statement difficult to confirm without specific context or references.\n3. UNKNOWN: Without specific evidence or studies, it's not clear whether ADAMTS18 has an established role in regulating estrogen and androgen receptors in breast cancer cells; therefore, this statement's validity is unclear.\n4. UNKNOWN: Similar to the previous statements, without concrete evidence, it is uncertain whether ADAMTS18 promotes the degradation of hormone receptors like estrogen and androgen receptors.\n5. UNKNOWN: The regulation of p53 by ADAMTS18 is not a widely established or recognized function in the scientific literature. P53 is a well-known tumor suppressor, but linking its expression directly to ADAMTS18 requires specific evidence.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "You MUST give a detailed answer to the following question: What is the mode of action of Thiazovivin?",
    "llama-7b_response": "Thiazovivin is an antibiotic that belongs to the class of drugs known as thiazolidinones. It is used to treat a variety of bacterial infections, including those of the respiratory tract, urinary tract, and skin.\n\nThe mode of action of Thiazovivin is similar to that of other antibiotics. It works by interfering with the ability of bacteria to produce a key component of their cell walls, called peptidoglycan. Without this component, the bacterial cell wall becomes weakened and the bacteria eventually die.\n\nThiazovivin also has some activity against certain types of fungal infections. However, its effectiveness against fungal infections is generally not as strong as its effectiveness against bacterial infections.\n\nOverall, Thiazovivin is an effective antibiotic that can be used to treat a variety of bacterial infections. However, like all antibiotics, it should only be used to treat bacterial infections, as it is not effective against viral infections.",
    "llama-7b_fact_raw": "1. Thiazovivin is an antibiotic.\n2. Thiazovivin belongs to the class of drugs known as thiazolidinones.\n3. Thiazovivin is used to treat bacterial infections of the respiratory tract, urinary tract, and skin.\n4. Thiazovivin works by interfering with the production of peptidoglycan in bacterial cell walls.\n5. Thiazovivin has some activity against fungal infections but is generally more effective against bacterial infections.",
    "llama-7b_fact": [
      "Thiazovivin is an antibiotic.",
      "Thiazovivin belongs to the class of drugs known as thiazolidinones.",
      "Thiazovivin is used to treat bacterial infections of the respiratory tract, urinary tract, and skin.",
      "Thiazovivin works by interfering with the production of peptidoglycan in bacterial cell walls.",
      "Thiazovivin has some activity against fungal infections but is generally more effective against bacterial infections."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Thiazovivin is not an antibiotic. It is a small molecule inhibitor used in stem cell research.\n2. FALSE [correction]: Thiazovivin does not belong to the class of drugs known as thiazolidinones. It is a ROCK inhibitor, which is a type of compound that inhibits the Rho-associated protein kinase.\n3. FALSE [correction]: Thiazovivin is not used to treat bacterial infections. It is used in a laboratory setting to improve the survival of human embryonic stem cells and induced pluripotent stem cells.\n4. FALSE [correction]: Thiazovivin does not work by interfering with the production of peptidoglycan in bacterial cell walls since it is not an antibiotic.\n5. FALSE [correction]: Thiazovivin is not used to treat infections of any kind, whether fungal or bacterial. It is used in cell culture to improve cell survival.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  }
]